‹Æшꗗ

2024”N‹ÆÑ
y‰¢•¶‘àz
Mitsuhashi A, Nishioka Y. Fibrocytes in tumor microenvironment:Identification of their fraction and novel therapeutic strategy. Cancer Sci, in press.

Nishioka Y, Araya J, Tanaka Y, Kumanogoh A. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease. Inflamm Regen 44(1):34, 2024.

Hanibuchi M, Ogino H, Sato S, Nishioka Y. Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives. J Med Invest 71(1,2):9-22, 2024.
y‰¢•¶Œ´’˜z
Soboh S, Vorontsova A, Farhoud M, Barash U, Naroditsky I, Gross-Cohen M, Weissmann M, Nishioka Y, Woolf AS, Roberts NA, Shaked Y, Ilan N, Vlodavsky I. Tumor- and host-derived heparanase-2 (Hpa2) attenuates tumorigenicity: role of Hpa2 in macrophage polarization and BRD7 nuclear localization. Cell Death Dis 15(12):894, 2024.

Yabuki Y, Mitsuhashi A, Ogino H, Yoshida A, Nguyen TN, Yoneda H, Ozaki R, Tsukazaki Y, Morita Y, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Nishioka Y. Hypoxia inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-ƒÁ-induced chemokines in tumor cells. Int J Cancer, in press.

Kondoh Y, Furukawa T, Hozumi H, Suda T, Egashira R, Jokoh T, Fukuoka J, Kuwana M, Teramachi R, Fujisawa T, Hasegawa Y, Ogura T, Miyazaki Y, Oyama S, Teramukai S, Horiguchi G, Naito A, Inoue Y, Ichikado K, Bando M, Tomioka H, Nishioka Y, Chiba H, Ebina M, Nakanishi Y, Satoh K, Shiratori Y, Hashimoto N, Ishii M. The providing multidisciplinary ILD diagnoses (PROMISE) study - study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis. BMC Pulm Med 24(1):511, 2024.

Hanibuchi M, Miki M, Hiraoka K, Nakamura M, Tsujimoto Y, Yamamura T, Murakami K, Ogino H, Sato S, Nishioka Y. A case of pulmonary Mycobacterium heckeshornense infection coexisted with lung cancer. J Med Invest 71(3.4):327-331, 2024.

Jenkins RG, Cottin V, Nishioka Y, Noth I, White ES, Ittrich C, Diefenbach C, Rohr KB, Selman M, Maher TM, on behalf of the INMARK trial investigators. Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis. ERJ Open Res, in press.

Yagi I, Yagi S, Nakanishi K, Tezuka K, Matsuyama K, Aibara Y, Ishida T, Yoneda H, Yamamoto M, Ise T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Kitagawa T, Nishioka Y, Sata M. Critical Limb Threatening Ischemia Due to Severe Polyarteritis Nodosa\A Case Report\. Intern Med, in press.

Nii K, Ogino H, Bando H, Yamamoto Y, Fujita K, Yoneda H, Naito N, Mitsuhashi A, Morita Y, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Hanibuchi M, Izumi Y, Nishioka Y. Immune checkpoint inhibitor-associated paraneoplastic cerebellar degeneration in a case of extensive-stage small-cell lung cancer with pre-existing anti-SOX1 antibody. J Med Invest, in press.

Yamashita Y, Sato S, Nii K, Mori K, Haji K, Naito N, Ogino H, Kawawno H, Hanibuchi M, Endo I, Nishioka Y. Isolated Adrenocorticotropic Hormone Deficiency Presenting With Arthritis: A Case Report. Mod Rheumatol Case Rep, in press.

Tsukazaki Y, Ogino H, Okano Y, Kakiuchi S, Harada S, Toyoda Y, Matsumura Y, Ichihara S, Imakura T, Matsumoto R, Ozaki R, Ogawa E, Morita Y, Mitsuhashi A, Yabuki Y, Yoneda H, Hanibuchi M, Hase K, Takeuchi E, Haku T, Nishioka Y. Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer. Int J Clin Oncol 29(10):1451-1460. 2024.

Maher TM, Jenkins RG, Cottin V, Nishioka Y, Noth I, Selman M, Song JW, Ittrich C, Diefenbach C, Stowasser S, White ES; on behalf of the INMARK trial investigators. Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ Open Res 10(4):00335-2023, 2024.

Miyamoto K, Ogino H, Kakimoto T, Matsumura Y, Haji K, Mitsuhashi A, Morita Y, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Bando Y, Nokihara N, Nishioka Y. Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review. Respir Med Case Rep 51:102076, 2024.

Inoue Y, Kitamura H, Okamoto M, Ogura T, Nishioka Y, Kuwana M, Taniguchi A, Ito T, Rohr KB, Suda T. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial. Respir Investig 62(4):589-596, 2024.

Matsumura Y, Sato S, Haji K, Masuda T, Yoneda H, Ogino H, Ogawa H, Hanibuchi M, Hattori N, Nishioka Y. A case of pleural mesothelioma with immunohistochemicalstaining positive for Krebs von den Lungen-6. Respir Med Case Rep 50:102040, 2024.

Ueno M, Egashira R, Hashisako M, Fujimoto K, Fukuda T, Hayashida Y, Sumikawa H, Tominaga J, Tanaka T, Terasaki Y, Fukuoka J, Nishioka Y, Aoki T, Gabata T, Hatabu H, Johkoh T. Idiopathic dendriform pulmonaryossification as the phenotype of interstitial lung abnormalities: CT-pathologic correlation and prevalence. Jpn J Radiol 42(9):993-1002, 2024.

Sugasaki M, Nakamura S, Teramoto K, Urushihara M, Inoue Y, Nakao T, Nishioka Y, Sata M. Lupus anticoagulant hypoprothrombinemia syndrome with multiple and high-titer antiphospholipid antibodies strongly interfered with coagulation assays. Blood Coagul Fibrinolysis 35(3):149-153, 2024.

Bando M, Homma S, Date H, Kishi K, Yamauchi H, Sakamoto S, Miyamoto A, Goto Y, Nakayama T, Azuma A, Kondoh Y, Johkoh T, Nishioka Y, Fukuoka J, Miyazaki Y, Yoshino I, Suda T; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition. Respir Investig 62(3):402-418, 2024.

Mima M, Sato S, Shinya T, Naito N, Shoji T, Harada S, Suzue R, Murakami K, Koyama K, Nishioka Y. Characteristics of chest high-resolution computed tomography in patients with anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 41(1):e2024005, 2024.

Kozai H, Ogino H, Mitsuhashi A, Nguyen N, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Shinohara T, Nokihara H, Nishioka Y. Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thorac Cancer 15(5):369-378, 2024.

Yoneda H, Mitsuhashi A, Yoshida A, Ogino H, Itakura S, Nguyen N, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Abe S, Kaneko Mika, Kato Y, Nishioka Y. Anti-podoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells. Cancer Sci 115(2):357-368, 2024.

Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol 26(2):335-347, 2024.

Takeuchi E, Ogino H, Kondou K, Okano Y, Ichihara S, Kunishige M, Kadota N, Machida H, Hatakeyama N, Naruse K, Nokihara H, Shinohara T, Nishioka Y. An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thorac Cancer 15(3):248-257, 2024.
y˜a•¶‘àz
“yŽtŒbŽq, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‚Æ”xüˆÛÇ. ‰ŠÇ‚ƖƉu 32(6):61-66, 2024.

²“¡³‘å, ¼‰ªˆÀ•F. ˆâ“`«ŠÔŽ¿«”xŽ¾Š³‚ƉƑ°«ŠÔŽ¿«”x‰Š‚Ì—Õ°‘œ. ŒÄ‹zŠí“à‰È 46(1):1-7, 2024.

ŒK–¼³—², ¼‰ªˆÀ•F, ‹ß“¡N”Ž. Phosphodiesterase 4B‘jŠQ–ònerandomilastFV‹K”xüˆÛÇŽ¡—Öò‚Æ‚µ‚Ä‚Ì“W–]. “úŒÄ‹zŽ 13(4):131-139, 2024.

V‰Æ’‹`, Œ´“c‰ëŽj, ¼‰ªˆÀ•F. ƒEƒCƒ‹ƒXŠ´õÇ‚Ì‹¹•”‰æ‘œf’f. Žl‘ˆãŽ 80(1,2):17-22, 2024.

¼‰ªˆÀ•F. ”x‘@ˆÛǂɑ΂·‚éRüˆÛ‰»–òŠJ”­F‚ª‚ñ‚ÆüˆÛ‰»”x‚ÌÚ“_‚𑨂¦‚½ƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`. ˆãŠw‚Ì‚ ‚ä‚Ý 288(2):148-161, 2024.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Kojin Murakami, Seidai Sato, Yuta Isomura, Trang Thi Hong Phuong, Noriko Bando, Ryoko Suzue, Nandin-Erdene Danzan, Yuya Yamashita, Hiroki Bando, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Noriaki Inamura, Kenji Hasumi, Yasuhiko Nishioka. SMTP-44D, a soluble epoxide hydrolase inhibitor, attenuated the progression of pulmonary fibrosis in vivo and in vitro. The ERS Congress 2024. Vienna, Austria. 2024”N9ŒŽ9“ú.

Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yuko Toyoda, Yugo Matsumura, Seiya. Ichihara, Takeshi. Imakura, Rikako. Matsumoto, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Kayoko Hase, Eiji Takeuchi, Takashi Haku, Yasuhiko Nishioka. The Conflicting Impacts of G-CSF on the Therapeutic Efficacy of Chemoimmunotherapy for Extensive Stage Small Cell Lung Cancer. 2024 World Conference on Lung Cancer. San Diego, CA, USA. 2024”N9ŒŽ7-10“ú.

Hirokazu Ogino, Nguyen Thi Na, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi, Yasuhiko Nishioka. The potential of fluoropyrimidine to be an immunologically optimal partner of immunotherapy for thoracic malignancies. 2024 World Conference on Lung Cancer. San Diego, CA, USA. 2024”N9ŒŽ7-10“ú.

Nobuaki Mamesaya, Kento Takagi, Go Saito, Hiroshi Tanaka, Sousuke Kubo, Takehito Shukuya, Ryosuke Tsugitomi, Takaaki Sasaki, Tomohiro Oba, Taro Yamanaka, Motoko Tachihara, Hiroshi Gyotoku, Hiromi Nagashima, Motohiro Tamiya, Hiroaki Kanemura, Takehiro Tozuka, Megumi Furuta, Shinya Sakata, Atsuto Mouri, Hideki Miwa, Hayato Kawachi, Takashi inomiya, Yoshiaki Nagai, Hirokazu Ogino, Kentaro Ito, Yosuke Tamura, Takaaki Tokito, Masashi Ishihara, Takuji Suzuki. Real-World Data on the Efficacy and Safety of Lenvatinib in Patients with Previously Treated Thymic Carcinoma. 2024 World Conference on Lung Cancer. San Diego, CA, USA. 2024”N9ŒŽ7-10“ú.

Keiko Haji, Seidai Sato, Hirohisa Ogawa, Yuta Isomura, Noriko Bando, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Yuya Yamashita, Kojin Murakami, Hiroki Bando, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, Katsutoshi Kobayashi, Toshiro Morohoshi, Yasuhiko Nishioka. The effect of novel autotaxin inhibitor, 2-carba cyclic phosphatidic acid, in lung fibrosis. ATS 2024. San Diego, CA, USA. 2024”N5ŒŽ19“ú.

Seidai Sato, Takushi Yamamoto, Yuki Morimoto, Yuta Isomura, Noriko Bando, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Yuya Yamashita, Kojin Murakami, Hiroki Bando, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. Analysis of Local Distribution and Residence Time of Nintedanib in Fibrotic Lung Tissue Using Mass Spectrometry Imaging. ATS 2024. San Diego, CA, USA. 2024”N5ŒŽ19“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. RüˆÛ‰»–ò‚ÌŠî‘b‚Æ—Õ°. ‘æ71‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[). ‚’m. 2024”N11ŒŽ29“ú.

Yoshitaka Zenke, Isamu Okamoto, Yuichiro Ohe, Koichi Azuma, Kyoichi Okishio, Hirokazu Ogino, Yoshitsugu Horio, Satoshi Oizumi, Manabu Hayama, Masatoshi Sugeno, Masaya Harada, Yuka Olivo, Haiyi Jiang, Suresh Senan. Durvalumab consolidation treatmentitxjin limited-stage SCLCFADRIATIC Japanese subgroup analysis. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(Presidential Session). ‰¡•l. 2024”N11ŒŽ2“ú.

’‡’nˆê˜Y, •£_Žj, –…”ö’¼, —t‹v‹MŽi, ˆÉ“¡Œ’ˆê˜Y, –{ŠÔ—Tˆê˜Y, •P˜H‘å•ã, Ÿì’, ‰z’qéº, ¬“c®œA, ‹à“cD˜a, ŽÂŒ´•×, ㌎–«K, ²“¡³“¹, ŽR“Y‰ëŒÈ, ¼‰ªˆÀ•F, ¬—Ñ‘•F, âE•”ˆÐ, ’Ã’[—R‰À—¢. “ú–{l‚—î”xŠàŠ³ŽÒ‚ɑ΂·‚éV‹K—LŠQŽ–Û—\‘ªƒVƒXƒeƒ€LACTA-score‚ÌŠJ”­FENSURE-GAŽŽŒ±‚æ‚è. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ[ƒNƒVƒ‡ƒbƒv). ‰¡•l. 2024”N11ŒŽ1“ú.

¬ŽRŒšˆê, ‚–ØŒ«l, âV“¡‡, ‹v•Û‘n‰î, ²X–Ø‚–¾, ‘åê’qL, “¤âLº, ‹Ê‰ª–¾—m, ’·“‡L‘Š, “c‹{Šî—T, ‹à‘º’ˆ¹, ŒË’Ë–Ò‘å, ŒÃ“cŒb, ‰Í“à—El, “ñ‹{’, ’·ˆä—Ǻ, ‰¬–ìL˜a, ˆÉ“¡Œ’‘¾˜Y, ÎŒ´¹Žu, —é–Ø‘ñŽ™. ŽÀ—Õ°‚Å‚ÌŠùŽ¡—ÃisÄ”­‹¹‘BŠàŠ³ŽÒ‚ɑ΂·‚郌ƒ“ƒoƒ`ƒjƒu‚Ì—LŒø«‚¨‚æ‚шÀ‘S«‚ÌŒŸ“¢F‚—îŽÒ‚É‚¨‚¯‚é‰ðÍ. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ[ƒNƒVƒ‡ƒbƒv). ‰¡•l. 2024”N11ŒŽ1“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, –—m•½, ”öè—Ì•F, ’Ëè—C‹M, û•£¹‹B, Œ¬Œ´_, ¼‰ªˆÀ•F. Fibrocyte •ª‰»§Œä‚É‚æ‚é–Ɖu”rœŽ•ž‚ÆV‹K•¡‡‚ª‚ñ–Ɖu—Ö@‚Ö‚Ì“WŠJ. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ[ƒNƒVƒ‡ƒbƒv). ‰¡•l. 2024”N10ŒŽ31“ú.

‰¬–ìL˜a. ‚ª‚ñ–ò•¨—Ö@‚ɂ‚¢‚Ä`ÅV‚̘b‘è‚ð’†S‚É`. “¿“‡Œ§–¯‚ª‚ñƒtƒH[ƒ‰ƒ€. “¿“‡. 2024”N10ŒŽ19“ú.

¼‰ªˆÀ•F. ’m‚Á‚Ä‚¨‚«‚½‚¢”x‚Ì•a‹CIuCOPDv‚ÆuŠÔŽ¿«”x‰Šv. ‘æ11‰ñ“¿“‡ŽsˆãŽt‰ïCOPDŽs–¯ŒöŠJuÀ. “¿“‡. 2024”N10ŒŽ14“ú.

²“¡³‘å. ”xüˆÛÇŒ¤‹†‚ÌÅ‘Oü `¡A’–Ú‚·‚ׂ«•W“IŒó•âˆöŽq‚ɂ‚¢‚Ä`. ‘æ44‰ñ“ú–{ƒTƒ‹ƒRƒCƒh[ƒVƒX^“÷‰èŽî«Ž¾Š³Šw‰ï‘‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[). _ŒË. 2024”N10ŒŽ11“úD

¼‰ªˆÀ•F. ”x‚ª‚ñ‚ɑ΂·‚錌ŠÇV¶‘jŠQ–ò‚ÆüˆÛ×–E. ‘æ92‰ñŒÄ‹zŠí‡“¯–k—¤’n•û‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[). ‹à‘ò. 2024”N5ŒŽ25“ú.

’Ëú±—C‹M, ”ò”~—º, ŽO‹´“ÕŽu, ”öè—Ì•F, –—m•½, •Ä“c_l, ‰¬–ìL˜a, û•£¹‹B, ¬ì”Ž‹v, ‘ê‘òGŒõ, ¼‰ªˆÀ•F. üˆÛ×–E‚ÌŽîᇓàZ‚¨‚æ‚Ñ‚»‚ê‚ð—U“±‚·‚é‘–‰»ˆöŽq‚ª”ñ¬×–E”xŠà‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚ẲðÍ. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ7“úD

’|“à‰hŽ¡, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, ¼‘º—LŒå, ŽsŒ´¹–ç, š d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨¶, ‰¬–ìL˜a, Œ¬Œ´_, ŽÂŒ´•×, ¼‰ªˆÀ•F. DŽ_‹…‚Í”ñ¬×–E”xŠàŠ³ŽÒ‚ɑ΂·‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŒø‰Ê—\‘ªƒoƒCƒIƒ}[ƒJ[. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ7“úD

¼‰ªˆÀ•F. «—ˆŒv‰æˆÏˆõ‰ï‚ÌŠˆ“®•ñ. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•Ê•ñ). ‰¡•l. 2024”N4ŒŽ7“úD

‚‘ºŒ\, “¡Œ´Œcˆê, ‰Pˆäˆê—T, ’†‘ºŒdˆê, ‚‹´‘, ŽRŒûŠo”Ž, ŽsŒ´‰pŠî, “n•”‘, “¡–{Lˆê, ’|“c—²”V, ûüú±r˜a, ¼‰ªˆÀ•F, ¬—Ñ‘•F, âE•”ˆÐ, ’Ã’[—R‰À—¢. ‚—îŽÒ‹@”\•]‰¿‚ð—p‚¢‚½ƒ‰ƒ“ƒ_ƒ€‰»‘æIII‘ŠŽŽŒ±iENSURE-GAŽŽŒ±jFQOLƒf[ƒ^‚̉ðÍŒ‹‰Ê. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ7“úD

²“¡Œ÷, ¼‰ªˆÀ•F. ­l”‚ÌŠw•”¶‚ɑ΂·‚é”x‹æˆæ‰ð–U‚̓ljeŽÀK. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ6“ú.

ˆ¢•”‚ ‚©‚Ë. ŒÄ‹zŠíŠ´õÇ‚ÌŒ»ó‚Æ“W–]. ‘æ268‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï Žs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€. “¿“‡. 2024”N3ŒŽ10“ú.

²“¡³‘å. ¬l‚ÌdÇšb‘§‚ƶ•¨Šw“I»Ü‚ɂ‚¢‚Ä. —ߘa5”N“x“¿“‡Œ§ƒAƒŒƒ‹ƒM[Ž¾Š³ Œ§–¯ŒöŠJuÀ. “¿“‡. 2024”N2ŒŽ23“ú.

¼‰ªˆÀ•F. ’m‚Á‚Ä‚¨‚«‚½‚¢”x‚Ì•a‹C`ŠÔŽ¿«”x‰Š‚Æ‚ÍH`. —ߘa5”N“x“¿“‡Œ§—§ŽOD•a‰@Œ§–¯ŒöŠJuÀ. “¿“‡. 2024”N1ŒŽ27“ú.

¼‰ªˆÀ•F. Žîᇔ÷¬ŠÂ‹«‚Ìfibrocyte`‹@”\‰ðÍ‚©‚ç•W“IŽ¡—ÂÖ`. “ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ï ‘æ19‰ñƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`ƒ[ƒNƒVƒ‡ƒbƒv. “Œ‹ž. 2024”N1ŒŽ26“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
’Ëè—C‹M, ‰¬–ìL˜a, ‰ª–ì‹`•v, Š`“à‘Ži, –L“c—DŽq, ¼–{—˜‰ÁŽq, ”öè—Ì•F, X“c—D, ŽO‹´“ÕŽu, –—m•½, û•£¹‹B, ’·’J‰Á—eŽq, ’|“à‰hŽ¡, —t‹v‹MŽi, ¼‰ªˆÀ•F. G-CSF‚ªi“WŒ^¬×–E”xŠà‚É‚¨‚¯‚鉻Šw–Ɖu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚É‹y‚Ú‚·‰e‹¿‚ðŒŸ“¢‚µ‚½‘½Ž{Ý‹¤“¯Œã•ûŽ‹“I‰ðÍ. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2024”N11ŒŽ2“ú.

–—m•½, ŽO‹´“ÕŽu, ‰¬–ìL˜a, ”öè—Ì•F, ’Ëè—C‹M, û•£¹‹B, ¼‰ªˆÀ•F. IFN-ƒÁ”½‰ž«ƒPƒ‚ƒJƒCƒ“ŽY¶§Œä‹@˜‚̉𖾂ÆV‹K•¡‡‚ª‚ñ–Ɖu—Ö@‚ւ̉ž—p. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2024”N11ŒŽ1“ú.

“ŒŒöˆê, –Ñ—˜“Äl, çÝŽL’m, âV“¡—Ç‘¾, Ô¼O˜N, •Äãm—Y, —P–ØŽ•F, ’·“‡L‘Š, ‚‹´‘, “¡“c¹Ž÷, ¼‰ªˆÀ•F, –ö’J“TŽq, “ñ‹{‹Mˆê˜N, ·Œ[‘¾, –k–쎠‹v, ‹Ê“c kŽ¡, Še–±”Ž, ŽR–{M”V, Œ·ŠÔº•F, Œõ•y“OÆ. Øœ•s”\IIIŠú”ñ¬×–E”xŠà‚ɑ΂·‚鉻Šw•úŽËü—Ö@ŒãDurvalumab‚̃oƒCƒIƒ}[ƒJ[Œ¤‹†G’†ŠÔ‰ðÍ. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2024”N10ŒŽ31“ú.

Žç“c—º, ŒÃ‰®’¼Ž÷, ‹à’nL‘ñ, ‰¡”öŒc‹I, –öì’, ŽR–{Š°, ûüŽR_ˆê, ‰Í£¬•ä, ¼‰i˜al, •“cŒ«ˆê, ’·“‡L‘Š, ã–{’qG, –x“c®½, ‘êŒû—Tˆê, –ìì‚ЂƂÝ, ¼‰ªˆÀ•F, ¬—Ñ‘•F, âE•”ˆÐ, ’Ã’[—R‰À—¢. ‚—îŽÒ‹@”\•]‰¿‚ƶ‘¶ŠúŠÔ‚¨‚æ‚Ñ–ò•¨—Ö@‚É‚¨‚¯‚é—LŠQŽ–Û‚Ì—\‘ª”\‚ÉŠÖ‚·‚錟“¢FENSURE-GA studyƒf[ƒ^‚æ‚è. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2024”N10ŒŽ31“ú.

’Ëú±—C‹M, ‰¬–ìL˜a, ‰ª–ì‹`•v, Š`“à‘Ži, –L“c—DŽq, ¼–{—˜‰ÁŽq, ”öè—Ì•F, X“c—D, ŽO‹´“ÕŽu, –—m•½, û•£¹‹B, ’·’J‰Á—eŽq, ’|“à‰hŽ¡, —t‹v‹MŽi, ¼‰ªˆÀ•F. G-CSF ‚ªi“WŒ^¬×–E”xŠà‚ɑ΂·‚鉻Šw–Ɖu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚É‹y‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚é‰ðÍ. ‘æ62‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. •Ÿ‰ª. 2024”N10ŒŽ24“ú.

—§‰Ô®‘¾˜Y, ¬ì”Ž‹v, ´…^—SŽq, â“ŒOŠî, ²“¡³‘å, ‚ŽR‘ì‘å, ˆä”Vã_ˆê, ¼‰ªˆÀ•F, íŽRKˆê. –«‹CŠÇŽxšb‘§‚É‚¨‚¯‚é”t×–E‰ßŒ`¬‚ɑ΂·‚éLPA1Žó—e‘Ì‚Ì–ðŠ„. ‘æ73‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. ‹ž“s. 2024”N10ŒŽ19“ú.

ìk‘¢, ²“¡³‘å, ¬ŽRˆë–ç, ˆé‘º—S‘¾, —é]—ÁŽq, ‘ºãsl, â“ŒOŠî, “yŽtŒbŽq, ¼‰ªˆÀ•F. ƒŠƒ“ƒp‹…“ÁˆÙ“Iƒ^ƒ“ƒpƒNŽ¿ƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ‚É‚æ‚éRüˆÛ‰»ì—p‚ÌŒŸ“¢. ‘æ4‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï. “Œ‹ž. 2024”N9ŒŽ29“ú.

²“¡³‘å, ŽR–{‘ìŽu, X–{—FŽ÷, ˆé‘º—S‘¾, —é]—ÁŽq, ‘ºãsl, â“ŒOŠî, “yŽtŒbŽq, ìk‘¢, ¼‰ªˆÀ•F. Ž¿—Ê•ªÍƒCƒ[ƒWƒ“ƒO‚ð—p‚¢‚½ƒjƒ“ƒeƒ_ƒjƒu‚Ì”x“à‹ÇÝ•ª•z‚Æ‘Ø—¯ŽžŠÔ‚ÌŒŸ“¢. ‘æ4‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï. “Œ‹ž. 2024”N9ŒŽ29“ú.

ŽO‹´“ÕŽu, ¬ŽRˆë–ç, ‰¬–ìL˜a, –—m•½, ”öè—Ì•F, ’Ëè—C‹M, X“c—D, ‹g“c•Él, Œ¬Œ´_, û•£¹‹B, ¼‰ªˆÀ•F. Fibrocyte §Œä‚É‚æ‚邪‚ñ–Ɖu”rœŽ•ž‚ÉŒü‚¯‚½Ž¡—Ãí—ª. ‘æ83‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. •Ÿ‰ª. 2024”N9ŒŽ20“ú.

¼žŠ“Ö˜Y, ‰¬–ìL˜a, ‰ª“cG•ä. ƒyƒvƒ`ƒhƒƒNƒ`ƒ“ IMA950 ‚Æ varlilumab •¹—p—Ö@‚͒ራ«“x_ŒoäPŽîŠ³ŽÒ––½ŒŒ‚É‚¨‚¢‚Ä effector memory T ×–E‚Ì•ª‰»‚ð‘£i‚·‚é. ‘æ83‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. •Ÿ‰ª. 2024”N9ŒŽ19“ú.

‰¬–ìL˜a, ¼žŠ“Ö˜Y, ¼‰ª ˆÀ•F, Nicholas A Butowski, Susan M Chang, Mitchel S Berger, ‰ª“cG•ä. ’ራ«“x_ŒoäPŽî‚ɑ΂·‚éƒ}ƒ‹ƒ`ƒyƒvƒ`ƒhƒƒNƒ`ƒ“IMA950‚ÆRCD27ƒAƒSƒjƒXƒgR‘Ìverlilumab•¹—p—Ö@‚̖ƉuŠw“IŒø‰Ê‚ɂ‚¢‚Ä. ‘æ28‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘‰ï¥‘æ37‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠwpW‰ï‘‰ï‡“¯‘å‰ï. “Œ‹ž. 2024”N7ŒŽ12“ú.

‹{–{Œ›Æ, û•£¹‹B, ˆé‘º—S‘¾, X“c—D, ‘ºãsl, â“ŒOŠî, ”öè—Ì•F, ìk‘¢, •Ä“c_l, ‰¬–ìL˜a, ¼‰ªˆÀ•F. ‹CŠÇŽx‹¾Œã‚̌ċzŠíŠ´õǃnƒCƒŠƒXƒNÇ—á‚É‚¨‚¯‚é—\–h“IR‹Û–ò“Š—^‚̈Ӌ`‚ɂ‚¢‚Ä‚ÌŒã•ûŽ‹“IŒ¤‹†. ‘æ47‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. ‘åã. 2024”N6ŒŽ28“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, –—m•½, ”öè—Ì•F, Œ¬Œ´_, ¼‰ªˆÀ•F. Fibrocyte •ª‰»‚ð•W“I‚Æ‚µ‚½–Ɖu”rœŽ•ž‚Ö‚ÌV‹KŽ¡—Ã’Tõ. ‘æ28‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2024”N6ŒŽ20“ú.

‰¬–ìL˜a, ¼žŠ“Ö˜Y, ¼‰ªˆÀ•F. ƒ}ƒ‹ƒ`ƒyƒvƒ`ƒhƒƒNƒ`ƒ“ IMA950 ‚ÆR CD27 ƒAƒSƒjƒXƒgR‘Ì verlilumab ‚Ì•¹—p—Ö@‚͒ራ«“x_ŒoäPŽî‚É‚¨‚¯‚é T ×–E–Ɖu‰ž“š‚ð—U“±‚·‚é. ‘æ28‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2024”N6ŒŽ20“ú.

ŽR‰º—Y–ç, ‰Í–ìO, ˆÀ‘Ž, ‘ºãsl, “à“¡Lm, ²“¡³‘å, ¼‰ªˆÀ•F. ƒŠƒEƒ}ƒ`ƒ‚ƒfƒ‹‚É‚¨‚¯‚éPLK‘jŠQ—Ö@‚ÌŽ¡—ÃŒø‰Ê. ‘æ68‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. _ŒË. 2024”N4ŒŽ18“ú.

²“¡³‘å, ŽR–{‘ìŽu, X–{—FŽ÷, â“Œ‹IŽq, ‘ºãsl, â“ŒOŠî, “yŽtŒbŽq, ìk‘¢, ¼‰ªˆÀ•F. Ž¿—Ê•ªÍƒCƒ[ƒWƒ“ƒOiMScope QT‚ð—p‚¢‚½ƒjƒ“ƒeƒ_ƒjƒu‚Ì”x“à‹ÇÝ•ª•z‚Æ‘Ø—¯ŽžŠÔ‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‰¡•l. 2024”N4ŒŽ7“úD

‰¬–ìL˜a, Nguyen Thi Na, ¼”Ž”V, ŽO‹´“ÕŽu, ’Ëú±—C‹M, –—m•½, ”öè—Ì•F, û•£¹‹B, ¼‰ªˆÀ•F. ‹¹•”Žîᇂɑ΂µ‚ĖƉuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Æ•¹—p‚·‚ׂ«ŽŠ“KR‚ª‚ñÜ‚Ì“¯’è‚ð–ÚŽw‚µ‚½–ƉuŠw“I‰ðÍ. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‰¡•l. 2024”N4ŒŽ7“úD

“yŽtŒbŽq, ²“¡³‘å, ¬ì”Ž‹v, ‘ºãsl, ¬ŽRˆë–ç, Trang Thi Hong Phung, ‰Í–ìO, ¬—ÑŽ—˜, ”¯r˜Y, ¼‰ªˆÀ•F. ƒI[ƒgƒ^ƒLƒVƒ“‘jŠQì—p‚ð—L‚·‚é2ccPA‚ÌRüˆÛ‰»ì—p‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‰¡•l. 2024”N4ŒŽ7“úD

Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku, Yasuhiko Nishioka. The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer. ‘æ21‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. –¼ŒÃ‰®. 2024”N2ŒŽ24“ú.

Hirokazu Ogino, Nguyen Thi Na, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi, Yasuhiko Nishioka. Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies. ‘æ21‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. –¼ŒÃ‰®. 2024”N2ŒŽ22“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
˜a“c’ë–¤, ‘ºãsl, â“ŒOŠî, â“Œ‹IŽq, –—m•½, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ƒŒƒ“ƒoƒ`ƒjƒu‚ª‘tŒø‚µ‚½FGFR3•ÏˆÙ—z«‹¹‘BŠà‚Ì1—á. ‘æ131‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2024”N12ŒŽ15“ú.

ˆÉ“¡ˆê‹P, ‘ºãsl, â“ŒOŠî, ’†¼Œk‰î, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, û•£¹‹B, ¼‰ªˆÀ•F. ‘ÌŠOŽ®–ŒŒ^lH”x‚𓱓ü‚µ‚Ä‹~–½‚µ‚½ŠÖ߃ŠƒEƒ}ƒ`ŠÖ˜AŠÔŽ¿«”xŽ¾Š³‹}«‘ˆ«‚Ì1—á. ‘æ131‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2024”N12ŒŽ15“ú.

ŽO–Ø^—, ¼žŠ“Ö˜Y, ŽR‘º“ÄŽi˜Y, “¡’†—Yˆê, ¼‰ªˆÀ•F, ˆÉè•x—R”ü, ‘ê‘òGŒõ. “«”xmycobacterium abscessusŠ´õÇ‚ÉŽèp—Ö@‚ðs‚¢•aóƒRƒ“ƒgƒ[ƒ‹‚𓾂½ˆê—á. ‘æ75‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï. ‚’m. 2024”N11ŒŽ30“ú.

ˆé‘º—S‘¾, ‘ºãsl, â“ŒOŠî, Š–{’B–ç, ‹ß“¡Œ\‘å, “yŽtŒbŽq, •Ÿ‰Æ–ƒ”ü, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ’Ò½Žm˜Y, Œ´—Ï¢, ¼‰ªˆÀ•F. •›t•s‘S‚ð‡•¹‚µ‚½ŒÇ”­«‚Ì—¼‘¤•›tŒ‹Šj‚̈ê—á. ‘æ75‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï. ‚’m. 2024”N11ŒŽ30“ú.

X“c—D, ‘ºãsl, â“ŒOŠî, ‹{–{Œ›Æ, ˆé‘º—S‘¾, Š–{’B–ç, ‹ß“¡Œ\‘å, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ‹CŠÇŽx‹¾‚Åf’f‚µ‚½”x“à_ŒoâŽî‚̈ê—á. ‘æ33‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. ‚’m. 2024”N11ŒŽ30“ú.

’†¼éD“l, ‘ºãsl, â“ŒOŠî, ˆé‘º—T‘¾, Š–{’B–ç, ‹ß“¡Œ\‘å, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ƒeƒ|ƒ`ƒjƒu“Š—^Œã‚É‚“x‚ÈŒŒ¬”ÂŒ¸­‚ÆD’†‹…Œ¸­‚𗈂µ‚½MET exon14 skipping•ÏˆÙ—z«”x‘BŠà‚̈ê—á. ‘æ71‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‚’m. 2024”N11ŒŽ29“ú.

Š–{’B–ç, ‰Í–ìO,‘ºãsl, ŽR‰º—Y–ç, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. Rituximab‚É‚æ‚éinfusion-related reactions‚𗈂µAWŠw“IŽ¡—Âð—v‚µ‚½‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚Ì1—á. ‘æ35‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. L“‡. 2024”N11ŒŽ3“ú.

’†¼éD“l, “à“¡Lm, ‘ºãsl, ŽR‰º—Y–ç, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, ¼‰ªˆÀ•F. _Œo¶ŒŸ‚Åf’f‚µ“¾‚½A‹•ŒŒ«––½_ŒoáŠQ‚ð’悵‚½RƒŠƒ“Ž‰Ž¿R‘ÌÇŒóŒQ‚Ì1—á. ‘æ35‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. L“‡. 2024”N11ŒŽ2“ú.

‹ß“¡Œ\‘å, ‘ºãsl, â“ŒOŠî, ’Ëú±—C‹M, ‰¬–ìL˜a, ¼–{—˜‰ÁŽq, X“c—D, ŽO‹´“ÕŽu, ”öè—Ì•F, –—m•½, ²“¡³‘å, û•£¹‹B, ‰ª–ì‹`•v, Š`“à‘Ži, –L“c—DŽq, ’·’J‰Á—eŽq, ’|“à‰hŽ¡, —t‹v‹MŽi, ¼‰ªˆÀ•F. i“WŒ^¬×–E”xŠà‚É‚¨‚¢‚Äè÷—±‹…ƒRƒƒj[ŽhŒƒˆöŽq‚ª‰»Šw–Ɖu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚É‹y‚Ú‚·‰e‹¿. ‘æ269‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2024”N7ŒŽ21“ú.

‰¬–ìL˜a, ¼‰ªˆÀ•F. p‘OŽ¡—ÂɂĔx‘S“E‚ð‰ñ”ð‚µ“¾‚½”ñ¬×–E”xŠà‚Ì2—á. ‘æ62‰ñ“ú–{”xŠàŠw‰ï ’†‘EŽl‘Žx•”ŠwpW‰ï(‰ï’·“Á•ÊŠé‰æ). •ÄŽq. 2024”N7ŒŽ19“ú.

ˆÉ“¡ˆê‹P, ‘ºãsl, â“ŒOŠî, ŽR–{_¶, ’Ëè—C‹M, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. EGFR L858R •ÏˆÙ—z«”x‘BŠà‚ɑ΂µ‚Ä CBDCA{nab-PTX{Atezolizumab ‚ª pseudoprogression ‚𔺂Á‚Ä’˜Œø‚µ‚½ˆê—á. ‘æ70‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. •ÄŽq. 2024”N7ŒŽ19“ú.

˜a“c’ë–¤, ‘ºãsl, â“ŒOŠî, “à“¡Lm, ²“¡³‘å, “Œ“‘ã, ²“¡‰ë”ü, û•£¹‹B, ’†‘º–ÎŽ÷, ¶•ûŒöŽq, ‚“c”ü²Žq, ¼‰ªˆÀ•F. COVID-19‚ɇ•¹‚µ‚½ŒŒ´Œ^15A ”x‰Š‹…‹Û‚É‚æ‚édÇ”x‰Š‚̈ê—á. ‘æ70‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. •ÄŽq. 2024”N7ŒŽ19“ú.

ŽR“c‹G, ‘ºãsl, â“ŒOŠî, ’†¼Œk‰î, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ƒ\ƒgƒ‰ƒVƒu‚ª‘tŒø‚µ‚½KRAS G12C•ÏˆÙ—z«‚Ì”xŒ´”­‘å×–E_Œo“à•ª”åŠà‚̈ê—á. ‘æ70‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. •ÄŽq. 2024”N7ŒŽ19“ú.

â“Œ‹IŽq, ‘ºãsl, â“ŒOŠî, ŽR‰º—Y–ç, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, û•£¹‹B, ¼‰ªˆÀ•F. ƒvƒŒƒhƒjƒ]ƒƒ“AƒgƒVƒŠƒYƒ}ƒuAƒŠƒcƒLƒVƒ}ƒu‚ÌŽOÜ“¯Žž•¹—p—Ö@‚ª‘tŒø‚µ‚½Ž¡—Ã’ïR«TAFROÇŒóŒQ‚Ì1—á. ‘æ130‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2024”N6ŒŽ16“ú.

’†¼éD“l, ‘ºãsl, â“ŒOŠî, ‹{–{Œ›Æ, â“Œ‹IŽq, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. •ïŠ‡“IƒQƒmƒ€ƒvƒƒtƒ@ƒCƒŠƒ“ƒOŒŸ¸‚É‚ÄPD-L1ˆâ“`Žq‘•‚ð”F‚ß‚½‹¹œŒ´”­•úŽËüŠÖ˜A“÷Žî‚Ì1—á. ‘æ130‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2024”N6ŒŽ16“ú.

â“Œ‹IŽq, â“ŒOŠî, “yŽtŒbŽq, ”ü”n³l, •Ÿ‰Æ–ƒ”ü, “à“¡Lm, ”öè—Ì•F, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, âŒû‹Å, û•£¹‹B, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚édÇšb‘§‚ɑ΂·‚鶕¨Šw“I»Ü‚ÌŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ268‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2024”N3ŒŽ10“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2023”N‹ÆÑ
y‰¢•¶Œ´’˜z
Yabuki Y, Hanibuchi M, Takeuchi E, Haku T, Kanematsu T, Nishimura N, Toyoda Y, Mitsuhashi A, Otsuka K, Sato S, Goto H, Yoneda H, Ogino H, Nokihara H, Shinohara T, Nishioka Y. A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent non-squamous non-small-cell lung cancer. Thorac Cancer 14(32):3232-3239, 2023.

Takeuchi E, Kondo K, Okano Y, Ichihara S, Kunishige M, Kadota N, Machida H, Hatakeyama N, Naruse K, Ogino H, Nokihara H, Shinohara T, Nishioka Y. Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thorac Cancer 14(30):3042-3050, 2023.

Harada S, Imakura T, Sato S, Nokihara H, Nishioka Y. A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab: Case report. J Med Invest 70(3,4):516-520, 2023.

Sato S, Koyama K, Ogawa H, Murakami K, Imakura T, Yamashita Y, Kagawa K, Kawano H, Hara E, Nishioka Y. A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect. Respir Investig 61(6):781-792, 2023.

Takahashi T, Sato Y, Kashihara T, Miyata Y, Fujino Y, Mitsui Y, Okamoto K, Miyamoto H, Nishioka Y, Takayama T. Nintedanib-Induced Gastric Antral Vascular Ectasia in Patients With Idiopathic Pulmonary Fibrosis. ACG Case Rep J 10:e01107, 2023.

Takahashi H, Ogino H, Bando H, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Nishioka Y. FoundationOne CDx Detected an Uncovered Variant of EGFR Exon 19 Deletion by Omcomine Dx Target Test in a Patient with Lung Adenocarcinoma. Respir Med Case Rep 45:101893, 2023.

Takeuchi E, Kondo K, Okano Y, Kunishige M, Kondo Y, Kadota N, Machida H, Hatakeyama N, Naruse K, Ogino H, Nokihara H, Shinohara T, Nishioka Y. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. J Cancer Res Clin Oncol 149(7):3139-3147, 2023.

Imakura T, Sato S, Koyama K, Ogawa H, Niimura T, Murakami K, Yamashita Y, Haji K, Naito N, Kagawa K, Kawano H, Zamami Y, Ishizawa K, Nishioka Y. A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis. Respir Res 24(1):148, 2023.

Yanagihara T, Tsubouchi K, Zhou Q, Chong M, Otsubo K, Isshiki T, Schupp JC, Sato S, Scallan C, Upagupta C, Revill S, Ayoub A, Chong SG, Dvorkin-Gheva A, Kaminski N, Tikkanen J, Keshavjee S, Pare G, Guignabert C, Ask K, Kolb MR. Vascular-Parenchymal Crosstalk Promotes Lung Fibrosis Through BMPR2 Signaling. Am J Respir Crit Care Med 207(11):1498-1514, 2023.

Nishioka Y, Homma S, Ogura T, Sato S, Arai N, Tomii K, Kamio K, Sakamoto S, Miyazaki Y, Tomioka H, Hisata S, Handa T, Azuma A. Exploratory phase 2 study of TAS-115, a novel oral multikinase inhibitor, in patients with idiopathic pulmonary fibrosis. Respir Investig 61(4):498-507, 2023.

Mitsuhashi A, Koyama K, Ogino H, Afroj T, Nguyen NT, Yoneda H, Otsuka K, Sugimoto M, Kondoh O, Nokihara H, Hanibuchi M, Takizawa H, Shinohara T, Nishioka Y. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Rep 42(3):112162, 2023.

Hanibuchi M, Mitsuhashi A, Saijo A, Kajimoto T, Sato S, Kitagawa T, Nishioka Y. A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist. J Med Invest 70(1,2):281-284, 2023.

Nguyen N, Mitsuhashi A, Ogino H, Kozai H, Yoneda H, Afroj T, Sato S, Nokihara H, Shinohara, T, Nishioka Y. S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor. Cancer Sci 114(2):384-398, 2023.

Kuwana M, Bando M, Kawahito Y, Sato S, Suda T, Kondoh Y; CTD-ILD Delphi Collaborators (Nishioka Y). Identification and management of connective tissue disease-associated interstitial lung disease:evidence-based Japanese consensus statements. Expert Rev Respir Med 17(1):71-80, 2023.

Azuma M, Oishi K, Akeda Y, Morino S, Motoki Y, Hanibuchi M, Nishioka Y. Safety and immunogenicity of the sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naive adults † 65 years of age: the comparison of booster effects by intervals of 0.5 year and 1.0 year. Vaccine 41(5):1042-1049, 2023.

Okuda R, Ogura T, Hisata S, Baba T, Kondoh Y, Suda T, Johkoh T, Iwasawa T, Tomioka H, Bando M, Azuma A, Inoue Y, Arai T, Nakamura Y, Miyamoto A, Miyazaki Y, Chiba H, Ishii H, Hamada N, Terasaki Y, Kuwahira I, Sato S, Kato S, Suzuki T, Sakamoto S, Nishioka Y, Hattori N, Hashimoto N, Morita S, Ichihara N, Miyata H, Hagiwara K, Nukiwa T, Kobayashi K. Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry. Respir Investig 61(1):95-102, 2023.

Hanibuchi M, Mitsuhashi A, Kajimoto T, Saijo A, Sato S, Kitagawa T, Nishioka Y. Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma. Respir Investig 61(1):16-22, 2023.

Ichihara S, Ogino H, Yoneda H, Haji K, Kagawa K, Murakami K, Mima M, Aoi Y, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Nokihara H, Nishioka Y. Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody. Respir Med Case Rep 41:101797, 2023.

Numasaki M, Ito K, Takagi K, Nagashima K, Notsuda H, Ogino H, Ando R, Tomioka Y, Suzuki T, Okada Y, Nishioka Y, Unno M. Diverse and divergent functions of IL-32ƒÀ and IL-32ƒÁ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8. Cell Immunol 383:104652, 2023.
y˜a•¶’˜‘z
²“¡³‘å, ¼‰ªˆÀ•F. is«üˆÛ‰»‚𔺂¤ŠÔŽ¿«”xŽ¾Š³‚Ìf’f‚ÆŽ¡—Ã. ŒÄ‹zŠíŽ¾Š³ÅV‚ÌŽ¡—Ã2023-2024, Œ·ŠÔº•F, ¼‰ªˆÀ•F, –˜a”Ž•ÒW, pp31-34, 2023, “ì]“°.

¼‰ªˆÀ•F. “Á”­«”xüˆÛÇ. ¡“ú‚ÌŽ¡—ÃŽwj2023”N”Å, •ŸˆäŽŸ–î, ‚–ؽ, ¬Žºˆê¬ ‘•ÒW, pp309-311, 2023, ˆãŠw‘‰@.
y˜a•¶‘àz
²“¡³‘å, ‘ºãsl, ¼‰ªˆÀ•F. ”xüˆÛÇ‚É‚¨‚¯‚éfibrocyte‚Ì–ðŠ„. ŒÄ‹zŠí“à‰È 44(3):336-341, 2023.

ŽO‹´“ÕŽu, ¼‰ªˆÀ•F. 1×–E‰ðÍ‚É‚æ‚éŽîᇓàfibrocyte‚Ì“¯’è. ×–E 55(7):55-59, 2023.

²“¡³‘å, ¼‰ªˆÀ•F. PF-ILD‚ÆRüˆÛ‰»–ò‚ɂ‚¢‚Ä. “ú–{—Õଠ81(5):764-770, 2023.

¼‰ªˆÀ•F, ²“¡³‘å. “Á”­«ŠÔŽ¿«”x‰ŠiIIPsjE”xüˆÛÇ. “ú–{ˆãŽ–V•ñ 5157:42-43, 2023.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Atsushi Mitsuhashi, Kazuya Koyama, Tania Afroj, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. The identification and analysis of fibrocyte regulating the tumor immune microenvironment. The 9th Joint Meeting 2023 (Tokushima Univ., Gifu Univ., SNU, and IBS-KAIST). Daejeon, South Korea. 2023”N10ŒŽ25“ú.

Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, NandinErdene Danzan, Hiroki Bando, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Eiji Hara, Yasuhiko Nishioka. A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ12“ú.

Hiroki Bando, Seidai Sato, Hirohisa Ogawa, Kazuya Koyama, Kojin Murakami, Yuya Yamashita, Nandin-Erdene Danzan, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. Anamorelin, a ghrelin receptor agonist, inhibited the allergic airway inflammation in mice. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ10“ú.

Yasuhiro Kondoh, Taiki Furukawa, Ryo Teramachi, Hironao Hozumi, Takafumi Suda, Tomoyuki Fujisawa, Ryoko Egashira, Takeshi Johkoh, Junya Fukuoka, Masataka Kuwana, Takashi Ogura, Yasunari Miyazaki, Masashi Bando, Yoshikazu Inoue, Hiromi Tomioka, Yasuhiko Nishioka, Hirofumi Chiba, Masahito Ebina, Kazuya Ichikado, Naozumi Hashimoto, Makoto Ishii. Diagnostic Criteria Arrangement in Nationwide All ILD Registry with Central MDD in Japan; PROMISE study. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ10“ú.

Taiki Furukawa, Yasuhiro Kondoh, Shintaro Oyama, Ryo Teramachi, Hironao Hozumi, Takafumi Suda, Tomoyuki Fujisawa, Ryoko Egashira, Takeshi Johkoh, Junya Fukuoka, Kensuke Kataoka, Hideya Kitamura, Osamu Nishiyama, Masaki Okamoto, Naoki Koshimizu, Nobuhisa Ishikawa, Satoshi Okamori, Yasunari Miyazaki, Masashi Bando, Yoshikazu Inoue, Takashi Ogura, Masataka Kuwana, Hiromi Tomioka, Yasuhiko Nishioka, Hirofumi Chiba, Masahito Ebina, Kazuya Ichikado, Yoichi Nakanishi, Naozumi Hashimoto, Yoshimune Shiratori, Yoshinori Hasegawa, Makoto Ishii: The Providing Multidisciplinary Ild Diagnoses [promise] Study Group. Nationwide All ILD registry with central MDD in Japan; Providing Multidisciplinary ILD diagnoses (PROMISE) study. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ10“ú.

Kojin Murakami, Haruka Nishimura, Hiroshi Kawano, Nandin-Erdene Danzan, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kazuya Koyama, Seidai Sato, Yasuhiko Nishioka. Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model. ATS 2023. Washington, DC, USA. 2023”N5ŒŽ21“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ŽO‹´“ÕŽu, ‰¬–ìL˜a, •Ä“c_l, Œ¬Œ´_, ¼‰ªˆÀ•F. ‹¹•”Žîᇂɂ¨‚¯‚éfibrocyte‚Ì“¯’è‚ÆV‹KŽ¡—ÕW“I‚Æ‚µ‚Ä‚Ì“WŠJ. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ[ƒNƒVƒ‡ƒbƒv). ç—t. 2023”N11ŒŽ3“ú.

¼‰ªˆÀ•F. “Á”­«Ž÷Ž}ó”xœ‰»Ç. ‘æ3‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). “Œ‹ž. 2023”N9ŒŽ30“ú.

¼‰ªˆÀ•F. ”xüˆÛǂɑ΂·‚镪Žq•W“IŽ¡—Â̊J”­‚ð–ÚŽw‚µ‚Ä`‘BˆöŽq‚©‚ç fibrocyte ‚Ö`. ‘æ3‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï(“Á•Êu‰‰). “Œ‹ž. 2023”N9ŒŽ30“ú.

ŽO‹´“ÕŽu, ¬ŽRˆë–ç, ƒAƒtƒ[ƒY ƒ^ƒjƒA, ¼žŠ“Ö˜Y, ”ò”~—º, ‰¬–ìL˜a, ™–{³“¹, ª“Œ, Œ¬Œ´_, ¼‰ªˆÀ•F. Žîᇓà fibrocyte ‚Ì“¯’è‚ƧŒä‚É‚æ‚éV‹K‚ª‚ñŽ¡—ÊJ”­‚Ö‚Ì‹´“n‚µŒ¤‹†. ‘æ82‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï(“ú–{ŠàŠw‰ï§—ãÜŽóÜu‰‰). ‰¡•l. 2023”N9ŒŽ22“ú.

¼‰ªˆÀ•F. Žîᇔ÷¬ŠÂ‹«‚ÌfibrocyteF‹@”\‰ðÍ‚©‚ç•W“IŽ¡—ÂÖ. ‘æ32‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï(ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[). å‘ä. 2023”N7ŒŽ20“ú.

‰¬–ìL˜a. •¡‡‚ª‚ñ–Ɖu—Ö@‚Ì Up-To-Date. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï(Year in Review). ²‰ê. 2023”N6ŒŽ22“ú.

¡‘qŒ’, ²“¡³‘å, ¼‰ªˆÀ•F. ERS2022‚ÉŽQ‰Á‚µ‚Ä. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•ÊŠé‰æ). “Œ‹ž. 2023”N4ŒŽ28“úD

¼‰ªˆÀ•F. “ú–{ŒÄ‹zŠíŠw‰ï«—ˆŒv‰æˆÏˆõ‰ï•ñ. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•Ê•ñ). “Œ‹ž. 2023”N4ŒŽ28“úD

Yasuhiko Nishioka. Molecular pathogenesis of pulmonary fibrosisFupdate by novel technology. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(International Symposium). “Œ‹ž. 2023”N4ŒŽ28“úD
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
’Ëè—C‹M, ”ò”~—º, ŽO‹´“ÕŽu, ”öè—Ì•F, –—m•½, •Ä“c_l, ‰¬–ìL˜a, û•£¹‹B, ¬ì”Ž‹v, ‘ê‘òGŒõ, ¼‰ªˆÀ•F. ”ñ¬×–E”xŠàÇ—á‚É‚¨‚¯‚éŽîá‡ZüˆÛ×–E‚Ì‘–‰»ˆöŽq‚ÆŽ¾Š³—\Œã‚Æ‚ÌŠÖ˜A«‚ɂ‚¢‚ẲðÍ. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ç—t. 2023”N11ŒŽ4“ú.

’|“à‰hŽ¡, ‰¬–ìL˜a, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, ¼‘º—LŒå, ŽsŒ´¹–ç, š d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨¶, Œ¬Œ´_, ŽÂŒ´•×, ¼‰ªˆÀ•F. DŽ_‹…‘‰Á‚͖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽ¡—ÂðŽó‚¯‚½”ñ¬×–E”xŠàŠ³ŽÒ‚ÌŒø‰Ê—\‘ªƒoƒCƒIƒ}[ƒJ[. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ç—t. 2023”N11ŒŽ3“ú.

‰¬–ìL˜a, ¼”Ž”V, ŽO‹´“ÕŽu, ’Ëè—C‹M, –—m•½, ”öè—Ì•F, •Ä“c_l, û•£¹‹B, Œ¬Œ´_, ¼‰ªˆÀ•F. ƒtƒb‰»ƒsƒŠƒ~ƒWƒ“‚Í‹¹•”Žîᇂ̖ƉuŒ´«×–EŽ€‚ð—U“±‚µ–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŽŠ“K•¹—p–ò‚ƂȂ蓾‚é. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ç—t. 2023”N11ŒŽ3“ú.

”öè—Ì•F, Œ¬Œ´_, ’Ëè—C‹M, –—m•½, ŽO‹´“ÕŽu, •Ä“c_l, ‰¬–ìL˜a, ¼‰ªˆÀ•F. i“WŒ^¬×–E”xŠà‚É‚¨‚¢‚Ä2ŽŸŽ¡—ªŽó‚¯‚ç‚ê‚È‚¢Š³ŽÒ‚Ì—Õ°“I”wŒi‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ç—t. 2023”N11ŒŽ3“ú.

²“¡³‘å, û•£¹‹B, ŽO‹´“ÕŽu, ¼‰ªˆÀ•F. ŠPšb‘§Ž¡—Âɂ¨‚¯‚éŒø‰Ê—\‘ªƒoƒCƒIƒ}[ƒJ[‚Ì’Tõ. ‘æ72‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. “Œ‹ž. 2023”N10ŒŽ21“ú.

â“ŒOŠî, ²“¡³‘å, ‘ºãsl, ŽR‰º—Y–ç, “à“¡L“ñ, ¬ŽRˆë–ç, ‰Í–ìO, ¬ì”Ž‹v, ¼‰ªˆÀ•F. ƒOƒŒƒŠƒ“Žó—e‘Ìì“®–òƒAƒiƒ‚ƒŒƒŠƒ“‚̃AƒŒƒ‹ƒM[«‹C“¹‰ŠÇƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ72‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. “Œ‹ž. 2023”N10ŒŽ20“ú.

¬ì”Ž‹v, ´…^—SŽq, •½C, â“ŒOŠî, ²“¡³‘å, íŽRKˆê, ¼‰ªˆÀ•F. ƒƒ^ƒ{ƒ[ƒ€‰ðÍ‚É‚æ‚é•¡”RŒ´Š´ìšb‘§ƒ‚ƒfƒ‹‚É‚¨‚¯‚é“«ˆöŽq‚Ì’Tõ. ‘æ72‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. “Œ‹ž. 2023”N10ŒŽ20“ú.

”öè—Ì•F, ¬ì‰l, Œ¬Œ´_, ŽO‹´“ÕŽu, –—m•½, •Ä“c_l, ‰¬–ìL˜a, ¼‰ªˆÀ•F. ALK—Z‡ˆâ“`Žq—z«”ñ¬×–E”xŠà‚ÌŒø‰Ê—\‘ªˆöŽq‚ÉŠÖ‚·‚錟“¢. ‘æ61‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‰¡•l. 2023”N10ŒŽ19“ú.

²“¡³‘å, ¬ì”Ž‹v, ‘ºãsl, ŽR‰º—Y–ç, “yŽtŒbŽq, ‰Í–ìO, Œ´‰p“ñ, ¼‰ªˆÀ•F. BRD4 ‘jŠQÜ ARV825 ‚ÌüˆÛ‰»ŠÖ˜Aˆâ“`Žq‚Ì”­Œ»—}§‚ƘV‰»×–Eœ‹Ž‚ð‰î‚µ‚½RüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ3‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï. “Œ‹ž. 2023”N9ŒŽ30“ú.

“yŽtŒbŽq, ²“¡³‘å, ¬ì”Ž‹v, ‘ºãsl, ŽR‰º—Y–ç, ¬ŽRˆë–ç, ‰Í–ìO, ¬—ÑŽ—˜, ”¯r˜Y, ¼‰ªˆÀ•F. ƒI[ƒgƒ^ƒLƒVƒ“‘jŠQì—p‚ð—L‚·‚é 2ccPA ‚Ì”xüˆÛÇ‚É‚¨‚¯‚é—LŒø«‚ÌŒŸ“¢. ‘æ3‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï. “Œ‹ž. 2023”N9ŒŽ30“ú.

–—m•½, ŽO‹´“ÕŽu, ‰¬–ìL˜a, Na T. Nguyen, •Ä“c_l, ”öè—Ì•F, ’Ëè—C‹M, û•£¹‹B, Œ¬Œ´_, ¼‰ªˆÀ•F. HIF1A ‘jŠQ‚É‚æ‚éŽîá‡×–E—R—ˆ CXCL10/11 §Œä‚ð‰î‚µ‚½R PDL1 R‘Ì‚Ö‚Ì‘Ï«Ž•ž. ‘æ82‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2023”N9ŒŽ22“ú.

ŽO‹´“ÕŽu, ¬ŽRˆë–ç, ‰¬–ìL˜a, ™–{³“¹, ª“Œ, Œ¬Œ´_, ¼‰ªˆÀ•F. Žîᇓà fibrocyte —V‘–E•ª‰»§Œä‚ª‚à‚½‚ç‚·ŽîᇖƉu”÷¬ŠÂ‹«‚ւ̉e‹¿. ‘æ82‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2023”N9ŒŽ22“ú.

‰¬–ìL˜a, Nguyen Na Thi, ¼”Ž”V, ŽO‹´“ÕŽu, ’Ëú±—C‹M, –—m•½, ”öè—Ì•F, •Ä“c_l, û•£¹‹B, ¼‰ªˆÀ•F. ‹¹•”ˆ««Žîᇂɂ¨‚¢‚ĖƉuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Æ•¹—p‚·‚ׂ«ŽŠ“KŽE×–E«R‚ª‚ñÜ‚Ì“¯’è‚ð–ÚŽw‚µ‚½–ƉuŠw“I‰ðÍ. ‘æ27‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘‰ï. ŽOd. 2023”N7ŒŽ21“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, Nguyen Na Thi, –—m•½, •Ä“c_l, ™–{³“¹, ª“Œ, Œ¬Œ´_, ¼‰ªˆÀ•F. Žîᇓàfibrocyte‚Ì“¯’è‚Æ‹@”\§Œä‚É‚æ‚éV‹K•¡‡‚ª‚ñ–Ɖu—Ö@‚ÌŠJ”­. ‘æ32‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. å‘ä. 2023”N7ŒŽ21“ú.

•Ä“c_l, ŽO‹´“ÕŽu, ‰¬–ìL˜a, Œ¬Œ´_, ˆ¢•”^Ž¡, ‹àŽq”ü‰Ø, ‰Á“¡K¬, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚¨‚æ‚ÑRCTLA-4R‘Ì‚É‚æ‚é•¡‡‚ª‚ñ–Ɖu—Ö@‚ÌŒŸ“¢. ‘æ32‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. å‘ä. 2023”N7ŒŽ20“ú.

’Ëè—C‹M, ŽO‹´“ÕŽu, ”öè—Ì•F, –—m•½, •Ä“c_l, ‰¬–ìL˜aA¼‰ªˆÀ•F. ”xŠà‚É‚¨‚¯‚éŽîá‡ZüˆÛ×–E‚Ì‘–‰»ˆöŽq‚Æ‚»‚ÌŽ¾Š³—\Œã‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚ẲðÍ. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ²‰ê. 2023”N6ŒŽ23“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, Nguyen Na Thi, •Ä“c_l, –—m•½, ™–{³“¹, ª“Œ, Œ¬Œ´_, ¼‰ªˆÀ•F. Fibrocyte ‚Ì•ª‰»§Œä‚É‚æ‚é•¡‡‚ª‚ñ–Ɖu—Ö@‚Ö‚Ì“WŠJ. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ²‰ê. 2023”N6ŒŽ22“ú.

–—m•½, ŽO‹´“ÕŽu, Nguyen Na Thi, ‰¬–ìL˜a, •Ä“c_l, ”öè—Ì•F, ¼‰ªˆÀ•F. IFN-g ”½‰ž«ƒPƒ‚ƒJƒCƒ“ŽY¶§Œä‹@˜‚̉𖾂ÆV‹K•¡‡‚ª‚ñ–Ɖu—Ö@‚ւ̉ž—p. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ²‰ê. 2023”N6ŒŽ22“ú.

‹g“c•Él, ‰Á“¡K¬, ¼‰ªˆÀ•F, ˆ¢•”^Ž¡. ‚ª‚ñ“ÁˆÙ“IR podoplanin R‘Ì chLpMab-2 ‚̃RƒAƒtƒR[ƒXœ‹Ž‚É”º‚¤ ADCC ‘‹­‚ÆNK ×–EŠˆ«‰»‚ÉŠÖ‚·‚錟“¢. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ²‰ê. 2023”N6ŒŽ22“ú.

â“ŒOŠî, ²“¡³‘å, ‘ºãsl, ŽR‰º—Y–ç, “à“¡Lm, ¬ŽRˆë–ç, ‰Í–ìO, ¬ì”Ž‹v, ¼‰ªˆÀ•F. ƒOƒŒƒŠƒ“Žó—e‘Ìì“®–òƒAƒiƒ‚ƒŒƒŠƒ“‚̃AƒŒƒ‹ƒM[«‹C“¹‰ŠÇƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ30“ú.

²“¡³‘å, û•£¹‹B, ŽO‹´“ÕŽu, ¼‰ªˆÀ•F. ŠPšb‘§‚É‚¨‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘f‚ÆŒŒ´ƒyƒŠƒIƒXƒ`ƒ“‚Ì—Õ°“IˆÓ‹`‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ30“ú.

û•£¹‹B, ŽO‹´“ÕŽu, ¼žŠ“Ö˜Y, ²“¡³‘å, ¼‰ªˆÀ•F. ƒXƒNƒŠ[ƒjƒ“ƒOŽ¿–â•[‚ð—p‚¢‚½COPDŒŸfƒVƒXƒeƒ€‚Ì—L—p«‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ30“ú.

‘ºãsl, ²“¡³‘å, ŽR‰º—Y–ç, “yŽtŒbŽq, â“ŒOŠî, “à“¡Lm, ¬ŽRˆë–ç, ‰Í–ìO, ˆî‘º“Tº, ˜@Œ©œ¨Ži, ¼‰ªˆÀ•F. V‹K‰Â—n«ƒGƒ|ƒLƒVƒqƒhƒƒ‰[ƒ[‘jŠQ–òSMTP-44D‚Ì”xüˆÛǂɑ΂·‚é—LŒø«‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ29“ú.

ˆ¢•”‚ ‚©‚Ë, “Œ“‘ã, ò˜ÐŠó, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éClostridioides difficileŒŸ¸‚ɑ΂·‚éDiagnostic stewardship‚ÌŽæ‚è‘g‚Ý‚ÌŒo‰ß•ñ. ‘æ97‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ï. ‰¡•l. 2023”N4ŒŽ29“ú.

¼‰ªˆÀ•F, T M Maher, R G Jenkins, F Bonella, S Assassi, C Diefenbach, C Ittrich, K B Rohr, M Kolb. PF-ILDŠ³ŽÒ‚ÌzŠÂƒoƒCƒIƒ}[ƒJ[‚ւ̃jƒ“ƒeƒ_ƒjƒu‚̉e‹¿. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ28“ú.

‰Í–ìO, ¬˜H‹Mr, ˆÀ‘Ž, ‘ºãsl, ŽR‰º—Y–ç, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. ƒŠƒ“ƒp‹…“ÁˆÙ“Iƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ–òA-770041‚ͧŒä«T×–E‚É‚æ‚éTGF-ƒÀsŽY¶—}§‚ð‰î‚µ‚Ä”xüˆÛÇ‚ð‰ü‘P‚·‚é. ‘æ67‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. •Ÿ‰ª. 2023”N4ŒŽ26“úD

‰¬–ìL˜a, ”öè—Ì•F, ‘åúœŒ›Ži, ŽO‹´“ÕŽu, ’Ëú±—C‹M, –—m•½, •Ä“c_l, Œ¬Œ´_, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‚ð‡•¹‚·‚éisŠú”xŠà‚ɑ΂·‚é“ñŽŸ‰»Šw—Ö@‚Ì—LŒø«‚¨‚æ‚шÀ‘S«‚ÉŠÖ‚·‚錟“¢. ‘æ120‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ16“ú.

Yuki Tsukazaki, Ei Ogawa, Hiroshi Nokihara, Atsushi Mitsuhashi, Kensuke Kondo, Youhei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka. The prognostic factors for the efficacy of anaplastic lymphoma kinase inhibitors in non-small cell lung cancer. ‘æ20‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. •Ÿ‰ªD2023”N3ŒŽ18“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tukazaki, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka. Clinical factors of not receiving second-line chemotherapy in ED-SCLC patients. ‘æ20‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. •Ÿ‰ªD2023”N3ŒŽ18“ú.

Hirokazu Ogino, Kensuke Kondo, Atsushi Mitsuhashi, Yuki Tsukazaki, Ryohiko Ozaki, Yohei Yabuki , Hiroto Yoneda, Hiroshi Nokihara, Yasuhiko Nishioka. The novel prognostic system for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. ‘æ20‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. •Ÿ‰ªD2023”N3ŒŽ17“ú.

²“¡³‘å, ŽR–{‘ìŽu, ¼‰ªˆÀ•F. ƒCƒ[ƒWƒ“ƒOŽ¿—ÊŒ°”÷‹¾iMScope TRIO‚É‚æ‚éRüˆÛ‰»–ò‚ÌüˆÛ«”x‘gD“à‹ÇÝ•ª•z‚ÌŒŸ“¢. ‘æ14‰ñŒÄ‹z‹@”\ƒCƒ[ƒWƒ“ƒOŒ¤‹†‰ïŠwpW‰ï. ŽD–y. 2023”N1ŒŽ27“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
—é]—ÁŽq, â“ŒOŠî, “yŽtŒbŽq, ”öè—Ì•F, •Ä“c_l, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. R‰¡–ä‹ØR‘Ì—z«‚ÌdÇirAE‹Ø‰ŠES‹Ø‰Š‚ɑ΂µ‚Ä‘Šú‚ÌWŠw“IŽ¡—ª‘tŒø‚µ‚½”xG•½ã”çŠà‚Ì1—á. ‘æ69‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

Ž›àV‰, â“ŒOŠî, “yŽtŒbŽq, •Ä“c_l, ‰¬–ìL˜a, ‰ª“c’¼Žq, ì’†’, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ƒyƒvƒ`ƒhŽó—e‘Ì•úŽË«ŠjŽí—Ö@‚ª‘tŒø‚µ‚½¶‰º—tŒ´”­isŠú”ñ’èŒ^ƒJƒ‹ƒ`ƒmƒCƒh‚Ì1—á. ‘æ69‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

ˆä—D, â“ŒOŠî, “yŽtŒbŽq, ‚‹´Œ[‹P, •Ä“c_l, ˆ¢•”‚ ‚©‚Ë, ²“¡³‘å, “Œ“‘ã, û•£¹‹B, ¼‰ªˆÀ•F. ‹CŠÇŽx‹¾ŒŸ¸‚Åf’f‚µ‚½COVID-19ŠÖ˜A”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì‚P—á. ‘æ32‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

’†¼Œk‰î, â“ŒOŠî, “yŽtŒbŽq, ¬‘q—Sˆê˜Y, ”ü”n³l, “à“¡L“ñ, ˆ¢•”‚ ‚©‚Ë, ì^“cƒ, ™‰YG—S, ²“¡³‘å, “Œ“‘ã, û•£¹‹B, ¼—Ç_ˆê, ¼‰ªˆÀ•F. Œ‹Šj«Ò’ʼnŠ‚ÌŽ¡—Ã’†‚Éparadoxical response‚Æ‚µ‚Ĕ牺”^ᇂªoŒ»‚µ‚½‚P—á. ‘æ74 ‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

‹{–{Œ›Æ, û•£¹‹B, â“ŒOŠî. •Ä“c_l. ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. ‹CŠÇŽx‹¾Œã‚̌ċzŠíŠ´õǂ̃ŠƒXƒNˆöŽq‚¨‚æ‚Ñ—\–h“IR‹Û–ò“Š—^‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ32‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. “¿“‡. 2023”N12ŒŽ16“ú.

ˆé‘º—S‘¾, â“ŒOŠî, “yŽtŒbŽq, “à“¡Lm, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ˆ««ƒŠƒ“ƒpŽî‚ÌŽ¡—ÃŒo‰ß’†‚É”­Ç‚µ‚½ƒÀ-DƒOƒ‹ƒJƒ“‰A«ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ì1—á.‘æ129‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼. 2023”N12ŒŽ2“ú.

ŽR–{_¶, â“ŒOŠî, “yŽtŒbŽq, ŽR‰º—Y–ç, “à“¡Lm, ²“¡³‘å, ‰Í–ìO, û•£¹‹B, ¼‰ªˆÀ•F. ƒXƒeƒƒCƒh’ïR«‚Ì‹C“¹•a•Ï‚ɑ΂µ‚ăVƒNƒƒzƒXƒtƒ@ƒ~ƒh‚ª’˜Œø‚µ‚½Ä”­«‘½”­“Š‚Ì‚P—á. ‘æ129‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼. 2023”N12ŒŽ2“ú.

‰Í–ìO, ˆä—D, ˆÀ‘Ž, ‘ºãsl, ŽR‰º—Y–ç, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. Œ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚Ìf’fŽž‚ÉEBV‚ÌÄŠˆ«‰»‚ð’悵AƒŠƒcƒLƒVƒ}ƒu‚É‚ÄŠ°‰ð“±“ü—Ö@‚ðs‚Á‚½1—á. ‘æ34‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰ªŽR. 2023”N12ŒŽ2“ú.

ˆä—D, ‰Í–ìO, ˆÀ‘Ž, ‘ºãsl, ŽR‰º—Y–ç, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. ‹¹–Œ‰ŠAŠÔŽ¿«”xŽ¾Š³‚ðæs‚µA”­”M«D’†‹…Œ¸­Ç‚Æ”x•a•Ï‚Ì‘ˆ«‚Å”­Ç‚µ‚½SLE‚Ì1—á. ‘æ34‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰ªŽR. 2023”N12ŒŽ2“ú.

Œ´“cŽÑŠó, â“ŒOŠî, “yŽtŒbŽq, “à“¡Lm, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¢‚ÄŠO‰ÈŽ¡—ÂðŽ{s‚µ‚½”xMycobacterium avium complex‚ÌŒŸ“¢. ‘æ267‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2023”N8ŒŽ20“ú.

Ž›àV‰Câ“ŒOŠîC“yŽtŒbŽqC¬˜H‹MrC•Ä“c_lC²“¡³‘åC‰Í–ìOCû•£¹‹BC¼‰ªˆÀ•F. ƒVƒNƒƒXƒ|ƒŠƒ“‚ª—LŒø‚Å‚ ‚Á‚½ŒŒ´IL-18‚’l‚ÌdǬl”­ÇƒXƒeƒBƒ‹•a‚Ì1—á. ‘æ128‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2023”N7ŒŽ23“ú.

’†¼Œk‰îCâ“ŒOŠîC“yŽtŒbŽqC¼‘º—LŒåCˆî—tDC•Ä“c_lC‰¬–ìL˜aC²“¡³‘åCû•£¹‹BC¼‰ªˆÀ•F. Carboplatin+etoposide‚â•úŽËüŽ¡—Âɕs‰ž‚ànab-paclitaxel‚ª‘tŒø‚µ‚½”xŒ´”­‘å×–E_Œo“à•ª”åŠà‚Ì1—á. ‘æ128‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2023”N7ŒŽ23“ú.

ŽR–{_¶, â“ŒOŠî, “yŽtŒbŽq, š d“¹‘å, Š–{’B–ç, ¬ŽRˆë–ç, ìk‘¢, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. Ž©‘RŒo‰ß‚Å”X–E«‰æ‘œ•Ï‰»‚¨‚æ‚ьċz‹@”\‚̉ü‘P‚ð”F‚ß‚½dÇCOVID-19‚Ì1—á. ‘æ68‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‚¼. 2023”N7ŒŽ15“úD

‘½“c—¢•ä, â“ŒOŠî, “yŽtŒbŽq, V‹D, •Ä“c_l, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. RPD-L1R‘Ì“Š—^‚É‚æ‚èŽîᇔº«¬”]•Ï«Ç‚ªŒ°Ý‰»‚µ‚½¬×–E”xŠà‚Ì1—á. ‘æ61‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‚¼. 2023”N7ŒŽ15“úD

‰““¡—T”ü, â“ŒOŠî, “yŽtŒbŽq, ‚‹´Œ[‹P, •Ä“c_l, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. •ïŠ‡“IƒQƒmƒ€ƒvƒƒtƒ@ƒCƒŠƒ“ƒO‚É‚æ‚èf’f‚µ“¾‚½EGFR Exon19Œ‡Ž¸•ÏˆÙ—z«”x‘BŠà‚Ì1—á. ‘æ61‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‚¼. 2023”N7ŒŽ15“úD
£ƒy[ƒW‚ÌTOP‚Ö
2022”N‹ÆÑ
y‰¢•¶Œ´’˜z
Hanibuchi M, Saijo A, Mitsuhashi A, Kajimoto T, Kitagawa T, Nishioka Y. The efficacy of mass screening for chronic obstructive pulmonary disease by using screening questionnaires in a medical health check-up population. Respir Investig 60(6):815-821, 2022.

Ogura T, Suda T, Inase N, Nishioka Y, Azuma A, Okamoto M, Takizawa A, Ito T, Rohr KB, Inoue Y. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. Respir Investig 60(6):787-797, 2022.

Otsuka K, Nokihara H, Mitsuhashi A, Ozaki R, Yabuki Y, Yoneda H, Ogino H, Nishioka Y. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease. Thorac Cancer 13(21):2978-2984, 2022.

Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-center, randomized controlled trial. Rheumatology (Oxford) 61(11):4445-4454, 2022.

Kagawa K, Sato S, Koyama K, Imakura T, Murakami K, Yamashita Y, Naito N, Ogawa H, Kawano H, Nishioka Y. The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-ƒÀ production in regulatory T-cells. PLOS ONE 17(10):e0275987, 2022.

Nishioka Y, Toyoda Y, Egashira R, Johkoh T, Terasaki Y, Hebisawa A, Abe K, Baba T, Fujikura Y, Fujita E, Hamada N, Handa T, Hasegawa Y, Hidaka K, Hisada T, Hisata S, Honjo C, Ichikado K, Inoue Y, Izumi S, Kato M, Kishimoto T, Okamoto M, Miki K, Mineshita M, Nakamura Y, Sakamoto S, Sano M, Tsukada Y, Yamasue M, Bando Y, Homma S, Hagiwara K, Suda T, Inase N. Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype. BMJ Open Respir Res 9(1):e001337, 2022.

Tobiume M, Mitsuhashi A, Saijo A, Ogino H, Afroj T, Ogawa H, Goto H, Sato S, Abe A, Haji K, Ozaki R, Takizawa H, Nishioka Y. Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer. Oncol Lett 24(5):417, 2022.

Goto Y, Tamura A, Matsumoto H, Isobe K, Ozaki T, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Nokihara H. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan. JTO Clin Res Rep3(9):100397, 2022.

Ueno Y, Harada S, Sato K, Momota K, Sato H, Akimoto Y, Arai Y, Nunomura T, Ishihara M, Tane N, Itagaki T, Nishioka Y, Oto J. Independent lung ventilation for the management of acute allograft rejection after single-lung transplantation for end-stage emphysema. J Med Invest 69(3.4):323-327, 2022.

Tanaka T, Koyama K, Takahashi N, Morito K, Ali H, Azuma M, Kagawa K, Kawano H, Has RY, Aihara M, Nishioka Y. Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiopathic pulmonary fibrosis. J Med Invest 69(3.4):196-203, 2022.

Nokihara H, Kijima T, Yokoyama T, Kagamu H, Suzuki T, Mori M, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Goto Y. Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan. Cancers (Basel)14(12):2846, 2022.

Kako J, Kobayashi M, Kajiwara K, Kimura Y, Oosono Y, Takegata M, Nakano K, Matsuda Y, Nakamura N, Kawashima N, Hirano Y, Kitae M, Yamaguchi K, Iwamoto H, Hattori N, Sawatari H, Shiono S, Ogino H, Nishioka Y, Amano K, Yorke J. Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients With Lung Cancer. J Pain Symptom Manage 64(2):e83-e89, 2022.

Ogawa H, Azuma M, Umeno A, Shimizu M, Murotomi K, Yoshida Y, Nishioka Y, Tsuneyama K. Singlet oxygen -derived nerve growth factor exacerbates airway hyperresponsiveness in a mouse model of asthma with mixed inflammation. Allergol Int 71:395-404, 2022.

Nokihara H, Ogino H, Mitsuhashi A, Kondo K, Ogawa E, Ozaki R, Yabuki Y, Yoneda H, Otsuka K, Nishioka Y. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. BMC Cancer 22(1):597, 2022.

Yoshioka T, Daizumoto K, Tada K, Mima M, Kagawa K, Fukawa T, Yamaguchi K, Takahashi M, Nishioka Y, Kanayama H. Retroperitoneal hemorrhage in a patient with coronavirus disease 2019 (COVID-19):A case report. J Med Invest 69(1.2):148-151, 2022.

Sakurada T, Nokihara H, Koga T, Zamami Y, Goda M, Yagi K, Hamano H, Aizawa F, Ogino H, Sato S, Kirino Y, Goto H, Nishioka Y, Ishizawa K. Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study. Oncologist 27(7):e554-e560, 2022.

Nishijima H, Sugita M, Umezawa N, Kimura N, Sasaki H, Kawano H, Nishioka Y, Matsumoto M, Oya T, Tsuneyama K, Morimoto J, Matsumoto M. Development of organ-specific autoimmunity by dysregulated Aire expression. Immunol Cell Biol 100(5):371-377, 2022.

Morita Y, Saijo A, Nokihara H, Mitsuhashi A, Yoneda H, Otsuka K, Ogino H, Bando Y, Nishioka Y. Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer. Thorac Cancer 13(7):1079-1082, 2022.

Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco M, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim-Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas. J Clin Invest 132(3):e151239, 2022.

Enomoto N, Homma S, Inase N, Kondoh Y, Saraya T, Takizawa H, Inoue Y, Ishii H, Taguchi Y, Izumi S, Yamano Y, Tanino Y, Nishioka Y, Toyoshima M, Yokomura K, Imokawa S, Koshimizu N, Sano T, Akamatsu T, Mukae H, Kato M, Hamada N, Chiba H, Akagawa S, Muro S, Uruga H, Matsuda H, Kaida Y, Kanai M, Mori K, Masuda M, Hozumi H, Fujisawa T, Nakamura Y, Ogawa N, Suda T. Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax 77(2):143-153, 2022.

Sako M, Nokihara H, Kondo K, Mitsuhashi A, Ozaki R, Yabuki Y, Abe A, Yoneda H, Ogino H, Otsuka K, Uehara H, Nishioka Y. A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab. Thorac Cancer 13(1):129-132, 2022.

Ogino H, Tobiume M, Kagawa K, Kawano H, Sakaguchi S, Saijo A, Matsumoto D, Takizawa H, Morikawa Y, Bando Y, Goto H, Nokihara H, Nishioka Y. A case of radiation-associated angiosarcoma presenting as a massive pleural effusion. Intern Med 61(9):1393-1397, 2022.

Imakura T, Sato S, Tomonari T, Murakami K, Takahashi N, Naito N, Mima M, Kagawa K, Koyama K, Nishimura H, Kawano H, Nokihara H, Azuma M, Takayama T, Nishioka Y. A case of lenvatinib-induced interstitial pneumonia in a patient with hepatocellular carcinoma. Intern Med 61(8):1211-1217, 2022.

Sebe M, Tsutsumi R, Senoura S, Kishi J, Iuchi M, Mishima Y, Tsutsumi Y, Kuroda M, Harada N, Nakaya Y, Kinoshita S, Nishioka Y, Sakaue H. Saturated fatty acids intake is associated with muscle atrophy in rheumatoid arthritis. JCSM Rapid Commun 5:86-101, 2022.
y˜a•¶’˜‘z
‰¬–ìL˜a, Œ¬Œ´_. CBDCA+nab-PTX/S-1. ”xŠà–ò•¨—Ö@ƒŒƒWƒƒ“ Expert's Choice, ‘q“c•ó•ÛE‹g‰ªO’Á•ÒWFpp87-90, 2022, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ.

¼‰ªˆÀ•F. ŒÄ‹zŠíŽ¾Š³‚̃oƒCƒIƒ}[ƒJ[D“à‰ÈŠwi‘æ12”Åj‡UFpp353-355C2022, ’©‘q‘“X.
y˜a•¶‘àz
–L“c—DŽq, ¼‰ªˆÀ•F. ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX. ŒÄ‹zŠí“à‰È 42(6):616-621, 2022.

¼‰ªˆÀ•F, ‘ºãsl, ¬ŽRˆë–ç, ²“¡³‘å. ”xüˆÛ‰»‹@˜. “ú–{—Õଠ80(9):1351-1355, 2022.

‘ºãsl, ¼‰ªˆÀ•F. ‚Ñ‚Ü‚ñ«”xŽ¾Š³‚Ì•a‘Ô‚©‚çlŽ@‚·‚éMDDf’f‚Ìd—v«‚ɂ‚¢‚Ä. ŒÄ‹zŠí“à‰È 42(2):142-148, 2022.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Kazuya Koyama, Seidai Sato, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa, Yasuhiko Nishioka. Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis. APSR 2022. Seoul, Korea. 2022”N11ŒŽ19“ú.

Yohei Yabuki, Kenji Otsuka, Hirokazu Ogino, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Masaki Hanibuchi, Atsushi Mitsuhashi, Yuki Tsukazaki, Ryohiko Ozaki, Hiroto Yoneda, Hiroshi Nokihara, Yasuhiko Nisihioka. A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer. APSR 2022. Seoul, Korea. 2022”N11ŒŽ19“ú.

Takeshi Imakura, Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka. Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis. ERS International Congress 2022. Barcelona, Spain. 2022”N9ŒŽ5“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Youhei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yasuhiko Nishioka. The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease. ERS International Congress 2022. Barcelona, Spain. 2022”N9ŒŽ4“ú.

Ryo Okuda, Takahi Ogura, Nobuhisa Ishikawa, Takafumi Suda, Naoki Arai, Takahisa Takihara, Megumi Hamaguchi, Yasuhiro Kondoh, Mikio Toyoshima, Keisuke Tomii, Mitsuhiro Abe, Motoyasu Kato, Michiko Kagajo, Yasuo Shimizu, Hiromi Tomioka, Kodai Kawamura, Kojiro Honda, Yasuhiko Nishioka, Motoaki Tanigawa, Hiroshi Chiba, Shinyu Izumi, Kazunori Tobino, Hiroyoshi Yamauchi, Tetsuharu Kawamura, Minoru Inomata, Kazuhiro Usui, Hirotsugu Ohkubo, Hidekaze Matsushima, Yoshitaka Oyamada, Takeshi Jokoh, Toru Arai, Tae Iwasawa, Fumikazu Sakai, Satoshi Morita, Naoaki Ichihara, Toshihiro Nukiwa, Kunihiko Kobayashi, Jips Registry Members. Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression. ERS International Congress 2022. Barcelona, Spain. 2022”N9ŒŽ4“ú.

Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko. Haji, Kozo Kagawa, Hiroshi Kawano, Eiji Hara, Yasuhiko Nishioka. A Novel Senolytic Agent, ARV-825, Ameliorates Bleomycin-InducedPulmonary Fibrosis in Mice. ATS 2022 International Conference. San Francisco, USA. 2022”N5ŒŽ17“ú.

Takeshi Imakura, Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka. Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis. ATS 2022 International Conference. San Francisco, USA. 2022”N5ŒŽ15“ú.

Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Sato, Hirohisa Ogawa, Yasuhilko Nishioka. Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model. ATS 2022 International Conference. San Francisco, USA. 2022”N5ŒŽ15“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. ‰Šú—Õ°Œ¤CˆãƒZƒ~ƒi[‚ÌÄŠJ‚Æ¡Œã‚̉ۑè. ‘æ67‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï(«—ˆŒv‰æˆÏˆõ‰ï•ñ). ‰ªŽR. 2022”N12ŒŽ16“ú.

û•£¹‹B. ”x‚̶ŠˆKŠµ•a "COPD(–«•ÂÇ«”xŽ¾Š³)". ‘æ9‰ñ“¿“‡ŽsˆãŽt‰ïCOPDŽs–¯ŒöŠJuÀ. ƒP[ƒuƒ‹ƒeƒŒƒr“¿“‡. 2022”N12ŒŽ13,15,20,22“ú.

¼‰ªˆÀ•F. ”xüˆÛǂɑ΂·‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ``PPF‚ɑ΂·‚éRüˆÛ‰»–ò‚ÌŠJ”­‚ÉŒü‚¯‚Ä`. ‘æ122‰ñ“ú–{ŒÄ‹zŠíŠw‰ï“ŒŠC’n•û‰ïi“Á•Êu‰‰j. ’ÃD2022”N11ŒŽ13“úD

Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara, Yasuhika Nishioka. PD-1/PD-L1 blockade mediates antiangiogenic effects by tumorderived CXCL10/11 as a potential predictive biomarker. ‘æ81‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï(Cancer Science Young Scientists Award Lectures). ‰¡•l. 2022”N9ŒŽ30“úD

¼‰ªˆÀ•F. ŠCŠO—¯Šw•¬‹à§“x‚ÌŒ»ó‚Æ–¢—ˆ. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïi“Á•ÊŠé‰æ). ‹ž“s. 2022”N4ŒŽ22“úD
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
¬ì‰l, Œ¬Œ´_, ŽO‹´“ÕŽu, ‹ß“¡Œ’‰î, ’Ëè—C‹M, –—m•½, ”öè—Ì•F, •Ä“c_l, ‰¬–ìL˜a, ¼‰ªˆÀ•F. ALK—Z‡ˆâ“`Žq—z«”ñ¬×–E”xŠà‚ÌŒø‰Ê—\‘ªˆöŽq‚ÉŠÖ‚·‚錟“¢. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. •Ÿ‰ª. 2022”N12ŒŽ2“ú.

–Ñ—˜“Äl, Še–±”Ž, ŽO‰Y—, ¼”ö½l, âV“¡—Ç‘¾, úå’J“TŽq, Œ¬Œ´_, ˆäŒ`•¶•Û, ¼–ì˜a”ü, Œ·ŠÔº•F, ŽOŠpr—T, ŠâàVrˆê˜Y, ’‡ìT‘¾˜Y, Œõ•y“OÆ. ƒAƒeƒ]ƒŠƒYƒ}ƒu‚ÌRŽîᇌø‰Ê‚Æ––½ŒŒT×–Eƒvƒƒtƒ@ƒCƒŠƒ“ƒOF‘½Ž{Ý‹¤“¯‘OŒü‚«ŠÏŽ@Œ¤‹†JTAIL•Œ¤‹†. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. •Ÿ‰ª. 2022”N12ŒŽ2“ú.

Na T. Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara, Yasuhiko Nishioka. Eliminates MDSCs and enhances the efficacy of immune checkpoint inhibitor in thoracic tumors. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. •Ÿ‰ª. 2022”N12ŒŽ1“ú.

Œ¬Œ´_, ‰¬–ìL˜a, ŽO‹´“ÕŽu, ‹ß“¡Œ’‰î, ¬ì‰l, ”öè—Ì•F, –—m•½, •Ä“c_l, ¼‰ªˆÀ•F. ‹¹…‚𔺂¤EGFRˆâ“`Žq•ÏˆÙ—z«”ñ¬×–E”x‚ª‚ñ‚ɑ΂·‚éƒIƒVƒƒ‹ƒ`ƒjƒu‚Ì—LŒø«‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. •Ÿ‰ª. 2022”N12ŒŽ1“ú.

’|“à‰hŽ¡, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, ŽsŒ´¹–ç, š d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨¶, ‰¬–ìL˜a, Œ¬Œ´_, ŽÂŒ´•×, ¼‰ªˆÀ•F. DŽ_‹…‚͖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽ¡—ÂðŽó‚¯‚½”ñ¬×–E”xŠàŠ³ŽÒ‚Ì—\Œã—\‘ªƒoƒCƒIƒ}[ƒJ[. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. •Ÿ‰ª. 2022”N12ŒŽ1“ú.

”öè—Ì•F, Œ¬Œ´_, ’Ëè—C‹M, –—m•½, ŽO‹´“ÕŽu, •Ä“c_l, ‰¬–ì˜aL, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‡•¹i“WŒ^¬×–E”xŠà‚É‚¨‚¯‚é2ŽŸ‰»Šw—Ö@‚Ì—LŒø«‚¨‚æ‚шÀ‘S«‚ɂ‚¢‚Ä. ‘æ60‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. _ŒËD2022”N10ŒŽ20“ú.

“à“¡Lm, ¼‘ºt‰À, ŽR‰º—Y–ç, ‘ºãsl, “yŽtŒbŽq, ¬ŽRˆë–ç, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, û•£¹‹B, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚ð—p‚¢‚½JAK‘jŠQ–ò‚ÌRüˆÛ‰»Œø‰Ê‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ50‰ñ“ú–{—Õ°–ƉuŠw‰ï‘‰ï. “Œ‹ž. 2022”N10ŒŽ13“ú.

¬ì”Ž‹v, ´…^—SŽq, ²“¡³‘å, íŽRKˆê, ¼‰ªˆÀ•F. ƒŠƒ]ƒzƒXƒtƒ@ƒ`ƒWƒ“Ž_iLPAj‚ÍLPA1Žó—e‘Ì‚ð‰î‚µ‚Ä”S‰t×–E‰ßŒ`¬‚ð‘£i‚·‚é. ‘æ71‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. “Œ‹ž(ƒnƒCƒuƒŠƒbƒh) . 2022”N10ŒŽ9“úD

Atsushi Mitsuhashi, Hirokazu Ogino, Masamichi Sugimoto, Hiroshi Nokihara, Yasuhiko Nishioka. Fibrocyte drives antitumor immunity via T cell-costimulation in combination immunotherapy. ‘æ81‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2022”N9ŒŽ30“úD

Hirokazu Ogino, Atsuro Saijo, Yasuhiko Nishioka. Neoadjuvant vaccination with tumor-cell lysate induces CD8 T cell response in low-grade gliomas in randomized trial. ‘æ81‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2022”N9ŒŽ29“úD

Hirokazu Ogino, Jennie Taylor, Takahide Nejo, David Gibson, Payal Watchmaker, Atsuro Saijo, Meghan Tedesco, Jane Rabbitt, Michael Olin, Christopher Moertel, Andres Salazar, Annette Molinaro, Joanna Phillips, Nicholas Butowski, Jennifer Clarke, Philip Theodosopoulos, Susan Chang, Yasuhiko Nishioka, Mitchel Berger, Hideho Okada. Randomized trial of neoadjuvant vaccination with GBM6-AD tumor-cell lysate induces T cell response in low-grade gliomas. ‘æ26‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘‰ï. “‡ª. 2022”N7ŒŽ22“úD

‰¬–ìL˜a, ¼žŠ“Ö˜Y, ¼‰ªˆÀ•F. Žîᇃ‰ƒCƒZ[ƒg‚ð—p‚¢‚½p‘O‚ª‚ñƒƒNƒ`ƒ“—Ö@‚͒ራ«“x_ŒoäPŽî‚É‚¨‚¯‚éT×–E–Ɖu‰ž“š‚ð—U“±‚·‚é. ‘æ26‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‹à‘ò. 2022”N6ŒŽ30“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, Nguyen Thi Na, •Ä“c_l, ‘å’ËŒ›Ži, ™–{³“¹, ª“Œ, Œ¬Œ´_, ¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇV¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓàfibrocyte‚Ì‹@”\‰ðÍ. ‘æ26‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‹à‘ò. 2022”N6ŒŽ30“ú.

•Ä“c_l, ŽO‹´“ÕŽu, ‰¬–ìL˜a, ”öè—Ì•F, –—m•½, Œ¬Œ´_, ˆ¢•”^Ž¡, ‰Á“¡K¬, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚¨‚æ‚ÑRCTLA-4R‘Ì‚É‚æ‚é•¡‡‚ª‚ñ–Ɖu—Ö@‚ÌŒŸ“¢. ‘æ26‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‹à‘ò. 2022”N6ŒŽ30“ú.

ˆ¢•”‚ ‚©‚Ë, “Œ“‘ã, ‰ª“c’¼l, ²“¡‰ë”ü, ‚‹´^—, –î–ì—R”üŽqC¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚錌‰t”|—{CClostridioides difficileŒŸ¸‚ɑ΂·‚éDiagnostic stewardship‚ÌŽæ‚è‘g‚Ý. ‘æ70‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï. Šò•Œ. 2022”N6ŒŽ5“ú.

“Œ“‘ã, ¼‰ªˆÀ•F, X–ìŽÑˆßŽq, ‘åΘa“¿. 65ΈÈã‚̬l‚ɑ΂·‚éPCV13-PPSV23˜A‘±ÚŽí‚̈À‘S«‚ƖƉuŒ´«‚ÌŒŸ“¢. ‘æ70‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï. Šò•Œ. 2022”N6ŒŽ5“ú.

‘ºãsl, Œ´“cŽÑŠó, ¡‘qŒ’, ŽO‹´“ÕŽu, ¬ì‰l, ’Ëè—C‹M, ”öè—Ì•F, –—m•½, ìk‘¢, •Ä“c_l, ˆ¢•”‚ ‚©‚Ë, ‰¬–ìL˜a, ¬ŽRˆë–ç, ²“¡³‘å, âŒû‹Å, ¼‰ªˆÀ•F. RGM-CSFR‘Ì‘ª’肪‘Šúf’f‚É—L—p‚Å‚ ‚Á‚½Ž©ŒÈ–Ɖu«”x–E’`”’ǂ̈ê—á. ‘æ45‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. Šò•Œ(ƒIƒ“ƒfƒ}ƒ“ƒh). 2022”N5ŒŽ27-28“ú.

¡‘qŒ’, ²“¡³‘å, Œ´“cŽÑŠó, ŽO‹´“ÕŽu, ¬ì‰l, ‘ºãsl, ’Ëè—C‹M, ”öè—Ì•F, –—m•½, ìk‘¢, •Ä“c_l, ˆ¢•”‚ ‚©‚Ë, ‰¬–ìL˜a, âŒû‹Å, ¼‰ªˆÀ•F. ”x–å•”EcŠuƒŠƒ“ƒpߎî‘å‚ɑ΂µ‚ÄEBUS-TBNA‚ðŽÀŽ{‚µŽq‹{èòŠàÄ”­‚Æf’f‚µ‚½1—á. ‘æ45‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. Šò•Œ(ƒIƒ“ƒfƒ}ƒ“ƒh). 2022”N5ŒŽ27-28“ú.

‰Í–ìO, ¡‘qŒ’, ŽR‰º—Y–ç, ‘ºãsl, “à“¡Lm, ²“¡³‘å, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éJAK‘jŠQ–ò‚ÌRüˆÛ‰»Œø‰Ê‚ÉŠÖ‚·‚錟“¢. ‘æ66‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. ‰¡•l(ƒnƒCƒuƒŠƒbƒh). 2022”N4ŒŽ25-27“ú.

Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Hiroshi Kawano, Eiji Hara, Yasuhiko Nishioka. Antifibrotic and senolytic activity of novel BRD4 degrader ARV825 in experimental model of lung fibrosis. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‹ž“sD2022”N4ŒŽ24“ú.

”ü”n³l, ²“¡³‘å, Œ´“cŽÑŠó, —é]—ÁŽq, ŽR‰º—Y–ç, ”öè—Ì•F, “yŽtŒbŽq, “à“¡Lm, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. RARSR‘Ì—z«ŠÔŽ¿«”xŽ¾Š³‚Ì‹¹•”‰æ‘œŠŒ©‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‹ž“sD2022”N4ŒŽ24“ú.

¬ŽRˆë–ç, ŽO‹´“ÕŽu, ¡‘qŒ’, ‘ºãsl, ìk‘¢, ²“¡³‘å, ‰Í–ìO, ¬ì”Ž‹v, ¼‰ªˆÀ•F. ƒVƒ“ƒOƒ‹ƒZƒ‹‰ðÍ‚ð—p‚¢‚½”xüˆÛǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éfibrocyte‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‹ž“sD2022”N4ŒŽ24“ú.

‰Í–ìO, ¡‘qŒ’, ‘ºãsl, “à“¡Lm, ìk‘¢, ¬ŽRˆë–ç, ²“¡³‘å, Œ¬Œ´_, ¼‰ªˆÀ•F. ƒŒƒ|[ƒ^[ƒ}ƒEƒX‚ð—p‚¢‚½”xüˆÛ×–E‚ÌV‹K“¯’è–@. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‹ž“sD2022”N4ŒŽ23“ú.

¡‘qŒ’, ²“¡³‘å, ¬ŽRˆë–ç, V‘º‹M”Ž, ‘ºãsl, ŽR‰º—Y–ç, “yŽtŒbŽq, ìk‘¢, ‰Í–ìO, ÀŠÔ–¡‹`l, ÎàVŒ[‰î, ¼‰ªˆÀ•F. In silico‰ðÍ‚É‚æ‚蓯’肳‚ꂽPLK‘jŠQ܂̃uƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŒø‰Ê‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‹ž“sD2022”N4ŒŽ23“ú.

Hirokazu Ogino, Taylor Jennie W, Takahide Nejo, Gibson David, Watchmaker Payal B, Kaori Okada, Atsuro Saijo, Tadesco Meghan, Rabbitt Jane, Olin Michael R, Moertel Christopher L, Salazar Andres M, Yasuhiko Nishioka, Molinaro Annette M, Phillips Joanna J, Butowski Nicholas A, Clarke Jennifer L, Chang Susan M, Berger Mitchel, Hideho Okada. Neoadjuvant vaccination with GBM6-AD, lysate of glioblastoma stem cell line, induces T-cell response in low-grade glioma. ‘æ19‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. ‹ž“s(ƒnƒCƒuƒŠƒbƒh). 2022”N2ŒŽ18“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yasuhiko Nishioka. Second-line chemotherapy for extensive-disease small cell lung cancer with interstitial lung disease. ‘æ19‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. ‹ž“s(ƒnƒCƒuƒŠƒbƒh). 2022”N2ŒŽ17-19“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
¼‘º—LŒå, “yŽtŒbŽq, —é]—ÁŽq, •Ä“c_l, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, ¬ì”Ž‹v, û•£¹‹B, ¼‰ªˆÀ•F. ŒŒ´Krebs von den Lungen-6 ‚ª‚’l‚ðŽ¦‚µ‚½ˆ««‹¹–Œ’†”çŽî‚Ì1—á. ‘æ127‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2022”N12ŒŽ18“ú.

V‹D, “yŽtŒbŽq, ˆä—D, ŽR‰º—Y–ç, “à“¡Lm, ‰¬–ìL˜a, ‰Í–ìO, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ŠÖ߉Š‚ð’悵‚½ACTH ’P“ÆŒ‡‘¹Ç‚Ì1—á. ‘æ127‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2022”N12ŒŽ18“ú.

‹{–{Œ›Æ, “yŽtŒbŽq, Œ´“cŽÑŠó, —é]—ÁŽq, ˆ¢•”‚ ‚©‚Ë, “Œ“‘ã, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚é”xMACǂɑ΂·‚éƒAƒWƒXƒƒ}ƒCƒVƒ“•¹—p—Ö@‚Ì—LŒø«EˆÀ‘S«‚ÌŒŸ“¢. ‘æ73‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

XʉÔ, “yŽtŒbŽq, ˆä—D, ‹{–{Œ›Æ, ‘ºãsl, ’Ëè—C‹M, â“ŒOŠî, ”öè—Ì•F, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽg—pŒã‚É”x–EoŒŒ‚ð‚«‚½‚µ‚½1—á. ‘æ31‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

Ž›àV‰, “yŽtŒbŽq, ŽsŒ´¹–ç, ŽR‰º—Y–ç, •Ÿ‰Æ–ƒ”ü, “à“¡Lm, •Ä“c_l, ìk‘¢, ‰¬–ìL˜a, ‰Í–ìO, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. RPD-L1R‘Ì“Š—^Œã‚ÉŒ°Ý‰»‚µ‚½RARSR‘Ì—z«ŠÔŽ¿«”x‰Š‚Ì1—á. ‘æ67‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

’†¼éD“l, “yŽtŒbŽq, ¼‘º—LŒå, ŽO‹´“ÕŽu, ¬ì‰l, ¡‘qŒ’, ”ü”n³l, ”öè—Ì•F, •Ä“c_l, ‰¬–ìL˜a, âŒû‹Å, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. “¯Žž‚ɈقȂé3‚‚̑gDŒ^‚ð”F‚ß‚½‘½”­«”xŠà‚Ì1—á. ‘æ67‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

¬˜H‹Mr, “à“¡Lm, ‰Í–ìO, ‘ºãsl, ŽR‰º—Y–ç, ”ü”n³l, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. —¼‘¤º‘Ñ–ƒáƒ‚ð’悵‚½‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚É”º‚¤”ìŒú«d–Œ‰Š‚Ì1—á. ‘æ33‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰ºŠÖD2022”N12ŒŽ3“ú.

ˆÀ‘Ž, ‰Í–ìO, ¬˜H‹Mr, ‘ºãsl, ŽR‰º—Y–ç, ”ü”n³l, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. Œ€Ç1Œ^“œ”A•a‚Æ“¯ŽžŠú‚É”­Ç‚µ‚½—¼‘¤“Á”­«ŠOŠá‹Ø‰Š‚Ì1—á. ‘æ33‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰ºŠÖD2022”N12ŒŽ3“ú.

’†¼éD“l, “yŽtŒbŽq, –—m•½, V‹D, ‚ŠÛ—˜‰ÁŽq, •Ä“c_l, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ƒZƒ‹ƒyƒ‹ƒJƒ`ƒjƒu‚ª‘tŒ÷‚µ‚½RET—Z‡ˆâ“`Žq—z«”x‘BŠà‚Ì1—á. ‘æ265‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2022”N7ŒŽ31“ú.

¬‘q—Cˆê˜N, “yŽtŒbŽq, ‹ß“¡Œ’‰î, ‘å’ËŒ›Ži, ‰¬–ìL˜a, ¬ŽRˆë–ç, ‘ºãsl, â“ŒOŠî, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‚Ö‚ÌŽ¡—Ô½‰ž«‚©‚çŠÌ”xÇŒóŒQ‚Ì•¹‘¶‚ªŒ°Ý‰»‚µ‚½ˆê—á. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ŽRŒû(ƒnƒCƒuƒŠƒbƒh). 2022”N7ŒŽ9“ú.

¼‘º—LŒå, “yŽtŒbŽq, ”ü”n³l, –—m•½, ‘å’ËŒ›Ži, •Ä“c_l, Œ¬Œ´_, ‰¬–ìL˜a, ”öè—Ì•F, ’Ëè—C‹M, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ¬×–E”xŠà‚Ö‚ÌŒ`Ž¿“]Š·‚ð”F‚ß‚½EGFRˆâ“`Žq•ÏˆÙ—z«”x‘BŠà‚Ì3—á. ‘æ60‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ŽRŒû(ƒnƒCƒuƒŠƒbƒh). 2022”N7ŒŽ9“ú.

V‹D, –—m•½, “yŽtŒbŽq, ‚ŠÛ—˜‰ÁŽq, •Ä“c_l, ‰¬–ìL˜a, ²“¡³‘å, û•£¹‹B, ¼‰ªˆÀ•F. ƒZƒ‹ƒyƒ‹ƒJƒ`ƒjƒu‚ª‘tŒø‚µ‚½RET—Z‡ˆâ“`Žq—z«”x‘BŠà‚Ì1—á. ‘æ60‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ŽRŒû(ƒnƒCƒuƒŠƒbƒh). 2022”N7ŒŽ9“ú.

“yŽtŒbŽqC–—m•½C”ü”n³lC•Ä“c_lC‰¬–ìL˜aC²“¡³‘åC‰Í–ìOCŒ¬Œ´_C¼‰ªˆÀ•F. MET‘jŠQ–ò‚ª’˜Œø‚µ‚½METˆâ“`Žq exon14 skipping •ÏˆÙ—z«”xG•½ã”çŠà‚Ì1—á. ‘æ126‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2022”N6ŒŽ5“ú.

‚‹´Œ[‹PC–—m•½CŽsŒ´¹–çC‰¬–ìL˜aC²“¡³‘åC‰Í–ìOCŒ¬Œ´_C¼‰ªˆÀ•F. d“x‚Ìš‹‰ºáŠQ‚ð‡•¹‚µ‚½RRo52R‘Ì—z«”畆‹Ø‰Š‚Ì1—á. ‘æ126‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2022”N6ŒŽ5“ú.

–—m•½C‘å’ËŒ›ŽiC’|“à‰hŽ¡C—t‹v‹MŽiCŒ“¼‹M‘¥C¼‘º’¼Ž÷C–L“c—DŽqCû•£¹‹BCŒ¬Œ´_C¼‰ªˆÀ•FD‚—îŽÒisEÄ”­”ñ¬×–E”xŠà‚ɑ΂·‚éPemetrexed + Bevacizumab •¹—p—Ö@‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢D‘æ264‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2022”N2ŒŽ20“úD
£ƒy[ƒW‚ÌTOP‚Ö
2021”N‹ÆÑ
y‰¢•¶Œ´’˜z
Yoneda H, Nokihara H, Mitsuhashi A, Ozaki R, Yabuki Y, Ogino H, Otsuka K, Nishioka Y. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma. BMC Pulm Med 21(1):373, 2021.

Tezuka T, Azuma M, Ogawa H, Kondo M, Uehara H, Aono Y, Hanibuchi M, Nishioka Y. A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells. Exp Lung Res 47(9):451-463, 2021.

Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, Inoue Y, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig, 59(6):709-740, 2021.

Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med 187:106574, 2021.

Mitsuhashi A, Kondoh K, Horikawa K, Koyama K, Nguyen N, Afroj T, Yoneda H, Otsuka K, Ogino H, Nokihara H, Shinohara T, Nishioka Y. PD-1/PD-L1 blockade mediates anti-angiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker. Cancer Sci 12(12):4853-4866, 2021.

Nishioka Y, Homma S, Okubo T, Azuma A. Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis. Contemp Clin Trials Commun 23:100832, 2021.

Muraoka S, Yamada Z, Kawazoe M, Hirose W, Kono H, Yasuda S, Komano Y, Kawano H, Hidaka T, Nakashima S, Kasama T, Teramoto T, Nanki T, ABT-ATS study group. Abatacept is efficacious in the treatment of older patients with csDMARD-refractory rheumatoid arthritis: a prospective, multicenter, observational study. Rheumatol Ther 8(4):1585-1601, 2021.

Isshiki T, Homma S, Eishi Y, Yabe M, Koyama K, Nishioka Y, Yamaguchi T, Uchida K, Yamamoto K, Ohashi K, Arakawa A, Shibuya K, Sakamoto S, Kishi K. Usefulness of imunohistochemical detection of Propionibacterium acnes in granulomas for differentiating sarcoidosis from other garanulomatous diseases; comparison between manual and automated immunohistochemical detection methods. Microorganisms 9(8):1668, 2021.

Haji K, Sato S, Yoneda H, Nisisho T, Nokihara H, Nishioka Y. Multidisciplinary treatment of skeletal muscle metastasis from lung cancer: A case of triceps muscle metastasis of lung squamous cell cancer. Respir Med Case Rep 33:101470, 2021.

Nakasuka F, Tabata S, Sakamoto T, Hirayama A, Ebi H, Yamada T, Umetsu K, Ohishi M, Ueno A, Goto H, Sugimoto M, Nishioka Y, Yamada Y, Tomita M, Sasaki AT, Yano S, Soga T. TGF-ƒÀ-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. Commun Biol. 4(1):782, 2021.

Hisata S, Bando M, Homma S, Kataoka K, Ogura T, Izumi S, Sakamoto S, Watanabe K, Saito Y, Shimizu Y, Kato M, Nishioka Y, Hara H, Waseda Y, Tanino Y, Yatera K, Hashimoto S, Mukae H, Inase N; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respir Investig 59(6):819-826, 2021.

Mukae H, Kaneko T, Obase Y, Shinkai M, Katsunuma T, Takeyama K, Terada J, Niimi A, Matsuse H, Yatera K, Yamamoto Y, Azuma A, Arakawa H, Iwanaga T, Ogawa H, Kurahashi K, Gon Y, Sakamoto H, Shibata Y, Tamada T, Nishioka Y, Haranaga S, Fujieda S, Miyashita N, Mochizuki H, Yokoyama A, Yoshihara S, Tamaoki J; JRS guidelines committee for the management of cough and sputum. The Japanese respiratory society guidelines for the management of cough and sputum (digest edition). Respir Investig 59(3):270-290, 2021.

Sato S, Chong SG, Upagupta C, Yanagihara T, Saito T, Shimbori C, Belleye PS, Nishioka Y, Kolb M. Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. Thorax 76(9):895-906, 2021.

Afroj T, Mitsuhashi A, Ogino H, Saijo A, Otsuka K, Yoneda H, Tobiume M, Nguyen TN, Goto H, Koyama K, Sugimoto M, Kondoh O, Nokihara H, Nishioka Y. Blockade of PD-1/PD-L1 pathway enhances the antigen-presenting capacity of fibrocytes. J Immunol 206(6):1204-1214, 2021.

Kawano H, Koyama K, Nishimura H, Toyoda Y, Kagawa K, Sato S, Naito N, Goto H, Inagaki Y, Nishioka Y. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. Immun Inflamm Dis 9(1):120-127, 2021.

Kondo M, Tezuka T, Ogawa H, Koyama K, Bando H, Azuma M, Nishioka Y. Lysophosphatidic acid regulates the differentiation of Th2 cells and its antagonist suppresses allergic airway inflammation. Int Arch Allergy Immunol 182(1):1-13, 2021.

Naito N, Kawano H, Yamashita Y, Kondo M, Haji S, Miyamoto R, Toyoda Y, Kanematsu Y, Izumi Y, Bando Y, Nishioka Y. Neuropsychiatric systemic lupus erythematosus wihcerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy. Mod Rheumatol Case Rep 5(1):52-57, 2021.

Sakamoto S, Kataoka K, Kondo Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S, and the Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized trial. Eur Respir J 57(1):2000348, 2021.

Homma S, Ebina M, Kuwano K, Goto H, Sakai F, Sakamoto S, Johkoh T, Sugino K, Tachibana T, Terasaki Y, Nishioka Y, Hagiwara K, Hashimoto N, Hasegawa Y, Hebisawa A; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Intractable Diffuse Pulmonary Diseases: Manual for Diagnosis and Treatment. Respir Investig 59(1):8-33, 2021.
y˜a•¶’˜‘z
²“¡³‘å, ¼‰ªˆÀ•F. “Á”­«ŠÔŽ¿«”x‰ŠDŒÄ‹zŠíÇŒóŒQi‘æ3”Åj‡VFpp60-64C2021, “ú–{—Õ଎Ð.

²“¡³‘å, ¼‰ªˆÀ•F. ŒÄ‹z׋CŠÇŽx‰Š‚𔺂¤ŠÔŽ¿«”xŽ¾Š³(RB-ILD). Œ©‚éf‚é‚í‚©‚éI‹¹•”‰æ‘œf’f, ‘ëì“Þ‹`•v •ÒW: pp145-149, 2021, ’†ŠOˆãŠwŽÐ.

²“¡³‘å, ¼‰ªˆÀ•F. ”ñ“ÁˆÙ«ŠÔŽ¿«”x‰Š(NSIP). Œ©‚éf‚é‚í‚©‚éI‹¹•”‰æ‘œf’f, ‘ëì“Þ‹`•v •ÒW: pp139-144, 2021, ’†ŠOˆãŠwŽÐ.

²“¡³‘å, ¼‰ªˆÀ•F. “Á”­«ŠíŽ¿‰»”x‰ŠiCOP^BOOPj.ŒÄ‹zŠíŽ¾Š³ÅV‚ÌŽ¡—Ã2021-2022, –å“c~ˆêEŒ·ŠÔº•FE¼‰ªˆÀ•F •ÒW, pp293-295, 2021, “ì]“°.
y˜a•¶‘àz
‰¬–ìL˜aC¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‡•¹”ñ¬×–E”xŠà‚ɑ΂·‚é–ò•¨—Ö@‚ɂ‚¢‚ÄDBIO Clinica 36(11):41-47, 2021.

¬ŽRˆë–ç, ¼‰ªˆÀ•F. ”x‚ÌüˆÛ‰»|”xüˆÛÇ‚ÆRüˆÛ‰»–ò|. —Õ°–ƉuEƒAƒŒƒ‹ƒM[‰È 76(2):139-146, 2021.

²“¡³‘å, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š. ƒŒƒWƒfƒ“ƒgƒm[ƒg 23(8)(‘Š§): 77-84, 2021.

¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚邪‚ñˆã—Ã. “ú–{“à‰ÈŠw‰ïŽGŽ 110(3):520-525, 2021.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Thi Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Kenji Otsuka, Hiroshi Nokihara, Yasuhiko Nishioka. S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Takeshi Imakura, Seidai Sato, Kazuya Koyama, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka.Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Kojin Murakami, Naoki Takahashi, Seidai Sato, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka.Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, Kensuke Kondou, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka. The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Nobuhito Naito, Hiroshi Kawano, Takeshi Imakura, Yuya Yamashita, Kojin Murakami, Kozo Kagawa, Kazuya Koyama, Seidai Sato, Hiroshi Nokihara, Yutaka Inagaki, Yasuhiko Nishioka. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka. Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Takeshi Imakura, Kojin Murakami, Yuya Yamashita, Naoki Takahashi, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. A Lck-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-b production in regulatory T cells. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hirokazu Ogino, Tania Afroj, Atsushi Mitsuhashi, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Na Thi Nguyen, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Seidai Sato. Novel senolytic drug ARV-825 promotes self-renewal of alveolar type 2 cells in lung. APSR 2021iEmerging Talent Symposia). Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hiroshi Kawano, Haruka Nishimura, Takeshi Imakura, Yuya Yamashita, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Sato, Hiroshi Nokihara, Yasuhiko Nishioka. Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Masahiko Azuma, Hirohisa Ogawa, Toshifumi Tezuka, Mayo Kondo, Yasuhiko Nishioka. A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Yasuhiko Nishioka, Takashi Ogura, Naohiko Inase, Ayako Takizawa, Atsushi Taniguchi, Yoshikazu Inoue. Effects of nintedanib on forced vital capacity categorical changes and disease progression in Japanese patients with progressive fibrosing interstitial lung diseases: Subanalysis of INBUILD study. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hiroshi Nokihara, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, Yasushi Goto. Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan. ESMO Congress 2021. Paris,France(Virtual). 2021”N9ŒŽ21“ú.

Yasushi Goto, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, Hiroshi Nokihara. Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS†50%), advanced NSCLC in Japan. ESMO Congress 2021. Paris,France(Virtual). 2021”N9ŒŽ21“ú.

Ryo Toyozawa, Kota Itahashi, Yasushi Goto, Yutaka Fujiwara, Yusuke Okuma, Takayasu Kurata, Toshihide Yokoyama, Hiroshi Nokihara, Takashi Yokoi, Teppei Yamaguchi, Yoshimasa Shiraishi, Masayuki Takeda, Takaaki Tokito, Atsushi Nakamura, Yuki Hosomi, Yuishiro Ohe. Two single-arm, multicenter phase-‡Utrials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). ESMO Congress 2021. Paris,France(Virtual). 2021”N9ŒŽ21“ú.

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Takeshi Imakura, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Haruka Nishimura, Hiroshi Kawano, Yasuhiko Nishioka. Anti-fibrotic efficacy of Lck inhibitor via the suppression of TGF-ƒÀ production in regulatory T cells. ERS International Congress 2021. WEB. 2021”N9ŒŽ7“úD

Antje Prasse, Toby M Maher, R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Moises Selman, Jin Woo Song, Carina Ittrich, Claudia Diefenbach, Klaus B. Rohr, Susanne Stowasser, Eric S. White. Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. The 61st DGP Annual CongressiDGP 2021 digitalj. 2021”N6ŒŽ2-5“ú.

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Klaus B Rohr, Daniel Wachtlin, Carina Ittrich, Claudia Diefenbach, R Gisli Jenkins: on behalf of the INMARK study investigators. Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study. The 61st DGP Annual CongressiDGP 2021 digitalj. 2021”N6ŒŽ2-5“ú.

Naoki Takahashi, Seidai Sato, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka. Oligonucleotide therapeutics PK-7010 in combination with nintedanib ameliorates bleomycin-induced pulmonary fibrosis in mice. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.

Kazuya Koyama, Hiroshi Kawano, Yuya Yamashita, Takeshi Imakura, Naoki Takahashi, Nobuhito Naitoh, Seidai Sato, Yasuhiko Nishioka. Clinical Features of the Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Naoki Takahashi, Haruka Nishimura, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. The Lck-Specific Inhibitor A-770041 Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.

Takuma Isshiki, Sakae Homma, Matsuko Yabe, Kazuya Koyama, Yasuhiko Nishioka, Tetsuo Yamaguchi, Keisuke Uchida, Yoshinobu Eishi, KazutoshiShibuya, Susumu Sakamoto, Kazuma Kishi. Usefulness of Immunohistochemical detection of Propionibacterium acnes in granulomas for the differentiation of sarcoidosis and other granulomatous diseases. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. With ƒRƒƒiŽž‘ã‚̌ċzŠíê–åˆã‚Ì–ðŠ„ `ŒÄ‹zŠíê–åˆã‚Ì–¢—ˆ`. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïA‘æ30‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ïA‘æ72‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï (3Šw‰ï‡“¯‰ï’·Šé‰æ). ¼](WEB). 2021”N12ŒŽ5“úD

¼‰ªˆÀ•F. PF-ILD‚Ìf’f‚ÆŽ¡—Ã. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[). ‰¡•l. 2021”N11ŒŽ26“úD

Œáȉë•FD’m‚Á‚Ä‚¨‚±‚¤|”x‚̶ŠˆKŠµ•aCOPD-D‘æ8‰ñCOPDŽs–¯ŒöŠJuÀDƒP[ƒuƒ‹ƒeƒŒƒr“¿“‡D2021”N10ŒŽ19`31“úD

¬ŽRˆë–çC‰Í–ìOC¼‰ªˆÀ•FD”xüˆÛ‰»‚É‚¨‚¯‚éƒVƒ“ƒOƒ‹ƒZƒ‹‰ðÍD‘æ1‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï(Šî‘bŒ¤‹†“Á•Êu‰‰)D“Œ‹žD2021”N10ŒŽ3“ú.

–öŒ´–LŽjC²“¡³‘åCMartin KolbD”xüˆÛÇ‚É‚¨‚¯‚é”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì•a‘Ô - ˆâ“`“IÆŽã«‚Ì’Tõ“I‰ðÍ‚àŠÜ‚ß‚Ä-D‘æ1‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï(Šî‘bŒ¤‹†“Á•Êu‰‰)D“Œ‹žD2021”N10ŒŽ3“ú.

¼‰ªˆÀ•FDTAS-115D‘æ1‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2021”N10ŒŽ2“ú.

Œáȉë•FD¬l‹CŠÇŽxšb‘§‚ÌÅ‹ß‚ÌŽ¡—Âɂ‚¢‚ÄD“¿“‡‘åŠw•a‰@ƒtƒH[ƒ‰ƒ€2021t(Žs–¯ŒöŠJuÀ). “¿“‡D2021”N2ŒŽ28“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
ŽO‹´“ÕŽu, ‰¬–ìL˜a, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. RPD-1/PD-L1R‘Ì‚É‚æ‚錌ŠÇV¶§ŒäƒƒJƒjƒYƒ€‚̉ðÍ‚ÆŽ¡—ÃŒø‰Ê—\‘ªƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳž—p. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2021”N11ŒŽ28“ú.

”öè—Ì•F, Œ¬Œ´_, ŽO‹´“ÕŽu, ‹ß“¡Œ’‰î, –—m•½, •Ä“c_l, ‰¬–ìL˜a, ‘å’ËŒ›Ži, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‡•¹¬×–E”xŠà‚ɑ΂·‚é“ñŽŸ‰»Šw—Ö@‚Ì—LŒø«‹y‚шÀ‘S«‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2021”N11ŒŽ26“ú.

–—m•½, ‘å’ËŒ›Ži, ’|“à‰hŽ¡, —t‹v‹MŽi, Œ“¼‹M‘¥, ¼‘º’¼Ž÷, –L“c—DŽq, û•£¹‹B, Œ¬Œ´_, ¼‰ªˆÀ•F. ‚—îŽÒisEÄ”­”ñ¬×–E”xŠà‚ɑ΂·‚é Pemetrexed { Bevacizumab •¹—p—Ö@‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‰¡•l. 2021”N11ŒŽ26“ú.

•Ä“c_l, Œ¬Œ´_, ŽO‹´“ÕŽu, ”öè—Ì•F, –—m•½, ‰¬–ìL˜a, ‘å’ËŒ›Ži, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽîŠ³ŽÒ‚É‚¨‚¯‚éƒjƒ{ƒ‹ƒ}ƒu‚̖ƉuŠÖ˜A—LŠQŽ–Û‚ÆŽ¡—ÃŒø‰Ê‚Ì‘ŠŠÖ«. ‘æ59‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‰¡•l(WEB)D2021”N10ŒŽ22“ú.

‘å’ËŒ›Ži, ŽO‹´“ÕŽu, ”öè—Ì•F, –—m•½, •Ä“c_l, ‰¬–ìL˜a, Œ¬Œ´_, ’|“à‰hŽ¡, ™‰Y”ª\¶, ’m‰ÔŒ«Ž¡, “c‘ºŒú‹v, ˆÀ‘îM“ñ, ¼‰ªˆÀ•F. i“WŒ^¬×–E”xŠà‚É‚¨‚¯‚é—\Œã‹K’èˆöŽq. ‘æ59‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‰¡•l(WEB)D2021”N10ŒŽ22“ú.

¡‘qŒ’C²“¡³‘åC¬ŽRˆë–çCV‘º‹M”ŽC‘ºãslC‚‹´’¼ŠóCìk‘¢CÀŠÔ–¡‹`lCÎàVŒ[‰îC¼‰ªˆÀ•FDIn silico ‰ðÍ‚ð—p‚¢‚½”xüˆÛǂɑ΂·‚éV‹KŽ¡—Öò‚Ì’TõD‘æ1‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ïD“Œ‹ž(WEB)D2021”N10ŒŽ2“ú.

‘ºãslC‚‹´’¼ŠóC²“¡³‘åC¡‘qŒ’CŽR‰º—Y–çCìk‘¢C¬ŽRˆë–çC‰Í–ìOC’J쌴–œŒ°C’¹ŠC˜iC¼‰ªˆÀ•FDƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éV‹KŠjŽ_ˆã–ò‚Ì—LŒø«‚ÌŒŸ“¢D‘æ1‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ïD“Œ‹ž(WEB)D2021”N10ŒŽ2“ú.

²“¡³‘åC¼‰ªˆÀ•FCMartin KolbDüˆÛ‰»”x‘gD‚Ì×–EŠOŠîŽ¿‚ªüˆÛ×–E‚ÌüˆÛ‰»‘£i«miRNA ”­Œ»‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢D‘æ1‰ñ“ú–{‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ïD“Œ‹ž(WEB)D2021”N10ŒŽ2“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, ¼žŠ“Ö˜YC‘å’ËŒ›Ži, ™–{³“¹CŒ¬Œ´_, ¼‰ªˆÀ•FD–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇV¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éfibrocyte‚Ì–ðŠ„D‘æ80‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïD‰¡•l(WEB). 2021”N10ŒŽ2“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. ”x‚ª‚ñŠÌ“]ˆÚ‚É‚¨‚¯‚éspheroidŒ`¬‚ª‚ñŠ²×–E—l•ª‰æ‚Ì–ðŠ„. ‘æ30‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. WEB. 2021”N7ŒŽ29“ú.

ŽO‹´“ÕŽu, Tania Afroj, Nguyen Thi Na, ‰¬–ìL˜a, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. RPD-1/PD-L1R‘Ì‚É‚æ‚éŽîᇌŒŠÇV¶—}§ƒƒJƒjƒYƒ€‚̉ðÍ‚ÆŽ¡—ÃŒø‰Ê—\‘ªƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳž—p. ‘æ25‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2021”N5ŒŽ28“ú.

Nguyen Thi Na, ŽO‹´“ÕŽu, ¼”Ž”V, •Ä“c_l, Tania Afroj, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. TS-1‚É‚æ‚éŽîᇊ֘Aœ‘—R—ˆ—}§×–E‚̧Œä‚ð‰î‚µ‚½–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚Æ‚Ì•¹—pŒø‰Ê‚ÌŒŸ“¢. ‘æ25‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2021”N5ŒŽ26“ú.

ŽR‰º—Y–ç, ¡‘qŒ’, ‚‹´’¼Šó, “à“¡Lm, ²“¡³‘å, ‰Í–ìO, ¼‰ªˆÀ•F. ŠÖ߃ŠƒEƒ}ƒ`‚É”º‚¤ŠÔŽ¿«”x‰Š‹}«‘ˆ«‚Ì—Õ°“I“Á’¥ `“Á”­«”xüˆÛÇ‹}«‘ˆ«‚Æ‚Ì”äŠrŒŸ“¢`. ‘æ65‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. WEB. 2021”N4ŒŽ26-28“ú.

¼‰ªˆÀ•F, Valenzuela C, Maher T, Bonella F, Pesci A, Jouneau S, Patel N, Fernandez Perez E, Goeldner R, Cottin V. is«üˆÛ‰»‚𔺂¤ŠÔŽ¿«”x‰ŠiPF-ILDj‚ł̃jƒ“ƒeƒ_ƒjƒu‚Ì—LŒø«‚ɑ΂·‚éƒx[ƒXƒ‰ƒCƒ““FVC•Ê•]‰¿FINBUILDŽŽŒ±’ljÁ‰ðÍ. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

¬ŽRˆë–ç, û•£¹‹B, –L“c—DŽq, ˆêF‘ô–, ŽODŽkb, â–{W, ‰Á“¡Œ³N, ûü‹´˜a‹v, •Ð‰ªŒ’‰î, ‹ß“¡N”Ž, ¼‰ªˆÀ•F, –{ŠÔ‰h. “Á”­«”xüˆÛÇ‚É‚¨‚¯‚éTOLLIPˆâ“`Žq‘½Œ^‚ÆN-ƒAƒZƒ`ƒ‹ƒVƒXƒeƒCƒ“‹z“ü—Ö@‚Ì—LŒø«‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

‘ºãsl, ²“¡³‘å, ¡‘qŒ’, ¼‘ºt‰À, ‚‹´’¼Šó, “à“¡Lm, ìk‘¢, ¬ŽRˆë–ç, ‰Í–ìO, Œáȉë•F, Œ¬Œ´_, ¼‰ªˆÀ•F. RüˆÛ‰»–ò2Ü‚ðØ‚è‘Ö‚¦‚ÄŽg—p‚µ‚½“Á”­«”xüˆÛÇÇ—á‚ÌŒã•ûŽ‹“IŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

‹ß“¡Œ’‰î, Œ¬Œ´_, ²“¡³‘å, ŽO‹´“ÕŽu, •Ä“c_l, ¼”Ž”V, ‘å’ËŒ›Ži, ¼‰ªˆÀ•F. ”ñ¬×–E”xŠà‚ɑ΂·‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚Ì—\Œã—\‘ªˆöŽq‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

rˆä’¼Ž÷, Ö“¡••¶, ¬‘qûüŽu, •xˆäŒ[‰î, _”öFˆê˜Y, â–{W, ‹{è‘׬, •y‰ª—mŠC, ‹v“cC, ”¼“c’mG, –{ŠÔ‰h, ¼‰ªˆÀ•F, ŒáȈÀ—Ç‘¾. “Á”­«”xüˆÛÇŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚½‘æII‘Š—Õ°ŽŽŒ±‚É‚¨‚¯‚éTAS-115‚Ì—LŒø«‚ƈÀ‘S«. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

¼”Ž”V, ŽO‹´“ÕŽu, ”öè—Ì•F, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. –ƉuŒ´«×–EŽ€‚ð—U“±‚·‚é×–EŠQ«RŠà܂ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

¼‘ºt‰À, ²“¡³‘å, ¡‘qŒ’, ‘ºãsl, “à“¡Lm, ìk‘¢, ¬ŽRˆë–ç, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éJAK‘jŠQÜ‚ÌŒø‰Ê‚ÉŠÖ‚·‚錟“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

‚‹´’¼Šó, ²“¡³‘å, ¡‘qŒ’, ‘ºãsl, “à“¡Lm, ìk‘¢, ¬ŽRˆë–ç, ‰Í–ìO, Œ¬Œ´_, ’J쌴–œŒ°, ’¹ŠC˜i, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠjŽ_ˆã–òPK-7010‚Ænintedanib‚Ì•¹—pŒø‰Ê‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

ˆêF‘ô–, –{ŠÔ‰h, –î•”ƒ}ƒcŽq, ¬ŽRˆë–ç, ¼‰ªˆÀ•F, ŽRŒû“N¶, “à“cŒ\‰î, ]΋`M, a’J˜ar, â–{W, ŠÝˆê”n. ƒTƒ‹ƒRƒCƒh[ƒVƒXf’f‚É‚¨‚¯‚éPABR‘̖ƉuõF‚Ì—L—p«‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

”öè—Ì•F, ŽO‹´“ÕŽu, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F, ŸN“cI, ÎàVŒ[‰î. ƒyƒƒgƒŒƒLƒZƒh“Š—^Œã‚Ì”ç]‚ɑ΂·‚éƒfƒLƒTƒƒ^ƒ]ƒ“—\–h“Š—^‚ÌŒø‰Ê‚ÌŒŸ“¢. ‘æ18‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. ‹ž“s(WEB). 2021”N2ŒŽ18-21“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
Γc‘ì–ç, ‰Í–ìO, ¡‘qŒ’, ‘ºãsl, ŽR‰º—Y–ç, ”ü”n³l, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éäPŒ´•aŠÖ˜AŠÔŽ¿«”xŽ¾Š³‚ɑ΂·‚éƒjƒ“ƒeƒ_ƒjƒu‚ÌŽg—pŒoŒ±. ‘æ32‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ¼ŽR. 2021”N12ŒŽ11“ú.

ŽsŒ´¹–çC‰Í–ìOC¡‘qŒ’, ‘ºãslCŽR‰º—Y–ç, ”ü”n³l, “à“¡Lm, ‰¬–ìL˜a, ²“¡³‘å, ¼‰ªˆÀ•F. Ä”­«‘½”­“ŠŽ¡—Ã’†‚Ì•s–¾”M¸¸‚ÅUBA1ˆâ“`Žq‰ðÍ‚É‚æ‚èf’f‚µ‚½VEXASÇŒóŒQ‚Ì1—á. ‘æ32‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ¼ŽR. 2021”N12ŒŽ10“ú.

ŽsŒ´¹–çC–—m•½C‘ºãslCìk‘¢C•Ä“c_lC‰¬–ìL˜aC²“¡³‘åC‰Í–ìOCŒ¬Œ´_C¼‰ªˆÀ•F. ˆŸ‹}«‚Éis‚µA–I‘ƒ”x—l‚ÌŠŒ©‚ð’悵‚½–òÜ«”xáŠQ‚Ì1—á. ‘æ125‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2021”N12ŒŽ5“ú.

Γc‘ì–çC–—m•½Cìk‘¢CŽR‰º—Y–çC‰¬–ìL˜aC²“¡³‘åC‰Í–ìOCŒ¬Œ´_C¼‰ªˆÀ•F. ¬lStill•a‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½‰Æ‘°«’n’†ŠC”M”ñ“TŒ^—á‚Ì1—á. ‘æ125‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2021”N12ŒŽ5“ú.

‘ºã®Æ, –—m•½, ”öè—Ì•F, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. Sitafloxacin‚ª‘tŒø‚µ‚½”xMycobacterium abscessus subsp. massiliense Ç‚Ì1—á. ‘æ72‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï. ¼](WEB). 2021”N12ŒŽ5“ú.

‚ŠÛ—˜‰ÁŽq, –—m•½, ˆé‘º—S‘¾, ìk‘¢, ‘å’ËŒ›Ži, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. Ž©‘R‘Þk‚ð”F‚ß‚½‹CŠÇŽxŒ´”­‘Á‰t‘BŒ^ŽîᇂÌ1—á. ‘æ30‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. ¼](WEB). 2021”N12ŒŽ5“ú.

¬ì‰l, –—m•½, ˆä—D, ìk‘¢, ¬ŽRˆë–ç, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. —¼‘¤”x‚É‘½”­‚·‚é”Áó‰e‚ð’悵‚½Ž©ŒÈ–Ɖu«”x–E’`”’Ç‚Ì1—á. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ¼](WEB). 2021”N12ŒŽ5“ú.

Œ´“cËŽq, –—m•½, ”ü”n³l, ”öè—Ì•F, ìk‘¢, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. ”ñŒ‹Šj«RŽ_‹ÛÇ‚Æ‚ÌŠÓ•Ê‚ð—v‚µAamikacin { minocycline‚ª‘tŒø‚µ‚½”xƒmƒJƒ‹ƒWƒA. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ¼](WEB). 2021”N12ŒŽ4“ú.

‰Ô–[‰, –—m•½, ¡‘qŒ’, •Ä“c_l, ˆ¢•”‚ ‚©‚Ë, ”ü”n³l, ŽR‰º—Y–ç, “à“¡Lm, ìk‘¢, ‘å’ËŒ›Ži, ²“¡³‘å, Œ¬Œ´_, ¼‰ªˆÀ•F. ƒXƒeƒƒCƒhƒpƒ‹ƒX—Ö@Œã‚É‘ˆ«‚µ“ñ“x–ڂ̃pƒ‹ƒX—Ö@‚ª‘tŒø‚µ‚½COVID-19”x‰Š‚Ì1—á. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‰ªŽR. 2021”N8ŒŽ8“ú.

âŒû‹Å, –—m•½, ¡‘qŒ’, •Ä“c_l, ‘ºãsl, ¬ŽRˆë–ç, ìk‘¢, ¬ì‰l, ‰¬–ìL˜a, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. õó‚̬—tŠÔŠu•Ç‚Ì”ìŒú‚ð”F‚ß‹¹o‹¾‰º”x¶ŒŸ‚É‚Äf’f‚µ‚½ŠÔŽ¿«”x‰Š‚Ì1—á. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‰ªŽR. 2021”N8ŒŽ8“ú.

’†“à—F‡], –—m•½, “yŽtŒbŽq, •Ä“c_l, ŽO‹´“ÕŽu, ˆä—D, Γc‘ì–ç, ‘ºã®Æ, ‰¬–ìL˜a, ²“¡³‘å, Œ¬Œ´_, ¼‰ªˆÀ•F. Tepotinib‚ª’˜Œø‚µ‚½METˆâ“`Žqexon14 skipping•ÏˆÙ—z«”x‘BŠà‚Ì1—á. ‘æ59‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰ªŽR. 2021”N8ŒŽ7“ú.

ŽsŒ´¹–ç, –—m•½, ”öè—Ì•F, ‹ß“¡Œ’‰î, •Ä“c_l, ‘å’ËŒ›Ži, •Ÿ‰Æ–ƒ”ü, ‚ŠÛ—˜‰ÁŽq, Œ´“cËŽq, ‰¬–ìL˜a, ²“¡³‘å, Œ¬Œ´_, ¼‰ªˆÀ•F. Atezolizumab‚ÌImmune-Related Adverse Event‚É‚æ‚é‹}«táŠQ‚ð”F‚ß‚½”ñ¬×–E”xŠà‚Ì1—á. ‘æ59‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰ªŽR. 2021”N8ŒŽ7“ú.

‚ŠÛ—˜‰ÁŽqC“à“¡LmCŒ´“cŽÑŠóCŽR‰º—Y–çC”öè—Ì•FC‚‹´’¼ŠóC²“¡³‘åC‰Í–ìOCŒ¬Œ´_C¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚ɑ΂·‚éƒxƒŠƒ€ƒ}ƒu‚ÌŽg—pŒoŒ±. ‘æ124‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2021”N5ŒŽ9“ú.

Γc‘ì–çC“à“¡LmC¡‘qŒ’Cìk‘¢C²“¡³‘åC‰Í–ìOCŒ¬Œ´_C‚ŽR“NŽ¡C¼‰ªˆÀ•F. ƒŒƒ“ƒoƒ`ƒjƒu‚É‚æ‚é–òÜ«”xáŠQ‚Ì1—á. ‘æ124‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2021”N5ŒŽ9“ú.

ˆä—D, “à“¡Lm, ¡‘qŒ’, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. Atezolizumab“Š—^Œã‚É’˜–¾‚ÈŒŒ¬”ÂŒ¸­Ç‚ð‚«‚½‚µ‚½1—á. ‘æ262‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. WEB. 2021”N3ŒŽ7“ú.

¡‘qŒ’, “à“¡Lm, ŽR‰º—Y–ç, Œ´“cŽÑŠó, ìk‘¢, •Ä“c_l, ²“¡³‘å, ‰Í–ìO, ’·’J‰Á—eŽq, Œ¬Œ´_, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é¬l”­ÇƒXƒeƒBƒ‹•aÇ—á‚ÌŒŸ“¢. ‘æ262‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. WEB. 2021”N3ŒŽ7“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2020”N‹ÆÑ
y‰¢•¶Œ´’˜z
Azuma M, Murakami K, Murata R, Kataoka K, Fujii H, Miyake Y, Nishioka Y. Clinical significance of carbapenem-tolerant Pseudomonas aeruginosa isolated in the respiratory tract. Antibiotics (Basel) 9(9):E626, 2020.

Morizumi S, Sato S, Koyama K, Okazaki H, Chen Y, Goto H, Kagawa K, Ogawa H, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Blockade of pan-fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis. Am J Respir Cell Moll Biol 63(3):317-326, 2020.

Okuma Y, Goto Y, Ohyanagi F, Sunami K, Nakahara Y, Kitazono S, Kudo K, Tambo Y, Kanda S, Yanagitani N, Horiike A, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Nishio M, Ohe Y, Hosomi Y. Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Med 9(20):7418-7427, 2020.

Imakura T, Toyoda Y, Sato S, Koyama K, Nishimura H, Kagawa K, Takahashi N, Naito N, Murakami K, Kawano H, Azuma M, Shinohara T, Nishioka Y. Distinct improvement of pulmonary function, ground-1 glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment: a case report with a review of the literature. J Med Invest 67(3,4):358-361, 2020.

Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer:a single-institution retrospective study. K Sci Rep 10(1):13773, 2020.

Kanda S, Ohe Y, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Yamamoto T, Tamura T. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Cancer Sci 111(6):1933-1942, 2020.

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With DocetaxelMonotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3. Randomized Clinical Trial. JAMA Oncol 6(5):e196828, 2020.

Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, Hamada N, Taniguchi H, Hattori N, Nishioka Y, Tanizawa K, Johkoh T, Yokoyama T, Mori K, Taguchi Y, Ebina M, Inase N, Hagiwara K, Ohnishi H, Mukae H, Inoue Y, Kuwano K, Chiba H, Ohta K, Tanino Y, Sakai F, Sugiyama Y. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res 6(2):00184-2019, 2020.

Otsuka K, Mitsuhashi A, Goto H, Hanibuchi M, Koyama K, Ogawa H, Ogino H, Saijo A, Kozai H, Yoneda H, Tobiume M, Kishuku M, Ishizawa K, Nishioka Y. Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer 146:86-96, 2020.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trialinvestigators(Nishioka Y). Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med: S2213-2600(20)30036-9, 2020.

Abe S, Sato S, Aono Y, Azuma M, Kishi M, Koyama K, Takahashi N, Kagawa K, Kawano H, Nishioka Y. Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects. J Med Invest 67:102-112, 2020.
y˜a•¶’˜‘z
²“¡³‘å, ¼‰ªˆÀ•F. nintedanib‚ÌŽg‚¢•û‚Æ•›ì—p‘Îô. ŠÔŽ¿«”xŽ¾Š³f—Ã}ƒjƒ…ƒAƒ‹ ‰ü’ù‘æ3”Å, ‹v•Ûœ¨Žk ŠÄC, “¡“cŽŸ˜Y ŠìŽÉê’©—Y •ÒW, pp202-208, 2020.“ì]“°.

–L“c—DŽq, ¼‰ªˆÀ•F. ƒXƒeƒƒCƒh. äPŒ´•a‚É”º‚¤ŠÔŽ¿«”xŽ¾Š³ f’fEŽ¡—ÃŽwj2020 •ÒW “ú–{ŒÄ‹zŠíŠw‰ï “ú–{ƒŠƒEƒ}ƒ`Šw‰ï‡“¯ äPŒ´•a‚É”º‚¤ŠÔŽ¿«”xŽ¾Š³f’fEŽ¡—ÃŽwj쬈ψõ‰ï(¼‰ªˆÀ•F,–L“c—DŽq ‘¼), pp176-178, 2020. ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ.

²“¡³‘å, ¼‰ªˆÀ•F. ƒTƒ‹ƒRƒCƒh[ƒVƒX. V—Õ°“à‰ÈŠw ‘æ10”Å ŠÄC –îú±‹`—Y, pp1800-1801, 2020. ˆãŠw‘‰@.

¼‰ªˆÀ•F. ”x–E”÷ÎÇ. ¡“ú‚Ìf’fŽwj ‘æ8”Å ‘•ÒW ‰iˆä—ÇŽO, pp995-996, 2020. ˆãŠw‘‰@.
y˜a•¶‘àz
‰Í–ìO, ¼‰ªˆÀ•F. ƒOƒbƒhƒpƒXƒ`ƒƒ[ÇŒóŒQ. “ú–{ˆãŽt‰ïŽGŽ 149(“Á•Ê†2):244-246, 2020.

¼‰ªˆÀ•F. ŠÔŽ¿«”x‰ŠFf’f‚ÆŽ¡—ÂÌÅ‘Oü. “ú–{“à‰ÈŠw‰ïŽGŽ 109(9):1899-1905, 2020.

ŽO‹´“ÕŽu, ¼‰ªˆÀ•F. ŒŒŠÇV¶‘jŠQ܂ɑ΂·‚é‘Ï«Šl“¾ƒƒJƒjƒYƒ€DŽÀŒ±ˆãŠw 38(15)(‘):157-162, 2020.

Œ¬Œ´_, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‡•¹”ñ¬×–E”xŠà‚ÌŽ¡—Ãí—ª. ”xŠà 60(2):74-80, 2020.

²“¡³‘å, ¼‰ªˆÀ•FD“Á”­«”xüˆÛÇ‚ÌŒŒ´Šw“IŠŒ©D–ò‹Ç 71(3):26-31, 2020.

¼‰ªˆÀ•FD“Á”­«”xüˆÛǂ̃KƒCƒhƒ‰ƒCƒ“‚Ì•Ï‘JD–ò‹Ç 71(3):16-20, 2020.

²“¡³‘å, ¼‰ªˆÀ•F, Martin Kolb. üˆÛ‰»”x‘gD‚Ì×–EŠOŠîŽ¿‚ªüˆÛ×–E‚ÌmiR-21”­Œ»‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. •ªŽqŒÄ‹zŠí•a 24(1):76-79, 2020.
y˜a•¶Œ´’˜z
•Ÿ‰Æ–ƒ”ü, ‰¬–ìL˜a, ’؈䖢Šó, ‹ß“¡^‘ã, ìk‘¢, û•£¹‹B, ŽRú±”Ž‹P, ‹{–{—º‰î, –L“c—DŽq, ¼‰ªˆÀ•FDƒGƒ^ƒ“ƒuƒg[ƒ‹‚É‚æ‚é’E‘«––½_ŒoáŠQ‚É‚æ‚è‹}‘¬is«‚Ì•àsáŠQ‚ð’悵‚½Œ‹Šj«‹¹–Œ‰Š‚Ì1—áDŒ‹Šj95(2):73-77, 2020.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Jin Woo Song, R Gisli Jenkins, Imre Noth, Moises Selman, Vincent Cottin, Yasuhiko Nishioka, Antje Prasse, Eric S White, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Toby M Maher. Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. KATRD International Conference 2020. WEB. 2020”N11ŒŽ12-13“ú.

Jin Woo Song, Moises Selman, R Gisli Jenkins, Eric S White, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Antje Prasse, Benjamin Strobel, German Leparc, Carina Ittrich, Claudia Diefenbach, Klaus Rohr, Susanne Stowasser, Toby M Maher. Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK trial. KATRD International Conference 2020. WEB. 2020”N11ŒŽ12-13“ú.

Seidai Sato, Takushi Yamamoto, Kana Waki , Yuki Morimoto, Takeshi Imakura, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Koichi Tsuneyama, Yasuhiko Nishioka. Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosisusing the iMScope TRIOS. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú-12ŒŽ30“ú.

Atsushi Mitsuhashi, Tania Afroj, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú-12ŒŽ30“ú.

Naoki Takahashi, Seidai Sato, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka. The novel oligonucleotide therapeutics PK-7010 for TGF-ƒÀ1 ameliorates bleomycin-induced pulmonary fibrosis in micen. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú-12ŒŽ30“ú.

Kazuya Koyama, Susumu Sakamoto, Sakae Homma, Seidai Sato, Masaki Hanibuchi, Kiyoshi Masuda, Isei Imoto, Yuko Toyoda, Takuma Isshiki, Shion Miyoshi, Motoyasu Kato, Kazuhisa Takahashi, Kensuke Kataoka, Yasuhiro Kondoh, Yasuhiko Nishioka. The Relationship Between Single-Nucleotide Polymorphisms Within Tollip and the Efficacy of Inhaled N-Acetylcysteine Therapy in Idiopathic Pulmonary Fibrosis. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú-11ŒŽ10“ú.

Moises Selman, R Gisli Jenkins, Eric S White, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Antje Prasse, Jin Woo Song, Benjamin Strobel, German Leparc, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Toby M Maher on behalf of the INMARK trial investigators. Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK Trial. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú-11ŒŽ10“ú.

Naoki Arai, Takefumi Saito, Takashi Ogura, Keisuke Tomii, Koichiro Kamio, Susumu Sakamoto, Yasunari Miyazaki, Hiromi Tomioka, Shu Hisata, Tomohiro Handa, Sakae Homma, Yasuhiko Nishioka, Arata Azuma. Final Results of the Primary Endpoint and Other Supportive Analysis: TAS-115 Phase 2 Study in Patients with Idiopathic Pulmonary Fibrosis. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú-11ŒŽ10“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚邪‚ñˆã—Ã. 2020”N“x“ú–{“à‰ÈŠw‰ï¶ŠU‹³ˆçu‰‰‰ï@BƒZƒbƒVƒ‡ƒ“. WEB(‹à‘ò)D2020”N11ŒŽ29“úD

Œ¬Œ´_DŠÌ“]ˆÚ‚̃}ƒlƒWƒƒ“ƒgD‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D‰ªŽRD2020”N11ŒŽ12“úD

Œ¬Œ´_. ”x‚ª‚ñ‚Ì–ò•¨—Ö@‚Ìi•à. —ߘa2”N“x“¿“‡‘åŠw‘åŠw‰@Žs–¯ŒöŠJuÀ(’†‘EŽl‘Lˆæ‚ª‚ñƒvƒ—{¬ƒRƒ“ƒ\[ƒVƒAƒ€).“¿“‡D2020”N10ŒŽ17“ú.

¼‰ªˆÀ•F, ²“¡³‘å. is«üˆÛ‰»«ƒtƒFƒmƒ^ƒCƒv‚Ì•ªŽq•a‘Ô. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). WEB. 2020”N9ŒŽ21“ú.

¼‰ªˆÀ•F, ¬ŽRˆë–ç, ŽO‹´“ÕŽu, Tania Afroji, ‰Í–ìO. ”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚éscRNA-Seq‚ð—p‚¢‚½üˆÛ×–E‚̉ðÍ. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). WEB. 2020”N9ŒŽ20“ú.

¼‰ªˆÀ•FDŠÔŽ¿«”x‰ŠFf’f‚ÆŽ¡—ÂÌÅ‘OüD‘æ117‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ï(‹³ˆçu‰‰). WEB(“Œ‹ž)D2020”N8ŒŽ7“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
ŽO‹´“ÕŽu, ŸN“cI, ‡“cŒõúª, ÀŠÔ–¡‹`l, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ÎàVŒ[‰î, ¼‰ªˆÀ•FDƒyƒƒgƒŒƒLƒZƒh“Š—^Œã‚Ì”ç]‚ɑ΂·‚é’á—p—ʃfƒLƒTƒƒ^ƒ]ƒ“—\–hŒø‰Ê‚ÌŒŸ“¢D‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD‰ªŽRD2020”N11ŒŽ14“ú.

‘å’ËŒ›Ži, ŽO‹´“ÕŽu, •Ä“c_l, Œ¬Œ´_, ’|“à‰hŽ¡, ’m‰ÔŒ«Ž¡, ˆÀ‘îM“ñ, “c‘ºŒú‹v, ¼‰ªˆÀ•FDi“WŒ^¬×–E”xŠà‚Ì—\Œã‹K’èˆöŽq‚ÌŒŸ“¢D‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD‰ªŽRD2020”N11ŒŽ12“úD

Œáȉë•F, –—m•½, ¼‰ªˆÀ•F. äPŒ´•a”x‚Æ‚ÌŠÓ•Ê‚ª–â‘è‚É‚È‚Á‚½’¹ŠÖ˜A‰ß•q«”x‰Š‚Ì 1 —á. ‘æ51‰ñ“ú–{E‹ÆEŠÂ‹«ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ïEŠwp‘å‰ï. ‰ªŽR^WEB. 2020”N11ŒŽ6“úD

¼”Ž”V, ŽO‹´“ÕŽu, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. ×–EáŠQ«R‚ª‚ñÜ‚É‚æ‚éŽîᇖƉuŒ´«×–EŽ€—U“±”\‚ÌŒŸ“¢. ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. WEB(‹ž“s). 2020”N10ŒŽ22-12ŒŽ25“ú.

ŸN“cI, ŽO‹´“ÕŽu, •Ä“c_l, ‘å’ËŒ›Ži, ‡“cŒõŠ°, ÀŠÔ–¡‹`l, ÎàVŒ[‰î, Œ¬Œ´_, ¼‰ªˆÀ•F. ƒyƒƒgƒŒƒLƒZƒh“Š—^Œã‚Ì”ç]‚ɑ΂·‚é’á—p—ʂ̃XƒeƒƒCƒh—\–h“Š—^‚Ì‘OŒü‚«—Õ°ŽŽŒ±. ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. WEB(‹ž“s). 2020”N10ŒŽ22-24“ú.

‰Í–ìO, ŽR‰º—Y–çC“à“¡LmC²“¡³‘åC–å“c@”VCˆÉ¨F”VC”ª–ØG‰îC²“c­—²CŒ¬Œ´_C¼‰ªˆÀ•F. ‚ˆÀ“®–¬‰Š‚É‚æ‚é“«”畆’×ᇂɑ΂µ‚Ă׃yƒ‹ƒ~ƒmƒQƒ“ ƒyƒ‹ƒvƒ‰ƒXƒ~ƒhiƒqƒgŠÌ×–E‘BˆöŽqƒvƒ‰ƒXƒ~ƒhƒxƒNƒ^[j“Š—^‚ª‘tŒø‚µ‚½1—á. ‘æ48‰ñ“ú–{—Õ°–ƉuŠw‰ï‘‰ï. WEB. 2020”N10ŒŽ15-17“ú.

ŽO‹´“ÕŽu, ‰¬–ìL˜a, ¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, ™–{³“¹, Œ¬Œ´_, ¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇV¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓà fibrocyte-like cell ‚Ì‹@”\‰ðÍ. ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. WEB. 2020”N10ŒŽ1-31“ú.

²“¡³‘å, X–{—FŽ÷, ŽR–{‘ìŽu, ŠÛ”ö•ü–ç, ˜e‰ØØ, ¼‰ªˆÀ•F. ƒCƒ[ƒWƒ“ƒOŽ¿—ÊŒ°”÷‹¾‚É‚æ‚éƒjƒ“ƒeƒ_ƒjƒu‚ÌüˆÛ«”x‘gD“à‹ÇÝ•ª•z‚ÌŒŸ“¢. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

ìk‘¢, ¬ŽRˆë–ç, ²“¡³‘å, ûü‹´’¼Šó, ¼‘ºt‰À, ‰Í–ìO, –L“c—DŽq, ŽÂŒ´•×, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éLck‘jŠQ‚ÌRüˆÛ‰»Œø‰Ê. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

ûü‹´’¼Šó, ²“¡³‘å, ¬ŽRˆë–ç, ìk‘¢, “à“¡Lm, ¡‘qŒ’, –L“c—DŽq, ‰Í–ìO, ’J쌴–œŒ°, ’¹ŠC˜i, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠjŽ_ˆã–òPK-7010‚ÌRüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

–L“c—DŽq, ²“¡³‘å, ¬ŽRˆë–ç, ìk‘¢, ãb„, ]“ª—æŽq, Ž›è‘×O, ŽÖàV», ”‹Œ´Oˆê, ˆî£’¼•F, ¼‰ªˆÀ•F. “Á”­«”xœ‰»Ç‘S‘’²¸i’†ŠÔ•ñj. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

’J–]–¢, ‹g‘º²h, ŽR“c’‰–¾, ‘åŒF—T‰î, –k‘ä—¯ˆß, ’|“c—²”V, Œ“¼‹M‘¥, Œã“Œ‹vŽk, •Ä“c_l, ¼‰ªˆÀ•F, Œ´“c‘åŽi, ŽR“c’‰›, ˆÉ’Bh“ñ, ‰–’ÃL‰î, ‰i“cˆê—m, 猴—C‰î, “à–쇎¡, ûüŽR_ˆê. ŠùŽ¡—Ôñ¬×–E”x‚ª‚ñ‚ð‘ÎÛ‚Æ‚µ‚½ƒhƒZƒ^ƒLƒZƒ‹{ƒ‰ƒ€ƒVƒ‹ƒ}ƒu•¹—p‚ÉŠÖ‚·‚鑽Ž{Ý‹¤“¯Œã•ûŽ‹“IŒŸ“¢. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

Hirohisa Ogawa, Masahiko Azuma, Aya Umeno, Mayuko Shimizu, Takaaki Tsunematsu, Mayo Kondo, Kazutoshi Murotomi, Koichi Tsuneyama, Yasuhiko Nishioka. Nerve growth factor exacerbates airway hyperresponsiveness via epithelial damage by neutrophils-derived singlet oxygen in a mouse model of asthma with mixed inflammation. ‘æ69‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïiJSA/WAO Joint Congress 2020j. WEB. 2020”N9ŒŽ17“ú-10ŒŽ20“ú.

¼”Ž”V, ŽO‹´“ÕŽu, Nguyen Thi Na, Tania Afroj, •Ä“c_l, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. ”xŠà‚É‚¨‚¢‚Ä×–EáŠQ«RŠàÜ‚ª–ƉuŒ´«×–EŽ€‚É—^‚¦‚é‰e‹¿‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

ŽO‹´“ÕŽu, Tania Afroj, ‰¬–ìL˜a, Nguyen Thi Na, •Ä“c_l, ¼”Ž”V, ‘å’ËŒ›Ži, ™–{³“¹, ª“Œ, Œ¬Œ´_, ¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇV¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓà fibrocyte-like cell ‚Ì‹@”\‰ðÍ. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

•Ä“c_l, ‹g‘º²h, Œã“Œ‹vŽk, ¼‰ªˆÀ•F, ŽR“c’‰–¾. ŠùŽ¡—Ôñ¬×–E”x‚ª‚ñ‚ð‘ÎÛ‚Æ‚µ‚½ƒhƒZƒ^ƒLƒZƒ‹{ƒ‰ƒ€ƒVƒ‹ƒ}ƒu•¹—p‚ÉŠÖ‚·‚鑽Ž{Ý‹¤“¯Œã•ûŽ‹“IŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

‹ß“¡Œ’‰î, Œ¬Œ´_, ŽO‹´“ÕŽu, •Ä“c_l, ¼”Ž”V, ‘å’ËŒ›Ži, ¼‰ªˆÀ•F. ”ñ¬×–E”xŠà‚É‚¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚Ì—\Œã—\‘ªˆöŽq‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

Tania Afroj, ‰¬–ìL˜a,ŽO‹´“ÕŽu, •Ä“c_l, ¼”Ž”V, ‘å’ËŒ›Ži, Œ¬Œ´_, ˆÀ”{³”Ž, ¼‰ªˆÀ•F. ŽîᇖƉu‚É‚¨‚¯‚éüˆÛ×–E‚̖Ɖu’²ß‹@”\‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

Nguyen Thi Na, ŽO‹´“ÕŽu, Tania Afroj, •Ä“c_l, ¼”Ž”V, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. ƒ}ƒEƒX’†”çŽî×–EŠ””牺ˆÚAƒ‚ƒfƒ‹‚É‚¨‚¯‚é×–EáŠQ«RŠàÜ‚ÌŽîᇊ֘Aœ‘—R—ˆ—}§×–E‚ւ̉e‹¿. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

¼žŠ“Ö˜Y, ¼”Ž”V, Œã“Œ‹vŽk, ‘å’ËŒ›Ži, •Ä“c_l, ŽO‹´“ÕŽu, ¼‰ªˆÀ•F. ”ñ¬×–E”x‚ª‚ñ‚ɇ•¹‚µ‚½ˆ««‹¹…‚ɑ΂·‚é bevacizumab ‚Ì—LŒø«‚Æ‘Ï«‰»‹@˜‚̉ðÍ. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

‰ª“c’¼l, ÀŠÔ–¡‹`l, ’†”n^K, ‡“cŒõŠ°, ¼‰ªˆÀ•F, ÎàVŒ[‰î. ”x‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚éŠÔŽ¿«”xŽ¾Š³‚Ì”­Œ»ƒŠƒXƒNˆöŽq‚ÌŒŸ“¢F’PŽ{ÝŒã‚ëŒü‚«Œ¤‹†. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

쌴ˆê‹P, ˆ¢•”^Ž¡, ‰Á“¡K¬, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚邪‚ñ“ÁˆÙ“IR podoplanin R‘Ì chLpMab-23f ‚Ì in vitro ‚É‚¨‚¯‚éRŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

‰Í–ìO, “à“¡Lm, ˆÀ‘Ž, ¡‘qŒ’, ŽR‰º—Y–ç, ‚‹´’¼Šó, ‹ß“¡^‘ã, ²“¡³‘å, –L“c—DŽq, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éis«üˆÛ‰»‚𔺂¤äPŒ´•aŠÖ˜AŠÔŽ¿«”xŽ¾Š³‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. WEB. 2020”N8ŒŽ17“ú-9ŒŽ15“ú.

²“¡³‘å, ‘ºãsl, –L“c—DŽq, ¬ŽRˆë–ç, ¼‘ºt‰À, ìk‘¢, ûü‹´’¼Šó, ‰Í–ìO, Œáȉë•F, ¼‰ªˆÀ•F. 2Ü‚ÌRüˆÛ‰»–ò‚ðŽg—p‚µ‚½“Á”­«”xüˆÛÇÇ—á‚ÌŒŸ“¢. ‘æ117‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ï. ŽãD2020”N8ŒŽ7-9“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
ŽR‰º—Y–ç, “à“¡Lm, Œ´“cŽÑŠó, ¡‘qŒ’, ûü‹´’¼Šó, ²“¡³‘å, ‰Í–ìO, ¼‰ªˆÀ•F. ST‡Ü‚É‚æ‚é–³‹Û«‘–Œ‰Š‚ð’悵‚½ƒVƒF[ƒOƒŒƒ“ÇŒóŒQ‚̈ê—á. ‘æ31‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. WEB. 2020”N12ŒŽ5“ú.

”ü”n³l, “à“¡Lm, Œ´“cŽÑŠó, ¡‘qŒ’, ŽR‰º—Y–ç, ûü‹´’¼Šó, ²“¡³‘å, ‰Í–ìO, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚éRARSR‘Ì—z«Ç—á‚ÌŒŸ“¢. ‘æ31‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. WEB. 2020”N12ŒŽ5“ú.

•Ä“c_l, “à“¡Lm, ¼”Ž”V, ‘å’ËŒ›Ži, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, Œáȉë•F, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鈫«‹¹–Œ’†”çŽî‚ɑ΂·‚énivolumab“Š—^Ç—á‚ÌŒŸ“¢. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

ˆ¢•”‚ ‚©‚Ë, “à“¡Lm, ‘å’ËŒ›Ži, ìãsšõ, “¡ˆäŽu˜N, Šâ–{½Ži, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. ”ñ¬×–E”xŠà‚ɇ•¹‚µ‚½Œã“V«ŒŒ—F•aA‚Ì1—á. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

Œ´“cŽÑŠó, “à“¡Lm, ‰ª–{—I—¢, ìk‘¢, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. •s–¾”M‚̸¸‚ÅMEFVˆâ“`Žq‰ðÍ‚É‚æ‚èf’f‚µ‚½‰Æ‘°«’n’†ŠC”M‚Ì1—á. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

“V–ì‰ë•¶, Š~Œ´F“T, “¡–ì‘׋P, “c’†‹v”üŽq, ‰ª–{kˆê, ‹{–{OŽu, ²“¡NŽj, ˜ZŽÔ’¼Ž÷, ¼‰ªˆÀ•F, ‚ŽR“NŽ¡. ƒjƒ“ƒeƒ_ƒjƒu‚É‚æ‚é“Á”­«”xüˆÛÇŽ¡—ÃŒo‰ß’†‚É”­Ç‚µ‚½‚Ñ‚Ü‚ñ«ˆÝ‘O’ë•”–Ñ׌ŒŠÇŠg’£Ç‚Ì2—á. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

š d“¹‘å, “à“¡Lm, Œ´“cŽÑ‹G, ŽR‰º—Y–ç, ‚‹´’¼Šó, ”ü”n³l, ¼”Ž”V, ²“¡³‘å, ‰Í–ìO, ¼¯r•F, •l“c‘å•ã, Œ¬Œ´_, ¼‰Y“N–ç, ¼—Ç_ˆê, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚éœEŠÖß•a•Ï‚ð’悵‚½”ñŒ‹Šj«RŽ_‹ÛÇ‚ÌŒŸ“¢. ‘æ71‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï’†‘Žl‘Žx•”‰ï. WEB. 2020”N11ŒŽ21“ú|12ŒŽ21“ú.

Š–{’B–ç, “à“¡Lm, “à“¡m”ü, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, Œáȉë•F, ¼‰ªˆÀ•F. ‘Sg«‹­”çÇ‚É”º‚¤ŠÔŽ¿«”x‰Š‚Ì‘ˆ«‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½’¹ŠÖ˜A‰ß•q«”x‰Š‚Ì1—á. ‘æ29‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. WEB. 2020”N11ŒŽ21“ú|12ŒŽ21“ú.

ˆé‘º—S‘¾, “à“¡Lm, ŽR‰º—Y–ç, •Ÿ‰Æ–ƒ”ü, ¬ŽRˆë–ç, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鋹…’™—¯‚ð’悵‚½äPŒ´•a‚¨‚æ‚Ñ—Þ‰Ž¾Š³Ç—á‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. WEB. 2020”N11ŒŽ21“ú|12ŒŽ21“ú.

Ü–ìˆíl, “à“¡Lm, “à“¡m”ü, ûü‹´’¼Šó, “c’†G“T, ²“¡³‘å, ‰Í–ìO, ㌴‹v“T, Œ¬Œ´_, ‚ŽR“NŽ¡, ¼‰ªˆÀ•F. ŠÌd•Ï‚ð‡•¹‚µAŠÌ”xÇŒóŒQ‚Éi“W‚µ‚½ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. WEB. 2020”N11ŒŽ21“ú|12ŒŽ21“ú.

ˆä—DCìk‘¢C“à“¡LmC²“¡³‘åC‰Í–ìOCŽODl³C¼‰Y•ü”üC”Œ´G–çC‹gìK‘¢C–L“c—DŽqCâ“Œ—Ç”üCŒ¬Œ´_C‚ŽR“NŽ¡C“‡“cŒõ¶C¼‰ªˆÀ•FDDŽ_‹…«‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚ÌŽ¡—Ã’†‚ɉñ’°oŒŒ‚ð‚«‚½‚µAŒŒŠÇ‰Š‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½CMV’°‰Š‚Ì1—áD‘æ260‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡D2020”N2ŒŽ2“úD
£ƒy[ƒW‚ÌTOP‚Ö
2019”N‹ÆÑ
y‰¢•¶Œ´’˜z
Takezaki A, Tsukumo SI, Setoguchi Y, Ledford JG, Goto H, Hosomichi K, Uehara H, Nishioka Y, Yasutomo K. A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis. J Exp Med 216 (12):2724-2735, 2019.

Chong SG, Sato S, Kolb M, Gauldie J. Fibrocytes and fibroblasts-Where are we now. Int J Biochem Cell Biol 116:105595, 2019.

Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, Goto H, Yoneda H, Harada T, Kubota Y, Yamada T, Date K, Shiotsu S, Nagata K, Chihara Y, Kaneko Y, Uchino J, Nishioka Y, Takayama K. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res 8(4):450-460, 2019.

Yanagihara T, Sato S, Upagupta C, Kolb M. What have we learned from basic science studies on idiopathic pulmonary fibrosis? Eur Respir Rev 28(153):190029, 2019.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig 57(6):512-533, 2019.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG: on behalf of the INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib(INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 7(9):771-779, 2019.

Okazaki H, Sato S, Koyama K, Morizumi S, Abe S, Azuma M, Chen Y, Goto H, Aono Y, Ogawa H, Kagawa K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Kouji H,e Nishioka Y. The novel inhibitor PRI-724 for Wnt/ƒÀ-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice. Exp Lung Res 45(7):188-199, 2019.

Toyoda Y, Koyama K, Kawano H, Nishimura H, Kagawa K, Morizumi S, Naito N, Sato S, Yamashita Y, Takahashi N, Goto H, Azuma M, Nishioka Y. Clinical features of interstitial pneumonia associated with systemic lupus erythematosus. Respir Investig 57(5):435-443, 2019.

Shimbori C, Upagupta C, Bellaye PS, Ayaub EA, Sato S, Yanagihara T, Zhou Q, Ognjanovic A, Ask K, Gauldie J, Forsythe P, Kolb MRJ. Mechanical stress-induced mast cell degranulation activates TGF-ƒÀ1 signalling pathway in pulmonary fibrosis. Thorax 74(5):455-465, 2019.

Hanibuchi M, Kanoh A, Kuramoto T, Saito T, Tobiume M, Saijo A, Kozai H, Kondo M, Morizumi S, Yoneda H, Kagawa K, Ogino H, Sato S, Kawano H, Otsuka K, Toyoda Y, Nokihara H, Goto H, Nishioka Y. Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA. Oncotarget:10(38):3654-3666, 2019.

Koyama K, Goto H, Morizumi S, Kagawa K, Nishimura H, Sato S, Kawano H, Toyoda Y, Ogawa H, Homma S, Nishioka Y. Novel multiple tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 60(4):478-487, 2019.

Saijo A, Hanibuchi M, Ogino H, Otsuka K, Goto H, Nokihara H, Nishioka Y. Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias. Mol Clin Oncol 10(5):541-546, 2019.

Ueda S, Murakami T, Ogino H, Matsuura M, Tamaki M, Kishi S, Hann M, Toyoda Y, Nagai K, Bando Y, Abe H, Nishioka Y, Doi T. Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions. Intern Med 58(5):679-684, 2019.

Ogino H, Hanibuchi M, Sakaguchi S, Toyoda Y, Tezuka T, Kawano H, Kakiuchi S, Otsuka K, Saijo A, Azuma M, Nokihara H, Goto H, Nishioka Y. The clinical features of older patients with lung cancer in comparison with their younger counterparts. Respir Investig 57(1):40-48, 2019.

Sato S, Yanagihara T, Kolb MR. Therapeutic targets and early stage clinical trials for pulmonary fibrosis. Expert Opin Investig Drugs: 28(1):19-28, 2019.
y˜a•¶’˜‘z
¼žŠ“Ö˜Y, Œ¬Œ´_. ALK-TKI‚É‚æ‚éˆêŽŸŽ¡—Âɂ©‚©‚í‚é”äŠrŽŽŒ±. ƒIƒ“ƒRƒƒW[ƒNƒŠƒjƒJƒ‹ƒKƒCƒh ”xŠà‰»Šw—Ö@ ‰ü’ù2”Å Œ·ŠÔº•FE—¢“à”ü–íŽq•ÒW pp215-217, 2019. “ìŽR“°.

Œ¬Œ´_. CBDCA+PEM(}BEV)(PEM’PÜ). ”x‚ª‚ñ‰»Šw—Ö@•›ì—pƒ}ƒlƒWƒƒ“ƒg ƒvƒ‚̃Rƒc@‘q“c•ó•ÛE‹g‰ªO’ÁE‹à“cr•F•ÒW pp55-58, 2019. ƒƒWƒJƒ‹ƒrƒ…[ŽÐ.

Œ¬Œ´_. CDDP+PEM(}BEV)(PEM’PÜ). ”x‚ª‚ñ‰»Šw—Ö@•›ì—pƒ}ƒlƒWƒƒ“ƒg ƒvƒ‚̃Rƒc@‘q“c•ó•ÛE‹g‰ªO’ÁE‹à“cr•F•ÒW pp51-54, 2019. ƒƒWƒJƒ‹ƒrƒ…[ŽÐ.

²“¡³‘å, ¼‰ªˆÀ•FD“Á”­«ŠÔŽ¿«”x‰Ši‚»‚Ì‘¼‚Ì”ñ“ÁˆÙ«ŠÔŽ¿«”x‰ŠCŠíŽ¿‰»”x‰ŠjDŽ„‚ÌŽ¡—à 2019-20”N“x”Å ‰Ž“c‹’jE–k‘º‘yˆê˜Y ŠÄC “dŽqƒRƒ“ƒeƒ“ƒcC2019D“ú–{ˆãŽ–V•ñŽÐD

²“¡³‘å, ¼‰ªˆÀ•FDŠÔŽ¿«”x‰ŠE‰ß•q«”x‰ŠD–ƉuE‰ŠÇ•a‘Ô~Ž¡—Ã@Update, ŒFƒm‹½~ •ÒW pp77-87, 2019. “ìŽR“°D

Œã“Œ‹vŽkDŽîá‡DŠPšuEš\á‚‚Ìf—ÃKƒCƒhƒ‰ƒCƒ“2019C“ú–{ŒÄ‹zŠíŠw‰ïŠPšuEš\á‚‚Ìf—ÃKƒCƒhƒ‰ƒCƒ“2019쬈ψõ‰ïi¼‰ªˆÀ•F ‘¼j•ÒW pp88-89, 2019Dˆê”ÊŽÐ’c–@l“ú–{ŒÄ‹zŠíŠw‰ïD

–L“c—DŽqDŠÔŽ¿«”x‰ŠiIPjDŠPšuEš\á‚‚Ìf—ÃKƒCƒhƒ‰ƒCƒ“2019C“ú–{ŒÄ‹zŠíŠw‰ïŠPšuEš\á‚‚Ìf—ÃKƒCƒhƒ‰ƒCƒ“2019쬈ψõ‰ïi¼‰ªˆÀ•F ‘¼j•ÒW pp85-87, 2019Dˆê”ÊŽÐ’c–@l“ú–{ŒÄ‹zŠíŠw‰ïD

‰Í–ìO, ¼‰ªˆÀ•FDäPŒ´•a‚Ì”x•a•ÏDŒÄ‹zŠíŽ¾Š³ ÅV‚ÌŽ¡—Ã2019-2020, –å“c~ˆêEŒ·ŠÔº•FE¼‰ªˆÀ•F •ÒW pp384-387, 2019D“ì]“°D

Œã“Œ‹vŽk, ¼‰ªˆÀ•FDŒŒŠÇV¶‘jŠQ–ò‘Ï«‹@\DŒÄ‹zŠíŽ¾Š³ ÅV‚ÌŽ¡—Ã2019-2020, –å“c~ˆêEŒ·ŠÔº•FE¼‰ªˆÀ•F •ÒW pp54-57, 2019. “ì]“°D

¼‰ªˆÀ•FDDŽ_‹…«”x‰ŠD¡“ú‚ÌŽ¡—ÃŽwj2019”N”Å, •ŸˆäŽŸ–î, ‚–ؽ, ¬Žºˆê¬ ‘•ÒW, pp320-321, 2019.ˆãŠw‘‰@D
y˜a•¶‘àz
–L“c—DŽq, ²“¡³‘å, ‰Í–ìO, ¼‰ªˆÀ•F. ŠÖ߃ŠƒEƒ}ƒ`Ž¡—Öò‚Æ”x•a•Ï. ŒÄ‹zŠí“à‰È 36(6):618-626, 2019.

Œã“Œ‹vŽkCŒáȉë•FC’†£Ÿ‘¥C–Lú±ã•C‰F“s‹{³“oC¼‰ªˆÀ•FDCOPDE”x‚ª‚ñ‚É‚È‚ç‚È‚¢‚½‚ß‚ÉDŽl‘ˆãŠwŽGŽ 75(1,2):23-30, 2019.

¼‰ªˆÀ•FDÅVçΛ{‚Ì•ÒWˆÏˆõ‚ð’S“–‚µ‚ÄDÅVçΛ{ 74(6):125, 2019.

¼‰ªˆÀ•FD”x‚ª‚ñŽîᇊ‹«‚É‚¨‚¯‚éfibrocyte-like cell‚Ì•a“IˆÓ‹`D‰ŠÇ‚ƖƉu 27(3):31-35, 2019.

ŽO‹´“ÕŽuCŒ¬Œ´_D–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŒø‰Ê‚ð‘‹­‚·‚镹—p—Ö@D•ªŽqŒÄ‹zŠí•a 23(1):49-53, 2019.

‰Í–ìO, ¼‰ªˆÀ•FDŠÔŽ¿«”x‰ŠE–«•ÂÇ«”xŽ¾Š³D–ò‹Ç 70(5):85-90, 2019.

¼‰ªˆÀ•FD”x‰Š‚ÆŠ´õ‘ÎôDŠé‹Æ‚Æ‘åŠw 5:57, 2019.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Yasuhiko Nishioka. Update immunotherapy therapy for mesothelioma. Hanoi,Vietnam. APSR 2019(Symposium). 2019”N11ŒŽ16“úD

Yasuhiko Nishioka. Jin Woo Song, Yasuhiro Kondoh, Young Whan Kim, Osamu Nishiyama, Susanne Stowasser, Andreas Michael, Claudia Diefenbach, Klaus B Rohr, Toby M Maher. Biomarkers of Disease Progression in Asian Subjects with Idiopathic Pulmonary Fibrosis Treated with Nintedanib: Subgroup Analysis of the INMARK Trial. Hanoi,Vietnam. APSR 2019. 2019”N11ŒŽ15“úD

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Naoki Takahashi, Haruka Nishimura, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda, Yasuhiko Nishioka. Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice. ERS International Congress 2019. Madrid, Spain. 2019”N10ŒŽ2“ú.

Kazuya Koyama, Susumu Sakamoto, Sakae Homma, Seidai Sato, Masaki Hanibuchi, Kiyoshi Masuda, Issei Imoto, Yuko Toyoda, Takuma Isshiki, Shion Miyoshi, Motoyasu Kato, Kazuhisa Takahashi, Kensuke Kataoka, Yasuhiro Kondoh, Yasuhiko Nishioka. Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

R Gisli Jenkins, Toby M Maher, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S White, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Moises Selman on behalf of the INMARK trial investigators. Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

Toby M Maher, R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Moises Selman, Jin Woo Song, Antje Prasse, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Eric S White. Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

Takashi Ogura, Yasuhiko Nishioka, Takefumi Saito, Keisuke Tomii, Koichiro Kamio, Hiromi Tomioka, Shu Hisata, Susumu Sakamoto, Tomohiro Handa, Yasunari Miyazaki, Sakae Homma, Arata Azuma. Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ29“ú.

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ Kolb, Yasuhiko Nishioka. Expression of pro-fibrotic microRNA of fibrocytes in bronchoalveolar lavage fluid. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ21“úD

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Klaus B Rohr, Daniel Wachtlin, Carina Ittrich, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ20“úD

Kazyua Koyama, Nobuhito Naitoh, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma, Yasuhiko Nishioka. Acute Respiratory Failure in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ19“úD
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•FD‚ª‚ñ–ƉuƒTƒCƒNƒ‹‚©‚çl‚¦‚é”xŠà‚ɑ΂·‚é•¡‡–Ɖu—Ö@D‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). •Ÿ‰ªD2019”N10ŒŽ25“úD

Œ¬Œ´_C‰ª–{—EC—t´—²C›Œ´rˆêC–x”V“àGmC“ŒŒöˆêC•Ä“ˆNbC‘ºã°‘×C‘ʉ갎qC׌©K¶CˆÀ‘îM“ñC”öè’q”ŽC–x’r“ÄC“¡“cŒ‹‰ÔC‰ª–{_–¾CˆÀ“¡¹•FC–쑺®ŒáCŽR–{M”VC‘å]—TˆêC’†ì˜a•F. Phase III study of CBDCA/PEM followed by PEM versus DOC in elderly pts withadvanced non-sq NSCLC iJCOG1210/WJOG7813Lj. ‘æ17‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï(Presidential Symposium). ‹ž“sD2019”N7ŒŽ18“úD

¼‰ªˆÀ•FD‚ª‚ñ–ƉuƒTƒCƒNƒ‹‚ðl—¶‚µ‚½•¡‡‚ª‚ñ–Ɖu—Ö@D2019”Nˆê”ÊŽÐ’c–@l “ú–{E‘½‘ŠÔ—Õ°ŽŽŒ±‹@\ƒ[ƒNƒVƒ‡ƒbƒv(‹³ˆçu‰‰)D–¼ŒÃ‰®D2019”N6ŒŽ29“úD

¼‰ªˆÀ•F, ‰¬–ìL˜a, ŽO‹´“ÕŽu. ŒŒŠÇV¶‘jŠQ–ò‘Ï«‚Æ‚»‚ÌŽ•ž. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘åã. 2019”N6ŒŽ13“úD

¼‰ªˆÀ•FD“Á”­«”xüˆÛÇUpdate -RüˆÛ‰»—Ö@‚ðŠî‘b‚Æ—Õ°‚©‚çl‚¦‚é-D‘æ234‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠÖ“Œ’n•û‰ï@‹³ˆçƒZƒ~ƒi[D“Œ‹žD2019”N5ŒŽ25“úD

–L“c—DŽq. À’k‰ïu—«ˆã‹Ç’·‚É•·‚­IvD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ~ƒjƒg[ƒNƒZƒbƒVƒ‡ƒ“)D“Œ‹žD2019”N4ŒŽ13“úD

²“¡³‘åDƒnƒ~ƒ‹ƒgƒ“Œ¤‹†•ú˜Q‹LD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•ÊŠé‰æ)D“Œ‹žD2019”N4ŒŽ12“úD

¼‰ªˆÀ•FD“ú–{ŒÄ‹zŠíŠw‰ï‚ÌŠCŠO—¯ŠwŽx‰‡‚ÆŠCŠO—¯Šw•¬‹à§“xD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•ÊŠé‰æ)D“Œ‹žD2019”N4ŒŽ12“úD

¼‰ªˆÀ•FD”x‚ª‚ñŽîᇊ‹«‚É‚¨‚¯‚éfibrocyte-like cell‚Ì•a“IˆÓ‹`D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2019”N4ŒŽ12“úD

Œáȉë•FD‹CŠÇŽxšb‘§‚ɂ‚¢‚ÄŠw‚Ú‚¤`ŒÄ‹zŠí“à‰Èˆã‚Ì—§ê‚©‚ç`DŒ§–¯ŒöŠJuÀ@“¿“‡ƒAƒŒƒ‹ƒM[ƒtƒH[ƒ‰ƒ€2019D“¿“‡D2019”N2ŒŽ24“úD

Œã“Œ‹vŽkDCOPDE”x‚ª‚ñ‚É‚È‚ç‚È‚¢‚½‚ß‚ÉD‘æ258‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïŽs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€D“¿“‡D2019”N2ŒŽ3“úD
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
ŽO‹´“ÕŽu, ‰¬–ìL˜a, –Øh¹r, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•FD–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇV¶‘jŠQ–ò‚É‚æ‚é•¡‡‚ª‚ñ–Ɖu—Ö@‚É‚¨‚¯‚éŽîᇓàfibrocytelike cell‚Ì‹@”\‰ðÍD‘æ32‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠwpW‰ï‘‰ïD‰ªŽRD2019”N11ŒŽ28“úD

‘å’ËŒ›Ži, •Ä“c_l, ŽO‹´“ÕŽu, ‰¬–ìL˜a, ¼”Ž”V, ”ò”~—º, Œ¬Œ´_, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‡•¹”ñ¬×–E”xŠà‚É‚¨‚¯‚é2ŽŸ‰»Šw—Ö@‚̈À‘S«‚Æ—LŒø«‚ÌŒŸ“¢. ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. •Ÿ‰ªD2019”N10ŒŽ24“úD

‘å’ËŒ›ŽiCŒã“Œ‹vŽkCû•£¹‹BC‰¬–ìL˜aC¼žŠ“Ö˜YC¼”Ž”VC•Ä“c_lC”ò”~—ºC¼‰ªˆÀ•FD‰»Šw—Ö@‚ÍŽîᇓà‚Ìœ‘—R—ˆ—}§×–E‚ðŒ¸­‚³‚¹‚邱‚Æ‚É‚æ‚èRPD-1R‘Ì‚ÌRŽîᇌø‰Ê‚ð‘‹­‚·‚é. ‘æ28‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ïCŽ­Ž™“‡D2019”N7ŒŽ26“úD

¼‘ºt‰À, •Ä“c_l, ìk‘¢, ¬ŽRˆë–ç, ”ò”~—º, ‰¬–ìL˜a, ¼žŠ“Ö˜Y, ‹{–{Œ›Æ, Œ´“cŽÑŠó, â“Œ‹IŽq, –L“c—DŽq, ¼‰ªˆÀ•F. Šà«ƒŠƒ“ƒpŠÇÇ‚Ìf’f‚ÉBAL ‚ª—L—p‚Å‚ ‚Á‚½‘½”­‚·‚èƒKƒ‰ƒX‰A‰e‚ð’悵‚½”x‘BŠà‚Ì1 —á. ‘æ42‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. “Œ‹ž. 2019”N7ŒŽ5“úD

•Ä“c_l, ¼‘ºt‰À, ìk‘¢, ”ò”~—º, ‰¬–ìL˜a, ¬ŽRˆë–ç, ¼žŠ“Ö˜Y, –L“c—DŽq, ¼‰ªˆÀ•F. ‹CŠÇŽx‹¾ŒŸ¸‚É‚Äf’f‚µ“¾‚½ƒŠƒ“ƒp–¬ŠÇ‹ØŽîÇ‚Ì1 —á. ‘æ42‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. “Œ‹ž. 2019”N7ŒŽ5“úD

¬ì”Ž‹v, Œáȉë•F, ”~–ìÊ, Žº•x˜ar, ‹ß“¡^‘ã, â“ŒOŠî, íŽRKˆê, ¼‰ªˆÀ•F. ‹CŠÇŽxšb‘§‚É‚¨‚¯‚éˆêd€Ž_‘fŽ_‰»ƒXƒgƒŒƒX‚Í‹C“¹‰ß•q«‚ð˜´i‚³‚¹‚é. ‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. “Œ‹žD2019”N6ŒŽ15“úD

¼žŠ“Ö˜Y, Œã“Œ‹vŽk, ¼”Ž”V, ‰¬–ìL˜a, ‘å’ËŒ›Ži, ¼‰ªˆÀ•F. ”ñ¬×–E”x‚ª‚ñ‚ɇ•¹‚µ‚½ˆ««‹¹…‚ɑ΂·‚ébevacizumab‚Ì—LŒø«‚Æ‘Ï«‰»‹@˜‚̉ðÍ. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‘åã. 2019”N6ŒŽ13“úD

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‰¬–ìL˜a, ‘å’ËŒ›Ži, ™–{³“¹, ª“Œ, ¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇV¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓàfibrocyte-like cell‚Ì‹@”\‰ðÍ. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‘åã. 2019”N6ŒŽ13“úD

˜aòrq, ˆ¢•”^Ž¡, Œã‰Í“à”üŽÑ, ¼ˆä•ü, Œã“Œ‹vŽk, ‰Á“¡K¬, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚邪‚ñ“ÁˆÙ“IRpodoplaninR‘ÌchLpMab-2‚Ìin vitro‚É‚¨‚¯‚éRŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‘åã. 2019”N6ŒŽ13“úD

²“¡³‘åC¼‰ªˆÀ•FCMartin Kolb. üˆÛ‰»”x‘gD‚Ì×–EŠOŠîŽ¿‚ªüˆÛ×–E‚ÌmiR-21”­Œ»‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. ‘æ18‰ñ”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒg•ªŽq•a‘ÔŒ¤‹†‰ï. ŽD–yD2019”N6ŒŽ1“úD

Œáȉë•FC’†£Ÿ‘¥C–Lè“ZC‰F“s‹{³“oC¼‰ªˆÀ•FD“¿“‡ŽsCOPDŒ[”­„iŽ–‹Æ‚Ì5”NŠÔ‚̬‰ÊD‘æ116‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïD–¼ŒÃ‰®D2019”N4ŒŽ26“úD

“à“¡Lm, ‰Í–ìO, ‹ß“¡^‘ã, ‰¬–ìL˜a, ²“¡³‘å, –L“c—DŽq, Œã“Œ‹vŽk, ¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‡•¹ŠÖ߃ŠƒEƒ}ƒ`‚ɑ΂·‚éJAK‘jŠQ–ò‚ÌŽg—pŒoŒ±D‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ïD‹ž“sD2019”N4ŒŽ16“úD

Tania Afroj, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Masatoshi Kisyuku, Atsuro Saijo, Atsushi Mitsuhashi, Kazuya Koyama, Hisatsugu Goto, Yasuhiko NishiokaDAnalyses of immuno-modulatory function of fibrocytes in tumor immunityD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ14“úD

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ. Kolb, Yasuhiko Nishioka. Fibrotic extracellular matrix upregulates pro-fibrotic miRNA expression of fibrocytesD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ14“úD

‰|–{‹I”V, –{ŠÔ‰h, ˆî£’¼•F, ‘êàVŽn, ˆäã‹`ˆê, Έ䊰, “cŒû‘P•v, òM—L, ŽR–ì‘וF, ’J–ìŒ÷“T, ¼‰ªˆÀ•F, –L“ˆŠ²¶, ‰¡‘ºŒõŽi, –…ìŽj˜N, ¬´…’¼Ž÷, {“c—²•¶DäPŒ´•a“I”wŒi‚ð—L‚·‚é“Á”­«ŠÔŽ¿«”x‰Š‚Ì—\Œã‚ÉŠÖ‚·‚錟“¢F‘½Ž{Ý‹¤“¯C‘OŒü‚«ƒRƒz[ƒgŒ¤‹†D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ14“úD

‰ªú±O‘×, ²“¡³‘å, XZr, ¬ŽRˆë–ç, ¬ì”Ž‹v, ìk‘¢, ¼‘ºt‰À, Yajuan Chen, –샓T, ˆ¢•”Gˆê, “Œ“‘ã, Œã“Œ‹vŽk, ‰Í–ìO, –L“c—DŽq, ㌴‹v“T, ¬˜HOs, ¼‰ªˆÀ•FDƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éWnt/B-ƒJƒeƒjƒ“/CBPƒVƒOƒiƒ‹‘jŠQ–òPRI-724‚É‚æ‚éRüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ14“úD

Hiroshi Nokihara, Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto, Yasuhiko NishiokaDA multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced NSCLC patients with interstitial lung diseaseD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ13“úD

¬ŽRˆë–ç, “à“¡Lm, ìk‘¢, ¼‘ºt‰À, ²“¡³‘å, ‰Í–ìO, –L“c—DŽq, Œã“Œ‹vŽk, Œáȉë•F, ¼‰ªˆÀ•FDŠÖ߃ŠƒEƒ}ƒ`‡•¹ŠÔŽ¿«”x‰ŠŠ³ŽÒ‚Ì‹}«ŒÄ‹z•s‘S‚Ì—Õ°“IŒŸ“¢D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ13“úD

¼‰ªˆÀ•F, Toby Maher, Gisli JenkinsDINMARKŽŽŒ±FIPFŠ³ŽÒ‚Å‚ÌECM ƒ^[ƒ“ƒI[ƒo[\ƒoƒCƒIƒ}[ƒJ[‚ÆŽ¾Š³is‚ÌŠÖ˜A‹y‚уjƒ“ƒeƒ_ƒjƒu‚ÌŒø‰Ê‚ð•]‰¿‚·‚鎎Œ±D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2019”N4ŒŽ13“úD
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
ˆÀ‘ŽC‰Í–ìOC¡‘qŒ’C“à“¡LmC‹ß“¡^‘ãC²“¡³‘åC–L“c—DŽqC¼‰ªˆÀ•FD’`”’àho«ˆÝ’°ÇAƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‚𔺂Á‚½MCTD‚Ì1—á. ‘æ30‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD‰ªŽRD2019”N12ŒŽ7“ú.

“à“¡LmC‰Í–ìOC¡‘qŒ’C‹ß“¡^‘ãC²“¡³‘åC–L“c—DŽqC¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚éANCA—z«ŠÔŽ¿«”x‰ŠÇ—á‚ÌŒŸ“¢. ‘æ30‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD‰ªŽRD2019”N12ŒŽ7“ú.

‰ª–{—I—¢, ìk‘¢, ‘å’ËŒ›Ži, ‹{–{’¼‹P, ‹g“cŒõ‹P, •Ä“c_l, –L“c—DŽq, Œáȉë•F, ¼‰ªˆÀ•FD‹¹o“à‚É‘½”­‚µ‚½ÎŠD‰»üˆÛ«ŽîᇂÌ1—áD‘æ121‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼D2019”N12ŒŽ1“úD

Γc‘ì–ç, ìk‘¢, •Ä“c_l, ¼‘ºŒ«“ñ, ŽR–{—y•½, ²“¡³‘å, ‰Í–ìO, Œ¬Œ´_, ¼‰ªˆÀ•F. Œ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚ÌŽ¡—Ã’†‚ÉdÇ‹Ø–³—ÍǃNƒŠ[ƒ[‚ð”­Ç‚µ‚½1—á. ‘æ121‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼D2019”N12ŒŽ1“úD

²ŒÃ‰ëG, ìk‘¢, ”ò”~—º, ûü‹´’¼Šó, ¡‘qŒ’, “à“¡Lm, ¼”Ž”V, ²“¡³‘å, –L“c—DŽq, Œ¬Œ´_, Œáȉë•F, ¼‰ªˆÀ•FDMycobacterium malmoense‚É‚æ‚é”xŠ´õÇ‚Ì2—áD‘æ70‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ï. ŽRŒûD2019”N11ŒŽ23“úD

ˆé‘º—S‘¾, ìk‘¢, •Ä“c_l, Œ¬Œ´_, ‘å’ËŒ›Ži, ²“¡³‘å, ”ò”~—º, ¼”Ž”V, âŒû‹Å, Œáȉë•F, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鈫«‹¹–Œ’†”çŽî‚Ì2ŽŸŽ¡—Â̌Ÿ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ŽRŒûD2019”N11ŒŽ23“úD

‘ºãsl, ìk‘¢, ¬ŽRˆë–ç, Œáȉë•F, ¼–{‘厑, ’؈äŒõO, ìãsšõ, ‹ß“¡˜a–ç, ²“¡³‘å, ‘å’ËŒ›Ži, Œ¬Œ´_, ¼‰ªˆÀ•F. ‘å—Ê‹¹…‚¨‚æ‚Ñ‹¹–ŒŽîᎂðŒ_‹@‚Éf’f‚³‚ꂽbó‘Bàh–EŠà‚̈ê—áD‘æ28‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ïDŽRŒûD2019”N11ŒŽ23“úD

Γc‘ì–çCìk‘¢C•Ä“c_lCâ“Œ‹IŽqC“à“¡LmC‰¬–ìL˜aC²“¡³‘åC‰Í–ìOC¼‘ºŒ«“ñCŽR–{—y•½C–L“c—DŽqCŒ¬Œ´_C¼‰ªˆÀ•FDŒ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚ÌŽ¡—Ã’†‚ÉdÇ‹Ø–³—ÍǃNƒŠ[ƒ[‚ð”­Ç‚µ‚½1—áD‘æ259‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2019”N8ŒŽ4“úD

ìk‘¢C¬ŽRˆë–çC²“¡³‘åC‚‹´’¼ŠóC¼‘ºt‰ÀC“à“¡LmC‰Í–ìOC–L“c—DŽqC¼‰ªˆÀ•FDƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éLck‘jŠQ‚ÌRüˆÛ‰»Œø‰ÊD‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD“¿“‡D2019”N7ŒŽ15“úD

‹ß“¡Œ’‰îC¼žŠ“Ö˜YCìk‘¢C‘å’ËŒ›ŽiC²“¡³‘åC•Ä“c_lC”ò”~—ºCŒã“Œ‹vŽkCŒ¬Œ´_C¼‰ªˆÀ•FD––½ŒŒŒŸ¸’l‚ð—p‚¢‚½”ñ¬×–E”xŠà‚ɑ΂·‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚ÌŒø‰Ê—\‘ªˆöŽq‚ÌŒŸ“¢D‘æ58‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2019”N7ŒŽ15“úD

ˆÀ‘ŽCìk‘¢C‹ß“¡^‘ãC²“¡³‘åC•Ä“c_lC‰¬–ìL˜aC”ò”~—ºC¼”Ž”VC‘å’ËŒ›ŽiCŒ¬Œ´_C¼‰ªˆÀ•F. Nivolumab“Š—^‚É‚æ‚è• …‚Ì’˜–¾‚ÈŒ¸­‚ð”F‚ß‚½ˆ««‹¹–Œ’†”çŽî‚Ì1—áD‘æ58‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2019”N7ŒŽ14“úD

‹ß“¡Œ\‘åCìk‘¢C‹ß“¡^‘ãC‰¬–ìL˜aC”ò”~—ºC•Ä“c_lC‘å’ËŒ›ŽiC²“¡³‘åCŒ¬Œ´_C¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚é‹ÇŠis”ñ¬×–E”xŠàŠ³ŽÒ‚ɑ΂·‚鉻Šw•úŽËü—Ö@Œã‚ÌDurvalumab‚É‚æ‚鎡—Â̗հ“IŒŸ“¢D‘æ58‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2019”N7ŒŽ14“úD

“à“¡m”üCìk‘¢C‹ß“¡^‘ãC²“¡³‘åC“à“¡LmC‰Í–ìOC–L“c—DŽqCŒáȉë•FCŒ¬Œ´_C¼‰ªˆÀ•F. ŠÖ߃ŠƒEƒ}ƒ`‚ÅŽ¡—Ã’†‚ÉRMDA5R‘Ì—z«‚ð‚Ý‚Æ‚ßA–³‹ØÇ«”畆‹Ø‰Š‚Æf’f‚³‚ꂽŠÔŽ¿«”x‰Š‚Ì2—á.‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD“¿“‡D2019”N7ŒŽ14“úD

•Ÿ‰Æ–ƒ”ü, –L“c—DŽq, ‰¬–ìL˜a, ‰Í–ìO, Œã“Œ‹vŽk, Œ¬Œ´_, Œáȉë•F, ¼‰ªˆÀ•F. Stevens-JohnsonÇŒóŒQŒã‚ɇ•¹‚µ‚½•Âǫ׋CŠÇŽx‰Š‚ɃXƒeƒƒCƒh‚¨‚æ‚у^ƒNƒƒŠƒ€ƒX‚ª—LŒø‚Å‚ ‚Á‚½1—á. ‘æ6‰ñ“ú–{ŒÄ‹zƒPƒAEƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï@’†‘EŽl‘Žx•”ŠwpW‰ï. “¿“‡D2019”N6ŒŽ8“úD

ŽO‹´“ÕŽu, ”ò”~—º, ‰¬–ìL˜a, ‹ß“¡^‘ã, –L“c—DŽq, Œã“Œ‹vŽk, ‹g“cŒõ‹P, ¬ì”Ž‹v, Œ¬Œ´_, ¼‰ªˆÀ•FD”x‘½Œ`Šà‚É‚¨‚¯‚éã”çŠÔ—t“]Š· (EMT)‚ÌŒŸ“¢D‘æ120‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚’mD2019”N5ŒŽ12“úD

ûü‹´’¼Šó, “à“¡Lm, ‹ß“¡^‘ã, ‰¬–ìL˜a, ‰Í–ìO, –L“c—DŽq, ŽO–Ø_˜a, Œáȉë•F, Œ¬Œ´_, ¼‰ªˆÀ•FDŽ¡—Ã’ïR«‚ÌSLE‚É”º‚¤Ô‰è‹…ᔂɃVƒNƒƒzƒXƒtƒ@ƒ~ƒhƒpƒ‹ƒX—Ö@‚ª’˜Œø‚µ‚½1—áD‘æ120‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚’mD2019”N5ŒŽ12“úD

ˆÀ‘Ž, ’†‘ºMŒ³, ‘å‰Y‰ë”Ž, ‘]‰ä•”ŒöŽq, Œ´“c•Žu, “¡ˆäŽu˜N, ŽO–Ø_˜a, ‰êì‹v”üŽq, ¼‰ªˆÀ•F, ˆÀ”{³”ŽD’·Šú‚ɂ킽‚錌¬”ÂŒ¸­‚ªæs‚µ‚½‰è‹…«Œ`Ž¿×–E—lŽ÷ó×–EŽîᇂÌ1—áD‘æ120‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚’mD2019”N5ŒŽ12“úD

¬ŽRˆë–çC“à“¡LmCìk‘¢C‹ß“¡^‘ãC¼‘ºt‰ÀC²“¡³‘åC‰Í–ìOC–L“c—DŽqCŒáȉë•FCŒã“Œ‹vŽkC¼‰ªˆÀ•F. ƒ}ƒEƒX”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚éV‹Kmulti-tyrosine kinase inhibitor TAS-115‚ÌRüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ258‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡D2019”N2ŒŽ3“úD

‹ß“¡^‘ã, ¬ì”Ž‹v, Žè’Ë•qŽj, â“ŒOŠî, Œáȉë•F, ¼‰ªˆÀ•FD‹CŠÇŽxšb‘§‚É‚¨‚¯‚郊ƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_(LPA)‚Ì–ðŠ„‚Æ‚»‚Ì‘jŠQŒø‰Ê‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ1‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï’†‘EŽl‘Žx•”’n•û‰ïDL“‡D2019”N2ŒŽ2“úD
£ƒy[ƒW‚ÌTOP‚Ö
2018”N‹ÆÑ
y‰¢•¶’˜‘z
Hisatsugu Goto, Yasuhiko Nishioka. ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer? Clinical Relevance of Genetic Factors in Pulmonary Diseases, Takeshi Kaneko, Editor, pp295-315, 2018. Springer.
y‰¢•¶‘à“™z
Goto H, Nishioka Y. Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression. Int J Mol Sci 19(1):98, 2018.
y‰¢•¶Œ´’˜z
Kishi M, Aono Y, Sato S, Koyama K, Azuma M, Abe S, Kawano H, Kishi J, Toyoda Y, Okazaki H, Ogawa H, Uehara H, Nishioka Y. Blockade of platelet-derived growth factor receptor-ƒÀ, not receptor-ƒ¿ ameliorates bleomycin-induced pulmonary fibrosis in mice. PLOS ONE 13(12):e0209786, 2018.

Ogawa H, Azuma M, Tsunematu T, Morimoto Y, Kondo M, Tezuka T, Nishioka Y, Tsuneyama K. Neutrophils induce smooth muscle hyperplasia via neutrophil elastase-induced FGF-2 in a mouse model of asthma with mixed inflammation. Clin Exp Allergy 48(12):1715-1725, 2018.

Mitsuhashi A, Okuma Y, Zenke Y, Hosomi Y. Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases. Mol Clin Oncol 9(5):561-565, 2018.

Hanibuchi M, Kakiuchi S, Atagi S, Ogushi F, Shimizu E, Haku T, Toyoda Y, Azuma M, Kondo M, Kawano H, Otsuka K, Sakaguchi S, Nokihara H, Goto H, Nishioka Y. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 125:93-99, 2018.

Chikugo M, Sebe M, Tsutsumi R, Iuchi M, Kishi J, Kuroda M, Harada N, Nishioka Y, Sakaue H. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. J Med Invest 65(3,4):166-170, 2018.

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP. Notch3-dependent ƒÀ-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat Commun 9(1):3198, 2018.

Kondo M, Ogino H, Ogawa H, Afroj T, Toyoda Y, Sakaguchi S, Tsuboi M, Bando Y, Goto H, Tsuneyama K, Nishioka Y. A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition. Respir Med Case Rep 25:119-121, 2018.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARKRtrial. BMJ Open Respir Res 5(1):e000325, 2018.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M. Macitentan reduces progression of TGF-ƒÀ1-induced pulmonary fibrosis and pulmonary hypertension. Eur Respir J 52(2): pii1701857, 2018.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig 56(4):268-291, 2018.

Kishi S, Minato M, Saijo A, Murakami N, Tamaki M, Matsuura M, Murakami T, Nagai K, Abe H, Nishioka Y, Doi T. A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. Intern Med 57(9):1259-1263, 2018.

Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget 9(32):22480-22497, 2018.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Toyoda Y, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells. Sci Rep 8(1):6760, 2018.

Kozai H, Toyoda Y, Goto H, Kishi J, Tobiume M, Yamashita Y, Nishimura H, Kondo M, Kawano H, Nishioka Y. A case of interstitial pneumonia associated with anti-PL-7 antibody in a patient with rheumatoid arthritis. J Med Invest 65(1,2):147-150, 2018.

Bellaye PS, Shimbori C, Upagupta C, Sato S, Shi W, Gauldie J, Ask K, Kolb MDLysyl Oxidase-like 1 Protein Deficiency Protects Mice from AdTGF-ƒÀ1 induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol 58(4):461-470,2018.

Saijo A, Goto H, Nakano M, Mitsuhashi A, Aono Y, Hanibuchi M, Ogawa H, Uehara H, Kondo K, Nishioka Y. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. Cancer Lett 421:17-27, 2018.

Goto H, Okano Y, Machida H, Hatakeyama N, Ogushi F, Haku T, Kanematsu T, Urata T, Kakiuchi S, Hanibuchi M, Sone S, Nishioka Y. Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer. Respir Investig 56(1):80-86, 2018.

Bellaye PS, Shimbori C, Yanagihara T, Carlson DA, Hughes P, Upagupta C, Sato S, Wheildon N, Haystead T, Ask K, Kolb M. Synergistic role of HSP90ƒ¿ and HSP90ƒÀ to promote myofibroblast persistence in lung fibrosis. Eur Respir J 51(2):pii1700386, 2018.

Nishijima H, Kajimoto T, Matsuoka Y, Mouri Y, Morimoto J, Matsumoto M, Kawano H, Nishioka Y, Uehara H, Izumi K, Tsuneyama K, Okazaki IM, Okazaki T, Hosomichi K, Shiraki A, Shibutani M, Mitsumori K, Matsumoto M. Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). J Autoimmun 86:75-92, 2018.
y˜a•¶’˜‘z
¬ŽRˆë–ç, ¼‰ªˆÀ•FDƒeƒƒƒAL’·‚Æ”xüˆÛÇDŒÄ‹zŠíŽ¾Š³f’fŽ¡—ÃAƒvƒ[ƒ`4uŠÔŽ¿«”x‰ŠE”xüˆÛÇ‚Æ—Þ‰Ž¾Š³v ŽO“ˆ—W ‘•ÒW, ŒáȈÀ—Ç‘¾ ê–å•ÒW pp20-25C2018D’†ŽR‘“XD

¼‰ªˆÀ•FD‰ß•q«”x‰ŠD¡“ú‚ÌŽ¡—ÃŽwj2018”N”Å@•ŸˆäŽŸ–î, ‚–ؽ, ¬Žºˆê¬ ‘•ÒW, pp309-310, 2018. ˆãŠw‘‰@D
y˜a•¶Œ´’˜z
XZrC‰Í–ìOC–L“c—DŽqC¬ŽRˆë–çC¼‘ºt‰ÀCìk‘¢CŒã“Œ‹vŽkC¼‰ªˆÀ•FDƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚éüˆÛ‰è×–E‘BˆöŽqŽó—e‘Ì‘jŠQ–ò‚ÌRüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢D•ªŽqŒÄ‹zŠí•a 22(1):96-98, 2018.
y˜a•¶‘àz
Œáȉë•FD‚º‚ñ‚»‚­‚ÌŽ¡—ÂőåØ‚È‚±‚ÆDŽl‘ˆãŠwŽGŽ 74(5,6):159-162, 2018.

¼‰ªˆÀ•FCûü‹´ÍDŠª“ªŒ¾DŽl‘ˆãŠwŽGŽ 74(5,6):125, 2018.

¼‰ªˆÀ•FD”x‚ª‚ñ–Ɖu—Ö@‚Ìŋ߂̘b‘èD“¿“‡Œ§—Õ°“à‰Èˆã‰ï‰ï•ñ 23:40-43, 2018D

–L“c—DŽqDŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—ÃD“¿“‡Œ§—Õ°“à‰Èˆã‰ï‰ï•ñ 23:36-39, 2018D

¬ŽRˆë–ç, ¼‰ªˆÀ•FDƒeƒƒƒAL’·‚Æ”xüˆÛÇDŒÄ‹zŠí“à‰È 34(3):300-303, 2018D

‰¬–ìL˜a, Œã“Œ‹vŽk, ¼‰ªˆÀ•FDŠPšu‚ÌŒ´ˆö‚Æ‚µ‚ÄŒ©“¦‚µ‚Ä‚Í‚È‚ç‚È‚¢Žîá‡DŒÄ‹zŠíƒWƒƒ[ƒiƒ‹ 66(3):458-465, 2018D

–L“c—DŽq, ¼‰ªˆÀ•FD–òÜ«”xáŠQDŒÄ‹zŠí“à‰È 34(Suppl.1):454-461, 2018.

¼žŠ“Ö˜Y, Œ¬Œ´_. ALK—z«”x‚ª‚ñ‚ÌŽ¡—ÃV[ƒNƒGƒ“ƒX. Žîᇓà‰È 21(5):536-543, 2018.

¼‰ªˆÀ•FDŽ¿‹^‰ž“š ƒvƒ‚©‚çƒvƒ‚Öu‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚É‚¨‚¯‚é‚׃Šƒ€ƒ}ƒuiƒxƒ“ƒŠƒXƒ^Rj‚ÌŽg—p–@viŽ¿–âŽÒjD“ú–{ˆãŽ–V•ñ 4908:55, 2018.

–L“c—DŽqC¼‰ªˆÀ•FDƒjƒ“ƒeƒ_ƒjƒu’P“ƗÖ@DŒÄ‹zŠíƒWƒƒ[ƒiƒ‹ 66(2):229-235, 2018D

¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—Ã`Å‹ß‚Ìi•à`D“ú–{“à‰ÈŠw‰ïŽGŽ 107(3):505-509, 2018.

Œã“Œ‹vŽkC¼žŠ“Ö˜YC¼‰ªˆÀ•FD‚ª‚ñ‚Ìi“W‚É‚¨‚¯‚éüˆÛ×–E‚Ì‹@”\‚Æ–ðŠ„`ŒŒŠÇV¶‘jŠQ–ò‘Ï«‚Æ‚ª‚ñŠ²×–E—l×–E‚Ì—U“±`D•ªŽqŒÄ‹zŠí•a 22(1):49-51, 2018.

¼‰ªˆÀ•FDŽ¿‹^‰ž“š ƒvƒ‚©‚çƒvƒ‚Öu‹­”çǂɇ•¹‚µ‚½ŠÔŽ¿«”x‰Š‚ÌŽ¡—Ö@vi‰ñ“šŽÒjD“ú–{ˆãŽ–V•ñ 4898:54-55, 2018.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hiroshi Nokihara, Hisatsugu Goto, Yasuhiko Nishioka. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. The IASLC 19th World Conference on Lung Cancer. Toronto,Canada. 2018”N9ŒŽ24“ú.

Toby Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Daniel Wachtlin, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ18“úD

Sakae Homma, Yasuhiro Kondoh, Motoyasu Kato, Tomoaki Hoshino, Hiroshi Mukae, Masashi Bando, Takafumi Suda, Takashi Kido, Yoshinori Tanino, Tomoo Kishaba, Noboru Hattori, Yoshio Taguchi, Takefumi Saitoh, Yasuhiko Nishioka, Kazuyoshi Kuwano, Kazuma Kishi, Naohiko Inase, Shinichi Sasaki, Hajime Takizawa, Takeshi Johkoh, Fumikazu Sakai, Susumu Sakamoto. Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ18“úD

Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Sato, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki, Yasuhiko Nishioka. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ16“úD

Hisatsugu Goto, Taito Yamago, Atsuro Saijo, Hirokazu Ogino, Makoto Tobiume, Kenji Otsuka, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara, and Yasuhiko Nishioka. Involvement of insulin-like growth factor in RANKL-targeted therapy in mouse model of lung cancer bone metastasis.@ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ23“ú.

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ Kolb. The fibrotic extracellular matrix induces exosomal pro-fibrotic miRNA production of fibrocytes. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ21“ú.

Kazuya Koyama, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Hirohisa Ogawa, Hisanori Uehara, Yasuhiko Nishioka. Novel Multi-tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Pulmonary Fibrosis In Mice. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ21“ú.

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric White, Vincent Cottin, Imre Noth, Moises Selman, Daniel Wachtlin, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Investigating the effect of nintedanib on changes in biomarkers of ECM turnover in patients with IPF and limited FVC impairment: design of the INMARK study. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ20“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•FD”xŠàŽ¡—Âɂ¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ܂̈ʒu‚¯‚ÆV“WŠJD‘æ27‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‚¼D2018”N12ŒŽ15“úD

Œã“Œ‹vŽkDüˆÛ×–Eifibrocytesj‚ð•W“I‚Æ‚µ‚½ŒŒŠÇV¶‘jŠQ–ò‘Ï«ƒƒJƒjƒYƒ€‚̉𖾂Ǝ¡—Âւ̓WŠJD‘æ59‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2018”N11ŒŽ30“úD

û•£¹‹B, ˆÀ‘îM“ñ, ‘å‹ø•¶—², ŽRèÍ, —t‹v‹MŽi, Œ¬Œ´_, ¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‡•¹–¢Ž¡—Ãis”ñ¬×–E”xŠà‚ɑ΂·‚é TS-1+CBDCA •¹—p—Ö@‚Ì‘æ II ‘Š—Õ°ŽŽŒ±D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ[ƒNƒVƒ‡ƒbƒv)D“Œ‹žD2018”N11ŒŽ30“úD

¼‰ªˆÀ•FD•Ï‰»‚·‚é“Á”­«”xüˆÛǂ̃}ƒl[ƒWƒƒ“ƒg\Ž¾Š³—‰ð‚ÆŽ¡—Ãí—ª\D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D“Œ‹žD2018”N11ŒŽ29“úD

¼‰ªˆÀ•F, ˆ¢•”^Ž¡, ‹àŽq”ü‰Ø, ŽO‹´“ÕŽu, ‘å’ËŒ›Ži, Œã“Œ‹vŽk, ‰Á“¡K¬. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éV‹KŽ¡—Ö@ŠJ”­‚ð–ÚŽw‚µ‚½‘O—Õ°Œ¤‹†. ‘æ56‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï(ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“). ‰¡•lD2018”N10ŒŽ20“úD

¼‰ªˆÀ•FD“Á”­«”xüˆÛÇ‚Ìf’f‚ÆŽ¡—Ã`RüˆÛ‰»–ò‚̈Ӌ``D‘æ81‰ñ“ú–{ŒÄ‹zŠíŠw‰ïE“ú–{Œ‹Šj•aŠw‰ïE“ú–{ƒTƒ‹ƒRƒCƒh[ƒVƒX^“÷‰èŽî«Ž¾Š³Šw‰ï‹ãBŽx•”H‹GŠwpu‰‰‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D’·èD2018”N10ŒŽ6“úD

Œáȉë•FD‚º‚ñ‚»‚­‚ÌŽ¡—ÂőåØ‚È‚±‚ÆD‘æ257‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïŽs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€D“¿“‡D2018”N8ŒŽ5“úD

¼‰ªˆÀ•FD”x‚ª‚ñi“W‚ÉŠÖ‚í‚éüˆÛ×–E‚Ì‹@”\‰ðÍ‚©‚玡—Âւ̓WŠJD‘æ27‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ï ŠwpW‰ïE‘‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D‰¡•lD2018”N7ŒŽ19“úD

¼‰ªˆÀ•FD”xŠàŽ¡—Âɂ¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ܂̈ʒu‚¯‚ÆV“WŠJD‘æ108‰ñ“ú–{”xŠàŠw‰ïŠÖ¼Žx•”ŠwpW‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‘åãD2018”N6ŒŽ30“úD

¼‰ªˆÀ•FDi‰»‚·‚é”x‚ª‚ñ‚ÌŽ¡—à `i‚ÞƒQƒmƒ€ˆã—Â̌»ê‚©‚ç`D‘æ31‰ñ“ú–{ŠàŠw‰ïŽs–¯ŒöŠJuÀD“¿“‡D2018”N5ŒŽ27“úD

Œã“Œ‹vŽkDŒŒŠÇV¶D‘æ22‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï(‹³ˆçƒZƒ~ƒi[)D“Œ‹žD2018”N5ŒŽ17“úD

û•£¹‹B, ˆÀ‘îM“ñ, ‘å‹ø•¶—², ´…‰pŽ¡, —t‹v‹MŽi, Œ¬Œ´_, ¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‡•¹–¢Ž¡—Ãis”ñ¬×–E”xŠà‚ɑ΂·‚éTS-1+CBDCA•¹—p—Ö@‚Ì‘æII‘Š—Õ°ŽŽŒ±. ‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€)D‘åãD2018”N4ŒŽ29“úD

¼‰ªˆÀ•FD”x‚ª‚ñf—ÂÌÅ‘Oü `i‚Þ•ªŽqf’f‚ƌ•ʉ»ˆã—Ã`D‘æ17‰ñ“ú–{ŠàŽ¡—Êw‰ïŽs–¯ŒöŠJuÀD“¿“‡D2018”N4ŒŽ14“úD
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
‰¬–ìL˜aC‘å’ËŒ›ŽiCŽO‹´“ÕŽuC–Øh¹rC¼‰ªˆÀ•FD”xŠàEˆ««‹¹–Œ’†”çŽîƒ}ƒEƒXƒ‚ƒfƒ‹‚ð—p‚¢‚½–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Ɖ»Šw—Ö@‚Ì•¹—pŒø‰Ê‚ÉŠÖ‚·‚錟“¢D‘æ31‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠwpW‰ï‘‰ïD“Œ‹žD2018”N12ŒŽ13“úD

•Ä“c_l, ‘å’ËŒ›Ži, ‰¬–ìL˜a, ¼žŠ“Ö˜Y, Œã“Œ‹vŽk, Œ¬Œ´_, ¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‡•¹”ñ¬×–E”xŠà‚ɑ΂·‚é 2 ŽŸ‰»Šw—Ö@‚ÌŒŸ“¢D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD“Œ‹žD2018”N12ŒŽ1“úD

¼žŠ“Ö˜Y, ¼”Ž”V, ‹ß“¡Œ’‰î, Œã“Œ‹vŽk, ‰¬–ìL˜a, Œ¬Œ´_, –L“c—DŽq, ¼‰ªˆÀ•FD”ñ¬×–E”x‚ª‚ñ‚ɑ΂·‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ܂̶‘¶ŠúŠÔ‚ÉŠÖ‚·‚é—\Œã•s—LjöŽq‚ÌŒŸ“¢D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD“Œ‹žD2018”N11ŒŽ30“úD

•Ä“c_lC‰¬–ìL˜aC–L“c—DŽqC‰Í–ìOC‘å’ËŒ›ŽiC¼žŠ“Ö˜YCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•F. ‚—î”xŠàŠ³ŽÒ‚ÌŽá”NŽÒ‚Æ”äŠr‚µ‚½—Õ°“I“Á’¥. ‘æ56‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‰¡•lD2018”N10ŒŽ18“úD

‘å’ËŒ›Ži, Œã“Œ‹vŽk, ‰¬–ìL˜a, ¼žŠ“Ö˜Y, ¼‰ªˆÀ•F. ‰»Šw—Ö@‚ÍŽîᇓà‚ÌMDSCs‚ðŒ¸­‚³‚¹‚邱‚Æ‚É‚æ‚èRPD-1R‘Ì‚ÌŒø‰Ê‚ð‘‹­‚·‚é. ‘æ77‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‘åã. 2018”N9ŒŽ27“ú.

ŽR“cT“ñ, ‹àŽq”ü‰Ø, ‘“cŽéŽq, ˆ¢•”^Ž¡, ”ˆär‰î, [ŽR³‹v, ¼‰ªˆÀ•F, ‰Á“¡K¬. ‚ª‚ñ“ÁˆÙ“Ipodoplanin‚ð”FŽ¯‚·‚éƒqƒgƒLƒƒ‰‰ü•Ïƒ‚ƒmƒNƒ[ƒiƒ‹R‘ÌichLpMab-23j‚ÌRŽîᇌø‰Ê‚¨‚æ‚шÀ‘S«. ‘æ77‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‘åã. 2018”N9ŒŽ27“ú.

”ˆär‰î, ‘åÎ’qˆê, ‹àŽq”ü‰Ø, ŽR“cT“ñ, ˆ¢•”^Ž¡, ¼‰ªˆÀ•F, ì“cŠw, Œ´“c_”V, ‰Á“¡K¬. ŒûoG•½ã”çŠà‚É‚¨‚¯‚éRƒ|ƒhƒJƒŠƒLƒVƒ“R‘Ì‚ÌADCC‚É‚æ‚éRŽîᇌø‰Ê. ‘æ77‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‘åã. 2018”N9ŒŽ27“ú.

XŒËŽ–í, ´…—Ç‘½, ‚‹´®Žq, ‰ºàVLs, “Œ“‘ã, ‰Í–ìO, ¼‰ªˆÀ•F, •Ÿ“c’B–ç, ¬•éŒ’‘¾˜N, “c’†•Û. ‘æ91‰ñ“ú–{¶‰»Šw‰ï‘å‰ï. ‹ž“sD2018”N9ŒŽ24-26“ú.

‰¬–ìL˜aCû•£¹‹BCŠ`“à‘ŽiCˆÀ‘îM“ñC‘å‹ø•¶—²C´…‰pŽ¡C—t‹v‹MŽiC‘å’ËŒ›ŽiC¼žŠ“Ö˜YCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‡•¹–¢Ž¡—Ãis”ñ¬×–E”xŠà‚ɑ΂·‚éTS-1+CBDCA•¹—p—Ö@‚Ì‘æ‡U‘Š—Õ°ŽŽŒ±D‘æ16‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ïD_ŒËD2018”N7ŒŽ21“úD

Œáȉë•FC–©‹`²C–؉ºŸOC‹ß“¡^‘ãC¼‰ªˆÀ•FDƒNƒŠ[ƒjƒ“ƒO‹Æ‚Ì•v•w‚É”­Ç‚µ‚½‰ÄŒ^‰ß•q«”x‰Š—áD‘æ49‰ñ“ú–{E‹ÆEŠÂ‹«ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ïEŠwp‘å‰ïD‰¡•lD2018”N7ŒŽ20“úD

¼žŠ“Ö˜YCŒã“Œ‹vŽkC¼”Ž”VC”ò”~—ºC‰¬–ìL˜aC•Ä“c_lC¼‰ªˆÀ•FD”x‚ª‚ñ‚̈««‹¹…‚ɑ΂·‚é bevacizumab ‚Ì—LŒø«‚Æ‘Ï«‰»‹@˜‚̉ðÍD‘æ27‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ï ŠwpW‰ïE‘‰ïD‰¡•lD2018”N7ŒŽ19“úD

‹ß“¡^‘ãCŽè’Ë•qŽjC¬ì”Ž‹vCŒáȉë•FC¼‰ªˆÀ•FDƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚ð•W“I‚É‚µ‚½ƒAƒŒƒ‹ƒM[«‹C“¹‰ŠÇ§Œä‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïDç—tD2018”N6ŒŽ22“úD

¬ì”Ž‹vCŒáȉë•FC‹ß“¡^‘ãC¼‰ªˆÀ•F. _Œo¬’·ˆöŽqiNGF)‚̓«šb‘§‚É‚¨‚¯‚é‹C“¹‰ß•q«˜´i‚ɑ΂·‚é–ðŠ„‚Æ‚»‚̃ƒJƒjƒYƒ€. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïDç—tD2018”N6ŒŽ22“úD

–L“c—DŽqC¬ŽRˆë–çC¼‘ºt‰ÀCìk‘¢C¼žŠ“Ö˜YC”ò”~—ºC‰¬–ìL˜aC•Ä“c_lC¼‰ªˆÀ•F. “ûŠàŠ³ŽÒ‚Ì•úŽËüŽ¡—ÃŒã‚É”­Ç‚µ‚½•úŽËü”x‰Š‚É‚¨‚¯‚é‹CŠÇŽx”x–Eôò‰t‚Ì—Õ°“IŒŸ“¢. ‘æ41‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. “Œ‹ž. 2018”N5ŒŽ25“ú.

ìk‘¢C–L“c—DŽqC¼žŠ“Ö˜YC”ò”~—ºC‰¬–ìL˜aC•Ä“c_lC¬ŽRˆë–çC¼‘ºt‰ÀC¼‰ªˆÀ•F. EBUS-TBNAŒã‚ÉcŠu‰Š‚ð”­Ç‚µ‚½Ç—á‚É‚¨‚¯‚éŠëŒ¯ˆöŽq‚ÌŒŸ“¢. ‘æ41‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. “Œ‹ž. 2018”N5ŒŽ24“ú.

‘å’ËŒ›ŽiCŒã“Œ‹vŽkC‰¬–ìL˜aC¼žŠ“Ö˜YCû•£¹‹BC¼‰ªˆÀ•F. ”xŠàEˆ««‹¹–Œ’†”çŽîƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Ɖ»Šw—Ö@‚Ì•¹—pŒø‰Ê. ‘æ22‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ïD“Œ‹žD2018”N5ŒŽ17“úD

‰¬–ìL˜aCŒã“Œ‹vŽkC‘å’ËŒ›ŽiC¼žŠ“Ö˜YCû•£¹‹BC¼‰ªˆÀ•F. üˆÛ×–E‚ªŽîᇖƉu‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ22‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ïD“Œ‹žD2018”N5ŒŽ16“úD

”ò”~—ºC‰¬–ìL˜aCAfroj TaniaCŒã“Œ‹vŽkCŒ¬Œ´_C‹g“cŒõ‹PCìãsšõC‘ê‘òGŒõC¬ì”Ž‹vCíŽRKˆêC¼‰ªˆÀ•FDã”çŠÔ—t“]Š· (EMT)‚ª”x‘½Œ`Šà‚̈««‰»‚ÉŠñ—^‚·‚é‰Â”\«‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‘åãD2018”N4ŒŽ28“úD

¬ŽRˆë–çC–L“c—DŽqC¼‘ºt‰ÀCìk‘¢CXZrC‰Í–ìOCŒã“Œ‹vŽkC¼‰ªˆÀ•FDƒ}ƒEƒX”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚émulti-tyrosine kinase inhibitor TAS-115‚ÌRüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‘åãD2018”N4ŒŽ28“úD

¼‘ºt‰ÀCXZrC–L“c—DŽqC—é]—ÁŽqC¬ŽRˆë–çCìk‘¢C“à“¡LmC‰Í–ìOCŒã“Œ‹vŽkC¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚é“Á”­«”xüˆÛǂɑ΂·‚éNintedanib‚ÌŽ¡—ÃÇ—á‚ÌŒŸ“¢D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‘åãD2018”N4ŒŽ27“úD

“à“¡LmC‰Í–ìOCŽR‰º—Y–çC‹ß“¡^‘ãC‰¬–ìL˜aC–L“c—DŽqCŠÝCŒã“Œ‹vŽkC¼‰ªˆÀ•FDƒAƒUƒ`ƒIƒvƒŠƒ“•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½ŠÔŽ¿«”x‰Š‡•¹RMDA5R‘Ì—z«”畆‹Ø‰Š‚Ì3—áD‘æ62‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ïD“Œ‹žD2018”N4ŒŽ26“úD

–L“c—DŽqCû•£¹‹BCŠ`“à‘ŽiCˆÀ‘îM“ñC‘å‹ø•¶—²C´…‰pŽ¡C—t‹v‹MŽiCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‡•¹–¢Ž¡—Ãis”ñ¬×–E”xŠà‚ɑ΂·‚éTS-1+CBDCA•¹—p—Ö@‚Ì‘æ‡U‘Š—Õ°ŽŽŒ±D‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïD‹ž“sD2018”N4ŒŽ14“úD

‰¬–ìL˜aCû•£¹‹BC¼žŠ“Ö˜YC‘å’ËŒ›ŽiC–L“c—DŽqCŒã“Œ‹vŽkC¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@‚Ì”xŠàÇ—á‚É‚¨‚¢‚Ä‚—îŽÒ‚ÆŽá”NŽÒ‚ð”äŠr‚µ‚½Œã‚ëŒü‚«Œ¤‹†D‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïD‹ž“sD2018”N4ŒŽ14“úD
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
²“¡³‘å, –L“c—DŽq, “à“¡Lm, •Ä“c_l, ìk‘¢, ¼‘ºt‰À, ‹ß“¡^‘ã, ¬ŽRˆë–ç, ‰Í–ìO, Œã“Œ‹vŽk, ¼‰ªˆÀ•FD‹CŠÇŽx”x–Eôò‰t’†fibrocyte‚É‚¨‚¯‚émiR-21”­Œ»‚ÌŽ¾Š³•Ê·ˆÙ‚ÉŠÖ‚·‚錟“¢D‘æ27‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ïD‚¼D2018”N12ŒŽ15“úD

â“ŒOŠî, ‹ß“¡^‘ã, ‹{é—º, ‰¬–ìL˜a, ”ò”~—º, ”ö–î„Žu, ¬ì”Ž‹v, ‰Í–ìO, –L“c—DŽq, Œ¬Œ´_, Œáȉë•F, Œã“Œ‹vŽk, ¼—Ç_, ¼‰ªˆÀ•FDƒGƒC‚ÌŽh‘nŒã‚É”­Ç‚µ‚½”畆Mycobacterium massilienseǂ̈ê—áD‘æ69‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ïD‚¼D2018”N12ŒŽ15“úD

Œ´“cŽÑŠó, ‹ß“¡^‘ã, ¼‘ºt‰À, “à“¡Lm, ‰Í–ìO, ‘åè—T—º, â“Œ—Ç”ü, ûü‹´’¼Šó, ìk‘¢, ¼‰ªˆÀ•F, ‰¬–ìL˜a, ”ò”~—º, ¼žŠ“Ö˜Y, Œ¬Œ´_, –L“c—DŽq, Œáȉë•F, Œã“Œ‹vŽk, ㌴‹v“T, Š—´™ZD–TŽîᇫ_ŒoÇŒóŒQ‚ð‡•¹‚µ‚½¬×–E”xŠà‚̈ê—áD‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD‚¼D2018”N12ŒŽ15“úD

â“Œ‹IŽq, ‹ß“¡^‘ã, ‰Í–ìO, “¡–ì‘׋P, ‰ª‹v–«–ç, –L“c—DŽq, Œ¬Œ´_, Œáȉë•F, Œã“Œ‹vŽk, ‚ŽR“NŽ¡, ¼‰ªˆÀ•FD’×ᇫ‘å’°‰Š‰Á—Ã’†‚É”­Ç‚µCŽ¡—Âɓïa‚µ‚½ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚̈ê—áD‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD‚¼D2018”N12ŒŽ15“úD

‹{–{Œ›ÆC‹ß“¡^‘ãC“à“¡LmCŽR蔎‹PC–L“c—DŽqC‰¬–ìL˜aC‰Í–ìOCŒã“Œ‹vŽkCŠ—´™ZC¼‰ªˆÀ•FD–Ɖu‰îÝ«‰óŽ€«ƒ~ƒIƒpƒ`[‚Ì1—áD‘æ119‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD¼ŽRD2018”N12ŒŽ2“úD

‹àŽq—y—SC‹ß“¡^‘ãCûü‹´’¼ŠóC”ò”~—ºC‰¬–ìL˜aC²“¡³‘åCŽO–Ø_˜aCŒã“Œ‹vŽkCˆÀ”{³”ŽC¼‰ªˆÀ•FD‘½”­¬Œ‹ß‰e‚ð”F‚ß‚½HIV—z«ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ì1—áD‘æ119‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD¼ŽRD2018”N12ŒŽ2“úD

ŽR‰º—Y–çC‰Í–ìOC¡‘qŒ’C“à“¡LmC‹ß“¡^‘ãC‰¬–ìL˜aC²“¡³‘åC–L“c—DŽqCŒã“Œ‹vŽkC¼‰ªˆÀ•FDTAFROÇŒóŒQ‚Ì1—áD‘æ29‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD‚¼D2018”N12ŒŽ1“úD

“à“¡LmC‰Í–ìOC‹ß“¡^‘ãC‰¬–ìL˜aC²“¡³‘åC–L“c—DŽqCŒã“Œ‹vŽkC¼‰ªˆÀ•FDEBƒEƒCƒ‹ƒXÄŠˆ«‰»‚𔽕œ‚µ‚½‚Ž¾Š³Šˆ“®«ŠÖ߃ŠƒEƒ}ƒ`‚ɑ΂µ‚ăAƒoƒ^ƒZƒvƒg‚ª—LŒø‚Å‚ ‚Á‚½1—áD‘æ29‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD‚¼D2018”N11ŒŽ30“úD

‹ß“¡^‘ãCâ“ŒOŠîCìk‘¢C¼‘ºt‰ÀC¬ŽRˆë–çC²“¡³‘åC–L“c—DŽqCŒáȉë•FC¬ì”Ž‹vCŒã“Œ‹vŽkC¼‰ªˆÀ•FDƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚ð•W“I‚É‚µ‚½ƒAƒŒƒ‹ƒM[«‹C“¹‰ŠÇ§Œä‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ257‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2018”N8ŒŽ5“úD

ûü‹´’¼ŠóC‰¬–ìL˜aCû•£¹‹BC¼žŠ“Ö˜YC”ò”~—ºC¼”Ž”VC•Ä“c_lC•Ÿ‰Æ–ƒ”üCŽO‹´“ÕŽuC‹{–{Œ›ÆCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚é‚—îŽÒ”xŠà‚Ì—Õ°“IŒŸ“¢D‘æ257‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2018”N8ŒŽ5“úD

X‚ ‚¸‚³C“à“¡LmCŽRú±”Ž‹PC—Ñ—ŒbCâ“Œ‹IŽqCŒ´“c¹ŠóC‰Í–ìOC–L“c—DŽqCŒã“Œ‹vŽkCŠ—´™ZC‹v•Û‹X–¾C¼‰ªˆÀ•FD–Ɖu‰îÝ«‰óŽ€«ƒ~ƒIƒpƒ`[‚Ì1—á. ‘æ257‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2018”N8ŒŽ5“úD

ŽO‹´“ÕŽuCìk‘¢C•Ä“c_lC¼žŠ“Ö˜YC”ò”~—ºC‰¬–ìL˜aC‹ß“¡^‘ãCûü‹´’¼ŠóCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚é–òÜ«ŠÔŽ¿«”xŽ¾Š³‚ÌŒŸ“¢B‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï^‘æ57‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï ŽáŽèŒü‚¯‚Ì‹³ˆçƒZƒ~ƒi[. o‰_D2018”N7ŒŽ15“úD
@
X•¶C•Ä“c_lC‹ß“¡^‘ãC‰¬–ìL˜aC”ò”~—ºC¼žŠ“Ö˜YC•Ÿ‰Æ–ƒ”üCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FD•¡Ž‹‚ð”­Ç‚µAŽÎ‘ä•”ŽîᇂðŒ_‹@‚Éf’f‚³‚ꂽ”ñ¬×–E”xŠà‚Ì1—áD‘æ57‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïDo‰_D2018”N7ŒŽ14“úD

š d“¹‘åC•Ä“c_lC‰Í–ìOC¼žŠ“Ö˜YC”ò”~—ºC‹ß“¡^‘ãCâ“ŒOŠîC¬ì”Ž‹vCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FD’°Œ^”x‘BŠà‚Ì1—áD‘æ57‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïDo‰_D2018”N7ŒŽ14“úD

â“Œ‹IŽqC–L“c—DŽqC‰Í–ìOC²“¡³‘åC¬ŽRˆë–çC¼‘ºt‰ÀCìk‘¢C“à“¡LmCŒáȉë•FC¼‰ªˆÀ•FD“–‰È‚ÅŒoŒ±‚µ‚½RMDA5R‘Ì—z«”畆‹Ø‰Š‡•¹ŠÔŽ¿«”x‰Š‚Ì—Õ°‘œ‚ÌŒŸ“¢D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïDo‰_D2018”N7ŒŽ14“úD

‘½”¦—Lä»”TC‰¬–ìL˜aC¼žŠ“Ö˜YC¼”Ž”VC‹ß“¡^‘ãCâ“Œ—Ç”üC¼–{‘厑CŒã“Œ‹vŽkC‘ê‘òGŒõC¼‰ªˆÀ•FDˆ««‹¹…‚ðŒ_‹@‚Éf’f‚³‚ꂽ•úŽËü—U”­ŒŒŠÇ“÷Žî‚Ì1—áD‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïDo‰_D2018”N7ŒŽ14“úD

“à“¡LmCX“c—DCìk‘¢C‹ß“¡^‘ãC¼‘ºt‰ÀC‰Í–ìOC–L“c—DŽqCŠÝCŒã“Œ‹vŽkC¼‰ªˆÀ•FDTocilizumab ‚ª—LŒø‚Å‚ ‚Á‚½dǬl”­ÇƒXƒeƒBƒ‹•a‚Ì1—áD‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD“¿“‡D2018”N6ŒŽ3“úD

•Ä“c_lC‰¬–ìL˜aC¼”Ž”VC‘å’ËŒ›ŽiC”ò”~—ºC¼žŠ“Ö˜YC–L“c—DŽqCŒã“Œ‹vŽkCŒ¬Œ´_C¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚é Pembrolizumab ‚ÌŽg—pŒoŒ±D‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD“¿“‡D2018”N6ŒŽ3“úD

”ü”n³lC‰¬–ìL˜aC‹ß“¡^‘ãC¼”Ž”VC‘å’ËŒ›ŽiC”ò”~—ºC²“¡³‘åC–L“c—DŽqCŒã“Œ‹vŽkC¼‰ªˆÀ•FD“Á”­«”xœ‰»Ç‚Ì2—áD‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD“¿“‡D2018”N6ŒŽ3“úD

‹{–{ˆ»C¼”Ž”VC‰¬–ìL˜aC‹ß“¡^‘ãC‘å’ËŒ›ŽiC¬ŽRˆë–çC–L“c—DŽqCŒáȉë•FC¼‰ªˆÀ•FD”xM.chelonae Ç‚ÌŒo‰ß’†‚Éf’f‚³‚ꂽ”xM.massiliense Ç‚Ì1—á. ‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD“¿“‡D2018”N6ŒŽ3“úD

“à“¡LmCX“c—DC‘å’ËŒ›ŽiC‰Í–ìOC–L“c—DŽqCŠÝCŒã“Œ‹vŽkC¼‰ªˆÀ•FDTocilizumab‚ª—LŒø‚Å‚ ‚Á‚½dǬl”­ÇƒXƒeƒBƒ‹•a‚Ì1—áD‘æ256‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2018”N2ŒŽ11“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2017”N‹ÆÑ
y‰¢•¶‘à“™z
Sato S, Kolb MR. Personalised medicine for IPF: getting closer, but not there yet. Lancet Respir Med 5(11):836-837, 2017.
y‰¢•¶Œ´’˜z
Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 18(1):172, 2017.

Nagai K, Kishi J, Morizumi S, Minakuchi J, Bando Y, Nishioka Y, Doi T. Henoch-Schonlein purpura nephritis occurring postpartum in a patient with anti-PL-7 anti-synthetase syndrome. Mod Rheumatol 27(5):910-913, 2017.

Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas. Monoclon Antib Immunodiagn Immunother 36(4):157-162, 2017.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Thymidine Catabolism as a Metabolic Strategy for Cancer Survival. Cell Rep 19(7):1313-1321, 2017.

Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(3):104-112, 2017.

Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med 6(4):768-777, 2017.

Saijo A, Hanibuchi M, Goto H, Toyoda Y, Tezuka T, Nishioka Y. An analysis of the clinical features of lung cancer in patients with connective tissue diseases. Respir Investig 55(2):153-160, 2017.

Kakiuchi S, Hanibuchi M, Tezuka T, Saijo A, Otsuka K, Sakaguchi S, Toyoda Y, Goto H, Kawano H, Azuma M, Ogushi F, Nishioka Y. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir Investig 55(2):145-152, 2017.

Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(1):20-24, 2017.

Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain. Monoclon Antib Immunodiagn Immunother 36(1):25-29, 2017.

Oyama Y, Enomoto N, Suzuki Y, Kono M, Fujisawa T, Inui N, Nakamura Y, Kuroishi S, Yokomura K, Toyoshima M, Imokawa S, Oishi K, Watanabe S, Kasahara K, Baba T, Ogura T, Ishii H, Watanabe K, Nishioka Y, Suda T. Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). Respir Med 123:63-70, 2017.

Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med 6(2):382-396, 2017.
y˜a•¶’˜‘z
–L“c—DŽq, ¼‰ªˆÀ•FDƒ‰ƒ“ƒQƒ‹ƒnƒ“ƒX×–E‘gD‹…ÇD‹CŠÇŽx”x–EôòuBALv–@‚ÌŽèˆø‚« ‰ü’ù‘æ3”ÅC“ú–{ŒÄ‹zŠíŠw‰ï‚Ñ‚Ü‚ñ«”xŽ¾Š³Šwp•”‰ï, Œú¶˜J“­È“«Ž¾Š³Ž•žŒ¤‹†Ž–‹Æ‚Ñ‚Ü‚ñ«”xŽ¾Š³’²¸Œ¤‹†”Ç •Ò, 2017. pp128-131DŽ½“°o”ÅD

û•£¹‹BC¼‰ªˆÀ•FD•ªŽq¶•¨Šw“I‚É‚Ý‚½ŠÔŽ¿«”x‰Š‚¨‚æ‚Ñ”xŠàDŠÔŽ¿«”x‰Š‡•¹Ç”xŠà‚ÉŠÖ‚·‚éƒXƒe[ƒgƒƒ“ƒgC“ú–{ŒÄ‹zŠíŠw‰ï Žîᇊwp•”‰ïE‚Ñ‚Ü‚ñ«”xŽ¾Š³Šwp•”‰ï •ÒW, 2017Dpp13-18. “ì]“°D

Œã“Œ‹vŽk, ¼‰ªˆÀ•FD”x–E”÷ÎÇD“«‚Ñ‚Ü‚ñ«”xŽ¾Š³f—Â̎èˆø‚«C“ú–{ŒÄ‹zŠíŠw‰ï ŠÄC, Œú¶˜J“­È‰ÈŠwŒ¤‹†”ï•â•‹à“«Ž¾Š³­ôŒ¤‹†Ž–‹Æu‚Ñ‚Ü‚ñ«”xŽ¾Š³‚ÉŠÖ‚·‚é’²¸Œ¤‹†v”Ç “«‚Ñ‚Ü‚ñ«”xŽ¾Š³f—Â̎èˆø‚«ì¬ˆÏˆõ‰ï* •ÒW, 2017. pp2-15D“ì]“°D

û•£¹‹BC¼‰ªˆÀ•FD‚¶‚ñ”xÇiŒ]”xCƒAƒXƒxƒXƒg”xjDŽ„‚ÌŽ¡—à 2017-18”N“x”Å, ‰Ž“c‹’jE–k‘º‘yˆê˜YŠÄC, 2017. pp242-243. “ú–{ˆãŽ–V•ñŽÐD

¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‚Ì‹}«‘ˆ«D¡“ú‚ÌŽ¡—ÃŽwj2017”N”Å •ŸˆäŽŸ–î, ‚–ؽ, ¬Žºˆê¬ •Ò, 2017Dpp308-309. ˆãŠw‘‰@D
y˜a•¶Œ´’˜z
‘ë‘q‹PŽÀ, û•£¹‹B, –L“c—DŽq, ‹ß“¡^‘ã, ¼”Ž”V, •Ÿ‰Æ–ƒ”ü, ¼‰ªˆÀ•FD‹¹…’†‚É‘½”‚ÌLanghansŒ^‹×–E‚ð”F‚ß‚½‹¹…IL-6”Z“x‚ª‚’l‚Å‚ ‚Á‚½Mycobacterium aviumÇ‚É”º‚¤‹¹–Œ‰Š‚̈ê—áDŒ‹Šj 92(9):559-566, 2017D
y˜a•¶‘àz
‰¬–ìL˜a, ¼‰ªˆÀ•FD‚ª‚ñ“]ˆÚ‚Ì—Õ°Œ¤‹†‚Ì—ðŽj‚Æ“W–]D“ú–{—Õଠ75(‘8):15-20, 2017.

ŠÝDäPŒ´•a‚Ì‘ŸŠíÇó‚ƃ}ƒlƒWƒƒ“ƒg‚Ìi•à@ŠÔŽ¿«”x‰ŠE”xüˆÛÇDƒAƒŒƒ‹ƒM[ 66(9):1161-1164, 2017D

–L“c—DŽq, ¼‰ªˆÀ•F. Precision MedicineGƒRƒ“ƒpƒjƒIƒ“f’f‚Æ“Á”­«”xüˆÛÇ. ŒÄ‹zŠí“à‰È 32(3):292-299, 2017.

¼‰ªˆÀ•F, ˆ¢•”^Ž¡Dƒ|ƒhƒvƒ‰ƒjƒ“‚ð•W“I‚Æ‚µ‚½ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éV‹KR‘̈ã–òŠJ”­D¶‰»Šw 89(4):564-567, 2017.

‘å’ËŒ›ŽiC¼‰ªˆÀ•FD”xŠà‚É‚¨‚¯‚é•W€Ž¡—ÂƂµ‚Ă̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òDŠà‚Ɖ»Šw—Ö@ 44(8):655-660, 2017.

ŠÝ, –L“c—DŽqDƒ‹[ƒvƒXt‰Š‚É‚¨‚¯‚é’·Šú—\Œã—\‘ªDƒŠƒEƒ}ƒ`‰È58(1):102-108, 2017D

‰¬–ìL˜a, Œ¬Œ´_D–Ɖu—Ö@‚ÌŒ»ó‚Æ¡Œã‚Ì“W–]D“ú–{—Õଠ75(7):1115-1120, 2017.

Œã“Œ‹vŽkC¼‰ªˆÀ•FDŒŒŠÇV¶‘jŠQ–ò‘Ï«‚̃ƒJƒjƒYƒ€D“ú–{—Õଠ75(7):1039-1043C2017.

“Œ“‘ãD•W€—\–hôE´Œ‰‘€ì(ƒKƒEƒ“ƒeƒNƒjƒbƒN‚È‚Ç)D‹~‹}EW’†Ž¡—à 29(—Õ‘):e1-e13, 2017D

Œã“Œ‹vŽkC¼‰ªˆÀ•FDüˆÛ×–E‚É‚æ‚é”x‚ª‚ñ‚ɑ΂·‚錌ŠÇV¶‘jŠQ–ò‚Ì‘Ï«ƒƒJƒjƒYƒ€DÅVˆãŠw 72(4):132-137C2017.

Œã“Œ‹vŽkCŽO‹´“ÕŽuC¼‰ªˆÀ•FDŒŒŠÇV¶‘jŠQ–ò‘Ï«‚ÆfibrocyteD•ªŽqŒÄ‹zŠí•a 21(1):4-7C2017D
yŠw‰ï”­•\-‘ÛŠw‰ïz
H. Goto. A. Mitsuhashi, Y. Nishioka. Mechanism of acquired resistance to anti-angiogenic therapy mediated by fibrocytes. The 22nd Congress of Asian Pacific Society of Respirology. Sydney, AustraliaD2017”N11ŒŽ24“úD

H. Ogino, H. Goto, Y. Okano, H. Machida, N. Hatakeyama, F. Ogushi, T. Haku, T. Kanematsu, T. Urata, S. Kakiuchi, M. Hanibuchi, S. Sone, Y. Nishioka. Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer. ERS International Congress 2017. Milan,Italy. 2017”N9ŒŽ10“ú.

A. Saijo, H. Goto, M. Nakano, A.Mitsuhashi, H. Ogino, M. Tobiume, K. Otsuka, H. Yoneda, M.Hanibuchi, Y. Nishioka.Bone Marrow-Derived Fibrocytes Promote Stem Cell-Like Properties of Lung Cancer Cells. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ24“ú.

Y. Toyoda, S. Morizumi, S. Sato, H. Okazaki, Y. Chen, H.Goto, H. Ogawa, H. Nishimura, K. Koyama, H. Kawano, Y. Aono, H. Uehara, Y. Nishioka.Role of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signal in Bleomycin-Induced Pulmonary Fibrosis in Mice. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ23“ú.

H. Goto, A.Mitsuhashi, A. Saijo, H. Ogino, K. Otsuka, M. Tobiume, H. Yoneda, M. Hanibuchi, Y. Nishioka. Fibrocytes as a Possible Cellular Biomarker for Anti-Angiogenic Therapy in Lung Cancer. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ21“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—Ã`Å‹ß‚Ìi•à`D•½¬29”N“x“ú–{“à‰ÈŠw‰ï¶ŠU‹³ˆçu‰‰‰ïBƒZƒbƒVƒ‡ƒ“(‘æ2‰ñ)D•ÄŽqD2017”N10ŒŽ29“úD

¼‰ªˆÀ•F. ‚ª‚ñ–Ɖu—Ö@‚ÌŠî‘b‚Æ—Õ°`ŋ߂̘b‘è`@‘æ56‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï@’†‘Žl‘Žx•”Šwp‘å‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[D“¿“‡D2017”N10ŒŽ22“úD

¼‰ªˆÀ•FDIIPs‚Ì•a‘ÔEŽ¡—©‚çPM/DM‚É”º‚¤ŠÔŽ¿«”x‰Š‚ðl‚¦‚é. ‘æ9‰ñ‹Ø‰Šƒ[ƒNƒVƒ‡ƒbƒv(‹³ˆçu‰‰)D“Œ‹žD2017”N10ŒŽ21“úD

¼‰ªˆÀ•FD“Á”­«”xüˆÛÇ‚ÌŽ¡—Ãí—ª-RüˆÛ‰»Ž¡—Ã‚ð‚¢‚ÂA’N‚É“±“ü‚·‚é‚Ì‚©H-@‘æ58‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[D‰¡•lD2017”N10ŒŽ15“úD

Œã“Œ‹vŽkC¼‰ªˆÀ•FDˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRŒŒŠÇV¶—Ö@‚̉”\«‚Æ‘Ï«‹@˜D‘æ24‰ñΖÈE’†”çŽîŒ¤‹†‰ïD‘åãD2017”N10ŒŽ7“úD

ˆ¢•”^Ž¡C‰Á“¡K¬C¼‰ªˆÀ•FDˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éƒ|ƒhƒvƒ‰ƒjƒ“‚ð•W“I‚Æ‚µ‚½R‘̗Ö@‚ÌŠJ”­D‘æ24‰ñΖÈE’†”çŽîŒ¤‹†‰ïD‘åãD2017”N10ŒŽ7“úD

Œã“Œ‹vŽkCŽO‹´“ÕŽuC¼žŠ“Ö˜YCû•£¹‹BC¼‰ªˆÀ•FDüˆÛ×–E(fibrocyte)‚ð•W“I‚Æ‚µ‚½‚ª‚ñ“]ˆÚEi“WƒƒJƒjƒYƒ€‚̉𖾂ƌŒŠÇV¶‘jŠQ–ò‘Ï«Ž•ž‚ÌŽŽ‚ÝD‘æ26‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D‘åã. 2017”N7ŒŽ27“úD

¼‰ªˆÀ•F. ”xüˆÛÇ‚Ì×–E•ªŽq•a‘Ô‚ÆŠÖ˜Aˆâ“`Žq. ‘æ38‰ñ“ú–{‰ŠÇEĶˆãŠw‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘åã. 2017”N7ŒŽ19“úD

¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—Ã`Å‹ß‚Ìi•à`D•½¬29”N“x“ú–{“à‰ÈŠw‰ï¶ŠU‹³ˆçu‰‰‰ïBƒZƒbƒVƒ‡ƒ“(‘æ1‰ñ)D“Œ‹žD2017”N6ŒŽ11“úD

¼‰ªˆÀ•FD“Á”­«”xüˆÛÇF‹´“n‚µŒ¤‹†‚̈Ӌ`‚Æ“W–]D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•Êu‰‰)D“Œ‹žD2017”N4ŒŽ22“úD

¼‰ªˆÀ•FDBlockade of growth factor signals in fibrogenesis of the lungFtherapeutic efficacy and mechanism of actionD‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(International Symposium)D“Œ‹žD2017”N4ŒŽ21“úD
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
¼žŠ“Ö˜YCû•£¹‹BC‰¬–ìL˜aCŒ¬Œ´_C–L“c—DŽqCŒã“Œ‹vŽkC¼‰ªˆÀ•FDÄ”­¬×–E”xŠà‚ɑ΂·‚épaclitaxel—Ö@‚ÌŒŸ“¢D‘æ58‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD‰¡•lD2017”N10ŒŽ15“úD

ŽR“cT“ñC‹àŽq”ü‰ØC‘“cŽéŽqC‘åÎ’qˆêCˆ¢•”^Ž¡C’£—s•¶C”ˆär‰îCì“cŠwC[ŽR³‹vC¼‰ªˆÀ•FC‰Á“¡K¬. ‚ª‚ñ“ÁˆÙ“Ipodocalyxin ‚ð”FŽ¯‚·‚éƒqƒgƒLƒƒ‰‰ü•Ïƒ‚ƒmƒNƒ[ƒiƒ‹R‘ÌichPcMab-6j‚ÌRŽîᇌø‰Ê‚¨‚æ‚шÀ‘S«. ‘æ76‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïD‰¡•lD2017”N9ŒŽ30“úD

’£—s•¶C‘“cŽéŽqC‹àŽq”ü‰ØC”ˆär‰îCŽR“cT“ñC‘åÎ’qˆêCˆ¢•”^Ž¡C¼‰ªˆÀ•FCì“cŠwC[ŽR³‹vC‰Á“¡K¬. ƒ|ƒhƒJƒŠƒLƒVƒ“‚ð•W“I‚Æ‚µ‚½ƒqƒgƒLƒƒ‰Œ^R‘ÌchPcMab-47 ‚É‚æ‚éƒqƒg‘å’°‚ª‚ñˆÚA•Ðƒ‚ƒfƒ‹‚Å‚ÌRŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ76‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïD‰¡•lD2017”N9ŒŽ30“úD

¼žŠ“Ö˜YCŒã“Œ‹vŽkC‰¬–ìL˜aCŒ¬Œ´_C¼‰ªˆÀ•FDœ‘—R—ˆüˆÛ×–E(fibrocyte)‚Í”xŠà‚Ì‚ª‚ñŠ²×–E—l“Á«‚ð‘£i‚·‚éD‘æ76‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïD‰¡•lD2017”N9ŒŽ28“úD

Œáȉë•FC’·@‰ë”üCŠâ“c‹MCì“Y˜a‹`CÎàVŒ[‰îC’|’J–LC¼‰ªˆÀ•FCÔ’r‰ëŽjD“¿“‡‘åŠw‚É‚¨‚¯‚é’S“–Š³ŽÒ‚ð—p‚¢‚½‘½EŽí˜AŒg‹³ˆç‚ÌŽæ‚è‘g‚ÝD‘æ49‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïDŽD–yD2017”N8ŒŽ19“úD

¼žŠ“Ö˜YC‰¬–ìL˜aC‘å’ËŒ›ŽiCŽè’Ë•qŽjCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•FDClinical efficacy of bevacizumab for non-squamous non-small cell lung cancer patients with malignant pleural effusion. ‘æ15‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ïD_ŒËD2017”N7ŒŽ29“úD

‰¬–ìL˜aCû•£¹‹BC¼žŠ“Ö˜YCŽè’Ë•qŽjCŒã“Œ‹vŽkC¼‰ªˆÀ•FD“¿“‡‘åŠw•a‰@‚É‚¨‚¯‚é‚—îŽÒ”xŠà‚ÆŽá”NŽÒ”xŠà‚Ì—Õ°“I“Á’¥‚ÉŠÖ‚·‚é”äŠrŒŸ“¢. ‘æ15‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ïD_ŒËD2017”N7ŒŽ29“úD

Œã“Œ‹vŽkC¼žŠ“Ö˜YC’†–ì–œ—L—¢C”ò”~—ºC‘å’ËŒ›ŽiC•Ä“c_lCû•£¹‹BC¼‰ªˆÀ•FD‚ª‚ñŠ²×–E‰»‚Ì—U“±‚ð‰î‚µ‚½fibrocyte‚Ì”x‚ª‚ñi“WE“]ˆÚ‘£iƒƒJƒjƒYƒ€D‘æ26‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ïD‘åã. 2017”N7ŒŽ27“úD

¬ì”Ž‹vCŒáȉë•FC‹ß“¡^‘ãCŽè’Ë•qŽjC¼‰ªˆÀ•FDIL-17/D’†‹…‚Í‹C“¹”S–ŒÚ’…•ªŽq‚ðáŠQ‚µFGF-2ŽY¶‚ð‰î‚µ‚½‹C“¹•½ŠŠ‹Ø”ìŒú‚ð—U“±‚·‚éD‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïD“Œ‹žD2017”N6ŒŽ17“úD

‹ß“¡^‘ãCŽè’Ë•qŽjC¬ì”Ž‹vCŒáȉë•FC¼‰ªˆÀ•FDƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚̓AƒŒƒ‹ƒM[«‹C“¹‰ŠÇ‚Ì—U“±‚ÉŠÖ—^‚µ‚Ä‚¢‚éD‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ïD“Œ‹žD2017”N6ŒŽ16“úD

˜aòrqCˆ¢•”^Ž¡C‰¬–ìL˜aCŒã“Œ‹vŽkCû•£¹‹BC‰Á“¡K¬C¼‰ªˆÀ•FDˆ««‹¹–Œ’†”çŽî“¯ŠˆÚAƒ}ƒEƒXƒ‚ƒfƒ‹‚ɑ΂·‚éV‹Kƒ}ƒEƒXRƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌLpMab-21‚É‚æ‚éRŽîᇌø‰Ê‚ÌŒŸ“¢D‘æ21‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŠw‰ïŠwpW‰ïD•Ÿ‰ªD2017”N6ŒŽ15“úD

ŽRŽq‘דlCŒã“Œ‹vŽkC¼žŠ“Ö˜YCû•£¹‹BC¼‰ª ˆÀ•FD”x‚ª‚ñœ“]ˆÚ‚É‚¨‚¯‚éRANKL•W“IŽ¡—Â̌ÀŠE‚Ɖ”\«D‘æ21‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŠw‰ïŠwpW‰ïD•Ÿ‰ªD2017”N6ŒŽ15“úD

‘å’ËŒ›ŽiCû•£¹‹BCŒã“Œ‹vŽkC¼‰ªˆÀ•FD”xŠàEˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRPD-1R‘ÌARPD-L1R‘̂Ɖ»Šw—Ö@‚Ì•¹—pŒø‰Ê‚ÌŠî‘b“IŒŸ“¢D‘æ21‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŠw‰ïŠwpW‰ïD•Ÿ‰ªD2017”N6ŒŽ15“úD

Hirokazu Ogino, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa, Yasuhiko Nishioka. Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€D2017”N4ŒŽ23“úD

û•£¹‹BC’†£Ÿ‘¥C–Lè“ZC–؉º¬ŽOC“‡“c‹v•vC’ß”ö”ü•äCŒ´“c˜a‘ãC…ˆäŒ¤Ž¡C—t‹v‹MŽiC¼‰ªˆÀ•FD“¿“‡Žs‚É‚¨‚¯‚éCOPD‘Šú”­Œ©‚ð–Ú“I‚Æ‚µ‚½ŒŸfƒVƒXƒeƒ€D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2017”N4ŒŽ23“úD

Žè’Ë•qŽjC¬ì”Ž‹vC‹ß“¡^‘ãC–L“c—DŽqC²“¡³‘åCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FDƒ_ƒjRŒ´—U“±«‚̃AƒŒƒ‹ƒM[«‹C“¹‰ŠÇ‚¨‚æ‚Ñ‹C“¹ƒŠƒ‚ƒfƒŠƒ“ƒO‚ÍPAR-2 antagonist‚Ì“Š—^‚É‚æ‚è—}§‚³‚ê‚éD‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2017”N4ŒŽ23“ú.

–L“c—DŽqCŠÝC‰Í–ìOCXZrC¬ŽRˆë–çC¼‘ºt‰ÀCìk‘¢CŽè’Ë•qŽjCŒã“Œ‹vŽkCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•FD“–‰@‚É‚¨‚¯‚é‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‡•¹ŠÔŽ¿«”x‰Š‚Ì—Õ°“IŒŸ“¢D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2017”N4ŒŽ22“úD

Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Atsushi Mitsuhashi, Hirokazu Ogino, Makoto Tobiume, Kenji Otsuka, Hiroto Yoneda, Masaki Hanibuchi, Yasuhiko Nishioka. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2017”N4ŒŽ22“úD

Shun Morizumi, Seidai Sato, Hiroyasu Okazaki, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano, Yasuhiko Nishioka.Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2017”N4ŒŽ21“ú.

‘åŽR‹gKC‰|–{‹I”VC—é–Ø—EŽOC‰Í–ì‰ëlC’†‘º—S‘¾˜YC“¡àV•üKCŠ£’¼‹PC•ÎdéC‰¡‘ºŒõŽiC–L“ˆŠ²¶C–…ìŽj˜NC‘åÎŒiŽmC“n•Ó’mŽuCŠ}Œ´Žõ˜YC”nê’q®C¬‘q‚ŽuCΈ䊰C“n•ÓŒ›‘¾˜NC¼‰ªˆÀ•FC{“c—²•¶. Pleuroparenchymal fibroelastosis‚É‚¨‚¯‚é”A’†ƒfƒXƒ‚ƒVƒ“‚Ì—L—p«‚ÌŒŸ“¢. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD“Œ‹žD2017”N4ŒŽ21“ú.

‰Í–ìOC–L“c—DŽqCŠÝCXZrC‹ß“¡^‘ãCŽR‰º—Y–çCŽè’Ë•qŽjCŒã“Œ‹vŽkCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿«”x‰Š‡•¹‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒXÇ—á‚Ì—Õ°“IŒŸ“¢D‘æ61‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ïD•Ÿ‰ªD2017”N4ŒŽ20“úD

û•£¹‹BC‰Á”[—ºC‘q–{‘ìÆCŒã“Œ‹vŽkC¼‰ªˆÀ•FCŠàŠ³ŽÒŒŒŸ÷’†—V—£DNA‚ð—p‚¢‚½ˆâ“`Žq•ÏˆÙŒŸ¸‹Zp‚Ì”äŠrD‘æ114‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïD“Œ‹žD2017”N4ŒŽ14“úD
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
•Ä“c_lC‘å’ËŒ›ŽiC¼žŠ“Ö˜YC”ò”~—ºC‰¬–ìL˜aC¼”Ž”VC–L“c—DŽqCŒã“Œ‹vŽkCŒ¬Œ´_C¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚énivolumab‚Ì—LŠQŽ–Û‚ÌŒŸ“¢D‘æ117‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚¼D2017”N12ŒŽ3“úD

’Ò–{‰ê”üC“à“¡LmC‹ß“¡^‘ãC¼”Ž”VC‰Í–ìOC‘å’ËŒ›ŽiCŒã“Œ‹vŽkCŠÝCŒáȉë•FC¼‰ªˆÀ•FD‘½”­’P_Œo‰Š‚ð‡•¹‚µ‚½DŽ_‹…«‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇiEGPAj‚É‚¨‚¢‚ĖƉuƒOƒƒuƒŠƒ“‘å—ʗÖ@iIVIGj‚ª—LŒø‚Å‚ ‚Á‚½3—áD‘æ117‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚¼D2017”N12ŒŽ3“úD

‰Í–ìOC¼–{–žC¼‰ªˆÀ•FD‚Ù‚Ú‚·‚ׂĂ̋¹‘B‘Ž¿ã”ç×–E‚ª¬n‰ß’ö‚ÅAire‚ð”­Œ»‚·‚é‹@”\‚ð”õ‚¦‚Ä‚¢‚éD‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2017”N11ŒŽ25“úD

‰¬–ìL˜aC–L“c—DŽqC‰Í–ìOCŠÝC‹ß“¡^‘ãCXZrCŽR‰º—Y–çCŒã“Œ‹vŽkCŒáȉë•FC¼‰ªˆÀ•FD“–‰@‚É‚¨‚¯‚é”x•a•Ï‡•¹‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒXÇ—á‚Ì—Õ°“IŒŸ“¢D‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2017”N11ŒŽ25“úD

¡‘qŒ’C“à“¡LmCŽR‰º—Y–çC‰¬–ìL˜aCŠÝC‰Í–ìOC‹ß“¡^‘ãCXZrC–L“c—DŽqCŒã“Œ‹vŽkCŒáȉë•FC¼‰ªˆÀ•FDƒ‹[ƒvƒXS‹Ø‰Š‚Ì2—áD‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2017”N11ŒŽ25“úD

ŽR‰º—Y–çC‰Í–ìOCŠÝC“à“¡LmC‰¬–ìL˜aC‹ß“¡^‘ãCXZrC–L“c—DŽqCŒã“Œ‹vŽkCŒáȉë•FC¼‰ªˆÀ•FD‘Sg«‹­”çÇ‚ð”wŒi‚Éposterior reversible encephalopathy syndrome‚ð”­Ç‚µ‚½ˆê—áD‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïD“¿“‡D2017”N11ŒŽ25“úD

”ò”~—ºCXZrC—é]—ÁŽqC”ê“c“N–çC‰¬–ìL˜aC‘å’ËŒ›ŽiCŒã“Œ‹vŽkC㌴‹v“TC‹v•Û‹X–¾C¼‰ªˆÀ•FDBRAF —z«”xŒ´”­ˆ««•FŽî‚Ì‚P—áD‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïDL“‡D2017”N10ŒŽ28“úD

X“c—DC–L“c—DŽqC‘å’ËŒ›ŽiC¼žŠ“Ö˜YC•Ä“c_lC‹ß“¡^‘ãC¼”Ž”VCŒã“Œ‹vŽkCŒ¬Œ´_C¼‰ªˆÀ•FD•úŽËüŽ¡—ẪAƒuƒXƒRƒpƒ‹Œø‰Ê‚É‚æ‚éŽîá‡k¬‚ð”F‚ß‚½Œã‚ÉÄ”­‚µApembrolizumab ‚ª‘tŒ÷‚µ‚½”xŠà‚Ì‚P—áD‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïDL“‡D2017”N10ŒŽ28“úD

•Ÿ“c‹ª‘¾˜YCX“c—DC‘å’ËŒ›ŽiC¼‘ºt‰ÀCXZrCìk‘¢C¬ŽRˆë–çC¡‘qŒ’CŒã“Œ‹vŽkC¼‰ªˆÀ•FDBAL ‚É‚æ‚èŠà«ƒŠƒ“ƒpŠÇÇ‚Æf’f‚µ‚¦‚½‘½”­ƒXƒŠƒKƒ‰ƒX‰e‚ð’悵‚½”x‘BŠà‚Ì‚P—áD‘æ26‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ïDL“‡D2017”N10ŒŽ28“úD

”ü”n³lC¼”Ž”VC”ò”~—ºC‘å’ËŒ›ŽiC“à“¡LmC–L“c—DŽqCŒã“Œ‹vŽkCŠÝCŒáȉë•FC¼‰ªˆÀ•FDR IFN- ƒÁR‘Ì‚ª—z«‚Å‚ ‚Á‚½”dŽí«”ñŒ‹Šj«RŽ_‹ÛÇ‚Ì‚P—áD‘æ68‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ïDL“‡D2017”N10ŒŽ28“úD

—é]—ÁŽqC¼‘ºt‰ÀC‰¬–ìL˜aC‘å’ËŒ›ŽiC”ò”~—ºC‰Í–ìOC•Ÿ‰Æ–ƒ”üCŽR‰º—Y–çCŒã“Œ‹vŽkC¼‰ªˆÀ•FDSƒ^ƒ“ƒ|ƒi[ƒf‚ð‚«‚½‚µ‚½Œ‹Šj«S–Œ‰Š‚Ì‚P—áD‘æ68‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ïDL“‡D2017”N10ŒŽ28“úD

‘弈êCXZrC”ê“c“N–çC¼—§‹gOC‰¬–ìL˜aC‘å’ËŒ›ŽiC”ò”~—ºCŒã“Œ‹vŽkC㌴‹v“TC‹v•Û‹X–¾C¼‰ªˆÀ•FDBRAF—z«”xŒ´”­ˆ««•FŽî‚Ì1—áD‘æ255‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2017”N8ŒŽ6“úD

ŽR‰º‹M‰›C¼‘ºt‰ÀC‰¬–ìL˜aC‘å’ËŒ›ŽiC”ò”~—ºC–L“c—DŽqCŒã“Œ‹vŽkC¼‰ªˆÀ•FDSƒ^ƒ“ƒ|ƒi[ƒf‚ð‚«‚½‚µ‚½Œ‹Šj«S–Œ‰Š‚Ì1—áD‘æ255‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2017”N8ŒŽ6“úD

—é]—ÁŽqCXZrC‘å’ËŒ›ŽiC–L“c—DŽqC‰Í–ìOC¬ŽRˆë–çC¼”Ž”VC¼‘ºt‰ÀCŒã“Œ‹vŽkC¼‰ªˆÀ•FD“Á”­«”xüˆÛǂɑ΂·‚énintedanib‚ÌŽg—pŒoŒ±D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD‚’mD2017”N7ŒŽ15“úD

”ü”n³lCŒáȉë•FC‘å’ËŒ›ŽiCŽR‰º—Y–çCŒã“Œ‹vŽkCŠÝC‹g“cŒõ‹PC㌴‹v“TC¼‰ªˆÀ•FDMinute Pulmonary Meningothelial-like Nodule‚Ì1—áD‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD‚’mD2017”N7ŒŽ14“úD

¡‘qŒ’C‘å’ËŒ›ŽiC¼žŠ“Ö˜YC”ò”~—ºC‰¬–ìL˜aC¼”Ž”VCŒã“Œ‹vŽkCŒ¬Œ´_C¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŽg—pŒoŒ±D‘æ56‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‚’mD2017”N7ŒŽ14“úD

Šì“c—L‰À—¢Cìk‘¢C‘å’ËŒ›ŽiC‰¬–ìL˜aC”ò”~—ºC¼žŠ“Ö˜YCŒ¬Œ´_CŒã“Œ‹vŽkC¼‰ªˆÀ•FD¬×–E”xŠà‚Ö‚Ì“]‰»‚ð”F‚ß‚½EGFRˆâ“`Žq•ÏˆÙ—z«”x‘BŠà‚Ì1—áD‘æ56‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‚’mD2017”N7ŒŽ14“úD

X“c—DC–L“c—DŽqCXZrC‘å’ËŒ›ŽiC‹ß“¡^‘ãC¬ŽRˆë–çC¼‘ºt‰ÀCŒã“Œ‹vŽkC¼‰ªˆÀ•FD•úŽËüŽ¡—ẪAƒuƒXƒRƒpƒ‹Œø‰Ê‚É‚æ‚é‚Æl‚¦‚ç‚ê‚éŽîá‡k¬‚ð”F‚ß‚½”xŠà‚Ì1—áD‘æ56‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‚’mD2017”N7ŒŽ14“úD

‹ß“¡^‘ãCŽè’Ë•qŽjC‰Í–ìOCŒã“Œ‹vŽkCŠÝCû•£¹‹BCŒáȉë•FC“yŽt³‘¾˜YCŠ—´™ZC¼‰ªˆÀ•FD¬”]•‚Žî‚¨‚æ‚Ñ…“ªÇ‚ð”F‚ߊJ“ªŒ¸ˆ³p‚ð—v‚µ‚½NPSLE‚Ì1—áD‘æ116‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚’mD2017”N5ŒŽ21“úD

¼‘ºt‰ÀCŽè’Ë•qŽjC¼žŠ“Ö˜YC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒ¬Œ´_Cû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•FD”xG•½ã”çŠàŽ¡—ÃŒã‚Ì‹ó“´•a•Ï‚É”F‚ß‚½”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì1—áD‘æ116‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïD‚’mD2017”N5ŒŽ21“úD
£ƒy[ƒW‚ÌTOP‚Ö
2016”N‹ÆÑ
y‰¢•¶’˜‘z
Yasuhiko Nishioka. Pathogenesis of IPF. Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease? In: Nakamura H, Aoshiba K (eds) Idiopathic Pulmonary Fibrosis, Springer, Tokyo, p43-58, 2016.
y‰¢•¶‘àz
Nishioka Y. Cancer immunotherapy as a promising fourth standard therapy for lung canser: Beyond 20 years for the development of immunotherapy. Respir Investig 54:297, 2016.
y‰¢•¶Œ´’˜z
Toyoda Y, Ozaki R, Kishi J, Hanibuchi M, Kinoshita K, Tezuka T, Goto H, Ono H, Nagai K, Bando Y, Doi T, Nishioka Y.@An autopsy case of aortic intimal sarcoma initially diagnosed as polyarteritis nodosa. Intern Med 55(21):3191-3195, 2016.

Toyoda Y, Hanibuchi M, Kishi J, Kawano H, Morizumi S, Sato S, Kondo M, Takikura T, Tezuka T, Goto H, Nishioka Y. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest 63(3,4):294-299, 2016.

Ogino H, Hanibuchi M, Kakiuchi S, Saojo A, Tezuka T, Toyoda Y, Tobiume M, Otsuka K, Sakaguchi S, Goto H, Arisawa K, Nishioka Y. Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. J Med Invest 63(3,4):286-293, 2016.

Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, Nishioka Y, Ohrui T, Numasaki M. Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-ă2 or IL-29/IFN-ă1. Cancer Gene Ther 23(8):266-277, 2016.

Numasaki M, Tsukamoto H, Tomioka Y, Nishioka Y, Ohrui T. A Heterodimeric Cytokine, Consisting of IL-17A and IL-17F, Promotes Migration and Capillary-Like Tube Formation of Human Vascular Endothelial Cells. Tohoku J Exp Med 240(1):47-56, 2016.

Abe S, Kato KM, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci 107(9):1198-1205, 2016.

Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, Langley RR, Lehembre F, Regenass U, Fidler IJ. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro-Oncology 18(4):486-496, 2016.

Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Hommma S, Sugiyama Y;Japan Pirfenidone Clinical Study Group.Clinical Experience of the Long-tern Use of Pirfenidone for Idiopathic Pulmonary Fibrosis. Intern Med 55(5):443-448, 2016.

Sato S, Hanibuchi M, Takahashi M, Fukuda Y, Morizumi S, Toyoda Y, Goto H, Nishioka Y. A patient with idiopathic pleuroparenchymal fibroelastosis showing sustained pulmonary function due to treatment with pirfenidone. Intern Med 55(5):497-501C2016.

Ogino H, Hanibuchi M, Takizawa H, Sakiyama S, Sumitomo H, Iwamoto S, Ikushima H, Nakajima K, Nagahiro H, Yamago T, Toyoda Y, Bando Y, Nishioka Y. Primary pulmonary synovial sarcoma showing prolonged survival with multimodality therapy. Intern Med 55(4):381-387C2016.
y˜a•¶’˜‘z
¼‰ªˆÀ•FD”ñ“ÁˆÙ«ŠÔŽ¿«”x‰Š(NSIP)D“Á”­«ŠÔŽ¿«”x‰Š f’f‚ÆŽ¡—Â̎èˆø‚«(‰ü’è‘æ3”Å), “ú–{ŒÄ‹zŠíŠw‰ï ‚Ñ‚Ü‚ñ«”xŽ¾Š³f’fEŽ¡—ÃKƒCƒhƒ‰ƒCƒ“쬈ψõ‰ï•ÒW, 2016. pp61-68. “ì]“°D

¼‰ªˆÀ•FD“Á”­«”xüˆÛÇ‚ÌŠî‘bDŒÄ‹zŠíŽ¾Š³ÅV‚ÌŽ¡—Ã2016-2018D™ŽRK”äŒÃE–å“c~ˆê,EŒ·ŠÔº•F•ÒD2016.pp57-60D“ì]“°

¼‰ªˆÀ•FD“Á”­«ŠÔŽ¿”x‰ŠD¡“ú‚ÌŽ¡—ÃŽwjD•ŸˆäŽŸ–îC‚–ؽC¬Žºˆê¬‘•ÒWD2016Dpp355-356DˆãŠw‘‰@D
y˜a•¶‘àz
‰ªú±O‘×C¼‰ªˆÀ•FD‰Á—î‚Æ”xüˆÛ‰»DThe Lung perspectives 24(3):50-54C2016D

ŠÝ, –L“c—DŽqDRA‚É‚¨‚¯‚é‹CŠÇŽxŠg’£Ç‚Í–«Š´õÇ‚ÅŽ©ŒÈ–Ɖu‚ªŽä‹N‚³‚ê‚郂ƒfƒ‹‚Å‚ ‚éDƒŠƒEƒ}ƒ`‰È56(1):86-91, 2016.

ŒáȈÀ—Ç‘¾C¬‘q‚ŽuC¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š Update À’k‰ï RüˆÛ‰»–òŽž‘ã‚ÌŠÔŽ¿«”x‰Šf—Âðl‚¦‚éDÅVçΊw 71(7):1235-1248C2016D

¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š Update ˜˜_DÅVçΊw 71(7):1233-1234C2016D

‰Í–ìOC¼‰ªˆÀ•FDäPŒ´•a‚É‚¨‚¯‚é”x•a•Ï‚ւ̃Aƒvƒ[ƒ`DƒŠƒEƒ}ƒ`‰È 55(4):345-352C2016D

²“¡³‘å, ‘å’J’¼Žq, Œ´‰p“ñ, ¼‰ªˆÀ•FD‚ª‚ñ—}§ˆâ“`Žq‚É‚æ‚é×–E‚ƌ‘̘V‰»‚̧ŒäD‚ª‚ñ•ªŽq•W“IŽ¡—Ã14(1):76-81, 2016.

Œã“Œ‹vŽkCŽO‹´“ÕŽuC¼‰ªˆÀ•FDüˆÛ×–E‚ª‚©‚©‚í‚錌ŠÇV¶‘jŠQ–ò‚ɑ΂·‚éŠl“¾‘Ï«ƒƒJƒjƒYƒ€D•ªŽqŒÄ‹zŠí•a 20(1):111-114C2016D

¼‰ªˆÀ•FC²“¡³‘åDƒjƒ“ƒeƒ_ƒjƒuD•ªŽqŒÄ‹zŠí•a 20(1):100-102C2016D

Œã“Œ‹vŽkC–샓TCŽO‹´“ÕŽuC¼‰ªˆÀ•FD–«‰ŠÇ‚ÆfibrocyteDŒÄ‹z‚ÆzŠÂ 64(2):149-155C2016D
y˜a•¶Œ´’˜z
ŽRŽq‘דlCû•£¹‹BC‰¬–ìL˜aC‘ºã‰i®CŠ—´™ZC¼‰ªˆÀ•FD‘½Ê‚È_ŒoÇó‚ð’悵‚½¬×–E”xŠà‚É”º‚¤–TŽîᇫ_ŒoÇŒóŒQ‚Ì1—áD”xŠà 56(3):199-204C2016D
yŠw‰ï”­•\-‘ÛŠw‰ïz
Morizumi S, Sato S, Abe S, Okazaki H, Yanjuan C, Goto H, Hanibuchi M, Aono Y, Ogawa H, Hanibuchi M, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity. ERS2016 International Conference, London, UK. 2016”N9ŒŽ4“úD

Yasuhiko Nishioka. Introduction of Session 152 - Repair pathways: from lung development to aging of the lung -. ERS2016 Internathional Conference(Invited lecture). London, UK. 2016”N9ŒŽ4“úD

Ogino H, Goto H, Kakiuchi S, Saijo A, Sakaguchi A, Tobiume M, Otsuka K, Hanibuchi M, Nishioka Y. Receptor tyrosine kinase-like orphan receptor 2, ROR2, regulates the proliferation of malignant pleural mesothelioma cells. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ17“ú

Sato S, Goto H, Morizumi S, Okazaki H, Yanjuan C, Kawano H, Toyoda Y, Hanibuchi M, Azuma M, Nishioka Y. Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ16“ú

Saijo A, Goto H, Mitsuhashi A, Nakano M, Ogino H, Aono Y, Sakaguchi S, Tobiume M, Otsuka K, Hanibuchi M, Nishioka Y. Bone marrow-derived fibrocytes maintain stem cell-like properties of lung cancer. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ15“ú

Goto H, Mitsuhashi A, Saijo A, Kuramoto T, Tabata T, Aono Y, Uehara H, Hanibuchi M, Nishioka YDFibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab in thoracic tumors. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ15“ú
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•FDŽîᇖƉuŠw‚ÌŠî‘b‚Æ”xŠà–Ɖu—Ö@‚Ì•à‚ÝD‘æ57‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). •Ÿ‰ª. 2016”N12ŒŽ21“úD

Yasuhiko Nishioka. The mechanism of immunotherapy for lung cancer. JICS/KASLC symposium. ‘æ57‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(JLCS/KASLC Joint-Symposium). •Ÿ‰ª. 2016”N12ŒŽ19“úD

¼‰ªˆÀ•FDŒÄ‹zŠíŽ¾Š³‚̃gƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ``ƒAƒJƒfƒ~ƒA”­‚Ì‘n–ò‚ð–ÚŽw‚µ‚½‘½EŽí˜AŒg`D‘æ64‰ñˆã—ÖòŠwŒöŠJƒVƒ“ƒ|ƒWƒEƒ€D“¿“‡D2016”N11ŒŽ20“úD

Yasuhiko NishiokaDAquired resistance to anti-angiogenic therapy and new insights toward the overcomingDJASMO 2016 Annual MeetingiInternational Symposium)D_ŒËD2016”N7ŒŽ28“úD

Œã“Œ‹vŽkC‰¬–ìL˜aCŽO‹´“ÕŽuC¼‰ªˆÀ•FD¬×–E”xŠà‚É‚¨‚¯‚éŠÌ“]ˆÚ‚̈ʒu‚¯‚Æ‚ª‚ñŠ²×–E—l×–E‚Ì–ðŠ„D‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D•ÄŽqD2016”N7ŒŽ22“úD

¼‰ªˆÀ•FD”x‚ª‚ñ‚ɑ΂·‚錌ŠÇV¶‘jŠQ–ò‚Ì‘Ï«‹@\‚Æ‚»‚ÌŽ•žD‘æ176‰ñ“ú–{”xŠàŠw‰ïŠÖ“ŒŽx•”ŠwpW‰ï(ƒR[ƒq[ƒuƒŒƒCƒNƒZƒ~ƒi[)D“Œ‹žD2016”N7ŒŽ16“úD

ŠÝDŠÔŽ¿«”x‰ŠE”xüˆÛÇD‘æ65‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2016”N6ŒŽ18“úD

¼‰ªˆÀ•FD”xüˆÛ‰»‚Ì×–E•ªŽq•a‘Ô‚ÆŽ¡–üí—ªD‘æ37‰ñ“ú–{‰ŠÇEĶˆãŠw‰ïD‹ž“sD2016”N6ŒŽ16“úD

¼‰ªˆÀ•FDŒÄ‹zŠíŠw‰ï‘ۈψõ‰ï‚ÌŠˆ“®‚Æ—¯ŠwŽx‰‡D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•ÊŠé‰æ)D‹ž“sD2016”N4ŒŽ9“úD

¼‰ªˆÀ•FDRole of fibrocytes and growth factors in lung fibrosis and cancerD‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(Inter-Assembly Symposium 2)D‹ž“sD2016”N4ŒŽ9“úD
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
û•£¹‹BCŽè’Ë•qŽjC¼žŠ“Ö˜YC‰¬–ìL˜aCŒã“Œ‹vŽkC¼‰ªˆÀ•FD“–‰È‚É‚¨‚¯‚é‚—îŽÒ”xŠà‚ÌŽá”NŽÒ‚Æ‚Ì”äŠrŒŸ“¢D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD•Ÿ‰ªD2016”N12ŒŽ21“úD

¼žŠ“Ö˜YCŽè’Ë•qŽjC‰¬–ìL˜aC–L“c—DŽqCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•FDˆ««‹¹…‚𔺂Á‚½”ñG•½ã”ç”ñ¬×–E”xŠà‚ɑ΂·‚é Bevacizumab •¹—p‰»Šw—Ö@‚ÌŒŸ“¢D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD•Ÿ‰ªD2016”N12ŒŽ19“úD

‰¬–ìL˜aCŒã“Œ‹vŽkC¼žŠ“Ö˜YCŠ`“à‘ŽiCû•£¹‹BC¼‰ªˆÀ•FD“¿“‡‘åŠw•a‰@‚É‚¨‚¯‚éi“WŒ^¬×–E”xŠàŠ³ŽÒ‚Ì—\ŒãˆöŽq‚ÉŠÖ‚·‚éŒã‚ëŒü‚«Œ¤‹†D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïD•Ÿ‰ªD2016”N12ŒŽ19“úD

’†h•¶ŠG, “c”¨Ë, ŽR“c’‰–¾, Œã“Œ‹vŽk, –î–칓ñ, ¼‰ªˆÀ•F, ‘]‰ä•ü‹`, •y“cŸ. ”ñ¬×–E”xŠà‚É‚¨‚¯‚é TGF-ƒÀ—U“±«ã”çŠÔ—t“]Š·‚Ì‘ãŽÓ“Á«. ‘æ75‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2016”N10ŒŽ7“ú.

‰¬–ìL˜a, û•£¹‹BC‘å’ËŒ›ŽiC¼žŠ“Ö˜YCâŒû‹ÅCŽè’Ë•qŽjCŠ`“à‘ŽiCŒã“Œ‹vŽkC¼‰ªˆÀ•FD“¿“‡‘åŠw•a‰@‚É‚¨‚¯‚éi“WŒ^¬×–E”xŠàŠ³ŽÒ‚Ì—\ŒãˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ14‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ïD_ŒËD2016”N7ŒŽ28“úD

‘å’ËŒ›ŽiCû•£¹‹BC‰¬–ìL˜aCŒã“Œ‹vŽkC¼‰ªˆÀ•FD”xŠàCˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚Ì—LŒø«‚ÌŠî‘b“IŒŸ“¢D‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ïD•ÄŽqD2016”N7ŒŽ21“úD

¼žŠ“Ö˜YCŒã“Œ‹vŽkCŽO‹´“ÕŽuC’†–ì–œ—L—¢C‘å’ËŒ›ŽiC‰¬–ìL˜aCâŒû‹ÅCû•£¹‹BC¼‰ªˆÀ•FDœ‘—R—ˆüˆÛ×–E(fibrocyte)‚Í”xŠà‚Ì‚ª‚ñŠ²×–E—l“Á«‚ð‘£i‚·‚éD‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ïD•ÄŽqD2016”N7ŒŽ21“úD

‰¬–ìL˜aCŒã“Œ‹vŽkC¼žŠ“Ö˜YC‘å’ËŒ›ŽiCû•£¹‹BC¼‰ªˆÀ•FDŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[ROR2‚͈««‹¹–Œ’†”çŽî×–E‚Ì‘B‚ð§Œä‚·‚éD‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ïD•ÄŽqD2016”N7ŒŽ21“úD

ˆ¢•”^Ž¡C‰Á“¡K¬CŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•FDƒ|ƒhƒvƒ‰ƒjƒ“‚ð•W“I‚Æ‚µ‚½R‘̗Ö@‚ƃyƒƒgƒŒƒLƒZƒh‚Ì•¹—p‚É‚æ‚鈫«‹¹–Œ’†”çŽî‚ɑ΂·‚éRŽîᇌø‰Ê‚ÌŒŸ“¢D‘æ20‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ïD•Ê•{D2016”N5ŒŽ31“úD

‰Í–ìOC‹ß“¡^‘ãC¼žŠ“Ö˜YC–L“c—DŽqCŠÝC¼‰ªˆÀ•FD“–‰@‚É‚¨‚¯‚éäPŒ´•a‚ɇ•¹‚µ‚½”xŠà‚ÌŒŸ“¢D‘æ60‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ïD‰¡•lD2016”N4ŒŽ23“úD

‰¬–ìL˜aCŒã“Œ‹vŽkC‘å‹ø•¶—²C—t‹v‹MŽiCŒ“¼‹M‘¥C‰Y“c’m”VCû•£¹‹BC‘]ªŽO˜YC¼‰ªˆÀ•FD‚—îŽÒis”ñ¬×–E”xŠàŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽS-1—Ö@‚Ì—Õ°‘æ‡U‘ŠŽŽŒ±D‘æ113‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïD“Œ‹žD2016”N4ŒŽ15“úD

–L“c—DŽqC²“¡³‘åCŠÝC‰Í–ìOCXZrCŠÝ¹”üCŽè’Ë•qŽjCâŒû‹ÅCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•FD“–‰@‚É‚¨‚¯‚éäPŒ´•aŠÖ˜AŠÔŽ¿«”x‰Š‚Ì‹}«‘žˆ«‚ÉŠÖ‚·‚é—Õ°“IŒŸ“¢D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‹ž“sD2016”N4ŒŽ10“úD

û•£¹‹BC’†£Ÿ‘¥C–Lè“ZC–؉º¬ŽOC“‡“c‹v•vC’ß”ö”ü•äCŒáȉë•FC—t‹v‹MŽiC¼‰ªˆÀ•FD“¿“‡Žs‚É‚¨‚¯‚éCOPDŒ’f‚ÌŒ»óD‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‹ž“sD2016”N4ŒŽ8“úD

Žè’Ë•qŽjC¬ì”Ž‹vC‹ß“¡^‘ãCŒáȉë•FC–L“c—DŽqC²“¡ ³‘åC‰ªú±O‘×C‰Í–ìOCŠÝCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•FDRAS‘jŠQÜiXRP44Xj‚ð—p‚¢‚½šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‹ž“sD2016”N4ŒŽ8“úD

ˆ¢•”^Ž¡C‰Á“¡K¬C‹àŽq”ü‰ØCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•FDˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éV‹KRƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNE-12‚ÌŒø‰ÊD‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïD‹ž“sD2016”N4ŒŽ8“úD
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
Œ´—Ï¢CŽè’Ë•qŽjC‹ß“¡^‘ãC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FDEB‚É‚æ‚é––½_ŒoáŠQ‚ð’悵‚½Œ‹Šj«‹¹–Œ‰Š‚Ì1—áD‘æ67‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ïD‰ªŽRD2016”N12ŒŽ23“úD

™•õ—DlCŽè’Ë•qŽjCìk‘¢C•Ä“c_lC‘å’ËŒ›ŽiC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FDEBUS-TBNAŒã‚ÉcŠu‰Š‚ð”­Ç‚µ‚½cŠuŒ´”­ƒZƒ~ƒm[ƒ}‚Ì1—áD‘æ25‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ïD‰ªŽRD2016”N12ŒŽ23“úD

‹e’r‚ŽjCŽè’Ë•qŽjC‹ß“¡^‘ãC‰¬–ìL˜aC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FDStevens-Johnson ÇŒóŒQŒã‚É”­Ç‚µ‚½•Âǫ׋CŠÇŽx‰Š‚ɃXƒeƒƒCƒh‚¨‚æ‚у^ƒNƒƒŠƒ€ƒX‚ª—LŒø‚Å‚ ‚Á‚½1—áD‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD‰ªŽRD2016”N12ŒŽ23“úD

‚“‡‘ñ–çCŽè’Ë•qŽjC‹ß“¡^‘ãC”ò”~—ºC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FDExon19‚Æexon21‚̈â“`Žq•ÏˆÙ‚𓯎ž‚É”F‚ß‚½”x‘BŠà‚Ì1—áD‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïD‰ªŽRD2016”N12ŒŽ23“úD

–L“c—DŽqCŽR‰º—Y–çCXZrC‹ß“¡^‘ãC‰¬–ìL˜aC‰Í–ìOCŽè’Ë•qŽjCŠÝCŒã“Œ‹vŽkCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•FD“–‰@‚É‚¨‚¯‚éäPŒ´•aŠÖ˜AŠÔŽ¿«”x‰Š‚Ì‹}«‘žˆ«‚Ì—Õ°“IŒŸ“¢D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïDL“‡D2016”N12ŒŽ3“úD

“c’†‚±‚±‚ëC‰¬–ìL˜aC‹{“c~–çCŽR‰º—Y–çCXZrC‹ß“¡^‘ãC‰Í–ìOCŽè’Ë•qŽjC–L“c—DŽqCŠÝCŒã“Œ‹vŽkCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•FD15”N‘O‚æ‚è”F‚ß‚é–«t‹@”\áŠQ‚ɑ΂µ‚ăXƒeƒƒCƒh‰Á—ª‘tŒ÷‚µ‚½tƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—áD‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïDL“‡D2016”N12ŒŽ2“úD

ŽR‰º—Y–çC–L“c—DŽqC‰¬–ìL˜aC‰Í–ìOCŽè’Ë•qŽjCŠÝCŒã“Œ‹vŽkCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•FD“–‰@‚É‚¨‚¯‚郋[ƒvƒXt‰Š‚ɑ΂·‚éIVCY‚ÆMMF‚ÌŽ¡—ÃŒoŒ±D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïDL“‡D2016”N12ŒŽ2“úD

‰¬–ìL˜aCŠÝC‰Í–ìOCŽè’Ë•qŽjC–L“c—DŽqCŒã“Œ‹vŽkCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•FDŠÖ߃ŠƒEƒ}ƒ`‚Ì–ò•¨—Ö@‚É‚¨‚¯‚é‰h—{ó‘Ԃ̕ω»‚ÌŒŸ“¢D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ïDL“‡D2016”N12ŒŽ2“úD

¼”Ž”VCŽè’Ë•qŽjCŽR‰º—Y–çC¼žŠ“Ö˜YC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FDGefitinib“Š—^’†‚ÉAchromobacter Xylosoxidans‚É‚æ‚é‹ÛŒŒÇ‚ð”­Ç‚µ‚½”x‘BŠà‚Ì‚P—áD‘æ115‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïDˆ¤•QD2016”N11ŒŽ27“úD

•Ä“c_lCŽè’Ë•qŽjC‰Í–ìOCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•FD‘½”­«ˆÝ\“ñŽw’°’×ᇂ𔺂Á‚½MTXŠÖ˜AƒŠƒ“ƒp‘B«Ž¾Š³‚Ì‚P—áD‘æ115‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ïDˆ¤•QD2016”N11ŒŽ27“úD

ŽR–{´¬CŽè’Ë•qŽjC‰¬–ìL˜aCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•F. ‰ºŠ{Ž•“÷ŠàŽ¡—ÃŒã‚É”­¶‚µ‚½•úŽËü—U”­ŒŒŠÇ“÷Žî‚Ì‚P—á. ‘æ253‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ïD“¿“‡D2016”N7ŒŽ24“úD

ìk‘¢CŽè’Ë•qŽjC‘å’ËŒ›ŽiCXZrCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC¼‰ªˆÀ•F. Crizotinib‚É‚æ‚éILD‚ð”­ÇŒã‚ÉAlectinib‚Ì“Š—^‚ª‰Â”\‚Å‚ ‚Á‚½ALK—Z‡ˆâ“`Žq—z«”x‘BŠà‚Ì1—á. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïDL“‡D2016”N7ŒŽ9“ú.

‹ß“¡^‘ãCŽè’Ë•qŽjC•Ä“c_lC–L“c—DŽqCŒã“Œ‹vŽkCŠÝCŒáȉë•FCû•£¹‹BC‘ºã‘¾ˆêC“yˆär•vC‰Í–k’¼–çC‘ê‘òGŒõC¼‰ªˆÀ•F. • oƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚É‚æ‚èf’f‚µ‰¡Šu–Œ–D‡•Â½p‚ðs‚Á‚½‰¡Šu–ŒŒð’ÊÇ‚Ì1—á. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïDL“‡D2016”N7ŒŽ9“úD

ŽR‰º—Y–çC¼žŠ“Ö˜YC²“¡³‘åCŽè’Ë•qŽjCâŒû‹ÅCŒã“Œ‹vŽkCŠÝCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éäPŒ´•a‡•¹”xŠà‚ÌŒŸ“¢. ‘æ114‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2016”N5ŒŽ22“ú.

XZrC²“¡³‘åC‰¬–ìL˜aC‰Í–ìOCâŒû‹ÅCŒã“Œ‹vŽkCŠÝCû•£¹‹BCŒáȉë•FC¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éƒjƒ“ƒeƒ_ƒjƒu‚Ì“Á”­«”xüˆÛǂɑ΂·‚éŽg—pŒoŒ±. ‘æ114‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2016”N5ŒŽ22“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2015”N‹ÆÑ
y‰¢•¶‘àz
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 10: 89-98, 2015.
y‰¢•¶Œ´’˜z
Fukushima K, Nakamura S, Inoue Y, Higashiyama Y, Ohmichi M, Ishida T, Yoshimura K, Sawai T, Takayanagi N, Nakahama C, Kakugawa T, Izumikawa K, Aoki N, Nishioka Y, Kosaka O, Kohno S. Utility of a sputum antigen detection test in pneumococcal and lower respiratory infectious disease in adults. Intern Med 54(22):2843-2850, 2015.

Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Efficacy of perfenidone and disease severity of idiopathic pulmonary fibrosis: extended analysis of phase III trial in Japan. Respir Investig 53(6):279-287, 2015.

Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomisa H, Sakiyama S, Nishioka Y. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 6:8792, 2015.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Konaka K, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Ishizawa K. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids. Biol Pharm Bull 38(11):1752-1756, 2015.

Kawano H, Nishijima H, Morimoto J, Hirota F, Morita R, Mouri Y, Nishioka Y, Matsumoto M. Aire expression is inherent to most medullary thymic epithelial cells during their differentiation program. J Immunol 195(11):5149-5158, 2015.

Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget 6(34):36003-36018, 2015.

Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. Mod Rheumatol. 25(4):609-614, 2015.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 49(4):398-404, 2015.

Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, Takasugi M, Yamakoshi K, Sorimachi H, Kanda H, Ishikawa Y, Sone S, Nishioka Y, Ohtani N, Hara E. Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice. Nat Commun 6:7035, 2015.

Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyama H, Kohsaka H, Miyasaka N, Harigai M; PREVENT Study Group. Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study. J Rheumatol 42(4):614-622, 2015.

Tezuka T, Ogawa H, Azuma M, Goto H, Uehara H, Aono Y, Hanibuchi M, Yamaguchi Y, Fujikawa T, Itai A, Nishioka Y. IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators. PLoS One 10(3):e0121615, 2015.

Kawano H, Hanibuchi M, Yoshijima T, Toyoda Y, Kishi J, Tezuka T, Nishioka Y. A case of atypical Takayasu arteritis initially presenting with peripheral artery disease. Case Reports in Clinical Pathology 2(2):34-40, 2015.

Sato S, Hanibuchi M, Tobiume M, Kishi J, Toyoda Y, Kawano H, Takahashi M, Fukuda Y, Nishioka Y. A case of IgG4-related interstitial lung disease showing usual interstitial pneumonia pattern: Unusual case for histological features with pathological proof. Case Reports in Clinical Pathology 2(1):6-11, 2015.
y˜a•¶’˜‘z
¼‰ªˆÀ•F. DŽ_‹…«”x‰Š. ¡“ú‚ÌŽ¡—ÃŽwj. •ŸˆäŽŸ–î, ‚–ؽ, ¬Žºˆê¬‘•ÒW. 2015. p330. ˆãŠw‘‰@.

²“¡³‘å, ¼‰ªˆÀ•F. ×–E¶•¨ŠwA•ªŽq•a‘Ô. ÅVˆãŠw•Êû “Á”­«”xüˆÛÇ‚Æ‚»‚ÌŽü•ÓŽ¾Š³. ŒáȈÀ—Ç‘¾•ÒW. 2015. pp42-47. ÅVˆãŠwŽÐ.

Œã“Œ‹vŽkD”x‚ª‚ñD“¿“‡‘åŠw•a‰@‚ÌÅVŽ¡—ª‚í‚©‚é–{C“¿“‡‘åŠw•a‰@•Ò’˜D2015Dpp30-31DƒoƒŠƒ…[ƒƒfƒBƒJƒ‹D

¼‰ªˆÀ•FD‡–°Žž–³ŒÄ‹zÇŒóŒQD“¿“‡‘åŠw•a‰@‚ÌÅVŽ¡—ª‚í‚©‚é–{C“¿“‡‘åŠw•a‰@•Ò’˜D2015Dpp32-33DƒoƒŠƒ…[ƒƒfƒBƒJƒ‹D

Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@ŒÄ‹zŠíEäPŒ´•a“à‰È. ŒÄ‹zŠíŽ¾Š³f—ÂÌÅæ’[. ™ŽRK”äŒÃ, ‹ß“¡‹u, ’†¼—mˆê, ‰œ‘º–¾”Vi, ‚‹´O‹B, ˆêƒm£³˜a, ‹g–ìˆê˜Y, –{ŠÔ‰h, Œ·ŠÔº•F, ’r“c“¿•F, {“c—²•¶, ˆÉ’B—mŽŠ, ‰iˆÀ•, Ž›“cOŽi•ÒW. 2015. pp432-434. æ’[ˆã—ËZpŒ¤‹†Š.

¼‰ªˆÀ•F. ”xŠà. ¡“ú‚Ìf—Â̂½‚ß‚É ƒKƒCƒhƒ‰ƒCƒ“ŠO—ˆf—Ã2015. òF‰p•ÒW. 2015. pp570-572. “úŒoƒƒfƒBƒJƒ‹ŠJ”­.
y˜a•¶‘àz
–L“c—DŽqC‰Í–ìOC¼‰ªˆÀ•FDŠÔŽ¿«”x‰Š‚̖Ɖu—Ö@‚Í—L—p‚©HDŒÄ‹zŠí“à‰È 28(6):451-455C2015.

¼‰ªˆÀ•F. IPF‚Ì•aˆö˜_. THE LUNG perspective 23(3): 66-69, 2015.

ŽRŒû•Žj, ”“Œ_, V’J•ÛŽÀ, —k‰ÍGÍ, ¼ˆä®Žq, d´r—Y, “c粕‘, ‚‰ª§, ”ÑŠÔ“w, ‘å‰Y‰ë”Ž, Šì‘½Gm, ŒËª¹D, –ì“c˜aŽ, XZrDˆÓŽ¯áŠQŠ³ŽÒ‚ÌŠÓ•Êf’f‚É‚¨‚¯‚éÚׂȕa—ðŠm”F‚Ìd—v«D“ú–{“à‰ÈŠw‰ïŽGŽ 104(7):1495-1503, 2015.

û•£¹‹B, ¼‰ªˆÀ•F. Current topics from major journals-‰p•¶´“lj‚ç ALK—z«”ñ¬×–E”xŠà‚ɑ΂·‚é1ŽŸŽ¡—Âł̃NƒŠƒ]ƒ`ƒjƒu‚Ɖ»Šw—Ö@‚Ì”äŠrŽŽŒ±. “ú–{‹¹•”—Õ° 74(6):717, 2015.

¼‰ªˆÀ•F. –ò•¨Ž¡—Âɂ¨‚¯‚éƒXƒeƒƒCƒh‚̈ʒu‚¯‚Æ‚ÍH. Modern Physician 6 35(6):766-768, 2015.

¼‰ªˆÀ•F. ”xüˆÛÇ. ŒÄ‹z‚ÆzŠÂ 63(4): 315-322, 2015.

¼‰ªˆÀ•F, ˆ¢•”Gˆê, ²“¡³‘å, Œã“Œ‹vŽk. Fibrocyte. Respiratory Medical Research 3(2):60-63, 2015.

¼‰ªˆÀ•F. ‚ª‚ñ–Ɖu—Ö@‚̉ߋŽ‚Æ–¢—ˆFƒGƒrƒfƒ“ƒX‚ªŽ¦‚µ‚½V‚½‚ȉ”\«D“ú–{Œûo‰ÈŠw‰ïŽGŽ 64(1):1-11, 2015.

“¿“‡‘åŠw‘åŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”@ŒÄ‹zŠíEäPŒ´•a“à‰ÈŠw•ª–ì. ŒÄ‹zŠí´“ljï. ŒÄ‹z 34(2):233, 2015.

û•£¹‹B, ¼‰ªˆÀ•F. R‚ª‚ñÜ‚Ì•›ì—p‚Ì—\–h“IŽ¡—Ã. “ú–{—Õଠ73(‘2):93-97, 2015.

¼‰ªˆÀ•F. ŒÄ‹zŠíŠ´õÇ|ŋ߂̘b‘è|. ¬¼“‡ˆãŽt‰ï‰ï•ñ 49:26-27, 2015.

Œã“Œ‹vŽk, ¼‰ªˆÀ•F. ŒŒŠÇV¶‘jŠQ܂ɑ΂·‚é‘Ï«ƒƒJƒjƒYƒ€. ˆãŠw‚Ì‚ ‚ä‚Ý 252(7):814-818C2015.

û•£¹‹B. COPD|•a‘Ô‚Ì—‰ð‚ƃ}ƒlƒWƒƒ“ƒg‚ÌŽÀÛ|. ¬¼“‡ˆãŽt‰ï‰ï•ñ 49:31-33, 2015.
y˜a•¶Œ´’˜z
’†–ì–œ—L—¢, ‹g“c¬“ñ, ’†ŽR³, ‘å‹ø•¶—², û•£¹‹B, ¼‰ªˆÀ•F. ƒCƒ“ƒtƒ‹ƒGƒ“ƒUiH1N1j2009‚É”º‚¤ARDS‚ÉPMX-DHP—Ö@‚ª‘tŒø‚µ‚½1—á. Š´õÇŠwŽGŽ 89(3):416-421, 2015.

û•£¹‹B, ‘å’ËŒ›Ži, ’Ëú±—C‹M, ≺’¼ŽÀ, Œ÷“‚µ‚Ì‚Ô, •Ÿ“c—I, ¼‰ªˆÀ•F. Acute fibrinous and organizing pneumoniaƒpƒ^[ƒ“‚Ì“Á”­«ŠÔŽ¿«”x‰Š‚ªŽ¦´‚³‚ꂽ1—á. THE LUNG perspectives 23(2):2-5, 2015.

²“¡³‘å, Œã“Œ‹vŽk, ˆ¢•”Gˆê, ’|ú±²•v, ‰Í–ìO, –샓T, ¼‰ªˆÀ•F. ƒqƒgfibrocyte•ª‰»‚É‚¨‚¯‚éˆâ“`Žq”­Œ»‰ðÍ‚Æ•ªŽq•W“IŽ¡—Öò‚É‚æ‚镪‰»§Œä‚ÌŒŸ“¢. •ªŽqŒÄ‹zŠí•a 19(1):135-139, 2015.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Yasuhiko Nishioka. Novel mechanisms in acquired resistance to anti-angiogenic therapy against lung cancer and mesothelioma. The 2nd Gene & Immunotherapy Conference Vietnam (Invited lecture). HCM City, Vietnam. 2015”N9ŒŽ25“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Yoshinori Aono, Hirokazu Ogino, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer. International Conference of Cancer Immunotherapy and Macrophages 2015. “Œ‹ž. 2015”N7ŒŽ9“ú.

Hirokazu Ogino, Atsushi Mitsuhashi, Hisatsugu Goto, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Hisanori Uehara, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. Characterization of Sphere-Forming Stem-Like Population of Lung Cancer Cell Line in Multi-Organ Metastasis Model. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ19“ú.

Yasuhiko Nishioka. What is a Role of Fibrocytes in Lung Fibrosis and Cancer? ATS 2015 International Conference (Invited lecture). Denver, CO. 2015”N5ŒŽ19“ú.

Seidai Sato, Hisatsugu Goto, Shuichi Abe, Terumi Yoshijima, Hiroyasu Okazaki, Akio Takezaki, Yoshinori Aono, Masaki Hanibuchi, Yasuhiko Nishioka. Effect of Kinase Inhibitors for Growth Factor Receptors on the Differentiation of Human Fibrocytes. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ17“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Hisanori Uehara, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. The Role of Fibrocytes in the Acquired Resistance to Anti-Angiogenic Therapy with Bevacizumab in Malignant Pleural Mesothelioma. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ17“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F.@‚ª‚ñ–Ɖu‚ðl‚¦‚é`i•à‚·‚éŠî‘bŒ¤‹†‚ð—Õ°‚Ö‚Ç‚¤Šˆ‚©‚·‚©H`.@‘æ24‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[).@¼]. 2015”N12ŒŽ20“ú.

¼‰ªˆÀ•F.@“Á”­«”xüˆÛÇ‚Ì×–E•ªŽq•a‘ÔŒ¤‹†‚ÆŽ¡—ÂÌi•à.@ ‘æ30‰ñ’·èDDSEĶˆã—ÃŒ¤‹†‰ï(“Á•Êu‰‰). ’·è.@2015”N12ŒŽ4“ú.

¼‰ªˆÀ•F.@‚ª‚ñ–Ɖu‚ÌABCF”x‚ª‚ñ‚ɑ΂·‚é–Ɖu—Ö@‚Ì—‰ð‚ÉŒü‚¯‚Ä.@‘æ56‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€).@‰¡•l.@2015”N11ŒŽ28“ú.

¼‰ªˆÀ•F. “úíf—Âɂ¨‚¯‚éäPŒ´•a”x‚ÌŠÓ•Ê–@. “ú–{ŒÄ‹zŠíŠw‰ï‘æ36‰ñ¶ŠU‹³ˆçu‰‰‰ï(‹³ˆçu‰‰). –¼ŒÃ‰®. 2015”N11ŒŽ1“ú.

Yasuhiko Nishioka, Hisatsugu Goto. Mechanisms of acquired resistance to anti-angiogenic therapy and new insights toward the overcoming. ‘æ74‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (Core Symposia 2). –¼ŒÃ‰®. 2015”N10ŒŽ8“ú.

‘å–ØOŽ¡, ¼‰ªˆÀ•F, ‰Á“¡K¬. V‹KRƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌLpMab-7‚ÌRŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ19‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï(ƒ[ƒNƒVƒ‡ƒbƒv). ¼ŽR. 2015”N6ŒŽ11“ú.

“Œ“‘ã. ‹ÛŒŒÇˆÈŠO‚ÌESBL Š´õÇ‚àƒJƒ‹ƒoƒyƒlƒ€‚ÌŽg—p‚ð„§‚·‚é. ‘æ63‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï(ƒ[ƒNƒVƒ‡ƒbƒv). “Œ‹ž. 2015”N6ŒŽ5“ú.

Œã“Œ‹vŽk. Life in DUKE -DUKE‘åŠw—¯Šw‘ÌŒ±-. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•ÊŠé‰æ). “Œ‹ž. 2015”N4ŒŽ19“ú.

¼‰ªˆÀ•F. V‹K•ªŽq•W“I–ò‚Æ‚»‚̃^[ƒQƒbƒg. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(‹³ˆçu‰‰). “Œ‹ž. 2015”N4ŒŽ17“ú.

¼‰ªˆÀ•F. “úíf—Âɂ¨‚¯‚éäPŒ´•a”x‚ÌŠÓ•Ê–@. “ú–{ŒÄ‹zŠíŠw‰ï‘æ36‰ñ¶ŠU‹³ˆçu‰‰‰ï(‹³ˆçu‰‰). “Œ‹ž. 2015”N4ŒŽ16“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
û•£¹‹BC‰Á”[—ºC‘q–{‘ìÆCŒã“Œ‹vŽkCâŒû‹ÅC–L“c—DŽqCŽè’Ë•qŽjC¼žŠ“Ö˜YC¼‰ªˆÀ•F.@ŠàŠ³ŽÒŒŒŸ÷’†—V—£DNA‚ð—p‚¢‚½ˆâ“`Žq•ÏˆÙŒŸ¸‹Zp‚Ì”äŠr.@‘æ56‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï.@‰¡•l.@2015”N11ŒŽ27“ú.

¼žŠ“Ö˜YCâŒû‹ÅAŽè’Ë•qŽjCŠ`“à‘ŽiC–L“c—DŽqCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•F.@“–‰@‚É‚¨‚¯‚éäPŒ´•a‚ɇ•¹‚µ‚½”xŠà‚ÌŒŸ“¢.@‘æ56‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï.@‰¡•l.@2015”N11ŒŽ26“ú.

‰¬–ìL˜a, ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ¼žŠ“Ö˜Y, ²“¡³‘å, âŒû‹Å, Žè’Ë•qŽj, ‘q–{‘ìÆ, “c”¨Ë, ㌴‹v“T, û•£¹‹B, ¼‰ªˆÀ•F. Sphere Œ`¬ŠàŠ²×–E—l•ª‰æ‚̃qƒg”xŠà‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é–ðŠ„‚É‚Â‚¢‚ẲðÍ. ‘æ74‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. –¼ŒÃ‰®. 2015”N10ŒŽ10“ú.

ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, ‘å’ËŒ›Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. V‹KƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì NZ-12 ‚̈««‹¹–Œ’†”çŽî‚ɑ΂·‚éRŽîᇌø‰Ê. ‘æ74‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. –¼ŒÃ‰®. 2015”N10ŒŽ9“ú.

‰¬–ìL˜a, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ¼žŠ“Ö˜Y, ²“¡³‘å, Š`“à‘Ži, û•£¹‹B, ㌴‹v“T, ¼‰ªˆÀ•F. Sphere Œ`¬ŠàŠ²×–E—l•ª‰æ‚Ì”xŠà‘½‘ŸŠí“]ˆÚ‚É‚¨‚¯‚é–ðŠ„‚É‚Â‚¢‚ẲðÍ. ‘æ24‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ‘åã. 2015”N7ŒŽ23“ú.

¼žŠ“Ö˜Y, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ’†–ì–œ—L—¢, ŽRŽq‘דl, âŒû‹Å, Š`“à‘Ži, û•£¹‹B, ¼‰ªˆÀ•F. Fibrocyte ‚Í‚ª‚ñŠ²×–E«ˆÛŽ‚É‚æ‚è”xŠài“W‚ð‘£i‚·‚é. ‘æ24‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ‘åã. 2015”N7ŒŽ23“ú.

âŒû‹Å, –L“c—DŽq, Žè’Ë•qŽj, ’|ú±²•v, ’†–ì–œ—L—¢, ‘ë‘q‹P”ü, ²“¡³‘å, ‰ªú±O‘×, ‘å’ËŒ›Ži, Š`“à‘Ži, Œã“Œ‹vŽk, ŠÝ, û•£¹‹B, ¼‰ªˆÀ•F. ”x–EoŒŒ‚ð‚«‚½‚µ‚½ 11 Ç—á‚ÌŒŸ“¢. ‘æ38‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. “Œ‹ž. 2015”N6ŒŽ11“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ¼žŠ“Ö˜Y, û•£¹‹B, ¼‰ªˆÀ•F. üˆÛ×–Eifibrocytesj‚ªŠÖ‚í‚錌ŠÇV¶‘jŠQ܂ɑ΂·‚éŠl“¾‘Ï«ƒƒJƒjƒYƒ€. ‘æ19‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ¼ŽR. 2015”N6ŒŽ11“ú.

‘å’ËŒ›Ži, û•£¹‹B, Œã“Œ‹vŽk, ¼‰ªˆÀ•F. ”xŠà‚ɑ΂·‚éRPD-L1R‘ÌŽ¡—Â̊î‘b“IŒŸ“¢. ‘æ19‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ¼ŽR. 2015”N6ŒŽ11“ú.

¬ì”Ž‹v, Žè’Ë•qŽj, ¼‰ªˆÀ•F. ƒ_ƒjRŒ´Œo•@Š´ì‚ÍIL-17‚ð‘‰Á‚³‚¹•½ŠŠ‹Ø”ìŒú‚𔺂¤‹C“¹ƒŠƒ‚ƒfƒŠƒ“ƒO‚ð—U“±‚·‚é. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï. “Œ‹ž. 2015”N5ŒŽ27“ú.

’}Œã“Žq, ŠÝ, –L“c—DŽq, ‰Í–ìO, ¼‰ªˆÀ•F. ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚É‚¨‚¯‚é‰h—{•]‰¿–@‚ÌŒŸ“¢. ‘æ59‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. –¼ŒÃ‰®. 2015”N4ŒŽ24“ú.

–L“c—DŽq, ‘ë‘q‹PŽÀ, ‹ß“¡^‘ã, ²“¡³‘å, ”öè—Ì•F, ŠÝ, Žè’Ë•qŽj, ‰Í–ìO, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. äPŒ´•a‚ɇ•¹‚µ‚½ŒŒ‹…æÃH«ƒŠƒ“ƒp‘gD‹…Ç‚Ì4Ç—á. ‘æ59‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. –¼ŒÃ‰®. 2015”N4ŒŽ24“ú.

²“¡³‘å, Œã“Œ‹vŽk, XZr, ˆ¢•”Gˆê, ‹g“ˆ‹PŽÀ, ‰ªú±O‘×, û•£¹‹B, ¼‰ªˆÀ•F. ”xüˆÛ‰è×–E‚ɑ΂·‚éfibrocyte‚Ìì—p‚Ænintedanib‚Ì—}§Œø‰Ê. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ19“ú.

û•£¹‹B, ’†£Ÿ‘¥, –Lé“Z, –؉º¬ŽO, “‡“c‹v•v, ’ß”ö”ü•ä, Œáȉë•F, —t‹v‹MŽi, ¼‰ªˆÀ•F. “¿“‡Žs‚É‚¨‚¯‚éCOPDŒŸfƒVƒXƒeƒ€‚Ì\’z. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ19“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. Fibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ18“ú.

’†‘ºMŒ³, “Œ“‘ã, ‰F‚Œ›Œá, ŽO–Ø_˜a, ‰êì‹v”üŽq, ¼‰ªˆÀ•F, ”nŒ´•¶•F, “¡“c”ŽŒÈ. “–‰@‚ÅŒoŒ±‚µ‚½dÇ”M«ŒŒ¬”ÂŒ¸­ÇŒóŒQ‚Ì3—á. ‘æ89‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ï. ‹ž“s. 2015”N4ŒŽ17“ú.

Žè’Ë•qŽj, ¬ì”Ž‹v, –L“c—DŽq, ’|ú±²•v, ²“¡³‘å, ‰ªú±O‘×, ‹g“ˆ‹PŽÀ, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Plasminogen Activator Inhibitor-1 ‘jŠQÜ(IMD-4690)‚Ì–«šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ17“ú.

Š`“à‘Ži, ‰¬–ìL˜a, ‘å’ËŒ›Ži, âŒû‹Å, ¼žŠ“Ö˜Y, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿«”x‰Š‡•¹”xŠà‚ÌŽ¡—Â̌»ó. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ17“ú.

“Œ “‘ã, ¼‰ªˆÀ•F. ‘Ï«—Δ^‹ÛŽ‘±Š´õ‚É‚¨‚¯‚é‘n•”‚ւ̃|ƒŠƒ~ƒLƒVƒ“ B —°Ž_‰–ŽU•z‚ÌŒŸ“¢. ‘æ89‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ï. ‹ž“s. 2015”N4ŒŽ17“ú.

’†–ì–œ—L—¢, ‹g“ˆ‹PŽÀ, û•£¹‹B, ’†‘ºMŒ³, ŽO–Ø_˜a, ‰êì‹v”üŽq, ¼‰ªˆÀ•F. Pneumocystis jiroveci‚ɑ΂µST‡Ü‚Ì’EŠ´ì—Ö@‚ðs‚Á‚½4Ç—á‚ÌŒŸ“¢. ‘æ89‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ï. ‹ž“s. 2015”N4ŒŽ16“ú.

Šââ–ƒˆßŽq, ²“¡³‘å, âŒû‹Å, –L“c—DŽq, ¬ì”Ž‹v, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚¯‚éŠÔŽ¿«”x‰Šƒ}[ƒJ[‚ÌŒŸ“¢. ‘æ112‰ñ“ú–{“à‰ÈŠw‰ï‘‰ï. ‹ž“s. 2015”N4ŒŽ11“ú.

‰¬–ìL˜a, –L“c—DŽq, ’†–ì–œ—L—¢, “Œ“‘ã, û•£¹‹B, ¼‰ªˆÀ•F. ”畆‹Ø‰Š‚ɑ΂µ‚ăXƒeƒƒCƒh‚¨‚æ‚іƉu—}§Ü‚É‚æ‚é‰Á—Ã’†‚É”­Ç‚µ‚½”dŽí«Mycobacterium aviumÇ‚Ì1—á. ‘æ90‰ñ“ú–{Œ‹Šj•aŠw‰ï‘‰ï. ’·è. 2015”N3ŒŽ27“ú.

“Œ“‘ã, ’†‘]ˆŸ²”ü, “¡Œ´”ÍŽq, ”¨”ü’qŽq, ‰Á“¡^‰î, ¼‰ªˆÀ•F. uHYDRO AGv‚ð—p‚¢‚½ƒ^ƒbƒ`ƒpƒlƒ‹‰t»•ÛŒìƒtƒBƒ‹ƒ€‚̈ã—ÃŒ»ê‚É‚¨‚¯‚é—L—p«‚ÌŒŸ“¢. ‘æ30‰ñ“ú–{ŠÂ‹«Š´õŠw‰ï‘‰ïEŠwpW‰ï. _ŒË. 2015”N2ŒŽ20“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
Žl‹{—R‹MC²“¡³‘åC’|ú±²•vC‹ß“¡^‘ãC‘ë‘q‹PŽÀCâŒû‹ÅA–L“c—DŽqCŒã“Œ‹vŽkCŠÝCû•£¹‹BC¼‰ªˆÀ•F.@ƒTƒ‹ƒRƒCƒh[ƒVƒXŒo‰ßŠÏŽ@’†‚É”­Ç‚µ‚½Œ‹Šj«‹¹–Œ‰Š‚Ì‚P—á.@‘æ24‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï.@¼]. 2015”N12ŒŽ20“ú.

•Ä“c_lC²“¡³‘åCìk‘¢C‰¬–ìL˜aC’|ú±²•vCâŒû‹ÅC–L“c—DŽqC“Œ“‘ãCŒã“Œ‹vŽkCŠÝCû•£¹‹BC¼‰ªˆÀ•F.@œ‘ˆÙŒ`¬ÇŒóŒQ‚É”dŽí«Œ‹ŠjÇ‚ð‡•¹‚µŽ¡—Âɓïa‚µ‚½ˆê—á.@‘æ66‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ï. ¼]. 2015”N12ŒŽ19“ú.

’–Žq–¢ŠóC‰¬–ìL˜aC’†–ì–œ—L—¢C‰ªú±O‘×C‘å’ËŒ›ŽiCŒã“Œ‹vŽkCŠÝCû•£¹‹BCâ“Œ—Ç”üCíŽRKˆêC¼‰ªˆÀ•F.@”]AŒûŠW‚AA“ª‚¨‚æ‚Ѭ’°‚ւ̉“Šu“]ˆÚ‚ðŒ`¬‚·‚é‹H‚È—Õ°Œo‰ß‚ð‚½‚Ç‚Á‚½‰Eã—tŒ´”­‘½Œ`Šà‚̈ê–UŒŸ—á.@ ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï.@¼]. 2015”N12ŒŽ19“ú.

‘]‰ä•”—m•½C²“¡³‘åC¼žŠ“Ö˜YC’†–ì–œ—L—¢C‰Í–ìOCâŒû‹ÅC–L“c—DŽqCŒã“Œ‹vŽkCŠÝCû•£¹‹BC¼‰ªˆÀ•F.@Šà«‘–Œ‰Š‚ɑ΂µƒAƒtƒ@ƒ`ƒjƒu‚ª‘tŒø‚µ‚½2—á.@‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï.@¼]. 2015”N12ŒŽ19“ú.

‹ß“¡^‘ãC²“¡³‘åCŽè’Ë•qŽjC–L“c—DŽqC”ò”~—ºCŒã“Œ‹vŽkCŠÝCû•£¹‹BC¼‰ªˆÀ•F.@‹¹–Œ‰ŠESŠO–Œ‰Š‚ðŒ_‹@‚Éf’f‚³‚ꂽ¬lStill•a‚Ì2—á.@ ‘æ113‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼.@2015”N12ŒŽ6“ú.

XZrC²“¡³‘åC‰¬–ìL˜aC‹ß“¡^‘ãCŽè’Ë•qŽjC–L“c—DŽqCŒã“Œ‹vŽkCŠÝCû•£¹‹BC¼‰ªˆÀ•F.@“–‰È‚ÅŽ{s‚³‚ꂽ‹¹–Œ–ü’…p‚É‚¨‚¯‚éƒ^ƒ‹ƒN»Ü‚ÆOK-432‚ÌŽg—p¬Ñ‚Ì”äŠr.@‘æ113‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼. 2015”N12ŒŽ6“ú.

ŽR‰º—Y–çC‰¬–ìL˜aCŠÝC–L“c—DŽqCXZrC‹ß“¡^‘ãC‘ë‘q‹PŽÀC²“¡³‘åC‰Í–ìOCŽè’Ë•qŽjCŒã“Œ‹vŽkCû•£¹‹BA¼‰ªˆÀ•F.@‹¹–Œ‰ŠAƒlƒtƒ[ƒ[ÇŒóŒQ‚¨‚æ‚ÑdÇ‘m–X•Ù•Â½•s‘SÇ‚ð’悵‚½‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚̈ê—á.@‘æ26‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï.@‰ªŽR. 2015”N12ŒŽ5“ú.

Š“cŒh‰î, ²“¡³‘å, –L“c—DŽq, âŒû‹Å, Žè’Ë•qŽj, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. PS•s—ÇALK—Z‡ˆâ“`Žq—z«‚ÌŽá”N”x‘BŠà‚ɑ΂µƒNƒŠƒ]ƒ`ƒjƒu‚ª‘tŒø‚µ‚½ˆê—á. ‘æ251‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2015”N8ŒŽ2“ú.

ìk‘¢, âŒû‹Å, ’Ëú±—C‹M, ²“¡³‘å, ”ò”~—º, •Ä“c_l, ’|ú±²•v, Žè’Ë•qŽj, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Šà«‘–Œ‰Š‚Éafatinib‚ª‘tŒø‚µ‚½EGFR exon18 G719A•ÏˆÙ‚ð‚à‚”x‘BŠà‚̈ê—á. ‘æ54‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”‰ï. ¼ŽR. 2015”N7ŒŽ3“ú.

’–Žq–¢Šó, ‰¬–ìL˜a, âŒû‹Å, ŠÝ¹”ü, –L“c—DŽq, ‹ß“¡^‘ã, ’†–ì–œ—L—¢, ŠÝ, û•£¹‹B, ¼‰ªˆÀ•F. Nocardia wallaceiŠ´õÇ‚Ì1—á. ‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ¼ŽR. 2015”N7ŒŽ3“ú.

•ˆä”ü‹MŽqC‹ß“¡^‘ãC²“¡³‘åC‰Í–ìOC–L“c—DŽqCû•£¹‹BC¼‰ªˆÀ•F. DŽ_‹…«’_ŠÇ‰Š‚ð‡•¹‚µ‚½‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚Ì‚P—á. ‘æ112‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2015”N6ŒŽ7“ú.

‘ë‘q‹PŽÀCâŒû‹ÅCXZrC‘å’ËŒ›ŽiCŠÝ¹”üCŽè’Ë•qŽjC¼žŠ“Ö˜YCŠ`“à‘ŽiCû•£¹‹BC¼‰ªˆÀ•F. N-acetylcysteine‹z“ü‚ª—LŒø‚Å‚ ‚Á‚½ƒsƒ‹ƒtƒFƒjƒhƒ“’ïR«“Á”­«”xüˆÛÇ‚Ì1—á. ‘æ112‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2015”N6ŒŽ7“ú.

”öè—Ì•F, âŒû‹Å, Žè’Ë•qŽj, ‘å’ËŒ›Ži, XZr, ŠÝ, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. ‹¹–Œ’¼‰º‚É‘Ñó‚É•ª•z‚·‚é‚·‚èƒKƒ‰ƒX‰A‰e‚Å”­Ç‚µ‚½AŽ©ŒÈ–Ɖu«”x–E’`”’ǂ̈ê—á. ‘æ23‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. ‚’m. 2015”N2ŒŽ28“ú.

’†–ì–œ—L—¢, “Œ“‘ã, ‘ë‘q‹PŽÀ, âŒû‹Å, –L“c—DŽq, ã‰ñŽÑ‘ã, ˆÀ•”GÄ, û•£¹‹B, “yˆär•v, ¼‰ªˆÀ•F. ’·ŠúŠÔƒXƒeƒƒCƒh“Š—^‚ª”­Ç‚ÌŒ_‹@‚Æ‚È‚Á‚½AMycobacterium intracellulare‚É‚æ‚éŠÖ߉Š‚Æœ‘‰Š‚Ì2Ç—á. ‘æ65‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ï. ‚’m. 2015”N2ŒŽ28“ú.

–ì“c˜aŽ, “Œ“‘ã, ¼”—Š°—², •š’JGŽ¡, ²“¡‰ë”ü, ”¨”ü’qŽq, ÎàVŒ[‰î, ¼‰ªˆÀ•F. ^‹ÛŠ´õBUNDLE‚Ì“¿“‡‘åŠw•a‰@‚Å‚ÌŠˆ—p‚ɂ‚¢‚Ä. ‘æ250‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2015”N2ŒŽ1“ú.

ˆîŠ_‘¾‘¢, ‰¬–ìL˜a, âŒû‹Å, –L“c—DŽq, ’†–ì–œ—L—¢, XZr, ²“¡³‘å, ¬ì”Ž‹v, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚¯‚éŠÔŽ¿«”x‰Šƒ}[ƒJ[‚ÌŒŸ“¢. ‘æ250‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2015”N2ŒŽ1“ú.

ŠÛ‹´•üŽq, ’†‘ºMŒ³, ‘]‰ä•”ŒöŽq, ”ª–؂Ђ©‚é, ‚‹´^”üŽq, ‰F‚Œ›Œá, “¡ˆäŽu˜N, ŽO–Ø_˜a, ‰êì‹v”üŽq, ˆÀ”{³”Ž, ¼žŠ“Ö˜Y, ’†–ì–œ—L—¢, “Œ“‘ã, ¼‰ªˆÀ•F, ‹ß“¡Œ›•Û, ˆä“àV, “¡“c”ŽŒÈ, ”nŒ´•¶•F. “–‰@‚ÅŒoŒ±‚µ‚½dÇ”M«ŒŒ¬”ÂŒ¸­ÇŒóŒQ‚Ì‚R—á. ‘æ250‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2015”N2ŒŽ1“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2014”N‹ÆÑ
y‰¢•¶‘à“™z
Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Invest 61(3,4):241-253, 2014.

Nishioka Y. Physician scientists in respiratory medicine. Respir Investig 52(5):279, 2014.

Nishioka Y. New wave of immunotherapy against lung cancer rolls in to clinic. Transl Lung Cancer Res 3(1):1, 2014.

Goto H, Mitsuhashi A, Nishioka Y. Role of surfactant protein A in non-infectious lung diseases. J Med Invest 61(1,2):1-6, 2014.
y‰¢•¶Œ´’˜z
Matsuo T, Dat LT, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T. Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS ONE 9(11):e113606, 2014.

Ogawa H, Ledford JG, Mukherjee S, Aono Y, Nishioka Y, Lee JJ, Izumi K, Hollingsworth JW. Surfactant protein D attenuates sub-epithelial fibrosis in allergic airways disease through TGF-beta. Respir Res 15(1):143, 2014.

Sato S, Hanibuchi M, Fukuya A, Yabuki Y, Bando H, Yoshijima T, Goto H, Ogawa H, Nishioka Y. Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but Not Krebs von den Lungen-6. Lung 192(5):711-717, 2014.

Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H, Uehara H, Izumi K, Nishioka Y. Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol 51(6):793-801, 2014.

Yokoi K, Tanei T, Godin B, van de Ven AL, Hanibuchi M, Matsunoki A, Alexander J, Ferrari M. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Letters 345(1):48-55, 2014.

Toyoda Y, Tabata S, Kishi J, Kuramoto T, Mitsuhashi A, Saijo A, Kawano H, Goto H, Aono Y, Hanibuchi M, Horikawa H, Nakajima T, Furukawa T, Sone S, Akiyama S, Nishioka Y. Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 66(3):560-568, 2014.
y˜a•¶’˜‘z
ŠÝ, ‰Í–ìO, ¼‰ªˆÀ•F. ‹­”çÇ. ÅVˆãŠwE•Êû V‚µ‚¢f’f‚ÆŽ¡—ÂÌABC 85, ™ŽRK”äŒÃ•ÒW. 2014. pp34-41. ÅVˆãŠwŽÐ.

û•£¹‹B. Œ‹Šj. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. p175. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

–L“c—DŽq. ƒVƒF[ƒOƒŒƒ“ÇŒóŒQEƒx[ƒ`ƒFƒbƒg•a. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp134-135. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

ŠÝ. ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒXE‘½”­«‹Ø‰Š/”畆‹Ø‰ŠE‘Sg«‹­”çÇ. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp132-133. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

ŠÝ. äPŒ´•aE–ƉuŽ¾Š³EƒAƒŒƒ‹ƒM[Ž¾Š³‚Æ‚Í. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp128-129. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

Š`“à‘Ži. ”x‚ª‚ñE‹Ö‰ŒŽw“±E‹Ö‰ŒŽx‰‡. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp65-67. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

–L“c—DŽq. ‰ßŠ·‹CÇŒóŒQ. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp63-64. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

Š`“à‘Ži. ‡–°Žž–³ŒÄ‹zÇŒóŒQ. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp61-62. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

Œã“Œ‹vŽk. ”x‰Š. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp59-60. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

Œã“Œ‹vŽk. –«•ÂÇ«”xŽ¾Š³EŠÔŽ¿«”x‰Š. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp57-58. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

û•£¹‹B. ŠPšuEá‚. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. p29. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

û•£¹‹B. ”­”M. Ž•ŠE“W–] •ÊûEŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ÕŒ´–«, Žsì“N—Y•ÒW. 2014. pp11-12. ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

¼‰ªˆÀ•F. ×–EE•ªŽq¶•¨. ŒÄ‹zŠíŽ¾Š³•¶Œ£ƒŒƒrƒ…[2014`2015. ‹´–{CŠÄC. 2014. pp12-25. Š”Ž®‰ïŽÐŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ.
y˜a•¶‘àz
¼‰ªˆÀ•F. COPDf—Â̌»ó‚Æ“¿“‡Œ§‚Å‚ÌŽæ‚è‘g‚Ý. ˆ¢“ìˆã•ñ 175:20-21, 2014.

¼‰ªˆÀ•F. ”xüˆÛÇ‚Æ‘BˆöŽqƒVƒOƒiƒ‹. ŒÄ‹z‚ÆzŠÂ 62(9):873-878, 2014.

Œã“Œ‹vŽk, ¼‰ªˆÀ•F. V–ò‚Ìŋ߂̘b‘èuƒfƒmƒXƒ}ƒuv. •ªŽqŒÄ‹zŠí•a 18(1):109-111, 2014.

¼‰ªˆÀ•F. V–òŽ¡—Öò‚ÌŠJ”­ó‹µ‚Æ«—ˆ“W–]. “ú–{ˆãŽt‰ïŽGŽ143(5):1011, 2014.
y˜a•¶Œ´’˜z
–؉ºŸO, –샓T, ’|ú±²•v, ‰ªú±O‘×, ‹g“ˆ‹PŽÀ, ŠÝ¹”ü, “Œ“‘ã, ŠÝ, òŒ[‰î, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚éFAKƒVƒOƒiƒ‹‘jŠQ–ò‚ÌRüˆÛ‰»Œø‰Ê. •ªŽqŒÄ‹zŠí•a 18(1):154-157, 2014.

’r’¼Žq, Š ’JƒAƒL, à_Œû^—, HX—eŽq, ¼”Ž”V, ’†–ì–œ—L—¢, ’¬“c‹v“T, ”©ŽR’¨¶, ‰ª–ì‹`•v,ŽÂŒ´•×, ‘å‹ø•¶—². ”xŠà‰»Šw—Ö@Š³ŽÒ‚ÌQOL/PRO•]‰¿‚É‹y‚Ú‚·Œ‡‘ª‚̉e‹¿. ‚’mŒ§ˆãŽt‰ïˆãŠwŽGŽ 19(1):112-121, 2014.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Yasuhiko Nishioka, Shuichi Abe, Seidai Sato, Yoshinori Aono, Hisatsugu Goto, Masami Kishi, Terumi Yoshijima, Hiroyasu Okazaki, Masaki Hanibuchi. Role of human fibrocytes in regulating pulmonary fibrosis: comprehensive analysis of their gene expression profile and growth factor production. The 18th International Colloquium on Lung and Airway Fibrosis (ICLAF). Mont-Tremblant, Quebec Canada. 2014”N9ŒŽ23“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Trung The Van, Yoshinori Aono, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Seiji Yano, Keisuke Izumi, Yasuhiko Nishioka. The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer. ATS 2014 International Conference (Mini-symposium). San Diego, CA. 2014”N5ŒŽ21“ú.

Seidai Sato, Hisatsugu Goto, Shuichi Abe, Masami Kishi, Katsuhiro Kinoshita, Momoyo Azuma,Akio Takezaki, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi, Yasuhiko Nishioka. Effect of Nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation. ATS 2014 International Conference. San Diego, CA. 2014”N5ŒŽ18“ú.

Hisatsugu Goto, Yasuhiko Nishioka.The role of surfactant protein A in the host defense of the lung. The 117th Conference of KATRD (Invited lecture). Buan, Korea. 2014”N4ŒŽ11“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
Œã“Œ‹vŽkC¼‰ªˆÀ•F. ‹}«EˆŸ‹}«Œo‰ß‚ðŽ¦‚·ŠÔŽ¿«”x‰Š‚Ì—Õ°. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï(‹³ˆçu‰‰j. ‚¼. 2014”N12ŒŽ13“ú.

¼‰ªˆÀ•F. ‚ª‚ñ–Ɖu—Ö@‚̉ߋŽ‚Æ–¢—ˆFƒGƒrƒfƒ“ƒX‚ªŽ¦‚µ‚½V‚½‚ȉ”\«D‘æ62‰ñ“ú–{ŒûoŠw‰ï ’†‘EŽl‘’n•û•”‰ï(“Á•Êu‰‰). “¿“‡. 2014”N10ŒŽ25“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ¼žŠ“Ö˜Y, ‘q–{‘ìÆ, “c”¨Ë, û•£¹‹B, Š`“à‘Ži, –샓T, ㌴‹v“T, ¼‰ªˆÀ•F. ƒxƒoƒVƒYƒ}ƒu‚ɑ΂·‚éŠl“¾‘Ï«ƒƒJƒjƒYƒ€‚Æ‚µ‚Ä‚ÌüˆÛ×–Eifibrocytesj‚Ì–ðŠ„. ‘æ18‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). å‘ä. 2014”N6ŒŽ27“ú.

¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š/”xüˆÛÇ. ‘æ61‰ñ“ú–{–ƒŒ‰ÈŠw‰ïŠwpW‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2014”N5ŒŽ16“ú.

¼‰ªˆÀ•F. ‰pŒê˜_•¶‚Ì‘‚«•û‚ÆŽw“±ƒ|ƒCƒ“ƒg`“–‰È‚É‚¨‚¯‚éŒoŒ±‚©‚ç`. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(“Á•ÊŠé‰æ). ‘åã. 2014”N4ŒŽ27“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ˆ¢•”Gˆê, –샓T, ¼‰ªˆÀ•F. ŒÄ‹zŠíŽ¾Š³‚É‚¨‚¯‚é–«‰ŠÇ‚Æ fibrocyte. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘åã. 2014”N4ŒŽ27“ú.

¼‰ªˆÀ•F. ”x‚ª‚ñE’†”çŽî‚É‚¨‚¯‚錌ŠÇV¶‘jŠQ–ò‘Ï«. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘åã. 2014”N4ŒŽ26“ú.

¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‡•¹”xŠà‚ÌŽ¡—Ãí—ª. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[). ‘åã. 2014”N4ŒŽ25“ú.

¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“IŽ¡—Â̊î‘b‚Æ—Õ°.•½¬25”N“x“¿“‡—Õ°×–EŠw‰ï‘‰ï‚¨‚æ‚ÑŠwpW‰ï(“Á•Êu‰‰). “¿“‡. 2014”N3ŒŽ6“ú.

¼‰ªˆÀ•F. ‚—îŽÒ”x‰Šf—ÂÌl‚¦•û. ‘æ25‰ñ“ú–{˜V”NˆãŠw‰ïŽl‘’n•û‰ï(‹³ˆçu‰‰). “¿“‡. 2014”N2ŒŽ23“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
Hitoshi Nishijima, Junko Morimoto, Yasuhiro Mouri, Hiroshi Kawano, Koichi Ikuta, Mitsuru Matsumoto. Approaches to identify Aire-regulated non-tissue-restricted antigen genes by the ectopic expression of Aire in thymic cortex. ‘æ43‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï. ‹ž“s. 2014”N12ŒŽ10“ú.

Hiroshi Kawano, Junko Morimoto, Yasuhiro Mouri, Hitoshi Nishijima, Yasuhiko Nishioka, Mitsuru Matsumoto. Unexpected disturbance of the development of medullary thymic epithelial cells at immature stages by the long-term ablation of mature Aire-expressing cells. ‘æ43‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï. ‹ž“s. 2014”N12ŒŽ10“ú.

Š`“à‘Ži, ‘å’ËŒ›Ži, ²“¡³‘å, ¼žŠ“Ö˜Y, âŒû‹Å, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿«”x‰Š‡•¹”xŠà‚ÌŽ¡—Â̌»ó. ‘æ55‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‹ž“s. 2014”N11ŒŽ16“ú.

ŸN“cŒ÷, Š`“à‘Ži, “c“‡‘sˆê˜Y, Ž›‰ª˜a•F, ’†‘º•qŒÈ, ì“Y˜a‹`, ¼‰ªˆÀ•F, —k‰ÍGÍ, …Œû˜a•v. ”xŠà–ò•¨—Ö@‚É‚¨‚¯‚é–òÜ«ŠÔŽ¿«”x‰Š‚Ì”­Ç‚Æ‚»‚̃ŠƒXƒNˆöŽq‚̉ðÍ. ‘æ55‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï. ‹ž“s. 2014”N11ŒŽ15“ú.

‰Á“¡K¬, ‹àŽq”ü‰Ø, ¬Š}Œ´—@, ¼‰ªˆÀ•F. ‚ª‚ñ“ÁˆÙ“IRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚ÌŽ÷—§. ‘æ73‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2014”N9ŒŽ27“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ¼žŠ“Ö˜Y, Š`“à‘Ži, û•£¹‹B, ㌴‹v“T, –î–칓ñ, ¼‰ªˆÀ•F. ƒxƒoƒVƒYƒ}ƒu‚ɑ΂·‚éŠl“¾‘Ï«ƒƒJƒjƒYƒ€‚Æ‚µ‚Ä‚ÌüˆÛ×–Eifibrocytesj‚Ì–ðŠ„. ‘æ73‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ‰¡•l. 2014”N9ŒŽ27“ú.

âŒû‹Å, Œã“Œ‹vŽk, ‘å‹ø•¶—², —t‹v‹MŽi, Œ“¼‹M‘¥, ‰Y“c’m”V, Š`“à‘Ži, û•£¹‹B, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ‚—îŽÒisNSCLCŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽTS-1—Ö@‚Ì—Õ°‘æ‡U‘ŠŽŽŒ±. ‘æ52‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‰¡•l. 2014”N8ŒŽ28“ú.

‘å’ËŒ›ŽiCŒã“Œ‹vŽkC—t‹v‹MŽi, Œ“¼‹M‘¥, ‰Y“c’m”V, Š`“à‘ŽiCû•£¹‹BC‘å‹ø•¶—², ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ‚—îŽÒis”ñ¬×–E”xŠàŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽTS-1—Ö@‚Ì—Õ°‘æ‡U‘ŠŽŽŒ±. ‘æ12‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. •Ÿ‰ª. 2014”N7ŒŽ18“ú.

‰Á“¡K¬, ¼‰ªˆÀ•F. ŒŒ¬”‹ÃWˆöŽqPodoplanin‚ɑ΂·‚邪‚ñ“ÁˆÙ“IR‘Ì‚ÌŠJ”­. ‘æ23‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ‹à‘ò. 2014”N7ŒŽ11“ú.

ŽRŽq‘דl, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ‘q–{‘ìÆ, “c”¨Ë, ¼žŠ“Ö˜Y, Š`“à‘Ži, û•£¹‹B, ¬ì”Ž‹v, ㌴‹v“T, ¼‰ªˆÀ•F. ƒqƒg¬×–E”xŠàœ“]ˆÚ‚ɑ΂·‚éRANKL•W“IŽ¡—Âɂ¨‚¯‚éIGF-1‚ÌŠÖ—^. ‘æ23‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ‹à‘ò. 2014”N7ŒŽ10“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ‘q–{‘ìÆ, “c”¨Ë, ¼žŠ“Ö˜Y, Š`“à‘Ži, û•£¹‹B, ㌴‹v“T, ¼‰ªˆÀ•F. ”xŠà‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚ésphereŒ`¬ŠàŠ²×–E—l•ª‰æ‚Ì–ðŠ„. ‘æ23‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ‹à‘ò. 2014”N7ŒŽ10“ú.

‘å’ËŒ›Ži, ˆ¢•”^Ž¡, û•£¹‹B, –Øh¹r, ì“Y˜a‹`, ‰Á“¡K¬, ¼‰ªˆÀ•F. ‹¹–Œ’†”çŽî“¯ŠˆÚAƒ‚ƒfƒ‹‚É‚¨‚¯‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚ÌRŽîᇌø‰Ê. ‘æ18‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. å‘ä. 2014”N6ŒŽ26“ú.

“Œ“‘ã, ¼‰ªˆÀ•F. —Δ^‹ÛŠ´õŠ³ŽÒ‚É‚¨‚¯‚éTolerance ‚ƃoƒCƒIƒtƒBƒ‹ƒ€Œ`¬”\‚ÌŒŸ“¢. ‘æ88‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ï. •Ÿ‰ª. 2014”N6ŒŽ20“ú.

’†–ì–œ—L—¢, ûü‹´’¼Šó, ‹g“ˆ‹PŽÀ, ¼žŠ“Ö˜Y, Žè’Ë•qŽj, “Œ“‘ã, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚ÅŒoŒ±‚µ‚½dÇ”M«ŒŒ¬”ÂŒ¸­ÇŒóŒQ(severe fever with thrombocytopenia syndrome: SFTS)‚Ì1—á. ‘æ88‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ï. •Ÿ‰ª. 2014”N6ŒŽ19“ú.

²“¡³‘å, ŠÝ¹”ü, –؉ºŸO, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. ŒŒ´ SP-D 㸂ð”F‚ß‚½ Idiopathic pleuroparenchymal fibroelastosis (IPPFE) Ç—á‚ÌŒŸ“¢. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‘åã. 2014”N4ŒŽ27“ú.

ŠÝ¹”ü, –샓T, “Œ“‘ã, –؉ºŸO, ²“¡³‘å, ‹g“ˆ‹PŽÀ, ’|ú±²•v, ¼‰ªˆÀ•F. PDGFƒŒƒZƒvƒ^[-ƒ¿, ƒÀ‘jŠQR‘̂̃uƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éRüˆÛ‰»Œø‰Ê. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‘åã. 2014”N4ŒŽ26“ú.

Š`“à‘Ži, ‘å’ËŒ›Ži, ²“¡³‘å, ¼žŠ“Ö˜Y, âŒû‹Å, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿«”x‰Š‡•¹”xŠà‚ÌŽ¡—Â̌»ó. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‘åã. 2014”N4ŒŽ26“ú.

–L“c—DŽq, ŠÝ, ‰Í–ìO, Œã“Œ‹vŽk, û•£¹‹B, ’†“‡—˜”Ž, ¼‰ªˆÀ•F. ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ—R—ˆ‚ÌüˆÛ‰è×–E—lŠŠ–Œ×–E‚É‚¨‚¢‚Ä thymidine phosphorylase‚ÍCXCL10 ‚ð§Œä‚·‚é. ‘æ58‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïŠwpW‰ï. “Œ‹ž. 2014”N4ŒŽ26“ú.

ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, “Œ–ž”ü, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî“¯ŠˆÚAƒ‚ƒfƒ‹‚É‚¨‚¯‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚ÌRŽîᇌø‰Ê. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. ‘åã. 2014”N4ŒŽ25“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
”“Œ’qŽqC‰¬–ìL˜aCâŒû‹ÅCŽè’Ë•qŽjCXZrC‹g“ˆ‹PŽÀCŠÝCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•F. ’¹“ÁˆÙ“IR‘Ì‚ª‚’l‚ð’悵‚½’¹ŠÖ˜A‰ß•q«”x‰Š‚̈ê—á. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‚¼. 2014”N12ŒŽ13“ú.

Šâ²‚ ‚ä‚ÝC²“¡³‘åCâŒû‹ÅC–L“c—DŽqC“c“‡‘sˆê˜YCŸN“cICŒã“Œ‹vŽkCŠ`“à‘ŽiCû•£¹‹BC¼‰ªˆÀ•F. UGT1A1ˆâ“`Žq‚̃wƒeƒÚ‡‘Ìi–6‚Ü‚½‚Í–28j‚ðŽ‚Š³ŽÒ‚É‚¨‚¯‚鉖Ž_ƒCƒŠƒmƒeƒJƒ““Š—^‚ÉŠÖ‚·‚錟“¢. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‚¼. 2014”N12ŒŽ13“ú.

‹ß“¡^‘ã, ²“¡³‘å, –L“c—DŽq, ŠÝ, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, ŠÝ¹”ü, ‰Í–ìO, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. ŒŒ¬”ÂŒ¸­‚ðŒ_‹@‚Æ‚µ‚Äf’f‚³‚ꂽ‚—îŽÒ‚ÌSLE‚Ì2—á. ‘æ25‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‚’m. 2014”N12ŒŽ6“ú.

XZrC²“¡³‘åCâŒû‹ÅC–L“c—DŽqCŠÝ¹”üC¬ì”Ž‹v, Š`“à‘ŽiCŒã“Œ‹vŽkCû•£¹‹BC¼‰ªˆÀ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚¯‚éŠÔŽ¿«”x‰Šƒ}[ƒJ[‚ÌŒŸ“¢. ‘æ111‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2014”N11ŒŽ30“ú.

ŒIŒ´Œ’Žm, ‹g“ˆ‹PŽÀ, âŒû‹Å, –L“c—DŽq, ’†–ì–œ—L—¢, ŠÝ, Žè’Ë•qŽj, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Œo‰ß’†‚ÉŒŒ‹…æÃHÇŒóŒQ‚ð”­Ç‚µAƒVƒNƒƒzƒXƒtƒ@ƒ~ƒhŠÔŸ[‘å—ÊÃ’—Ö@‚ª‘tŒø‚µ‚½dÇSLE‚Ì1—á. ‘æ111‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2014”N11ŒŽ30“ú.

ŽR‰º—Y–ç, ‰¬–ìL˜a, ˆ¢‰ÍO˜a, ŠÝ¹”ü, âŒû‹Å, ‹g“ˆ‹PŽÀ, ²“¡³‘å, Š`“à‘Ži, Œã“Œ‹vŽk, ŠÝ, û•£¹‹B, ¼‰ªˆÀ•F. ’¹“ÁˆÙ“IR‘Ì‚ª‚’l‚ð’悵‚½’¹ŠÖ˜A‰ß•q«”x‰Š‚̈ê—á. ‘æ249‰ñ“¿“‡ˆãŠw‰ïŠwpW‰ï. “¿“‡. 2014”N7ŒŽ27“ú.

ˆ¢‰ÍO˜a, ²“¡³‘å, ‹ß“¡^‘ã, ’Ëú±—C‹M, Žè’Ë•qŽj, –L“c—DŽq, âŒû‹Å, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鈫«‹¹…’™—¯—á‚ɑ΂·‚éƒ^ƒ‹ƒN»Ü‚ÌŽg—pŒoŒ±. ‘æ53‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”‰ï. •ÄŽq. 2014”N7ŒŽ12“ú.

¼–{N•½, ”öè—Ì•F, –L“c—DŽq, ’†–ì–œ—L—¢, XZr, ‰Í–ìO, ŠÝ, Š`“à‘Ži, û•£¹‹B, ¼‰ªˆÀ•F. ‚CaŒŒÇ‚É‚Ä”­Ç‚µ‚½‘½‘ŸŠíƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. •ÄŽq. 2014”N7ŒŽ12“ú.

’Ëú±—C‹M, ‘å’ËŒ›Ži, ŠÝ¹”ü, ‹ß“¡^‘ã, ‹g“ˆ‹PŽÀ, ²“¡³‘å, ‰ªú±O‘×, ’|ú±²•v, “Œ“‘ã, û•£¹‹B, ≺’¼ŽÀ, •Ÿ“c—I, ¼‰ªˆÀ•F. Acute Fibrinous and Organizing PneumoniaiAFOPj‚̈ê–UŒŸ—á. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. •ÄŽq. 2014”N7ŒŽ12“ú.

‰¬–ìL˜a, ¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, âŒû‹Å, Žè’Ë•qŽj, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Lambert-Eaton‹Ø–³—ÍÇŒóŒQ‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ¬×–E”xŠà‚̈ê—á. ‘æ53‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”‰ï. •ÄŽq. 2014”N7ŒŽ11“ú.

”öè—Ì•F, –L“c—DŽq, ŠÝ, –؉ºŸO, Žè’Ë•qŽj, ŠÝ¹”ü, ²“¡³‘å, Š`“à‘Ži, û•£¹‹B, ¼‰ªˆÀ•F. ¶t“®–¬•ÂÇ“™‚É‚æ‚茋߫‘½”­“®–¬‰Š‚ª‹^‚í‚ꂽŒŒŠÇ“à–Œ“÷Žî‚Ì1–UŒŸ—á. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2014”N6ŒŽ8“ú.

‹ß“¡^‘ã, XZr, âŒû‹Å, ¼žŠ“Ö˜Y, ‹g“ˆ‹PŽÀ, ’†–ì–œ—L—¢, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Pemetrexed‚ÆBevacizumab‚Ì•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½‚—îŽÒ”ñ¬×–E”xŠà‚Ì1—á. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2014”N6ŒŽ8“ú.

âV“¡—FŽq, ˆÉ¨F”V, ᢒm~Žq, ŽRŒû_Ži, Šâ£r, ŽR“c”Žˆû, “Y–Ø•, Žá’ΓNŽO, Œã“Œ‹vŽk, ²“c­—². ¶ŽºŽûk•s‘S‚ÆŠÔŽ¿«”x‰Š‚É”º‚¤”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚½”畆‹Ø‰Š‚Ì1—á. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2014”N6ŒŽ8“ú.

ŽR–{¹Žq, û•£¹‹B, XZr, ŠÝ¹”ü, –؉ºŸO, ‰Í–ìO, ’|ú±²•v, –L“c—DŽq, “Œ“‘ã, Œã“Œ‹vŽk, ŠÝ, ¼‰ªˆÀ•F. ¶ã—t–³‹C”x‚ð’悵‚½ƒAƒŒƒ‹ƒM[«‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒXǂ̈ê—á. ‘æ248‰ñ“¿“‡ˆãŠw‰ï. “¿“‡. 2014”N2ŒŽ16“ú.

’ÕۗF, û•£¹‹B, ‘ê‘òGŒõ, ‹g“cŒõ‹P, ‹g“ˆ‹PŽÀ, ‘å’ËŒ›Ži, ²“¡³‘å, ¼žŠ“Ö˜Y, –L“c—DŽq, Žè’Ë•qŽj, Š`“à‘Ži, Œã“Œ‹vŽk, â“Œ—Ç”ü, æŽR³“ñ, ¼‰ªˆÀ•F. ”xŒ´”­ŠŠ–Œ“÷Žî‚̈ê—á. ‘æ248‰ñ“¿“‡ˆãŠw‰ï. “¿“‡. 2014”N2ŒŽ16“ú.

”öè—Ì•F, ûü‹´’¼Šó, Œã“Œ‹vŽk, –L“c—DŽq, Žè’Ë•qŽj, ‘å’ËŒ›Ži, ¼žŠ“Ö˜Y, âŒû‹Å, –؉ºŸO, Š`“à‘Ži, ¬ì”Ž‹v, ìãsšõ, û•£¹‹B, ‹ß“¡˜a–ç, æŽR³“ñ, òŒ[‰î, ¼‰ªˆÀ•F. ‹CŠÇŽx‹¾’¼Ž‹‰º¶ŒŸ‚É‚Äf’f‚ÉŽŠ‚Á‚½oncocytic carcinoid‚̈ê—á. ‘æ22‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. ‰ªŽR. 2014”N2ŒŽ15“ú.

¥¼–ƒ”ü, “à“¡Lm, ŠÝ¹”ü, ’†–ì–œ—L—¢, ‹g“cŒõ‹P, ìãsšõ, –؉ºŸO, “Œ“‘ã, ‹g“ˆ‹PŽÀ, ²“¡³‘å, ŠÝ, X‰Í—R—¢Žq, ¼ŽR—F—Žq, å”ü‰À, â“Œ—Ç”ü, “nç³r‰î, ㌴‹v“T, òŒ[‰î, æŽR³“ñ, û•£¹‹B, ¼‰ªˆÀ•F. ‹¹…’†‚É‘½”‚ÌLanghansŒ^‹×–E‚ð”F‚ß‚½Mycobacterium aviumÇ‚É”º‚¤‹¹–Œ‰Š‚̈ê—á. ‘æ64‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ï. ‰ªŽR. 2014”N2ŒŽ15“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2013”N‹ÆÑ
y‰¢•¶‘àz
Nishioka Y, Azuma M, Kishi M, Aono Y. Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis. J Med Invest 60(3,4):175-183, 2013.

y‰¢•¶Œ´’˜z
Honjo A, Ogawa H, Azuma M, Tezuka T, Sone S, Biragyn A, Nishioka Y. Targeted reduction of CCR4+ cells is sufficient to suppress allergic inflammation. Respir Investig 51(4):241-249, 2013.

Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic effects of focal adhesion klinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 49(4):536-543, 2013.

Okamoto T, Miyazaki Y, Ogura T, Chida K, Kohno N, Kohno S, Taniguchi H, Akagawa S, Mochizuki Y, Yamauchi K, Takahashi H, Johkoh T, Homma S, Kishi K, Ikushima S, Konno S, Mishima M, Ohta K, Nishioka Y, Yoshimura N, Munakata M, Watanabe K, Miyashita Y, Inase N. A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51(3):191-199, 2013.

Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S. Akt kinase@-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene 32(37):4427-4435, 2013.

Huang J, Tabata S, Kakiuchi S, The Van T, Goto H, Hanibuchi M, Nishioka Y. Identification of pregnancy -associated plasma protein A as a migration-promoting gene in malignant pleural@mesothelioma cells: a potential therapeutic target. Oncotarget 4(8):1172-1184, 2013.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J. Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama SI, Sone S. Minakuchi K, Kato Y, Nishioka Y. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 190(12):6239-6249, 2013.

Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, Nishioka Y. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol 182(5):1843-1853, 2013.

Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M, Iguratimod-Clinical Study Group (Kishi J). Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23(3):430-439, 2013.

Matsui S, Hebisawa A, Sakai F, Yamamoto H, Terasaki Y, Kurihara Y, Waseda Y, Kawamura T, Miyashita T, Inoue H, Hata N, Masubuchi H, Sugino K, Kishi J, Kobayashi H, Usui Y, Komazaki Y, Kawabata Y, Ogura T. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology 18(3):480-487, 2013.

Sato S, Hanibuchi M, Kuramoto T, Yamamori N, Goto H, Ogawa H, Mitsuhashi A, Van TT, Kakiuchi S, Akiyama SI, Nishioka Y, Sone S. Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment. Clin Exp Metastasis 30(3):333-344, 2013.

Makino H, Aono Y, Azuma M, Kishi M, Yokota Y, Kinoshita K, Takezaki A, Kishi J, Kawano H, Ogawa H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic effects of CXCR4 antagonist in bleomycin -induced pulmonary fibrosis in mice. J Med Invest 60(1-2):127-137, 2013.

Yuasa S, Yamaguchi H, Nakanishi Y, Kawaminami S, Tabata R, Shimizu N, Kohno M, Shimizu T, Miyata J, Nakayama M, Kishi J, Toyoda Y, Nishioka Y, Tani K. Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. J Med Invest 60(1-2):77-90, 2013.
y˜a•¶’˜‘z
¼‰ªˆÀ•F, –샓T. ˆÀ’èŠú‚Æ‘ˆ«Šú‚̑Ήž. “Á”­«ŠÔŽ¿«”x‰Š‚ÌŽ¡—ÂƊǗ, ™ŽRK”äŒÃ•ÒW. 2013. pp 177-184. Ž½“°o”ÅŠ”Ž®‰ïŽÐ.

¼‰ªˆÀ•F. “Á”­«ŠíŽ¿‰»”x‰Š. “à‰ÈŠw ‘æ10”Å, –îú±‹`—Y‘•ÒW. 2013. pp 806-808. ’©‘q‘“X.

¼‰ªˆÀ•F. Fibrocyte‚ƌċzŠíŽ¾Š³. •ÊûEˆãŠw‚Ì‚ ‚ä‚Ý ŒÄ‹zŠíŽ¾Š³-state of arts Ver.6, –k‘º—@, ’F_ˆê˜Y, Έä–FŽ÷•ÒW. 2013. pp 23-25, ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ.

¼‰ªˆÀ•F. Çó‚Æ•a‘Ô¶—. —Õ°•a‘ÔŠw1Šª(‘æ2”Å), –k‘º¹‘•ÒW. 2013. pp 231-233. ƒk[ƒ”ƒFƒ‹ƒqƒƒJƒ.

¼‰ªˆÀ•F. •›t”玿ƒXƒeƒƒCƒh–ò. ŒÄ‹zŠíŽ¾Š³ÅV‚ÌŽ¡—Ã2013-2015, ŠÑ˜a•q”Ž, ™ŽRK”äŒÃ, –å“c~ˆê•ÒW. 2013. pp 97-101. “ì]“°.

¼‰ªˆÀ•F. ”xüˆÛ‰»‚É‚¨‚¯‚éfibrocyte‚Ì–ðŠ„. Annual Review 2013 ŒÄ‹zŠí. ‰iˆäŒúŽu, ’F_ˆê˜Y, ŒK–ì˜a‘P, ‚‹´˜a‹v•ÒW. 2013. pp28-33. ’†ŠOˆãŠwŽÐ.
y˜a•¶‘àz
¼‰ªˆÀ•F, Œã“Œ‹vŽk. ”x–Eã”çáŠQ‚ÆC•œ. ŒÄ‹z‚ÆzŠÂ 61(12):1146-1151, 2013.

Œã“Œ‹vŽk, ¼‰ªˆÀ•F. •úŽËü”x‘Ÿ‰Š. “ú–{—Õଠ71(‘6):526-529, 2013.

¼‰ªˆÀ•F, –샓T. Fibrocyte‚Ì–ðŠ„. “ú–{‹¹•”—Õ° 72(‘):S186-189, 2013.

¼‰ªˆÀ•F. “¿“‡‘åŠw‘åŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”ŒÄ‹zŠíEäPŒ´•a“à‰ÈŠw•ª–ì‚Ì‚²Ð‰î. “¿“‡Œ§ˆãŽt‰ï•ñ 508:32-33, 2013.

¼‰ªˆÀ•F. •ªŽq•W“IŽ¡—ÂƖƉu—Ö@. Šà‚Ɖ»Šw—Ö@ 40(8):1004-1008, 2013.

²“¡³‘å, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ƒqƒg”xŠà‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚Æmacrophage stimulatuing protein. THE LUNG perspectives 21(3):72-77, 2013.

¼‰ªˆÀ•F. IPF‚Ì—Õ°ŽŽŒ±‚ðl‚¦‚é(Šª“ªŒ¾). ŒÄ‹z‚ÆzŠÂ 61(7):603, 2013.

Œã“Œ‹vŽk, Š`“à‘Ži, ¼‰ªˆÀ•F. ”x‚ª‚ñ×–E‚Ìœ“]ˆÚ‚ÉŠÖ—^‚·‚éˆâ“`Žq‚Ì’Tõ. ¶‘̂̉Ȋw 64(3):279-282, 2013.

¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—Ã:Å‹ß‚Ìi•à. “ú–{—Õ°“à‰Èˆã‰ï‰ïŽ 28(1):46-50, 2013.

¼‰ªˆÀ•F,–샓T. ŠÔŽ¿«”x‰Š‚Æ‘BˆöŽq. ƒAƒŒƒ‹ƒM[‚Ì—Õ° 443(33):421-424, 2013.

¼‰ªˆÀ•F. “«ŒÄ‹zŠíŽ¾Š³‚Ì•ªŽq•a‘ԉ𖾂ÆV‹KŽ¡—Ö@‚ÌŠJ”­. Žl‘ˆãŠwŽGŽ 69(1,2):52-56, 2013.

Š`“à‘Ži, ¼‰ªˆÀ•F. mTOR‘jŠQ–ò‚É‚æ‚é”xáŠQ‚Æ‚»‚̑Ήž. •ªŽqŒÄ‹zŠí•a 17(1):42-45, 2013.

ŠÝ, ‰Í–ìO, ¼‰ªˆÀ•F. ŠÖ߃ŠƒEƒ}ƒ`‚ÆŠÔŽ¿«”x•a•Ï.ƒŠƒEƒ}ƒ`‰È 49(2):161-165, 2013.

¼‰ªˆÀ•F, –샓T, ˆ¢•”Gˆê.@”xüˆÛÇ‚É‚¨‚¯‚éüˆÛ‰è×–E‚Ì—R—ˆ.@ŒÄ‹zŠí“à‰È 23(1):20-24, 2013.
y˜a•¶Œ´’˜z
“Œ“‘ã, ’†‘]ˆŸ²”ü, ¼–삳‚¨‚è, ‚ŠJ“o–ÎŽq, æŽR³“ñ, ‰Á“¡^‰î, ¼‰ªˆÀ•F. ˆã—Ã]Ž–ŽÒ‚É‚¨‚¯‚é–AóƒAƒ‹ƒR[ƒ‹«ŽèŽwÁ“ÅÜ‚ÌŽE‹ÛŒø‰Ê, “h•z–ÊÏ‹y‚ÑŽg—pŠ´‚ÉŠÖ‚·‚錟“¢. “ú–{ŠÂ‹«Š´õŠw‰ïŽ 28(6):342-347, 2013.

–샓T, ŠÝ¹”ü, ‰ªú±O‘×, ’|ú±²•v, ¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚éPDGFƒŒƒZƒvƒ^[ƒ¿CƒÀ‘jŠQR‘Ì‚ÌRüˆÛ‰»Œø‰Ê. •ªŽqŒÄ‹zŠí•a 17(1):136-139, 2013.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Yoshinori Aono, Shuichi Abe, Katsuhiro Kinoshita, Masami Kishi, Yasuhiko Nishioka. Fibrocyte regulates lung fibroblast acivation via producing growth factors.@18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G Ledford, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. 18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Yasuhiko Nishioka, Isaiah J. Fidler. Therapeutic efficacy of endothelin receptor blockade on experimental brain metastases of human non-small cell lung cancer.@18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Hisatsugu Goto, Fumitaka Ogushi, Takashi Haku, Tomoyuki Urata, Takanori Kanematsu, Soji Kakiuchi, Masaki Hanibuchi, Saburo Sone, Yasuhiko Nishioka. Phase ‡U study of S-1 with patient-reported outcome evaluation in elderly patients with advanced non-small cell lung cancer.@18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Katsuhiro Kinoshita, Yoshinori Aono, Hisatsugu Goto, Momoyo Azuma, Akio Takezaki, Terumi Yoshijima, Masami Kishi, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Shuichi Abe, Toshifumi Tezuka, Hisanori Uehara, Keisuke Izumi, Yasuhiko Nishioka. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. 18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ12“ú.

Momoyo Azuma, Keiji Murakami, Katuhiko Hirota, Tsuneko Ono, Yoichiro, Miyake, Yasuhiko Nishioka. The relationship between antibiotic tolerance and severity of clinical isolated Pseudomonas aeruginosa in respiratory disease patients. The28th International Congress of Chemotherapy and Infection and the 14th Asia-pacific Society of Clinical Microbiology and Infection. ‰¡•l. 2013”N6ŒŽ7“ú.

Yasuhiko Nishioka, Shuichi Abe, Yoshinori Aono, Katsuhiro Kinoshita, Hideki Makino, Masami Kishi, Masaki Hanibuchi. Fibrocytes regulate function of lung fibroblasts by producing profibrotic growth factors.@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ22“ú.

Hirohisa Ogawa, J.G. Ledford, S. Mukherjee, Yoshinori Aono, Yasuhiko Nishioka, Keisuke Izumi, J.W. Hollingsworth. Surfactant protein D attenuates sub-epithelial fibrosis in a model of allergic airways disease trough regulation of TGF-ƒÀ.@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ21“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, and Yasuhiko Nishioka. Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ21“ú.

Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice.@AACR Annual Meeting 2013. Washington, DC. 2013”N4ŒŽ7“ú.

Yasuhiko Nishioka. Application of dendritic cells and antibodies in cancer treatment. The first Gene & Immunotherapy Conference (Invited lecture). HCM City, Vietnam. 2013”N3ŒŽ21“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Trung The Van, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Saburo Sone, Yasuhiko Nishioka. Acquired resistance to anti-VEGF therapy via angiogenic switch in orthotopically implanted human malignant pleural mesothelioma in SCID mice.@Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, HI. 2013”N2ŒŽ24“ú.

Sawaka Yukishige, Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijyo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.@Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, HI. 2013”N2ŒŽ24“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. “Á”­«ŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—Ã-ŋ߂̘b‘è-. ‘æ49‰ñ“ú–{“à‰ÈŠw‰ïŽl‘Žx•”¶ŠU‹³ˆçu‰‰‰ïi‹³ˆçu‰‰j. ‚¼. 2013”N12ŒŽ1“ú.

¼‰ªˆÀ•F. ”xŠà‚É‚¨‚¯‚éƒxƒoƒVƒYƒ}ƒu‚ð—p‚¢‚½RŒŒŠÇV¶—Ö@‚ɑ΂·‚éŠl“¾‘Ï«ƒƒJƒjƒYƒ€.@‘æ72‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïiInternational Sessionj. ‰¡•l. 2013”N10ŒŽ3“ú.

¼‰ªˆÀ•F. Translational Research.@‘æ11‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ïi‹³ˆçu‰‰j. å‘ä. 2013”N8ŒŽ30“ú.

¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“IŽ¡—Â̊î‘b‚Æ—Õ°.@“ú–{•úŽËüŽîᇊw‰ï@‘æ15‰ñ•úŽËüŽîᇊw‰Ä‹GƒZƒ~ƒi[(‹³ˆçu‰‰). “¿“‡. 2013”N8ŒŽ3“ú.

ˆ¢•”Gˆê, –샓T, ‰ªú±O‘×, ŠÝ¹”ü, ’|ú±²•v, –؉ºŸO, “Œ“‘ã, ŠÝ, ¼‰ªˆÀ•F. ”xüˆÛÇ‚É‚¨‚¯‚é‘BˆöŽqŽY¶‚ð‰î‚µ‚½fibrocyte‚Ì–ðŠ„‚ÆŒŸ“¢.@‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ20“ú.

–샓T. ˆ¢•”Gˆê, ’|ú±²•v, ‰ªú±O‘×, ŠÝ¹”ü, ¼‰ªˆÀ•F. DNAƒ}ƒCƒNƒƒAƒŒƒC–@‚ð—p‚¢‚½Fibrocyte‚Æ’P‹…‚̈â“`Žq”­Œ»‰ðÍ‚ÌŒŸ“¢.@‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ20“ú.

¬ì”Ž‹vC–샓TCŽè’Ë•qŽjCŒã“Œ‹vŽkC¼‰ªˆÀ•F. Surfactant Protein D‚̓_ƒjRŒ´–«–\˜I‚É‚æ‚é‹C“¹üˆÛ‰»‚ð—}§‚·‚éD‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ20“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽuC–샓TC¼‰ªˆÀ•F. ”xŠài“W‚É‚¨‚¯‚éSP-A‚ÆŽîᇊ֘Aƒ}ƒNƒƒtƒ@[ƒW.@‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ19“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
Žè’Ë•qŽj, ¬ì”Ž‹v, –؉ºŸO, û•£¹‹B, ¼‰ªˆÀ•F. Calpain inhibitoriCalpeptinj‚Ìšb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï. “Œ‹ž. 2013”N11ŒŽ30“ú.

‰ª–ì‹`•v, Œã“Œ‹vŽk, —t‹v‹MŽi, Œ“¼‹M‘¥, ‰Y“c’m”V, Š`“à‘Ži, û•£¹‹B, ‘å‹ø•¶—², ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ‚—îŽÒis”ñ¬×–E”xŠàŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽTS-1—Ö@‚Ì—Õ°‘æ‡U‘ŠŽŽŒ±. ‘æ54‰ñ“ú–{”xŠàŠw‰ï‘‰ï. “Œ‹ž. 2013”N11ŒŽ21“ú.

Žè’Ë•qŽj, –L“c—DŽq, Š`“à‘Ži, ‘å’ËŒ›Ži, ¼žŠ“Ö˜Y, –؉ºŸO, Œã“Œ‹vŽk, ŸN“cI, û•£¹‹B, ¼‰ªˆÀ•F. “–‰È‚Ì”xŠà‰»Šw—Ö@‚É‚¨‚¯‚éshort-hydration Cisplatin‚Ì”E—e«‚ÉŠÖ‚·‚錟“¢. ‘æ51‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‹ž“s. 2013”N10ŒŽ25“ú.

¼žŠ“Ö˜Y, Š`“à‘Ži, Žè’Ë•qŽj, Œã“Œ‹vŽk, ŽRŽq‘דl, ‘å’ËŒ›Ži, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éBevacizumab’·ŠúˆÛŽ“Š—^Ç—á‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï. ‹ž“s. 2013”N10ŒŽ25“ú.

Š`“à‘Ži, ‘å’ËŒ›Ži, ¼žŠ“Ö˜Y, Žè’Ë•qŽj, –L“c—DŽq, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿«”x‰Š‡•¹”xŠà‚ÌŽ¡—Â̌»ó. ‘æ11‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï. å‘ä. 2013”N8ŒŽ31“ú.

¼žŠ“Ö˜Y, Œã“Œ‹vŽk, “c”¨Ë, ŽO‹´“ÕŽu, –L“c—DŽq, û•£¹‹B, Š`“à‘Ži, HŽRLˆê, ¼‰ªˆÀ•F. ‚ª‚ñ×–E‚Ì—V‘–‚É‚¨‚¯‚éthymidine phosphorylase‚ÆCXCL11‚Ì–ðŠ„. ‘æ22‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ¼–{. 2013”N7ŒŽ11“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ‘q–{‘ìÆ, “c”¨Ë, ¼žŠ“Ö˜Y, û•£¹‹B, Š`“à‘Ži, –샓T, ㌴‹v“T, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ”xsurfactant protein A (SP-A) ‚Ì”xŠài“W‚É‚¨‚¯‚é‹@”\‰ðÍ. ‘æ22‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. ¼–{. 2013”N7ŒŽ11“ú.

‹ß“¡ˆç”ü, ‘剺’Žj, Œ³–Ø—R”ü, û•£¹‹B, •‹v—mŽO. –«Šú•a‰@‚ł̈ã—ÃNƒ‰[ƒN‚Ì–ðŠ„‚É‚Â‚¢‚Ä.‘æ63‰ñ“ú–{•a‰@Šw‰ï. VŠƒ. 2013”N6ŒŽ28“ú.

‘å¼O—S, ‘厭•Û, ˆ¢•”“ú“o”ü, Œ³–Ø—R”ü, û•£¹‹B, •‹v—mŽO. –«Šú•a“‚Å‚Ìš\á‚‹zˆøƒJƒe[ƒeƒ‹ŠÇ—•û–@‚ɂ‚¢‚Ä. ‘æ63‰ñ“ú–{•a‰@Šw‰ï. VŠƒ. 2013”N6ŒŽ28“ú.

Œ³–Ø—R”ü, ‘厭•Û, ˆ¢•”“ú“o”ü, ’·”ö—DŽq, û•£¹‹B, •‹v—mŽO. ˆÝᑉh—{Š³ŽÒ‚É‚¨‚¯‚é“œŽ¿§ŒÀH‚Ì—LŒø«‚ɂ‚¢‚Ä. ‘æ63‰ñ“ú–{•a‰@Šw‰ï. VŠƒ. 2013”N6ŒŽ27“ú.

û•£¹‹B, ‘å’ËŒ›Ži, Œã“Œ‹vŽk, ‘q–{‘ìÆ, ŽO‹´“ÕŽu, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, ƒtƒBƒhƒ‰[ ƒCƒUƒCƒA[ J. EndothelinŽó—e‘ÌhRÜ‚É‚æ‚é”xŠà”]“]ˆÚ—}§Œø‰Ê‚ÌŒŸ“¢. ‘æ17‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‹ž“s. 2013”N6ŒŽ13“ú.

‰©r, “c”¨Ë, û•£¹‹B, ¼‰ªˆÀ•F. ˆ««’†”çŽî‚É‚¨‚¯‚éPAPPA‚Ì‹@”\‰ðÍ‚Æ•ªŽq•W“IŽ¡—Ö@ŠJ”­‚ÌŒŸ“¢. ‘æ17‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‹ž“s. 2013”N6ŒŽ13“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ¼žŠ“Ö˜Y, ‘q–{‘ìÆ, “c”¨Ë, û•£¹‹B, –î–칓ñ, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî“¯ŠˆÚAƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éRVEGFŽ¡—Ñϫ‰»ƒƒJƒjƒYƒ€‚ÌŒŸ“¢. ‘æ17‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. ‹ž“s. 2013”N6ŒŽ13“ú.

ŠÝ, ’†ì–ƒ–ë, ‰Í–ìO, ¼”öi, •½“c—L‹IØ, ŽR“c”Žˆû, ²“c­—², ¼‰ªˆÀ•F. äPŒ´•a‚ÌŠÖ߉Š‚É‚¨‚¯‚éãüâ|ƒŠƒ“ƒpß‚Ì’´‰¹”g«ó‚ÉŠÖ‚·‚錟“¢. ‘æ86‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ï. ‘åã. 2013”N5ŒŽ25“ú.

ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, –Øh¹r, ì“Y˜a‹`, “Œ–ž”ü, û•£¹‹B, …Œû˜a¶, ¼‰ªˆÀ•F. ƒqƒgNK×–E‚ð‰î‚µ‚½Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-8‚̈««‹¹–Œ’†”çŽî‚ɑ΂·‚éRŽîᇌø‰Ê. ‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ21“ú.

Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice. ‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ21“ú.

‹g“ˆ‹PŽÀ, ‰Í–ìO, Žè’Ë•qŽj, –L“c—DŽq, ŠÝ, ¼‰ªˆÀ•F. Œ´ˆö•s–¾‚Ì––½•ÂÇ«“®–¬Ž¾Š³‰Á—Ã’†‚ÉŠ¥“®–¬áŽ‚ª”­Šo‚µ‚ˆÀ“®–¬‰Š‚Æf’f‚µ‚½1—á. ‘æ57‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. ‹ž“s. 2013”N4ŒŽ20“ú.

û•£¹‹B, Œã“Œ‹vŽk, ‹ß“¡^‘ã, ŽRŽq‘דl, ‰ªú±O‘×, Žè’Ë•qŽj, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éIdiopathic pleuroparenchymal fibroelastosis(IPPFE)Ç—á‚ÌŒŸ“¢-IgG4ŠÖ˜AŽ¾Š³‚Æ‚ÌŠÖ˜A«-. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ13“ú.

Š`“à‘Ži, ‘å’ËŒ›Ži, ŽRŽq‘דl, ¼žŠ“Ö˜Y, Žè’Ë•qŽj, Œã“Œ‹vŽk, –샓T, û•£¹‹B, ¼‰ªˆÀ•F.“–‰@‚É‚¨‚¯‚éŠÔŽ¿«”x‰Š‡•¹”xŠà‚ÌŽ¡—Â̌»ó. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ12“ú.

Œã“Œ‹vŽk. ¬—t’†S«¬—±ó‰A‰e‚Æ‹­‚¢•ÂÇ«Š·‹CáŠQ‚ð’悵‚½–«‰ß•q«”x‰Š‚̈ê—á. ‘æ5‰ñŒÄ‹z‹@”\ƒCƒ[ƒWƒ“ƒOŒ¤‹†‰ïŠwpW‰ï. “¿“‡. 2013”N1ŒŽ13“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
“à“¡Lm, ‰Í–ìO, ‘å’ËŒ›Ži, –L“c—DŽq, ŠÝ, Žè’Ë•qŽj, –؉ºŸO, ‹g“ˆ‹PŽÀ, ŠÝ¹”ü, û•£¹‹B, ¼‰ªˆÀ•F. • •”‘å“®–¬ŽüˆÍ‰Š‚𔺂Á‚½‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚Ì2—á. ‘æ24‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. •ÄŽq. 2013”N12ŒŽ7“ú.

ŽR–{¹Žq, û•£¹‹B, XZr, ŠÝ¹”ü, –؉ºŸO, ‰Í–ìO, ’|ú±²•v, –L“c—DŽq, “Œ“‘ã, Œã“Œ‹vŽk, ŠÝ, ¼‰ªˆÀ•F. ¶ã—t–³‹C”x‚ð’悵‚½ƒAƒŒƒ‹ƒM[«‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒXǂ̈ê—á. ‘æ50‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. L“‡. 2013”N12ŒŽ7“ú.

’ÕۗF, û•£¹‹B, ‘ê‘òGŒõ, ‹g“cŒõ‹P, ‹g“ˆ‹PŽÀ, ‘å’ËŒ›Ži, ²“¡³‘å, ¼žŠ“Ö˜Y, –L“c—DŽq, Žè’Ë•qŽj, Š`“à‘Ži, Œã“Œ‹vŽk, â“Œ—Ç”ü, æŽR³“ñ, ¼‰ªˆÀ•F. ”xŒ´”­ŠŠ–Œ“÷Žî‚̈ê—á. ‘æ50‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. L“‡. 2013”N12ŒŽ7“ú.

–—m•½, ¼žŠ“Ö˜Y, –؉ºŸO, ŠÝ¹”ü, ‘å’ËŒ›Ži, û•£¹‹B, ¼‰ªˆÀ•F, ˆä“àV, –샓T. “¿“‡Œ§‚Å”­¶‚µ‚½dÇ”M«ŒŒ¬”ÂŒ¸­ÇŒóŒQisevere fever with thrombocytopenia syndrome: SFTSj‚Ì1—á. ‘æ109‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼. 2013”N12ŒŽ1“ú .

â“ŒOŠî, û•£¹‹B, –L“c—DŽq, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, Œã“Œ‹vŽk, Š`“à‘Ži, ŠÝ, ¼‰ªˆÀ•F, â–{K—T. ‹CŠÇŽxŠg’£Ç‚ð’悵‚½Œ´”­«ü–щ^“®•s‘SÇ‚Ì1—á. ‘æ109‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï.‚¼. 2013”N12ŒŽ1“ú.

’·£ŽÑ‹G, –L“c—DŽq, ˆ¢•”Gˆê, ŠÝ, ‰Í–ìO, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, û•£¹‹B, ’r“c^—R”ü, æŽR³“ñ, ¼‰ªˆÀ•F. ƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÌŒo‰ßŠÏŽ@’†‚É”x‘BŠà‚ð‡•¹‚µ‚½1—á. ‘æ49‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‚¼. 2013”N7ŒŽ20“ú.

¥¼–ƒ”ü, ŠÝ¹”ü, –샓T, ’|ú±²•v, “Œ“‘ã, –؉ºŸO, ˆ¢•”Gˆê, û•£¹‹B, ‹g“cŒõ‹P, æŽR³“ñ, •Ÿ“c—I, ¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@‚É‚¨‚¯‚鋹o‹¾iVATSj‰º”x¶ŒŸÇ—á‚ÌŒŸ“¢. ‘æ49‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‚¼. 2013”N7ŒŽ19“ú.

”öè—Ì•F, Š`“à‘Ži, Žè’Ë•qŽj, ¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, ŽRŽq‘דl, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@‚É‚¨‚¯‚éBevacizumab ’·ŠúˆÛŽ“Š—^—á‚ÌŒŸ“¢. ‘æ52‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”‰ï. ‚¼. 2013”N7ŒŽ19“ú.

‚‹´’¼Šó, û•£¹‹B, –샓T, –؉ºŸO, “Œ“‘ã, ŠÝ¹”ü, ’|ú±²•v, ¼žŠ“Ö˜Y, Œã“Œ‹vŽk, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éidiopathic pleuroparenchymal fibroelastosis(IPPFE)Ç—á‚ÌŒŸ“¢. ‘æ108‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2013”N6ŒŽ9“ú.

XZr, ‘å’ËŒ›Ži, –L“c—DŽq, ‰Í–ìO, ŠÝ, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, Š`“à‘Ži, û•£¹‹B, ¼‰ªˆÀ•F. ”]‰Š‚Æ• •”‘å“®–¬áŽ‚ð‡•¹‚µ‚½‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚Ì1—á. ‘æ108‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2013”N6ŒŽ9“ú.

•Ä“c_l, Žè’Ë•qŽj, –샓T, ìk‘¢, ¼žŠ“Ö˜Y, ŽRŽq‘דl, ‘å’ËŒ›Ži, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, òŒ[‰î, ¼‰ªˆÀ•F. ‹¹o‹¾‰º‹¹–Œ¶ŒŸ‚Åf’f‚µ‚¦‚½tá±Šà‹¹–Œ“]ˆÚ‚Ì1—á. ‘æ21‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. “¿“‡. 2013”N2ŒŽ16“ú.

‹g“ˆ‹PŽÀ, û•£¹‹B, “Œ“‘ã, –L“c—DŽq, ‰Í–ìO, ŠÝ, ’|ú±²•v, ‰ªú±O‘×, ’·”ö‘½”üŽq, —é–Ø—íŽq, ‚ŠJ“o–ÎŽq, æŽR³“ñ, ¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@Eˆõ‚É‚¨‚¯‚éöÝ«Œ‹ŠjŠ´õÇ‚ÌŒ»ó. ‘æ63‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”‰ï. “¿“‡. 2013”N2ŒŽ16“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2012”N‹ÆÑ
y‰¢•¶‘àz
Nishioka Y. Malignant pleural effusion: further translational research is crucial. Transl Lung Cancer Res 1(3):167-169, 2012.
y‰¢•¶Œ´’˜z
Kuramoto T, Goto H, Mitsuhashi A, Tabata S, Ogawa H, Uehara H, Saijo A, Kakiuchi S, Maekawa Y, Yasutomo K, Hanibuchi M, Akiyama SI, Sone S, Nishioka Y. Dll4-Fc, an inhibitor of Dll4-Notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-kappa-B activity. Mol Cancer Ther 11(12):2578-2587, 2012.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 103(11):1913-1919, 2012.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol 181(3):1034-1043, 2012.

Tabata S, Ikeda R, Yamamoto M, Furukawa T, Kuramoto T, Takeda Y, Yamada K, Haraguchi M, Nishioka Y, Sone S, Akiyama S. Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells. Oncol Rep 28(3):895-902, 2012.

Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology 17(6):984-990, 2012.

Dat le T, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S, Katagiri T. Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice. Int J Oncol 40(5):1455-1469, 2012.

Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S; Japan NAC Clinical Study Group. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 17(3):467-477, 2012.

Ogawa H, Azuma M, Uehara H, Takahashi T, Nishioka Y, Sone S, Izumi K. Nerve growth factor derived from bronchial epithelium after chronic mite antigen exposure contributes to airway hyperresponsiveness by inducing hyperinnervation, and is inhibited by in vivo siRNA. Clin Exp Allergy 42(3):460-470, 2012.

Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR. SP-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185(5):525-536, 2012.

Gabr AG, Goto H, Hanibuchi M, Ogawa H, Kuramoto T, Suzuki M, Saijo A, Kakiuchi S, Trung VT, Sakaguchi S, Moriya Y, Sone S, Nishioka Y. Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis 29(3):207-216, 2012.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18(6):1663-1671, 2012.

Tezuka T, Azuma M, Goto H, Nishioka Y, Sone S. Psychiatric symptoms in a patient with Churg-Strauss syndrome. Intern Med 51(3):301-303, 2012.

Miyake K,, Tani K, Kakiuchi S, Suzuka C, Toyoda Y, Kishi J, Tezuka T, Yuasa S, Hanibuchi M, Aono Y, Nishioka Y, Sone S. Epidermal growth factor tyrosine kinase inhibitor (gefitinib) augments pnumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest 59(1-2):174-185, 2012.
y˜a•¶’˜‘z
¼‰ªˆÀ•F.@–ò•¨—Ö@. ŠÔŽ¿«”x‰Š‚ð‹†‚ß‚é, ‘êàVŽn•ÒW. 2012. pp86-95. Š”Ž®‰ïŽÐƒƒWƒJƒ‹ƒrƒ…[ŽÐ.

ŠÝ. ^‹ÛŠ´õÇ. äPŒ´•a‚Ì”x‡•¹Ç f—Ã}ƒjƒ…ƒAƒ‹, ‹{âM”V•Ò. 2012. pp147-153.@ˆã–òƒWƒƒ[ƒiƒ‹ŽÐ.

¼‰ªˆÀ•F.@äPŒ´•a‚Ì”x‡•¹Ç|ŒŸ¸‚ÌŠî–{|. äPŒ´•a‚Ì”x‡•¹Ç f—Ã}ƒjƒ…ƒAƒ‹, ‹{âM”V•Ò. 2012. pp43-51.@ˆã–òƒWƒƒ[ƒiƒ‹ŽÐ.
y˜a•¶‘àz
Œã“Œ‹vŽk. –Ú‚Å‚Ý‚éƒgƒŒ[ƒjƒ“ƒO. Medicina 49(8):1434,1437, 2012.

–샓T, ¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“I–ò‚ɇ•¹‚·‚éŠÔŽ¿«”x‰Š. Medical Science Digest 38(9):396-399, 2012.

¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“IŽ¡—Âɂ¨‚¯‚éˆê‘̉»ŠJ”­‚ÌŒ»ó‚Æ“W–]. ‚ª‚ñ•ªŽq•W“IŽ¡—à 10(4):267-275, 2012.

¼‰ªˆÀ•F. “«ŒÄ‹zŠíŽ¾Š³‚ÌŽ¡—Ö@‚ÌŠJ”­‚ð–ÚŽw‚µ‚Ä. ŒÄ‹z 31(7):587-588, 2012.

¼‰ªˆÀ•F, ‘]ªŽO˜Y.@ŒÄ‹zŠíŽ¾Š³‚É‚¨‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`:Œ»ó‚Æ«—ˆ“W–]. ŒÄ‹zŠí“à‰È 21(6):483-484, 2012.

–샓T, Jo Rae Wright, ¼‰ªˆÀ•F. ”xüˆÛÇ‚É‚¨‚¯‚éSP-D‚Ì–hŒä“I–ðŠ„. •ªŽqŒÄ‹zŠí•a 16(1):147-150, 2012.

ŠÝ, ¼‰ªˆÀ•F. ƒTƒ‹ƒRƒCƒh[ƒVƒXƒ‚ƒfƒ‹‚ÆV‹KŽ¡—ÕW“I. •ªŽqŒÄ‹zŠí•a 16(1):56-58, 2012.

û•£¹‹B, ¼‰ªˆÀ•F. ”x‚ª‚ñ‚ƉŠÇ. ÅVˆãŠw 67(3):479-484, 2012.

Œã“Œ‹vŽk. ”x‚̶‘Ì–hŒä‹@\‚É‚¨‚¯‚éƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’‚`‚Ì–ðŠ„. ŒÄ‹z 31(1):79-89, 2012.
y˜a•¶Œ´’˜z
â–{Wˆê, Š‰Ykˆê˜Y, ‘ê‘òGŒõ, ’†ì–õŽm, ’r“c^—R”ü, ŒÃ쑸Žq, X–{‰ë”ü, ¼–ì‹Žu, Œã“¡³˜a, ’†ì”ü»Žq, ŽR–{—m‘¾, ŒÃ–k—Rm, •’m_˜a, ‹g“cŒõ‹P, ìãsšõ, “cŠ—R‹IŽq, æŽR³“ñ, ‹ß“¡˜a–ç, â“Œ—Ç”ü, ‰ªèO‘×, Œã“Œ‹vŽk, ¼‰ªˆÀ•F, ’O•Í. Erlotinib ‚Åinduction therapy ‚ðs‚Á‚½‡VAŠú”ñ¬×–E”xŠà‚Ì1Žèp—á. Žl‘ˆãŽ 68(5,6):251-256, 2012.

Œã“Œ‹vŽk, –샓T, ¼‰ªˆÀ•FD”x‚̶‘Ì–hŒä‹@\‚É‚¨‚¯‚éƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’A‚Ì–ðŠ„. “ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ʈãŠw‰ïŽGŽ 43:9-15, 2012.

–î–ì‘c, ¼žŠ“Ö˜Y, ‹ß“¡^‘ã, ‰Í–ìO, –L“c—DŽq, Š`“à‘Ži, ŠÝ, û•£¹‹B, ŒÃì‹M‘å, “¡“c_Ži, ¼‰ªˆÀ•F. _ŒoªáŠQ‚Å”­Ç‚µ‚½_ŒoƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á. Žl‘ˆãŽ 68(3,4):153-158, 2012.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, Yasuhiko Nishioka Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. Tokushima University-Seoul National University-KAIST joint meeting, Seoul, Korea. 2012”N12ŒŽ20“ú.

Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Sho Tabata, Takuya Kuramoto, Hisasugu Goto, Yasuhiko Nishioka, Isaiah J Fidler. Eradication of experimental brain metastases of human non-small cell lung cancer by macitentan, a dual antagonist of the endothelin A and B receptor, combined with paclitaxel. Markers in Cancer 2012 : A Joint Meeting by ASCO, EORTC and NCI. Hollywood, FL. 2012”N10ŒŽ12“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Soji Kakiuchi, Sho Tabata, Atsuro Saijo, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model.14th International Biennial Congress of the Metastasis Research Society, Brisbane, Australia. 2012”N9ŒŽ4“ú.

Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Atsuro Saijo, Soji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone, Yasuhiko Nishioka. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity.14th International Biennial Congress of the Metastasis Research Society. Brisbane, Australia. 2012”N9ŒŽ4“ú.

Yasuhiko Nishioka, Shinji Abe, Yuki Morita, Mika Kato Kaneko, Masaki Hanibuchi, Hisatsugu Goto, Soji Kakiuchi, Yoshinori Aono, Jun Huang, Atsushi Mitsuhashi, Seidai Sato, Kazuo Minakuchi, Yukinari Kato. Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma.@14th International Biennial Congress of the Metastasis Research Society. Brisbane, Australia. 2012”N9ŒŽ3“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Soji Kakiuchi, Sho Tabata, Atsuro Saijo, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model.@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ23“ú.

Yasuhiko Nishioka, Shinji Abe, M.K. Kaneko, Yoshinori Aono, Jun Huang, Hisatsugu Goto, Masatoshi Kishuku, Masaki Hanibuchi, Saburo Sone, Kazuo Minakuchi, Yukinari Kato. Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma via ADCC.@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ23“ú.

Shuichi Abe, Hiroyasu Okazaki, Masami Kishi, Akio Takezaki, Katsuhiro Kinoshita, Momoyo Azuma, Jun Kishi, Yoshinori Aono, Yasuhiko Nishioka. Fibrocyte regulates lung fibroblast function. ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ22“ú.

Yoshinori Aono, Masami Kishi, Yasuhiko Nishioka. Different functions of PDGF receptor-alpha and beta in lung fibrosis.@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ22“ú.

Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Seidai Sato, Soji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone, Yasuhiko Nishioka. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity. AACR Annual Meeting 2012. Chicago, IL. 2012”N4ŒŽ2“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Š‚Ìf’f‚ÆŽ¡—ÃFÅ‹ß‚Ìi•à.@‘æ26‰ñ“ú–{—Õ°“à‰ÈˆãŠw‰ï(‹³ˆçu‰‰). “¿“‡. 2012”N10ŒŽ7“ú.

¼‰ªˆÀ•F. ŠÔŽ¿«”x‰Šf—Â̌»ó‚Ɖۑè.@‘æ47‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ïiŒÄ‹zŠíƒZƒ~ƒi[j.‰ºŠÖ. 2012”N7ŒŽ21“ú.

“c”¨Ë, ’r“c—´“ñ, ŽR–{‰ë’B, ŒÃì—´•F, ‘q–{‘ìÆ, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, HŽRLˆê. ƒqƒgŠà×–E‚ÌROSŽY¶‚¨‚æ‚Ѷ‘¶‚É‚¨‚¯‚éƒ`ƒ~ƒWƒ“ˆÙ‰»ì—p‚Ì–ðŠ„.@‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ïiƒ[ƒNƒVƒ‡ƒbƒvj. –k‹ãB. 2012”N6ŒŽ28“ú.

Jun Huang, Shinji Abe, Yuki Morita, Shuji Ozaki, Masatoshi Kishuku, Kazuo Minakuchi, Masaki Hanibuchi, Toshio Matsumoto, Saburo Sone, Yasuhiko Nishioka. Antibody-dependent cellular cytotoxicity against mesothelioma cells mediated by anti-HM 1.24 antibodies.@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiEnglish Mini-Symposiumj. _ŒË. 2012”N4ŒŽ22“ú.

–샓T, Jo Rae Wright, Œã“Œ‹vŽk, ¼‰ªˆÀ•F. ”x‘¹EC•œ‚ÆSP-D:RüˆÛ‰»‚ÌŽ‹“_‚©‚ç. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiƒVƒ“ƒ|ƒWƒEƒ€j. _ŒË. 4ŒŽ22“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Syo Tabata, Hirohisa Ogawa, Hisanori Uehara, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï(English Mini-Symposium). _ŒË. 2012”N4ŒŽ21“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, ‰©r, û•£¹‹B, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘̗Ö@‚ÌŒŸ“¢.@‘æ25‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠwpW‰ï‘‰ï. ‰ªŽR. 2012”N12ŒŽ14“ú.

“c“‡‘sˆê˜Y, ŸN“cI, Š`“à‘Ži, 㼑ì, •Ð“‡‚é‚Ý, Ž›‰ª˜a•F, ‹vŽŸ•Ä•qG, ì“Y˜a‹`, ¼‰ªˆÀ•F, —k‰ÍGÍ, …Œû˜a¶. UGT1A1ˆâ“`Žq‚̃wƒeƒÚ‡‘Ì(*6‚Ü‚½‚Í*28)‚ðŽ‚ƒCƒŠƒmƒeƒJƒ““Š—^Š³ŽÒ‚É‚¨‚¯‚鎡—ÈÀ‘S«‚È‚ç‚Ñ‚ÉŒp‘±«‚ÉŠÖ‚·‚錟“¢.@‘æ33‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ï . ‰«“ê. 2012”N11ŒŽ29“ú.

û•£¹‹B, ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, –Øh¹r, ì“Y˜a‹`, ‰©r, ŽO‹´“ÕŽu, …Œû˜a¶, ¼‰ªˆÀ•F. Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-1‚̈««‹¹–Œ’†”çŽî‚ɑ΂·‚éR‘̈ˑ¶«×–EáŠQŠˆ«‚ÆRŽîᇌø‰Ê.@‘æ53‰ñ“ú–{”xŠàŠw‰ï‘‰ï. ‰ªŽR. 2012”N11ŒŽ9“ú.

–L“c—DŽq, Š`“à‘Ži, û•£¹‹B, Žè’Ë•qŽj, Œã“Œ‹vŽk, ¼‰ªˆÀ•F. Patient-Reported-Outcome(PRO)‚É‚æ‚é”xŠà–ò•¨—Ö@‚Ì—LŒø«‚ÌŒŸ“¢.@‘æ53‰ñ“ú–{”xŠàŠw‰ï‘‰ï. ‰ªŽR. 2012”N11ŒŽ8“ú.

Œ³–Ø—R”ü, ˆ¢•”“ú“o”ü, ’–“àG˜a, û•£¹‹B, •‹v—mŽO. “–‰@‚Å‚Ì‘Ï«‹Û‚ɑ΂·‚éŽæ‚è‘g‚Ý.@‘æ20‰ñ“ú–{–«Šúˆã—Êw‰ï. •Ÿˆä. 2012”N11ŒŽ8“ú.

Œ³–Ø—R”ü, ˆ¢•”“ú“o”ü, ’–“àG˜a, û•£¹‹B, •‹v—mŽO. “–‰@‚Å‚Ì‘Ï«‹Û‚ɑ΂·‚éŽæ‚è‘g‚Ý.@‘æ54‰ñ‘S“ú–{•a‰@Šw‰ï. ‰¡•l. 2012”N9ŒŽ21“ú.

“c”¨Ë, ’r“c—´“ñ, ŽR–{‰ë’B, ŒÃì—´•F, ‘q–{‘ìÆ, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, HŽRLˆê. ƒqƒgŠà×–E‚̶‘¶‚É‚¨‚¯‚éƒ`ƒ~ƒWƒ“ˆÙ‰»ì—p‚Ì–ðŠ„.@‘æ71‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ŽD–y. 2012”N9ŒŽ20“ú.

¼‰ªˆÀ•F, ˆ¢•”^Ž¡, –Øh¹r, ì“Y˜a‹`, ‰©r, û•£¹‹B, …Œû˜a¶, ‘]ªŽO˜Y, ‰Á“¡K¬. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚郉ƒbƒg]ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-8‚ÌRŽîᇌø‰Ê.@‘æ71‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ŽD–y. 2012”N9ŒŽ19“ú.

‰Á“¡K¬, ‘“cŽéŽq, ¼‰ªˆÀ•F. Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚É‚æ‚é“]ˆÚ—}§Œø‰Ê‚ÌŒŸ“¢.@‘æ71‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ŽD–y. 2012”N9ŒŽ19“ú.

ƒŒ@ƒ^ƒ“ƒ_[, ¼”ö‘×—C, ‹gŠÛ“N˜Y, Š`“à‘Ži, Œã“Œ‹vŽk, ‘q–{‘ìÆ, ŽO‹´“ÕŽu, ‘]ªŽO˜Y, ¼‰ªˆÀ•F, •Ð‹Ë–L‰ë. ”xŠà‚Ìœ“]ˆÚ‚ð§Œä‚·‚éV‹K“]ŽÊˆöŽqLBMTF‚Ì‹@”\‰ðÍ.@‘æ71‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. ŽD–y. 2012”N9ŒŽ19“ú.

’Ò–{—Y‘¾, ‘“cŽéŽq, ¼‰ªˆÀ•F, ‰Á“¡K¬. ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚É‚æ‚é“]ˆÚ—}§Œø‰Ê‚ÌŒŸ“¢.@‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. L“‡. 2012”N7ŒŽ12“ú.

‘å’ËŒ›Ži, û•£¹‹B, Œã“Œ‹vŽk, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, Fidler Isaiah J. Endothelin Žó—e‘ÌhRÜ‚É‚æ‚é”xŠà”]“]ˆÚ—}§Œø‰Ê‚ÌŒŸ“¢. ‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. L“‡. 2012”N7ŒŽ12“ú.

‘q–{‘ìÆ, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, “c”¨Ë, ㌴‹v“T, ¼žŠ“Ö˜Y, Š`“à‘Ži, û•£¹‹B, ‘Oì—mˆê, ˆÀ—FN“ñ, HŽRLˆê, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ¬×–E”x‚ª‚ñ“]ˆÚ‚É‚¨‚¯‚éDll4-NotchƒVƒOƒiƒ‹‚Ì‘ŸŠí“ÁˆÙ«‚ÉŠÖ‚·‚錟“¢. ‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. L“‡. 2012”N7ŒŽ12“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‘q–{‘ìÆ, “c”¨Ë, ¬ì”Ž‹v, ㌴‹v“T, HŽRLˆê, Wright Jo Rae, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ”xsurfactant protein AiSP-Aj‚Ì”xŠài“W‚É‚¨‚¯‚é‹@”\‰ðÍ.@‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï. L“‡. 2012”N7ŒŽ12“ú.

¼‰ªˆÀ•F, ˆ¢•”^Ž¡, ‰Á“¡K¬, –Øh¹r, ì“Y˜a‹`, ‰©r, û•£¹‹B, …Œû˜a¶, ‘]ªŽO˜Y. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-8‚ÌRŽîᇌø‰Ê. ‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. –k‹ãB. 2012”N6ŒŽ28“ú.

‰Á“¡K¬, ˆ¢•”^Ž¡, …Œû˜a¶, ¼‰ªˆÀ•F. ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚É‚æ‚é“]ˆÚ—}§‹@˜‚̉ð–¾.@‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. –k‹ãB. 2012”N6ŒŽ28“ú.

‘q–{‘ìÆ, Œã“Œ‹vŽk, ²“¡³‘å, ŽO‹´“ÕŽu, “c”¨Ë, ¼žŠ“Ö˜Y, ㌴‹v“T, Welm Alana, û•£¹‹B, HŽRLˆê, ‘]ªŽO˜Y, ¼‰ª ˆÀ•F. ƒqƒg”x‚ª‚ñ‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚éMacrophage-stimulating protein ‚Ì–ðŠ„‚ÉŠÖ‚·‚錟“¢.@‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. –k‹ãB. 2012”N6ŒŽ28“ú.

–L“c—DŽq, û•£¹‹B, Š`“à‘Ži, ŸN“cI, Œã“Œ‹vŽk, Žè’Ë•qŽj, ŠÝ, –샓T, ¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚éI––Šú‚Ì’ÁÂɂ‚¢‚Ä‚ÌŒŸ“¢.@‘æ17‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïŠwp‘å‰ï. _ŒË. 2012”N6ŒŽ23“ú.

¼žŠ“Ö˜Y, Š`“à‘Ži, ¼”Ž”V, ‘å’ËŒ›Ži, ŽRŽq‘דl, Žè’Ë•qŽj, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F. Cycleave–@‚ÆPCR-Clamp–@‚É‚æ‚éEGFRˆâ“`Žq•ÏˆÙ‘ª’茋‰Ê‚ÆEGFRƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQÜ‚ÌŽ¡—ÃŒø‰Ê‚Æ‚Ì‘ŠŠÖ.@‘æ35‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï. “Œ‹ž. 2012”N5ŒŽ31“ú.

‰Í–ìO, ŠÝ¹”ü, Žè’Ë•qŽj, –L“c—DŽq, ŠÝ, ¼‰ªˆÀ•F. • •”‘å“®–¬ŽüˆÍ‰Š‚𔺂Á‚½granulomatosis with polyangiitis‚Ì1—á.@‘æ56‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï. “Œ‹ž. 2012”N4ŒŽ27“ú.

‘ˆî“c—DŽq, ¼ˆäËŽq, ŽR–{—m, “¡‘º­Ž÷, —L“c^’mŽq, Έ䊰, ‹îè‹`—˜, ™ŽRK”äŒÃ, “n•Ó³Ž÷, ‰Pˆä—T, ‰Í‘º“NŽ¡, ¬—щp•v, ¼‰ªˆÀ•F, –{ŠÔ‰h, ¬‘q‚Žu. IgG4ŠÖ˜AŽ¾Š³(IgG4RD)‚̌ċzŠí•a•Ï‚É‚¨‚¯‚é—Õ°‰æ‘œ•a—Šw“IŒŸ“¢.@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. _ŒË. 2012”N4ŒŽ22“ú.

ˆ¢•”Gˆê, ‰ªú±O‘×, ŠÝ¹”ü, ’|ú±²•v, –؉ºŸO, “Œ“‘ã, ŠÝ, –샓T, ¼‰ªˆÀ•F. Fibrocyte‚Ì”xüˆÛ‰è×–E‹@”\‚É‹y‚Ú‚·Œø‰Ê‚ÌŒŸ“¢.@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. _ŒË. 2012”N4ŒŽ20“ú.

ŠÝ¹”ü, –샓T, ’|貕v, “Œ“‘ã, ŠÝ, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éƒsƒ‹ƒtƒFƒjƒhƒ““Š—^Ç—á‚ÌŒŸ“¢.@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. _ŒË. 2012”N4ŒŽ20“ú.

ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, –Øh¹r, ì“Y˜a‹`, “Œ–ž”ü, …Œû˜a¶, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-1‚ÌRŽîᇌø‰Ê‚ÉŠÖ‚·‚錟“¢.@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. _ŒË. 2012”N4ŒŽ20“ú.

Š`“à‘Ži, û•£¹‹B, “c‰ª—²¬, ¼žŠ“Ö˜Y, Žè’Ë•qŽj, –L“c—DŽq, Œã“Œ‹vŽk, ‚‹´³K, ‹àŽR”Žb,¼‰ªˆÀ•F. mTOR‘jŠQÜ“Š—^Ç—á‚É‚¨‚¯‚éŠÔŽ¿«”xáŠQ‚Ì—Õ°“I“Á’¥.@‘æ109‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ï. ‹ž“s. 2012”N4ŒŽ15“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
‘ºã‰i®, “‡’J‰ÀŒõ, ŽRŽq‘דl, ‘åè—T—º, ‹{鈤, X“ÖŽq, –쎛—T”V, ˜aò—BM, ¼‰ªˆÀ•F, Š—´™Z. ‘½Ê‚È_ŒoÇó‚ð’悵‚½¬×–E”xŠà‚Ì1—á. ‘æ107‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2012”N12ŒŽ8“ú.

ìk‘¢, ‰Í–ìO, “¡“c_Ži, ‘ºã‰i®, Žè’Ë•qŽj, ŠÝ, û•£¹‹B, Š—´™Z, ¼‰ªˆÀ•F. MPO-ANCAŠÖ˜A”ìŒú«d–Œ‰Š‚Ì1—á. ‘æ107‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2012”N12ŒŽ2“ú.

•Ä“c_l, ‘å’ËŒ›Ži, –샓T, –L“c—DŽq, ¼–ì‹Žu, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F.“«‚Ìt«EŠÌ«‹¹…‚ɑ΂µ‚Ä‹¹o|• oƒVƒƒƒ“ƒg‚ª‘tŒø‚µ‚½1—á. ‘æ107‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ¼ŽR. 2012”N12ŒŽ2“ú.

‰Í–ìO, –L“c—DŽq, ŠÝ, û•£¹‹B, ¼‰ªˆÀ•F. RCCPR‘Ì‚’l‚ð’悵AŠÖ߉Š‚𔺂킸‚É”­Ç‚µ‚½ƒXƒeƒƒCƒh’ïR«ŠíŽ¿‰»”x‰Š‚Ì1—á. ‘æ23‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ‰F•”. 2012”N10ŒŽ20“ú.

û•£¹‹B, ’·”ö‘½”üŽq, —é–Ø—íŽq, ‚ŠJ“o–ÎŽq, “Œ“‘ã, ¼‰ªˆÀ•F. öÝ«Œ‹ŠjŠ´õÇ(latent tuberculosis infection: LTBI)‚ɑ΂·‚鎡—Â̌»ó‚Æ–â‘è“_. ‘æ6‰ñ“ú–{Œ‹Šj•aŠw‰ï’†‘Žl‘Žx•”Œ¤‹†‰ï. ‰ªŽR. 2012”N9ŒŽ29“ú.

’†¼‰ÃŒ›, ‰Í–ìO, ˆ¢•”Gˆê, ’|ú±²•v, Œã“Œ‹vŽk, –샓T, û•£¹‹B, æŽR³“ñ, •Ÿ“c—I, ¼‰ªˆÀ•F. “Á”­«”xœ‰»Ç‚Ì1—á. ‘æ47‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‰ºŠÖ. 2012”N7ŒŽ21“ú.

ìk‘¢, ¼žŠ“Ö˜Y, Š`“à‘Ži, ‘å’ËŒ›Ži, ŽRŽq‘דl, Žè’Ë•qŽj, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F.‘ª’è–@‚É‚æ‚èEGFR•ÏˆÙ‚Ì‘ª’茋‰Ê‚ɉ𗣂ª‚Ý‚ç‚ꂽ”ñ¬×–E”xŠà‚Ì3—á. ‘æ51‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”‰ï. ‰ºŠÖ. 2012”N7ŒŽ20“ú.

•Ä“c_l, –샓T, ŠÝ¹”ü, –L“c—DŽq, ‹ß“¡^‘ã, ‰ªú±O‘×, ŠÝ, û•£¹‹B, ŠÄèFˆê˜Y, •Ÿ“c—I, ¼‰ªˆÀ•F. ‚IgGŒŒÇ‚Ì’·ŠúŠÔ‚ÌŒo‰ßŠÏŽ@’†‚É‘½’†S«ƒLƒƒƒbƒXƒ‹ƒ}ƒ“•a‚Ìf’f‚ÉŽŠ‚Á‚½ˆê—á. ‘æ47‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‰ºŠÖ. 2012”N7ŒŽ20“ú.

‘å’ËŒ›Ži, –L“c—DŽq, ŠÝ, –샓T, û•£¹‹B, ¼‰ªˆÀ•F, Œ´’m–ç, ŽRŒû_Ži, ²“c­—². S‹Ø‰Š‚ð‡•¹‚µ‚½Churg-StraussÇŒóŒQ‚Ì1—á. ‘æ106‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2012”N6ŒŽ17“ú.

“c‰ªŽu•Û, ‰Í–ìO, Žè’Ë•qŽj, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, ¼‰ªˆÀ•F, ‰ª–{kˆê, ‚ŽR“NŽ¡. FDG-PET/CT‚É‚æ‚謒°“]ˆÚ‚ð”­Œ©‚µ‚½”xŠà‚Ì2Ç—á. ‘æ106‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. “¿“‡. 2012”N6ŒŽ17“ú.

‹ß“¡^‘ã, –L“c—DŽq, ˆ¢•”Gˆê, ‰Í–ìO, ŠÝ¹”ü, ’|ú±²•v, “Œ“‘ã, Š`“à‘Ži, Œã“Œ‹vŽk, –샓T, û•£¹‹B, ¼‰ªˆÀ•F. •a¨‚ÉŠÖ˜A‚µ‚ÄCA19-9‚Ì•Ï“®‚ð”F‚ß‚½”ñŒ‹Šj«RŽ_‹ÛÇ‚Ì1—á. ‘æ20‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. o‰_. 2012”N3ŒŽ3“ú.

¼”Ž”V, Žè’Ë•qŽj, ‰Í–ìO, ’|ú±²•v, “Œ“‘ã, Š`“à‘Ži, Œã“Œ‹vŽk, ŠÝ, –샓T, û•£¹‹B, ¼‰ªˆÀ•F. ”ñŒ‹Šj«RŽ_‹ÛÇ‚ð‡•¹‚µ‚½ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á. ‘æ20‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. o‰_. 2012”N3ŒŽ3“ú.

’|ú±²•v, ¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, ŠÝ¹”ü, Žè’Ë•qŽj, Š`“à‘Ži, Œã“Œ‹vŽk, ŠÝ, –샓T, û•£¹‹B, ¼‰ªˆÀ•F. “–‰È‚ÅŒoŒ±‚µ‚½”x–EoŒŒ4Ç—á‚Ì—Õ°“IŒŸ“¢. ‘æ20‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. o‰_. 2012”N3ŒŽ3“ú.
£ƒy[ƒW‚ÌTOP‚Ö
2011”N‹ÆÑ
y‰¢•¶‘àz
Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S.@Antiangiogenic therapies for malignant pleural mesothelioma. Front Biosci 16:740-748, 2011.

Nishioka Y, Aono Y, Sone S. Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy 3:107-116, 2011.
y‰¢•¶Œ´’˜z
Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci 102:2157-2163, 2011.

Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T, Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 12:143-153, 2011.

Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine Nnetwork. Am J Pathol 179:1483-1493, 2011.

Goto H, Hanibuchi M, Sakaguchi S, Kanematsu T, Kakiuchi S, Tomimoto H, Azuma M, Tezuka T, Tada H, Miki Y, Nakamura T, Sone S, Nishioka Y. Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital. J Med Invest 58:219-226, 2011.

Batmunkh R, Nishioka Y, Aono Y, Azuma M, Kinoshita K, Kishi J, Makino H, Kishi M, Takezaki A, Sone S. CCN6 as a profibrotic mediator that stimulates the proliferation of lung fibroblasts via the integrin ƒÀ1/focal adhesion kinase pathway. J Med Invest 58:188-196, 2011.

Van TT, Hanibuchi M, Kakiuchi S, Sato S, Kuramoto T, Goto H, Mitsuhashi A, Nishioka Y, Akiyama SI, Sone S. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol 68:497-504, 2011.

Kishi J, Nishioka Y, Kuwahara T, Kakiuchi S, Azuma M, Aono Y, Makino H, Kinoshita K, Kishi M, Batmunkh R, Uehara H, Izumi K, Sone S. Blockade of Th1 chemokine receptors ameriolates pulmonary granulomatosis in mice. Eur Respir J 38:415-424, 2011.

Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 10:1218-1228, 2011.

Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T. Pirfenidone Clinical Study Group in Japan. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12:93-101, 2011.

Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S. A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Lett 2:465-470, 2011.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17:2260-2269, 2011.

Yokoi K, Hawke D, Oborn CJ, Jang JY, Nishioka Y, Fan D, Kim SW, Kim SJ, Fidler IJ. Identification and validation of Src and phospho-Src family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer. Transl Oncol 4:83-91, 2011.

Sakai T, Furoku S, Nakamoto M, Shuto E, Hosaka T, Nishioka Y, Sone S. Soy isoflavone equol perpetuates dextran sulfate sodium-induced acute colitis in mice. Biosci Biotechnol Biochem 75:593-595, 2011.

Ogawa H, Azuma M, Muto S, Nishioka Y, Honjo A, Tezuka T, Uehara H, Izumi K, Itai A, Sone S. IkB kinase b inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus -sensitized mouse model of chronic asthma. Clin Exp Allergy 41:104-115, 2011.
y˜a•¶’˜‘z
¼‰ªˆÀ•F.@ƒxƒoƒVƒYƒ}ƒu@•ªŽq•W“IŽ¡—Öò|ÅV‚Ì‘I‚Ñ•ûEŽg‚¢•û|.@‚ª‚ñf—ÃŒƒNƒ`ƒƒ[ 2, Ήªç‰ÁŽj•Ò. 2011. pp262-263. ‘‡ˆãŠwŽÐ.

–؉ºŸO, ¼‰ªˆÀ•F.@•¶Œ£ŒŸõ‚ÌŽd•û, ˆãŠw˜_•¶‚Ì“Ç‚Ý•ûE‘‚«•û, Šw‰ï‚Ö‚ÌŽæ‚è‘g‚Ý•û, ‘åŠw‰@EˆãŠw”ŽŽmE—¯Šw‚ɂ‚¢‚Ä, ŒÄ‹zŠí‰Èˆã‚É‚Æ‚Á‚ÄŒ¤‹†‚Ƃ͉½‚©? ŒÄ‹zŠí Œ¤Cƒm[ƒg, ˆ°àV˜al, ‘åò‘Žj, ‰«‰i‘sŽ¡, •ž•”“o, ¯ìN•Ò. 2011. pp82-93. f’f‚ÆŽ¡—ÃŽÐ.
y˜a•¶‘àz
–샓T, ¼‰ªˆÀ•F.@äPŒ´•a‚ÆŠÖ˜A‚µ‚½‚Ñ‚Ü‚ñ«”xŽ¾Š³.@‘‡—Õ° 60:2463-2469, 2011.

¼‰ªˆÀ•F.@Gremlin‚Æ“Á”­«ŠÔŽ¿«”x‰Š.@ŒÄ‹z 30:955-958, 2011.

‘]ªŽO˜Y.@ˆãŠwŒ¤‹†‚É‚¨‚¯‚éCOIƒ}ƒl[ƒWƒƒ“ƒg.@Š´õÇŠw‰ïŽGŽ 85:396-397, 2011.

û•£¹‹B. QOL•]‰¿–@‚Æ‚µ‚Ä‚Ìpatient-reported outcome(PRO)‚Æ‚Í.@CLITICAL EYES on Clinical Oncology 40:11, 2011.

ŠÝ¹”ü, ‘]ªŽO˜Y. ‹¹–Œ‰Š, ”^‹¹.@Medical Practice 28(‘):334-338, 2011.

–؉ºŸO, ¼‰ªˆÀ•F.@–òÜ«”xáŠQ‚ÌÅV‚Ì’mŒ©. •ªŽqŒÄ‹zŠí•a 15(1):66-68, 2011.

Œã“Œ‹vŽk, Julie G Ledford, Sambuddho Mukherjee, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, Jo Rae Wright. ‹}«”x‘¹‚É‚¨‚¯‚éSurfactant Protein A‚Ì–ðŠ„. •ªŽqŒÄ‹zŠí•a15:74-76, 2011.
y˜a•¶Œ´’˜z
“¡‰ªŒ[‰î, ¼žŠ“Ö˜Y, –L“c—DŽq, Š`“à‘Ži, û•£¹‹B, Œáȉë•F, ’|“à‹±Žq, “¡ˆäŽu˜N, ’†‘ºMŒ³, ‰F‚Œ›Œá, ‰êì‹v”üŽq, ˆÀ”{³”Ž, …’J—FÆ, ¼‰ªˆÀ•F.@”畆ƒ‰ƒ“ƒ_ƒ€¶ŒŸ‚ªf’f‚É—LŒø‚Å‚ ‚Á‚½ŒŒŠÇ“àƒŠƒ“ƒpŽî‚̈ê—á. Žl‘ˆãŠwŽGŽ 67:257-262, 2011.

Œ“¼‹M‘¥, –L“c—DŽq, Œã“Œ‹vŽk, ˆ¢•”Gˆê, ‰Í–k’¼–ç, æŽR³“ñ, ¼‰ªˆÀ•F, ‘]ªŽO˜Y.@”x‘½”­Œ‹ß•a•Ï‚ð’悵‚½Œ´”­«”x•½ŠŠ‹Ø“÷Žî‚Ì1—á. “ú–{ŒÄ‹zŠíŠw‰ïŽGŽ 49:167-171, 2011.

–؉ºŸO, ¼‰ªˆÀ•F, ŠÝ¹”ü, ’|貕v, –샓T, “Œ“‘ã, ŠÝ, ㌴‹v“T, òŒ[‰î, ‘]ªŽO˜Y. Ž¾Š³Œ`¬‚É‚¨‚¯‚é•W“I•ªŽq‚Ì–ðŠ„ FAKƒVƒOƒiƒ‹‚Ì”xüˆÛ‰»‚É‚¨‚¯‚é–ðŠ„ ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ‚ƒfƒ‹‚Å‚ÌŒŸ“¢. •ªŽqŒÄ‹zŠí•a 15:124-127, 2011.
yŠw‰ï”­•\-‘ÛŠw‰ïz
Masaki Hanibuchi, Shinji Abe, Masatoshi Kisyuku, Soji Kakiuchi, Kasuyoshi Kawazoe, Kazuo Minakuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka. Targeted therapy for mesothelioma using anti-podoplanin antibody NZ-1 via ADCC. 5th EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer'. Brussels, Belgium. 2011”N10ŒŽ27“ú.

Saburo Sone, Seiji Yano. Role of hepatocyte growth factor in resistance acquisition to EGFR-TK inhibitor (Gefitinib/Erlotinib) in EGFR mutant lung cancer patients. The 19th Catholic allergic and Respiratory Workshop. Seoul, Korea. 2011”N6ŒŽ26“ú.

Yasuhiko Nishioka. Novel targets for treatment of pulmonary fibrosis: lessons from animal study for the clinic. The 19th Catholic allergic and Respiratory Workshop. Seoul, Korea. 2011”N6ŒŽ26“ú.

Katsuhiro Kinoshita, Yasuhiko Nishioka, Masami Kishi, Momoyo Azuma, Yoshinori Aono, Hisanori Uehara, Akio Takezaki, S. Hatakeyama, E. Kawahara, Saburo Sone. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ18“ú.

Yoshinori Aono, J.G. Ledford, Yasuhiko Nishioka, Saburo Sone, M.F. Beers, J.R. Wright. SP-D attenuates bleomycin induced lung fibrosis via regulating recruitment and activation of macrophages and fibrocytes.ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ18“ú.

Atsushi Mitsuhasi, Hisatsugu Goto, Takuya Kuramoto, Soji Kakiuchi1, Seidai Sato, Van The Trung, Atsuro Saijo, Makoto Tobiume, Kenji Otsuka, Yasuhiko Nishioka, Jo Rae Wright, Saburo Sone. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ17“ú.

Momoyo Azuma, Yasuhiko Nishioka, Reham Mohammed El-morshedy, Jun Kishi, Masami Kishi, Katsuhiro Kinoshita, Hisanori Uehara, Keisuke Izumi, Saburo Sone. The role of sphingosine 1-phospate (SIP) signaling in pulmonary fibrosis. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ15“ú.
yŠw‰ï”­•\-‘“àŠw‰ïi“Á•Êu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
¼‰ªˆÀ•F. •ªŽq•W“IŽ¡—Âɂ¨‚¯‚éˆê‘̉»ŠJ”­‚Ö‚ÌŠú‘Ò. JAMTTCEJSGDT‡“¯ƒVƒ“ƒ|ƒWƒEƒ€ “Œ‹ž. 2011”N12ŒŽ9“ú.

Œã“Œ‹vŽk, –샓T, ¼‰ªˆÀ•F. ”x‚̶‘Ì–hŒä‹@\‚É‚¨‚¯‚éƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’A‚Ì–ðŠ„. “ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ʈãŠw‰ï‘æ47‰ñŠwpŒ¤‹†‰ï(‹³ˆçu‰‰). “¿“‡. 2011”N10ŒŽ29“ú.

¼‰ªˆÀ•F, ’Ò–{—Y‘¾, ‰Á“¡K¬, ‘]ªŽO˜Y. ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ì‚ÌŠˆ«•]‰¿. ‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïiƒ[ƒNƒVƒ‡ƒbƒvj. ɪ. 2011”N6ŒŽ30“ú.

‰Á“¡K¬, ¼‰ªˆÀ•F, ˆ¢•”^Ž¡, …Œû˜a•v, ‘]ªŽO˜Y. ˆ««ƒOƒŠƒI[ƒ}‚ɑ΂·‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-1‚ÌŠˆ«•]‰¿. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ïiƒ[ƒNƒVƒ‡ƒbƒvj. “Œ‹ž. 2011”N6ŒŽ24“ú.

‘q–{‘ìÆ, Œã“Œ‹vŽk, Š`“à‘Ži, ¬ì”Ž‹v, ŽO‹´“ÕŽu, “c”¨Ë, ²“¡³‘å, ‘Oì—mˆê, ˆÀ—FN“ñ, ¼‰ªˆÀ•F, HŽRLˆê, ‘]ªŽO˜Y. ¬×–E”x‚ª‚ñ“]ˆÚ‚É‚¨‚¯‚éDLL4-NotchƒVƒOƒiƒ‹‚Ì‘ŸŠí“ÁˆÙ«‚ÉŠÖ‚·‚錟“¢. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ïiƒ[ƒNƒVƒ‡ƒbƒvj. “Œ‹ž. 2011”N6ŒŽ24“ú.

“Œ“‘ã. —Õ°–òÜŽt‚ÆTDM`ˆãŽt‚Ƃ̃Rƒ~ƒjƒ…ƒP[ƒVƒ‡ƒ“‚Ìd—v«`. ‘æ28‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïiƒVƒ“ƒ|ƒWƒEƒ€j. L“‡. 2011”N6ŒŽ18“ú.

–؉ºŸO, ¼‰ªˆÀ•F, ŠÝ¹”ü, “Œ“‘ã, –샓T, ’|貕v, ㌴‹v“T, ”©ŽRT“ñ, ‰ÍŒ´‰pŽ¡, ‘]ªŽO˜Y. ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛǃ‚ƒfƒ‹‚É‚¨‚¯‚éFAK‘jŠQÜTAE226‚ÌRüˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiƒ|ƒXƒ^[ƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2011”N4ŒŽ24“ú.

Shinji TakeuchiCWei WangCQi LiCTadaaki YamadaCHitomi KoizumiCIvan S DonevCYasuhiko NishiokaCSaburo SoneCToshimitsu Uenaka. E7050, A Dual MET/VEGFR-2 Kinase Inhibitor, Circumvents EGFR-TKIs Resistance in EGFR Mutant Lung Cancer cells Induced by HGF. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiEnglish@Mini-symposiumj. “Œ‹ž. 2011”N4ŒŽ24“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya KuramotoCSoji KakiuchiCSeidai SatoCVan The TrungCMakoto TobiumeCKenji OtsukaCYasuhiko Nishioka. SP-A suppresses lung cancer progression and pleural effusion of human lung cancer cells in experimental mice model. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ïiEnglish@Mini-symposiumj. “Œ‹ž. 2011”N4ŒŽ23“ú.
yŠw‰ï”­•\-‘“àŠw‰ïiˆê”ʉ‰‘èjz
ˆ¢•”^Ž¡, ‰Á“¡K¬, ‹àŽq”ü‰Ø, ‰©r, û•£¹‹B, ‘]ªŽO˜Y, ¼‰ªˆÀ•F. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘̗Ö@‚ÌŒŸ“¢.@‘æ24‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠwpW‰ï‘‰ï. ˜a‰ÌŽR. 2011”N12ŒŽ1“ú.

Žè’Ë•qŽj, ¬ì”Ž‹v, Œáȉë•F, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. Plasminogen Activator Inhibitor-1‘jŠQÜiIMD-4690)‚Ì–«šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢.@‘æ61‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï. “Œ‹ž. 2011”N11ŒŽ10“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‘q–{‘ìÆ, Š`“à‘Ži, ²“¡³‘å, Ttung The Van, ¼žŠ“Ö˜Y, “c”¨Ë, ¬ì”Ž‹v, ㌴‹v“T, HŽRLˆê, ¼‰ªˆÀ•F, Jo Rae Wright, ‘]ªŽO˜Y. ”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’SP-A”x‚ª‚ñi“W‚É‚¨‚¯‚é‹@”\‰ðÍ.@“ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ʈãŠw‰ï‘æ47‰ñŠwpŒ¤‹†‰ï. “¿“‡. 2011”N10ŒŽ29“ú.

–샓T, ¼‰ªˆÀ•F. ”xüˆÛÇ‚É‚¨‚¯‚éSP-D‚Ì–hŒä“I–ðŠ„.@“ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ʈãŠw‰ï‘æ47‰ñŠwpŒ¤‹†‰ï. “¿“‡. 2011”N10ŒŽ29“ú.

¼‰ªˆÀ•F, ‰Á“¡K¬, û•£¹‹B, ‘]ªŽO˜Y. ˆ««‹¹–Œ’†”çŽî‚ɑ΂·‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-1‚ÌRŽîᇌø‰Ê.@‘æ70‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. –¼ŒÃ‰®. 2011”N10ŒŽ5“ú.

“c”¨Ë, ŽR–{‰ë’B, ’r“c—´“ñ, ŒÃì—´•F, ‘q–{‘ìÆ, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, HŽRLˆê. ƒ`ƒ~ƒWƒ“ƒzƒXƒzƒŠƒ‰[ƒ[‚É‚æ‚Á‚ă`ƒ~ƒWƒ“‚©‚ç”h¶‚µ‚½“œ‚̉𓜌n‚ւ̈Ús.@‘æ70‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï. –¼ŒÃ‰®. 2011”N10ŒŽ3“ú.

ƒŒ@ƒ^ƒ“ƒ_[, ¼”ö‘×—C, ‹gŠÛ“N˜Y, ‘q–{‘ìÆ, û•£¹‹B, Œã“Œ‹vŽk, Š`“à‘Ži, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, •Ð‹Ë–L‰ë. ƒqƒg”ñ¬×–E”xŠà‚Ì‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹ƒ}ƒEƒX‚ð—p‚¢‚½œ“]ˆÚŠÖ˜Aˆâ“`Žq‚Ì–Ô—…“I‰ðÍ.@“ú–{ŠàŠw‰ïŠwp‘‰ï. –¼ŒÃ‰®. 2011”N10ŒŽ3“ú.

²“¡³‘å, Œã“Œ‹vŽk, ‘q–{‘ìÆ, ¬ì”Ž‹v, ŽO‹´“ÕŽu, ƒeƒoƒ“ ƒ`ƒ…ƒ“, Š`“à‘Ži, “c”¨Ë, HŽRLˆê, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ƒqƒg”x‚ª‚ñ‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚éMacrophage Stimulationg Protein‚Ì–ðŠ„‚ÉŠÖ‚·‚錟“¢.@‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ï. ɪ. 2011”N6ŒŽ30“ú.

Œã“Œ‹vŽk, ƒAƒfƒ‹ ƒKƒuƒ‹, û•£¹‹B, ‘q–{‘ìÆ, Š`“à‘Ži, ²“¡³‘å, “c”¨Ë, ƒeƒoƒ“ ƒ`ƒ…ƒ“, ¬ì”Ž‹v, HŽRLˆê, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ƒqƒg”xŠà“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚éerlotinib‚ÌhŽå‰îÝ«RŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ï. ɪ. 2011”N6ŒŽ30“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‘q–{‘ìÆ, Š`“à‘Ži, ²“¡³‘å, ƒeƒoƒ“ ƒ`ƒ…ƒ“, ¼žŠ“Ö˜Y, “c”¨Ë, HŽRLˆê, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’SP-A‚Ì”xŠài“W‚É‚¨‚¯‚é‹@”\‰ðÍ.@‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ï. ɪ. 2011”N6ŒŽ30“ú.

²“¡³‘å,@¼‰ªˆÀ•F, ‘]ªŽO˜Y, ‘å’J’¼Žq. ‚ª‚ñƒ}ƒCƒNƒRNAƒNƒ‰ƒXƒ^[Mir17-92”­Œ»‚̶‘Ì“àƒCƒ[ƒWƒ“ƒO‚Æ‚ª‚ñŽ¡—Âւ̉ž—p.@‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2011”N6ŒŽ24“ú.

¼‰ªˆÀ•F, ˆ¢•”^Ž¡, ‰Á“¡K¬, –Øh¹r, ì“Y˜a‹`, ‰©r, û•£¹‹B, …Œû˜a•v, ‘]ªŽO˜Y. Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ÌNZ-1‚̈««‹¹–Œ’†”çŽî‚ɑ΂·‚éR‘̈ˑ¶«×–EáŠQŠˆ«‚ÆRŽîᇌø‰Ê.@‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2011”N6ŒŽ24“ú.

ƒŒ ƒ^ƒ“ ƒ_[, ¼”ö‘×—C, Œã“Œ‹vŽk, Š`“à‘Ži, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, •Ð‹Ë–L‰ë. ”xŠà‚Ìœ“]ˆÚ‚ð§Œä‚·‚éV‚½‚È“]ŽÊˆöŽq‚Ì“¯’è‚Æ‚»‚Ì‹@”\‰ðÍ. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2011”N6ŒŽ24“ú.

“c”¨Ë, ŽR–{‰ë’B, ’r“c—´“ñ, ŒÃì—´•F, ‘q–{‘ìÆ, ¼‰ªˆÀ•F, ‘]ªŽO˜Y, HŽRLˆê. ƒ`ƒ~ƒWƒ“ƒzƒXƒzƒŠƒ‰[ƒ[‚É‚æ‚Á‚ă`ƒ~ƒWƒ“‚©‚ç”h¶‚µ‚½“œ‚̉𓜌n‚ւ̈Ús. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2011”N6ŒŽ23“ú.

ƒoƒ“ ƒe ƒ`ƒ…ƒ“, û•£¹‹B, Œã“Œ‹vŽk, Š`“à‘Ži, ‘q–{‘ìÆ@ƒŒ ƒ^ƒ“ ƒ_[, –î–칓ñ, HŽRLˆê, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ŒŒŠÇV¶‘jŠQÜTSU-68‚̈««‹¹–Œ’†”çŽî“¯ŠˆÚAƒ‚ƒfƒ‹‚É‚¨‚¯‚éRŽîᇌø‰Ê‚ÌŒŸ“¢.‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï. “Œ‹ž. 2011”N6ŒŽ23“ú.

Œáȉë•F, –{ŸÄWŽj, Žè’Ë•qŽj, ¬ì”Ž‹v, •Ä“c˜a•v, —t‹v‹MŽi, ™“c–¾”ü, –©‹`², ¼‰ªˆÀ•F, ‘]ªŽO˜Y. “¿“‡Œ§‚É‚¨‚¯‚é‹CŠÇŽxšb‘§Š³ŽÒ‚̃Rƒ“ƒgƒ[ƒ‹‚ÉŠÖ‚·‚éŽÀ‘Ô’²¸‘æ2•ñ. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ°‘å‰ï. ç—t. 2011”N5ŒŽ14“ú.

’|貕v, “Œ“‘ã, –؉ºŸO, Œã“Œ‹vŽk, ‘½“c_–ç, Œáȉë•F, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. “–‰@‚É‚¨‚¯‚é–«‰óŽ€«”xƒAƒXƒyƒ‹ƒMƒ‹ƒXǂɑ΂·‚éƒAƒ€ƒrƒ][ƒ€‚ÌŽg—pŒoŒ±. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2011”N4ŒŽ24“ú.

“Œ“‘ã, ¼‰ªˆÀ•F, Mohammed Elmorshedy Reham, ŠÝ, ŠÝ¹”ü, –؉ºŸO, ’|貕v, Jun Huang, ㌴‹v“T, òŒ[‰î, HŽRLˆê, ‘]ªŽO˜Y. ”xüˆÛÇ‚É‚¨‚¯‚éƒXƒtƒBƒ“ƒSƒVƒ“-1-ƒŠƒ“Ž_ƒVƒOƒiƒ‹‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2011”N4ŒŽ23“ú.

Žè’Ë•qŽj, ¬ì”Ž‹v, Œáȉë•F, –{òWŽj, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚ÌRŒ´Š´ì‚É‚¨‚¯‚éIKKƒÀ-NF-ƒÈBŒo˜H‚̉e‹¿‚ɂ‚¢‚Ä. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï. “Œ‹ž. 2011”N4ŒŽ22“ú.
yŠw‰ï”­•\-‘“à’n•ûŠw‰ïz
‰ªú±O‘×, –L“c—DŽq, ŠÝ, ‰Í–ìO, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, Œáȉë•F, å”ü‰À, ¼‰ªˆÀ•F. ‘gDf’f‚ª“¾‚ç‚ꂽŠÌƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì2Ç—á. ‘æ22‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†‘EŽl‘Žx•”ŠwpW‰ï. ¼ŽR. 2011”N12ŒŽ10“ú.

‘å’ËŒ›Ži, –L“c—DŽq, Š`“à‘Ži, Œã“Œ‹vŽk, û•£¹‹B, Œáȉë•F, ¼‰ªˆÀ•F, ŠÄú±Fˆê˜Y, •ŸX’mŽ¡, â“Œ—Ç”ü. ‘½”­Œ‹ß‰e‚ð’悵‚½Langerhans cell histiocytosis‚Ì1—á. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼. 2011”N11ŒŽ6“ú.

‹ß“¡^‘ã, ‰Í–ìO, Š`“à‘Ži, ŠÝ, û•£¹‹B, Œáȉë•F, ‹ß“¡ŠG—¢, ‡“c³˜a, Ίے¼Ÿ, ¼‰ªˆÀ•F. IgG4ŠÖ˜A‰º‚‘̉Š‚Ì1—á. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚¼. 2011”N11ŒŽ6“ú.

‚‹´’¼Šó, ”ò”~—º, Žè’Ë•qŽj, –L“c—DŽq, “Œ“‘ã, Œã“Œ‹vŽk, Š`“à‘Ži, ŠÝ, –샓T, û•£¹‹B, Œáȉë•F, ‘]ªŽO˜Y, ¼‰ªˆÀ•F, ‚‹´”ü‹IŽq, •Ÿ“c—I. ŠÔŽ¿«”x‰Š‚̸¸‚É‚æ‚èf’f‚³‚ꂽIgG4ŠÖ˜AŽ¾Š³‚Ì1—á. ‘æ46‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‘q•~. 2011”N7ŒŽ16“ú.

¼”Ž”V, –L“c—DŽq, Š`“à‘Ži, ’|ú±²•v, ŠÝ¹”ü, ‘å’ËŒ›Ži, Žè’Ë•qŽj, Œã“Œ‹vŽk, û•£¹‹B, Œáȉë•F, ¼‰ªˆÀ•F. ‹C‹¹‚ð‡•¹‚µ‚½”xŠà10—á‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ50‰ñ“ú–{”xŠàŠw‰ï’†‘EŽl‘Žx•”‰ï. ‘q•~. 2011”N7ŒŽ15“ú.

“c‰ª—²¬, ŠÝ¹”ü, ’|ú±²•v, –؉ºŸO, –L“c—DŽq, Š`“à‘Ži, û•£¹‹B, ˆäú±”Ž•¶, ‚‹´³K, •ŸX’mŽ¡, ‹àŽR”Žb, ¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚émTOR‘jŠQ–ò“Š—^Š³ŽÒ‚É”­Ç‚µ‚½ŠÔŽ¿«”x‰Š‚Ì—Õ°“IŒŸ“¢. ‘æ46‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†‘EŽl‘’n•û‰ï. ‘q•~. 2011”N7ŒŽ15“ú.

‘¾“c—ŠG, Šâ£r, ‹v‰ª”’—z‰Ô, ŽR“c”Žˆû, ¼‰ªˆÀ•F, ‚”ö³ˆê˜Y, â“Œ²’mŽq, ”\¨”¹l, “í£Œ«–ç, m–Ø•q”V, •y“c‹IŽq, ã“c—R‰À, ŽRŒû_Ži, ’|’J‘P—Y, “Y–Ø•, Žá’ΓNŽO, Ô’r‰ëŽj, ‘]ªŽO˜Y, ²“c­—². SŽºŒÅ—L’²—¥‚ªS•a•Ïf’f‚Ì‚«‚Á‚©‚¯‚Æ‚È‚Á‚½ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á. ‘æ98“ú–{zŠÂŠíŠw‰ï ’†‘EŽl‘‡“¯’n•û‰ï. “¿“‡. 2011”N5ŒŽ13“ú.

ˆÀÏ–ƒˆß, Šâ£r, m–Ø•q”V, Žá’ΓNŽO, ²“c­—², Ô’r‰ëŽj, ‚”ö³ˆê˜Y, Œ´“c‰ëŽj, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. Šá, ”x, ‹Ø•a•Ï‚É‘±‚¢‚ÄŒo‰ß’†‚ÉV•a•Ï‚ÌŒ°Ý‰»‚ð”F‚ß‚½ƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á. ‘æ104‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2011”N5ŒŽ8“ú.

–؉ºŸO, ²“¡³‘å, Œã“Œ‹vŽk, Š`“à‘Ži, û•£¹‹B, Œáȉë•F, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ƒxƒoƒVƒYƒ}ƒu‚ª‘tŒ÷‚µ‚½”ñ¬×–E”xŠà‚Ì2Ç—á. ‘æ104‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2011”N5ŒŽ8“ú.

ŠÝ¹”ü, ¼‰ªˆÀ•F, –L“c—DŽq, ŠÝ, Œã“Œ‹vŽk, Œáȉë•F, ‘]ªŽO˜Y. Rbó‘B–ò•ž—p’†‚ÉMPO-ANCAŠÖ˜AŒŒŠÇ‰ŠÇŒóŒQ‚ð”­Ç‚µ‚½2—á. ‘æ104‰ñ“ú–{“à‰ÈŠw‰ïŽl‘’n•û‰ï. ‚’m. 2011”N5ŒŽ8“ú.

m–ع“¿, ¼žŠ“Ö˜Y, Œã“Œ‹vŽk, –{ŸÄWŽj, –؉ºŸO, “Œ“‘ã, ‘½“c_–ç, Œáȉë•F, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ClarithromycinAAmikacinAImipenem/cilastatinAMoxifloxacin‚Ì•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½”xMycobacterium abscessusŠ´õÇ‚Ì1—á. ‘æ19‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. V‹•l. 2011”N1ŒŽ22“ú.

”ò”~—º, ²“¡³‘å, –L“c—DŽq, Œã“Œ‹vŽk, ‘½“c_–ç, ¼‰ªˆÀ•F, ‘]ªŽO˜Y. ˆÙ‚È‚éEGFRˆâ“`Žq•ÏˆÙ‚ð—L‚·‚鑽”­”x‘BŠà‚̈ê—á. ‘æ19‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†‘Žl‘Žx•”‰ï. V‹•l. 2011”N1ŒŽ22“ú.
£ƒy[ƒW‚ÌTOP‚Ö
“¿“‡‘åŠw‘åŠw‰@ˆãŽ•–òŠwŒ¤‹†•”ŒÄ‹zŠíEäPŒ´•a“à‰ÈŠw•ª–ì
§770-8503“¿“‡Œ§“¿“‡Žs‘ –{’¬‚R’š–Ú‚P‚W”Ô’n‚Ì‚P‚T
TEL:088-633-7127@FAX:088-633-2134
Copyright Department of Respiratory Medicine and Rheumatology
Graduate School of Biomedical Sciences
Tokushima University